

Division of Extramural Activities Annual Report 2014

PRECISION MEDICINE: NCI-MATCH* CLINICAL TRIAL

EXPLORES TREATING PATIENTS BASED ON THE MOLECULAR PROFILES OF THEIR TUMORS

Precision Medicine

NCI-MATCH IS FOR ADULTS WITH:

- solid tumors (including rare tumors) and lymphomas
- tumors that no longer respond to standard treatment




~ 3,000 CANCER PATIENTS WILL BE SCREENED WITH A TUMOR BIOPSY




THE BIOPSIED TUMOR TISSUE WILL UNDERGO GENE SEQUENCING



GENE SEQUENCING WILL EXAMINE CHANGES (MUTATIONS, AMPLIFICATIONS, AND TRANSLOCATIONS) IN 143 GENES



PATIENTS WITH TUMORS THAT SHARE THE SAME GENETIC ABNORMALITY, REGARDLESS OF TUMOR TYPE, WILL RECEIVE THE DRUG THAT TARGETS THAT ABNORMALITY



*NCI-Molecular Analysis for Therapy Choice

Molecular Analysis for Therapy Choice (NCI-MATCH): A Novel Clinical Trial


Recently, the ability to assess hundreds to thousands of genomic variants in a single next-generation sequencing assay, together with gene sequencing data from The Cancer Genome Atlas (TCGA) and the development of treatment protocols that target cancer-specific molecular abnormalities, has contributed significantly to realizing the promise of precision medicine in oncology. Although various drugs have received Food and Drug Administration (FDA) approval for the treatment of specific mutations in certain cancers, it is less clear whether the same drug will be efficacious in tumors of different histologic type bearing the same mutation.

The goal of NCI-MATCH is to provide clinical evidence that a drug targeting a particular molecular profile may also be effective in the treatment of more than one tumor type. NCI-MATCH is a unique master protocol of phase II clinical trials, each of which targets a particular molecular profile for eligibility, rather than the histology of a particular tumor (e.g., lung, breast, colon or prostate cancer). As a master protocol, these phase II trials, or arms, are planned to be completed at different times, and new “arms” can be added when evidence suggests that a given drug or investigational agent or combination of agents has efficacy against tumors with a particular molecular profile. Initial stages of NCI-MATCH will include 10 arms. Each arm will enroll adults 18 years of age or older with advanced solid tumors or lymphomas that are no longer responsive to standard treatment and have begun to grow. All patients will have a tumor biopsy taken at trial entry. Biopsy specimens will be sent to one of four genetic testing CLIA-certified laboratories where they will be analyzed using next-generation sequencing for more than 4,000 variants (mutations, amplifications, rearrangements, and translocations) from 143 cancer genes.

NCI-MATCH is the most rigorous and complex trial to be performed in the NCI’s National Clinical Trial Network (NCTN). The trial is coordinated by the ECOG-ACRIN Cancer Research Group in concert with the three other adult NCTN groups (Alliance for Clinical Trials in Oncology, NRG Oncology Group, and SWOG) and the NCI Community Oncology Research Program (NCORP). The combined networks currently consist of approximately 2,400 clinical sites; therefore, patients may not need to travel far from their home to participate in the trial. Scientific expertise from NCI-Designated Cancer Centers and the NCTN groups will be employed to ascertain that treatments in NCI-MATCH and the gene variants used for eligibility meet inclusion criteria. Either single drugs (FDA approved or investigational) or combinations with a defined safe dose are eligible, provided that they have been shown to shrink tumors that have the particular molecular abnormality. For a given genomic variant to be “actionable” for NCI-MATCH, it must either be the subject of a companion diagnostic test, been shown to be associated with tumor shrinkage in patients whose tumors carry the abnormality, or have high-level preclinical evidence (model systems) that the variant can predict for drug efficacy.

NCI-MATCH is part of a portfolio of precision medicine clinical trials launched with NCI support that includes ALCHEMIST (a trial for patients with lung cancer removed by surgery) and Lung-MAP (a trial using targeted treatment in patients with squamous lung cancer that has progressed after standard treatment). In these trials, additional correlative information is being sought, including data from broader sequencing studies that may help refine which patients are most likely to benefit from targeted treatment.

The Promise of Precision Oncology



References Cited:

- Conley BA and Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. *Semin Oncol*. 2014;41(3):297-9.
- Hyman DM, Puzanov I, Subbiah V, Faris JE, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. *N Engl J Med*. 2015;373(8):726-36.
- Kandath C, McLellan MD, Vandin F, Ye K, Niu G, Lu Ch, et al. Mutational landscape and significance across 12 major cancer types. *Nature*. 2013; 502: 333-9
- Kim ES, Herbst RS, Wistuba H, Lee JJ, Bumenschein GR Jr, Tsao A, et al. The BATTLE trial: Personalizing therapy for lung cancer. *Cancer Discov*. 2011;1:44-53.
- Mody RJ, Wu Y-M, Lonigro RJ, Cao X, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. *JAMA*. 2015;314(9):913-25.

Division of Extramural Activities Annual Report 2014

PRECISION MEDICINE: NCI-MATCH* CLINICAL TRIAL

EXPLORES TREATING PATIENTS BASED ON THE MOLECULAR PROFILES OF THEIR TUMORS

Precision Medicine

NCI-MATCH IS FOR ADULTS WITH:

- solid tumors (including rare tumors) and lymphomas
- tumors that no longer respond to standard treatment




~ 3,000 CANCER PATIENTS WILL BE SCREENED WITH A TUMOR BIOPSY




THE BIOPSIED TUMOR TISSUE WILL UNDERGO GENE SEQUENCING



GENE SEQUENCING WILL EXAMINE CHANGES (MUTATIONS, AMPLIFICATIONS, AND TRANSLOCATIONS) IN 143 GENES



PATIENTS WITH TUMORS THAT SHARE THE SAME GENETIC ABNORMALITY, REGARDLESS OF TUMOR TYPE, WILL RECEIVE THE DRUG THAT TARGETS THAT ABNORMALITY



*NCI-Molecular Analysis for Therapy Choice

Images and narrative are the courtesy of Dr. Barbara Conley, Associate Director of the Cancer Diagnosis Program (CDP) in the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI). The Precision Medicine: NCI-MATCH Clinical Trial illustration is modified from the “NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial” graphic (www.cancer.gov/nci-match). The Promise of Precision Oncology illustration is the courtesy of Dr. James Doroshow, Director, DCTD, NCI and Deputy Director, NCI.

Contents

Introduction	1
Overview of the Division of Extramural Activities	3
Special Activities in the Office of the Director, DEA	4
Program Coordination: A Resource for New Funding Initiatives	6
Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications	7
Peer Review — The Next Step	9
NCI Grant and RFA Funding	17
Supporting Peer Review Consultants	19
DEA's Role in Advisory Activities	21
Committee Management Activities	23
Portfolio Tracking and Analysis	25
Information Resources Management	29
Organizational Structure of the Division of Extramural Activities	32

Figures

Figure 1. Receipt and Referral of NCI Grant Applications, FY2010– 2014	7
Figure 2. DEA Review Workload, FY2010 – 2014	10
Figure 3. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed, FY2010 – 2014	12
Figure 4. Program Project (P01), SPORE, and Other Multi-Project Research Applications Reviewed, FY2010 – FY2014	13
Figure 5. Technology Initiatives Applications Reviewed, FY2010 – 2014	16
Figure 6. NCI Grant and RFA Funding Percentages by Concept Area, FY2013	17
Figure 7. NCI Grant and RFA Funding Percentages by Concept Area, FY2014	18
Figure 8. BSA-Approved RFA Concept Set-Asides by Division/Office/Center (DOC)	18
Figure 9. FY2014 Success Rates for Applications in High Incidence Cancers	27
Figure 10. FY2014 Success Rates for Applications in Selected Special Interest Categories	28

Tables

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2014, Sorted by Date of Publication	45
Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2014, Sorted by Division, Office, and Center	46
Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2014, Sorted by Date of Publication	47
Table 3a. Program Announcements (PAs) Published by the NCI in FY2014, Sorted by Date of Publication	49
Table 3b. Program Announcements (PAs) Published by the NCI in FY2014, Sorted by Division, Office, and Center	50
Table 4. NCI Participation in Trans-NIH Program Announcements (PAs/PARs) in FY2014, Sorted by Date of Publication	51
Table 5. Applications Received for Referral by the NCI/DEA in FY2014, Sorted by Mechanism	54
Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2014, Sorted by Mechanism	56

Table 7.	Applications Reviewed by NCI Initial Review Group (IRG) Subcommittees and Special Emphasis Panels (SEPs) in FY2014	57
Table 8.	Summary of Investigator-Initiated Program Project (P01) Applications Reviewed in FY2014	57
Table 9.	Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2014	57
Table 10.	Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2014.	58
Table 11.	Program Announcements (PAs) Reviewed by the NCI/DEA in FY2014	60
Table 12.	Requests for Proposals (RFPs) Reviewed by the NCI/DEA in FY2014	63
Table 13.	Summary of NCI Grant Awards by Mechanism in FY2014	64
Table 14.	Average Total Cost and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2010 – FY2014	66
Table 15.	NCI Organ and Related Site-Specific Dollars for FY2010 – FY2014 – Annual Percent Change	69
Table 16.	NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change	77
Table 17.	NCI Funding of Foreign Research Grants in FY2014.	97
Table 18.	Foreign Components of U.S. Domestic Research Grants in FY2014	100

Appendixes

Appendix A:	Activities of the National Cancer Advisory Board (NCAB)	102
Appendix B:	Activities of the Board of Scientific Advisors (BSA)	103
Appendix C:	List of Chartered Committees	104
Appendix D:	NCI Initial Review Group Consultants	116
Appendix E:	NCI Grant Mechanisms and Descriptions	170
Appendix F:	Glossary of Acronyms	182
Appendix G:	Cancer Information Sources on the Internet	184

Introduction



The Division of Extramural Activities (DEA) is the organizational component of the National Cancer Institute (NCI) responsible for coordinating the scientific review of extramural research before funding and for conducting systematic surveillance of that research after funding. The Division solicits advice from individuals and/or committees of experts on the technical and scientific merit of grants, cooperative agreements, and contracts. The peer review process is critically important to science in that it allows good ideas to surface and be evaluated based on their merit and promise. The peer review system is the keystone for ensuring that the best science is supported.

DEA coordinates the activities of: (1) the National Cancer Advisory Board (NCAB), which consists of members appointed by the President, conducts the second-level review of grants and cooperative agreements and advises the Director, NCI, on policy for the conduct of the National Cancer Program; (2) the Board of Scientific Advisors (BSA), which is composed of distinguished scientists from outside the NCI and representatives from the advocacy community who advise the NCI leadership on the progress and future direction of the NCI extramural program, evaluates NCI extramural programs, and reviews NCI-initiated research concepts; and (3) extramural training opportunities for NCI Program and Review staff.

As a Division, we evaluate the content of all extramural research funded by the NCI and annually track the NCI research portfolio of more than 8,000 research and training awards by using consistent budget-linked scientific information to provide a basis for budget projections; maintain extensive records of this research and provide specialized


analyses of the costs, goals, and accomplishments of the research; and serve as an NCI resource to others for reporting and dissemination of the NCI's research portfolio. DEA monitors budgetary limitations for grant applications; participates in establishing policies to expedite funding; and initiates and implements changes to applications, guidelines, and award processes. The Division also coordinates the review and response to appeals from applicants regarding the peer review process or the subsequent disposition and management of grants, cooperative agreements, and contracts; and responds to and coordinates requests from the NIH Office of Extramural Research's Agency Extramural Research Integrity Officer (RIO) for information and assistance regarding scientists (or institutions) supported by NCI research funds who were the subject of allegations, inquiries, and/or investigations of possible research misconduct.

The intent of this annual report is to provide insight and useful information about the research funding process and the role of DEA in support of NCI's mission. A comprehensive look at each of the major areas of responsibility within the Division is provided. The data presented cover Fiscal Year (FY) 2014 (1 October 2013 - 30 September 2014) and provide data comparison with previous years.

To implement a biomedical research program of the highest quality, the NCI draws on the national pool of scientists actively engaged in research for assistance in selecting the best research and training projects. We sincerely want to thank the more than 2,400 researchers, clinicians, and advocates who gave unselfishly of their time in FY2014 and have contributed to the continuing success of NCI's peer review and advisory activities.

Paulette S. Gray, Ph.D.
Director
Division of Extramural Activities

Division of Extramural Activities



Overview of the Division of Extramural Activities

The paramount goal of the National Cancer Institute (NCI) is to develop the knowledge base that will ultimately lessen the impact of cancer. Among the most important contributors to this base are the outstanding extramurally funded scientists supported by the NCI through grants, contracts, and cooperative agreements. The DEA was established within the NCI to provide the Institute and the scientific community with expert scientific review of the merits of extramural research. An important part of DEA's mission is to manage and coordinate the second level of grant review by the National Cancer Advisory Board (NCAB); concept review of all new and reissued Requests for Applications (RFAs) and Research and Development (R&D) Requests for Proposals (RFPs) by the Board of Scientific Advisors (BSA), and activities of the Frederick National Laboratory Advisory Committee (FNLAC), which reviews the state of research at the Frederick National Laboratory of Cancer Research (FNLRC).

The **Committee Management Office (CMO)** provides oversight of all NCI-chartered advisory boards and committees, working groups, task forces, and chartered review groups. The CMO also serves as an NIH service center for the National Institutes of Health (NIH), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the NIH Council of Councils (CoC). The CMO provides policy guidance and assistance to ensure that the NCI and client HHS/NIH Institutes, Centers, and Offices operate within the appropriate Federal Advisory Committee Act (FACA), the Government in Sunshine Act, and various other policies, procedures, and guidelines.

The DEA also provides effective and timely coordination of program initiatives from the initial concept stage through publication of RFAs, Program Announcements (PAs), RFPs, Notices, and, finally, the peer review of grant and cooperative agreement applications and contract proposals. The **Office of Referral, Review, and Program Coordination (ORRPC)**, which consists of four review branches and a program coordination and referral branch, provides: (1) coordination of the development and issuance of NCI program initiatives; (2) execution of grant receipt and referral; and (3) management of NCI peer review activities. Review

activities include the organization and management of peer review for all applications and proposals received in response to RFAs, PAs, PAs with Special Receipt (PARs), complex, multi-component grant and cooperative agreement initiatives, and R&D RFPs. The program coordination responsibilities of the DEA, in cooperation with NCI extramural program Divisions, Offices, and Centers, extend to the development of all new extramural program guidelines and funding opportunity announcements (FOAs).

Another program coordination activity is the development and maintenance of referral guidelines for assignment of grant applications to the NCI. These guidelines, included in the *Referral Guidelines for Funding Components of PHS*, are critical to the development of program initiatives across the NIH, as well as the prompt referral of unsolicited grant applications to the NCI. These guidelines differ from the NCI Internal Referral Guidelines, which are vital to the prompt referral of grant applications to the appropriate NCI program areas.

The **Research Analysis and Evaluation Branch (RAEB)** works closely with the NCI Office of Budget and Finance (OBF) to provide budget-linked portfolio data for NCI grants, cooperative agreements, and contracts. In doing so, the Institute has the capability of responding expeditiously to congressional and other inquiries. RAEB has historical budget-linked portfolio data that go back to the 1930s.

The DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as possible to NCI staff, advisory groups, and applicants. To facilitate this evaluation, the DEA **Office of Extramural Applications (OEA)**, through the **Applied Information Systems Branch (AISB)**, maintains a Web-based information system to provide key information on new initiatives. This Web-based information system includes early notice of approved concepts, listings of active PAs and recently published RFAs, and policies related to the clearance of new program initiatives. This information is provided in both public accessible Internet (<http://deainfo.nci.nih.gov/funding.htm>) and NCI limited-access Intranet versions.

Special Activities in the Office of the Director, DEA

In addition to managing and coordinating the extramural operations described in this report, the DEA Office of the Director (OD) is a focal point and repository of information and policies related to various funding mechanisms for NIH grants, staff and awardee responsibilities, eligibility requirements, receipt dates for all granting mechanisms, and special programs. The DEA OD ensures that NCI meets the congressional mandate to promote increased participation of women, children, and members of minority and medically underserved populations in the research areas of cancer cause, prevention, control, diagnosis, and treatment. The NIH Revitalization Act of 1993 mandates that women and members of minority groups be included as subjects in each research project, unless there are clear scientific or ethical reasons that inclusion is inappropriate with respect to the health of the subject or the purpose of the research. In 1998, an NIH inclusion policy was implemented requiring applicants and grantees to include children (as defined as an individual less than 21 years of age) in clinical research, unless there is strong justification for their exclusion. Administrative procedures allow NCI staff to resolve inclusion problems after initial review of grant applications that are otherwise highly meritorious. In the event that an applicant believes the proposed study does not warrant or require inclusion of women, children, or persons from minority or medically underserved population groups, he or she can apply for a waiver of this requirement. The DEA Director is the Appeals Officer for the NCI and has the authority to grant waivers. In FY2014, 26 applications with preliminary bars to award were received by the DEA. Through corrective action, working with the applicants and program directors, all bars to award were brought into compliance before awards were made.

Additionally, the DEA Director serves as the locus for implementation and oversight of NCI policies concerning extramural research integrity and serves as a resource to all NCI staff with questions in this area. In this role, the DEA Director and designees work to address concerns about extramural research misconduct, misuse of human and animal research subjects, financial mismanagement, and financial conflict of interest involving NCI-supported research. The DEA Director functions as the NCI Research Integrity Officer (RIO) and receives from the appropriate sources all documents related to research misconduct for transmittal and reporting to relevant sources. In FY2014, 12 cases of alleged research misconduct involving NCI funding were opened and under investigation by the Office of Research Integrity, HHS, and referred to the Director, DEA. Six cases were closed, three cases were found to involve research misconduct, and three cases are currently under investigation.*

Extramural Staff Training

Program and Review Extramural Staff Training Office (PRESTO)

The Program and Review Extramural Staff Training Office (PRESTO), which resides in the DEA OD, develops and coordinates the training of Program, Review, and other extramural staff. The mission of PRESTO is to increase the knowledge base of new and experienced staff members and optimize their effectiveness in supporting the goals of the NCI. To accomplish this mission, PRESTO: (1) designs and implements a broad-based curriculum for Program and Review staff; (2) provides training on specialized topics related to understanding of and compliance with NIH policies;

*Cases found to involve research misconduct are published in the *Federal Register* and *NIH Guide for Grants and Contracts*.

and (3) identifies and develops resources to facilitate individual learning and performance. Finally, PRESTO tracks the participation of extramural staff in NIH- and NCI-sponsored training activities as well as continuously evaluates the efficacy of these activities.

During FY2014, PRESTO activities included:

- Development and implementation of the Program Official (PO) Basic Training Series, which provides basic training to new program officials with 3 years or less experience as a PO. The series included seven sessions over a 3-week period. The topics included receipt and referral, Funding Opportunity Announcement (FOA) development, PO and principal investigator interactions, the peer review process, pre and post award activities, and commonly used electronic tools. PRESTO plans to provide the PO Basic Training Series every year.
- Production of recorded PRESTO-sponsored training sessions that have been posted on the PRESTO website for employees' use if they were unable to attend in person.
- Organization of forums on core administrative responsibilities, including those related

to Electronic Systems, Human Subjects Protection, Inclusion Policy, and the Inclusion Management System.

- Coordination of State-of-the-Science forums on Complementary and Alternative Medicine: The Interface between Worlds of Clinical Practice and Cancer Research, Big Data: Emerging Practice in Cancer Research, NCI Cancer Clinical Trials Network, and High Risk and High Impact Research Opportunities in Cancer Research: Common Fund.
- Continued enhancement of the PRESTO website (<http://deaintranet.nci.nih.gov/presto/index.htm>) on the DEA intranet.

During FY2015, PRESTO will continue to offer a variety of training opportunities for NCI extramural staff, including new Staff Assistants. PRESTO plans to launch a revamped website in the spring of 2015 that will provide improved access to NCI and NIH training resources. The NCI Scientific Review Officer Handbook also will be revised to increase its usability. Various information technology tools will be employed to enhance the effectiveness of PRESTO-sponsored training activities. PRESTO will develop trainings on new and emerging topics of broad interest to NCI extramural staff.

Program Coordination: A Resource for New Funding Initiatives

The DEA performs critical functions in the development of new strategic funding initiatives at the NCI and in the coordination of their publication as Funding Opportunity Announcements (FOAs), which comprise both RFAs and PAs. Members of the **Program Coordination and Referral Branch (PCRB)** provide expert assistance to NCI Program staff to develop and publish new (or reissue) FOAs. PCRB staff members disseminate various operating policies and procedures pertaining to extramural funding programs. To maintain consistency and completeness, all new and reissued NCI FOAs, Notices, and associated guidelines are reviewed, edited as needed, and cleared through the DEA, under PCRB coordination, before being forwarded to the NIH Office of Extramural Research (OER) for approval and publication in the *NIH Guide for Grants and Contracts* and on Grants.gov. In these steps, PCRB staff members help to streamline and clarify FOA technical parameters and requirements as well as optimize accuracy, precision, and clarity of their presentation in proper format. PCRB verifies consistency with NIH-wide requirements, provides quality control, and coordinates timelines throughout the development and publication processes. Overall, these services ensure the high quality and timely availability of NCI's funding opportunities for cancer researchers as prospective applicants.

Tables 1a and **1b** show the variety of RFAs issued by the NCI in FY2014, and **Table 2** lists RFAs

issued by other NIH Institutes or Centers (ICs) that the NCI has joined as a participating partner. **Tables 3a** and **3b** show the variety of PAs issued by the NCI in FY2014, and **Table 4** lists PAs issued by other NIH ICs that the NCI has joined as a participating partner.


PCRB staff members continue to provide relevant information and timely updates to all NCI extramural staff members on activities and results related to the requirements for and uses of electronic grant applications. The Branch also serves as a direct source of guidance on this topic for program officials at the NCI and applicants in the extramural scientific community. Staff members in the Referral Office (RO) in PCRB collaborated with NCI information technology staff members and their contractors to successfully develop and deploy an improved Web-based Awaiting Receipt of Application (ARA) management system (permission for special application receipts), which contributes to an improved efficiency of use by NCI staff members and quality of service for the NCI's grant applicants and awardees. In addition to performing their program coordination and referral responsibilities, PCRB Health Scientist Administrators also served as Scientific Review Officers (SROs) in managing the reviews of 348 student loan repayment program (LRP) contract proposals in FY2014 (**Table 12**).

Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications

In FY2014, a total of 13,988 grant and cooperative agreement applications were submitted to the NCI for funding with appropriated funds (see Figure 1 and Table 5). Applications encompassed 51 different types of award mechanisms (Appendix E), including investigator-initiated Research Project (R01), Career Development (K series), Research Program Project (P01), Cancer Center Support (P30), Specialized Program of Research Excellence (SPORE, P50), Small Research Project (R03), Exploratory/Developmental Project (R21), Exploratory/Developmental Phase II Project (R33), Small Business Technology Transfer (STTR) (R41/R42), Small Business Innovation Research (SBIR) (R43/R44), and Cooperative Agreement (U-series) activity codes.

All applications seeking NIH support are initially submitted to the NIH Center for Scientific Review (CSR) Division of Receipt and Referral (DRR), which assigns each application to a specific NIH funding Institute or Center (IC) and the locus of review for the application (i.e., either to a CSR Study Section or within a specific IC). The ICs, in turn, have well-defined processes in place for the internal assignment and review of submitted applications. Upon receipt of applications from CSR, the NCI Referral Officers (ROs) in PCRB: (1) assign all incoming applications to one of the 50 NCI extramural research program areas; (2) track program acceptance of the applications; and (3) if necessary, negotiate transfers of grant applications to and from the NCI to other NIH

**Figure 1. Receipt and Referral of NCI Grant Applications
FY2010 – 2014**



*Includes NCI Primary and Secondary applications received and referred.

ICs and even other HHS research funding agencies, such as the Agency for Healthcare Research and Quality (AHRQ), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).

The first point of contact for applicants seeking NCI support for their research is often a PCRB RO who provides the investigators with information related to funding opportunities, peer review policies and process, and contact information of an NCI Program staff member who can provide guidance through the application process. In addition, the RO assists members of the extramural community in navigating NIH and NCI Web pages to obtain current information, forms, and guidelines. PCRB also is the information and coordinating center for the submission of applications for the Academic Research Enhancement Award (AREA, R15) grants for research at institutions and organizations that have little or no current NIH grant support.

For certain FOAs, in particular Program Projects and specialized initiatives, applicants are encouraged to submit a Letter of Intent (LOI) to the PCRB prior to the submission of their application. The LOI typically provides the name of the

contact principal investigator and other participating key investigators, a listing of the specific aims and a brief description of the research, an approximate cost and years to be requested, and any additional information requested in the FOA. In most instances, the LOI is not mandatory or binding, but provides the Institute with an estimate of the number of applications that might be submitted in response to a specific FOA.

All applications requesting \$500,000 or more in direct costs in any year require prior agreement by NIH staff to accept the assignment of that application to that IC unless stated otherwise in the FOA. This is accomplished by the applicant contacting Program staff well in advance of the anticipated submission date. If the Program agrees to accept the application, the Program must submit an Awaiting Receipt of Applications (ARA) form to CSR DRR. The ARA form also facilitates requests for assignments from ICs and other information that needs to be connected to a specific application. For additional guidance on this process, refer to NOT-OD-02-004 "Revised Policy on the Acceptance for Review of Unsolicited Applications That Request \$500,000 or More in Direct Costs."

Peer Review—The Next Step

Once an application is referred to the NCI and the appropriate program, it must be reviewed. The high caliber of NCI-sponsored research is maintained through a rigorous peer review process in which established experts in the appropriate scientific fields review and evaluate the scientific and technical merit of research grant applications, cooperative agreements, and contract proposals. The peer review process helps to ensure that the NCI uses its resources wisely and supports highly meritorious research that has the potential to make a significant contribution and impact in science and medicine. The NCI's extramural programs and activities are funded primarily through peer reviewed grants and cooperative agreements. Programs that are funded through research and development (R&D) contracts also are subject to peer review, including contract-supported projects conducted within the intramural research program.

The NIH peer review system consists of two sequential levels of review mandated by statute and regulation. The first level of review is managed by Scientific Review Officers (SROs) who serve as the Designated Federal Officer (DFO) and are conducted in either an NIH CSR study section, a chartered NCI Initial Review Group (IRG), or an NCI Special Emphasis Panel (SEP). The purpose of this initial review is to evaluate the scientific and technical merit, protection of human subjects, inclusion plans, animal welfare, and budget and/or administrative issues of the applications or cooperative agreements under review. The second level of review, which is not a re-review of scientific merit but a validation of the initial review and an evaluation of program relevance, is conducted by the National Cancer Advisory Board (NCAB).

Most investigators are familiar with the functions of an NIH CSR study section, which has the primary responsibility for the peer review of most investigator-initiated Research Program Grants (RPGs) (R01) and Fellowship (F) applications. What is less widely known, however, is that grant applications requesting more than 50 percent of

the NCI's overall extramural budget are reviewed by chartered NCI IRGs and SEPs that are conducted within the DEA. The locus of the peer review, whether by the CSR or the DEA, is usually determined by the type of grant mechanism of the application under review.

Although the NCI has no direct input into the selection of CSR study section reviewers, members of NCI IRGs and SEPs are selected by DEA Review staff, with suggestions from NCI Program staff. NCI IRGs and SEPs provide advice on the scientific and technical merit of applications for research, research training, education, and career development; cooperative agreements; and contract proposals relating to scientific areas relevant to cancer.

All chartered IRG Subcommittee members are approved by the Director, DEA, based on their knowledge and demonstrated expertise in various disciplines and fields related to cancer. The NCI currently has four specialized IRG Subcommittees. Subcommittee A reviews Cancer Center Support grant (CCSG) applications. Subcommittee F reviews Institutional Training and Education applications. Subcommittee I reviews Transition to Independence applications, and Subcommittee J reviews Career Development applications. NCI IRG members are appointed for varying terms of service, which may be up to 6 years. DEA SEPs are selected *ad hoc* on a one-time, as-needed basis to review specific grant and cooperative agreement applications received in response to RFAs, PAs, PARs, other specialized applications, or R&D contract proposals received in response to RFPs.

The peer review of grant applications and contract proposals generally occurs in the fall, winter, and spring prior to the January, May, and October NCAB meetings, respectively. The membership of NCI-chartered subcommittees may be found in [Appendix C](#) and at <http://deainfo.nci.nih.gov/advisory/irg/irg.htm>, and information about NCI SEPs can be accessed at <http://deainfo.nci.nih.gov/advisory/sep/sep.htm>.

Review Workload


In FY2014, DEA organized, managed, and reported the review of a total of 4,795 research grant and cooperative agreement applications (Table 6) and 512 contract proposals (Table 12) assigned to the NCI for funding with appropriated dollars. The total number of grant applications, cooperative agreements, and contract proposals reviewed in FY2014 was 5,307 (Figure 2). In addition, the DEA conducted 12 Cancer Center site visits, 12 IRG Subcommittee review meetings, 155 SEPs to review grant applications and contract proposals, and 51 other review-associated meetings, such as orientation teleconferences. Tables 7 and 12 provide a summary of the applications and proposals reviewed by NCI IRG Subcommittees and SEPs. Approximately 2,400 peer reviewers served on the NCI DEA-managed IRG Subcommittees, SEPs, and workgroups in FY2014 (see Appendixes C and D). Members were selected on the basis

of their demonstrated experience and expertise in relevant fields of biomedical research or their informed consumer perspectives.

Peer Review Functions

The Office of Referral, Review, and Program Coordination (ORRPC) is responsible for the coordination and management of the review of NCI grant applications, cooperative agreements, and contract proposals. ORRPC is composed of four review branches, a coordination and referral branch, and the Office of the Associate Director. The review branches are responsible for organizing, managing, and reporting the results of scientific peer review of grant and cooperative applications or proposals for a wide variety of grant mechanisms and topics. Reviews of grant applications are conducted by either one of four NCI IRG Subcommittees or by specially convened SEPs as shown in Table 7. Contract proposals and Small Business

**Figure 2. DEA Review Workload
FY2010 – 2014**



Innovation Research (SBIR) Special Topics are reviewed by SEPs as shown in [Table 12](#).

The **Resources and Training Review Branch (RTRB)** is primarily responsible for the peer review of multicomponent (*aka* “complex”) Cancer Center Support as well as single component Training, Education, and Career Development grant applications (see [Table 6](#)). The RTRB also has responsibility for the management of the four NCI IRG Subcommittees (see [Appendix D](#)).

The **Research Programs Review Branch (RPRB)** has primary responsibility for review of unsolicited multicomponent Program Project (P01) and Special Program of Research Excellence (SPORE) (P50) translational research applications focused on various disease sites.

In February 2014, as a result of significant increases in the total number of research and special initiative applications received by DEA for review, the previous **Special Review Logistics Branch (SRLB)** was reorganized and split into two new review branches, the **Special Review Branch (SRB)** and the **Research Technology and Contract Review Branch (RTCRB)**. The SRB is primarily responsible for the peer review of grant applications submitted in response to NCI issued RFAs (e.g., NCI Provocative Questions) and PAs/PARs (e.g., NCI Omnibus R03/R21) as well as other special initiatives. The RTCRB is primarily responsible for the peer review of Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) grant applications and Special Topics, technology-related applications, and R&D contract proposals submitted in response to Request for Proposals (RFPs). All review meetings managed by SRB and RTCRB are conducted using SEPs.

Resources and Training Review Branch (RTRB)

The RTRB has primary responsibility for review of Cancer Center Support, Training and Education, and Career Development applications. RTRB is also responsible for the management of the four NCI IRG Subcommittees A, F, I, and J ([Appendix D](#)).

The review of Cancer Center Support Grant (CCSG) applications involves a two-tier initial

peer review process. Normally, the first tier of the review involves a site visit to the applicant institution by a non-FACA working group review panel. The site visit reviewers serve as a fact-finding body of experts to obtain updated information and/or clarification of any issues identified in the written application through an onsite face-to-face discussion with the Cancer Center investigators with focus on addressing CCSG-specific review criteria, thereby enhancing the review process. The site visit committee prepares a site visit review report that is presented, along with the written CCSG application, to the NCI IRG Subcommittee A for discussion, evaluation, and final impact scoring of the application. Final scoring by Subcommittee A provides a more uniform evaluation of individual CCSG applications than scoring based solely on the initial site visit review group. In FY2014, new guidelines were implemented in which Cancer Centers may elect not to have a site visit. In this case, the review will be based only on the information provided in the written application (i.e., “paper” review) with final evaluation and impact scoring by NCI Subcommittee A. During FY2014, Subcommittee A reviewed 12 CCSG applications.


Training and Career Development (CD)

Career Development and Training and Education grant applications are reviewed by IRG Subcommittees F, I, and J. The number of CD applications decreased slightly from 474 in 2010 to 438 in 2011, stabilized in 2012, and increased to 527 in 2014. The number of Training and Education grant applications has remained fairly constant from 2010 (157) to 2013 (141) with a slight decrease to 107 applications in 2014 ([Figure 3](#)).

NCI Community Oncology Research Program (NCORP)

Late in 2012, the NCI initiated efforts to develop a national network of investigators, cancer care providers, academic institutions, and other health-related organizations for the conduct of multi-site cancer clinical trials and studies in diverse populations with the establishment of the NCI Community Oncology Research Program (NCORP). NCORP integrated two prior networks:

Figure 3. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed FY2010 – 2014



the NCI Community Clinical Oncology Program (Community Clinical Oncology Programs and Minority-Based CCOP, Research Bases), and NCI Community Cancer Centers Program (NCCCP) for the conduct of clinical research in the community setting. The goal of NCORP is to facilitate the design and conduct of clinical trials to improve cancer prevention, cancer control, screening for early cancers, and post-treatment surveillance; and the delivery of cancer care and performance of comparative effectiveness research. In addition, NCORP seeks to facilitate access to treatment and imaging trials conducted by the National Clinical Trials Network (NCTN). In November 2013, three FOAs were issued soliciting cooperative agreement applications for NCORP Research Bases; Community Sites; and Minority/Underserved Community Sites. In April of FY2014, the DEA received and reviewed 76 applications for 10 (7 single project UG1 and 3 complex structure UM1) Research

Bases, 45 (34 UG1 and 11 UM1) Community Sites, and 21 (12 UG1 and 9 UM1) Minority/Underserved Community Sites.

Other RTRB Activities

To assist reviewers in their participation for RTRB peer review, Reviewer Guides are maintained for all of the different types of applications reviewed by the RTRB. Reviewer Guides were updated for the newly reissued FOAs and for the electronic submission of grant applications. Reviewer Guides also contain general information on peer review and NIH policies regarding the use of human subjects in research, as well as specific instructions for each of the mechanisms to be reviewed. These mechanism-specific guides have been completed for all Training, Education, and Career Development and Cancer Center Support applications. This resource is especially helpful for IRG Subcommittee members who often participate in the

review of single component Training, Education, and Career Development grant applications or multicomponent CCSG grant applications, each with their own specific review criteria.


Research Programs Review Branch (RPRB)

Program Project (P01) Applications

A significant effort of RPRB during FY2014 was the review of unsolicited multicomponent Program Project (P01) applications. P01 applications are typically reviewed using a one-tier, “paper only” review process. The applications are grouped based on their scientific focus and typically clustered into three to four groups of up to 10 applications each. The groupings vary depending on the number of applications received and the science proposed. The applications often represent a continuum of research from basic through translational to pre-clinical and clinical studies. All P01 review panels are constituted as SEPs, with reviewers recruited

based on the scientific expertise needed for the applications being reviewed. The SEP review committees evaluate the technical and scientific merit of the individual projects and supporting core resource facilities, determine the level of program integration and leadership, and then assign an overall impact score to each application. During FY2014, RPRB managed the review of 57 new, renewal (competing), resubmitted (amended), and revised (competitive supplement) P01 applications (Figure 4 and Table 8). Twenty-three (40%) of the applications proposed new multidisciplinary research programs, 13 (23%) of the applications were amended (Table 8), and 10 (17%) included multiple Principal Investigators (PIs). Twenty-eight (49%) of the 57 applications were referred to NCI’s Division of Cancer Treatment and Diagnosis (DCTD) (see Table 9). The 57 applications requested \$121,582,570 in total costs for the first year (see Table 9) and \$617,087,370 in total costs for 5 years.

Figure 4. P01, SPORE, and Other Multi-Project Research Applications Reviewed FY2010 – 2014



Specialized Programs of Research Excellence (SPORE, P50)

Another major responsibility of RPRB is the review of NCI Specialized Programs of Research Excellence (SPORE) P50 applications. These complex, multidisciplinary translational applications focus on research directly applicable to human disease in various organ sites. In FY2014, RPRB organized and managed six SEPs for the review of 40 SPORE applications (Figure 4). The applications addressed multiple organ sites, with the following distribution of applications: Brain (3); Breast (5); Cervical (1); Endometrial (1); Gastrointestinal (2); Head and Neck (3); Kidney (2); Leukemia (1); Lymphoma (3); Lung (6); Mesothelioma (1); Myeloma (1); Ovarian (2); Pancreas (3); Prostate (4); Skin (1); and Thyroid (1). Overall, 24 (60%) of the 40 applications were submitted for new SPOREs, and 16 (40%) were renewal applications. The disease sites addressed in the SPORE applications vary from round to round. Nine applications addressing four different disease sites were reviewed for the January 2014 NCAB cycle, 26 applications addressing 15 disease sites were reviewed for the May 2014 NCAB cycle, and five applications addressing four disease sites were reviewed for the October 2014 NCAB meeting. The applications requested \$100,074,110 in total costs for the first year of support and \$496,484,706 in total costs for 5 years.

Potential applicants for P01 and P50 grant submissions are strongly encouraged to participate in a pre-submission conference with the appropriate NCI Program and DEA Review staff members so that they can fully understand the guidelines, requirements, and goals of these complex applications. SROs from RPRB routinely participate in these pre-submission conferences to assist the applicants in the application formatting requirements, the review process, the special review criteria, and the scoring paradigms for these applications.

Special Review Branch (SRB)

The SRB organizes and manages the peer review of applications submitted in response to NCI-issued RFAs, PAs, and PARs. Following approval of RFA

concepts by the NCI Scientific Program Leaders (SPL) and the Board of Scientific Advisors (BSA), Program staff prepares RFAs for publication in the *NIH Guide for Grants and Contracts*. DEA PCR staff, including DEA SROs, assist in critically reading the draft documents and in providing recommendations for clarity relative to application requirements and review criteria. In an RFA, a specific, published dollar amount is set aside by the Institute, whereas for a PA/PAR, there is no dollar set-aside and no requirement for BSA review. Table 10 summarizes the number of applications submitted for the RFAs and Table 11 summarizes the number of applications submitted in response to PAs or PARs and reviewed by DEA. During FY2014, the DEA reviewed a total of 4,795 applications received in response to 43 RFAs (1,216 applications) (Table 10) and 62 PAs/PARs (3,579 applications) (Table 11). The review of these applications was conducted by SEPs and involved the recruitment of scientists with the appropriate expertise for each review meeting.

Research Answers to NCI's Provocative Questions (PQ)

Following input from the scientific community through focus groups, forums, and online postings, 28 perplexing scientific questions were identified and grouped, 4-6 questions each, into five thematic cancer areas: Cancer Prevention and Risk (Group A); Mechanisms of Tumor Development or Recurrence (Group B); Tumor Detection, Diagnosis, and Prognosis (Group C); Cancer Therapy and Outcomes (Group D); and Clinical Effectiveness (Group E). There were 371 R01 Research Project application and 231 R21 Exploratory/Developmental applications submitted in response to 18 RFAs (Table 10). Applications were peer reviewed in nine face-to-face SEP review meetings to assess the scientific and technical merit and assign a final impact score to each application.

Exploratory/Developmental Research

In FY2014, the DEA reviewed 1,945 R21 applications submitted for the NCI Omnibus Exploratory/Developmental Research Grant Program (Table 11). The applications are initially grouped based on

their scientific focus and typically reviewed in 11 to 14 SEPs. The groupings varied depending on the number of applications received and the science proposed. The applications represent a continuum of research from basic through translational to preclinical and clinical studies. The Omnibus applications were reviewed in a total of 38 SEPs over the three review cycles.

Small Grant Programs

Several small grant (R03) PAR program initiatives in the areas of cancer prevention (PAR11-079), cancer epidemiology (PAR12-039), and NCI Omnibus R03 for cancer research (PAR12-144 and PAR14-007) stimulated increased interest in the applicant community. In FY2014, 625 applications were submitted and reviewed by the DEA in response to these initiatives.

Research Technology and Contract Review Branch (RTCRB)

The RTCRB organizes and manages the peer review of SBIR/STTR applications and Special Topics, technology-related applications, and R&D contract proposals submitted in response to RFPs.

SBIR/STTR and Technology Research Applications

The SBIR program supports Phase I feasibility applications (R43), Phase II applications (R44), and Fast-Track applications (R43/R44). In 2009, the first issued SBIR Phase II Bridge Award RFA was designed to “bridge the gap” between the end of the Phase II award and commercial development. That program continued in FY2014 with the review of 12 R44 SBIR Phase II Bridge Award applications. The majority of technology research initiatives use the R21 Exploratory/Developmental award mechanism and the R33 Exploratory/Developmental Phase II award mechanism. The R21 mechanism is intended to encourage exploratory/developmental research by providing support for exploratory pilot projects in the early stages of project development. The R33 mechanism is suitable for projects where

“proof-of-principle” of the proposed technology or methodology already has been established and supportive preliminary data are available. Both of these mechanisms are well suited for technology development. In 2014, 276 technology applications (**Figure 5**) for Exploratory/Developmental grants (R21) and Exploratory /Developmental Phase II grants (R33) were reviewed for the Innovative Molecular Analysis Technologies (IMAT) for Cancer Research program (RFA-CA14-003 [R21] and RFA CA14-004 [R33]) as well as the Innovative Technologies for Biospecimen Science program (RFA-CA14-005 [R21] and RFA CA14-006 [R33]).


Research and Development (R&D) Contract Proposals

In FY2014, RTCRB received and reviewed 512 contract proposals, including 348 Loan Repayment L30 and L40 proposals, in response to 20 RFPs (**Table 12**). During review, specific elements of each proposal are individually evaluated and scored, with the combined score indicating the overall merit. After negotiations, contract awards are made for the RFP solicitation. Phase II SBIR proposals are submitted to Topics and are openly announced in a Broad Agency Agreement Announcement.

Other RTCRB Activities

In FY2014, RTCRB participated in the critical reading and editing of pre-publication drafts for Funding Opportunity Announcements (PAs, PARs, RFAs) and research contract acquisition plans that are published as Requests for Proposals (RFPs), and were a part of presentations to prospective applicants during pre-application webinars and teleconferences. Members of the branch also assisted in the review of applications for initiatives that were coordinated by the SRB, including the NCI Provocative Questions Initiative, the NCI Omnibus Exploratory (R21) Grant program, and the Small Grant (R03) program.

**Figure 5. Technology Initiatives Applications Reviewed*
FY2010 – 2014**



*Withdrawn applications are not included.

NCI Grant and RFA Funding


The Board of Scientific Advisors (BSA) is responsible for advising the NCI Director on the extramural program and the future direction and funding of each Division's extramural research. As such, the BSA provides concept review for NCI-sponsored RFAs. **Figures 6 and 7** show total NCI Grant and RFA funding according to scientific concept area in FY2013 and FY2014. **Figure 8** shows RFA concepts that the BSA approved from FY2010 through FY2014 according to the sponsoring NCI Division, Office, and Center.

Table 13 presents a summary of total funding of NCI grant awards by mechanism for FY2014. In **Table 14**, a comparison is made of the average cost

and number of NCI R01, P01, R03, R13, R21, P30, P50, U01, U10/ U19, and U54 grants and cooperative agreements awarded in FY2010 through FY2014 according to the extramural Divisions, Offices, and Centers.


Trends in grant funding according to scientific discipline and organ site are provided in **Tables 15 and 16**. **Table 17** reports NCI's funding of foreign research grants in FY2014, and **Table 18** reports foreign components of U.S. domestic research grants in FY2014. **Note:** Some grant awards made during a fiscal year may have been for grant applications reviewed in a prior fiscal year.

Figure 6. NCI Grant and RFA Funding Percentages by Concept Area FY2013




Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants. Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 7. NCI Grant and RFA Funding Percentages by Concept Area FY2014



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants. Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 8. BSA-Approved RFA Concept Set-Asides by Division/Office/Center



Legend:

DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCP	Division of Cancer Prevention
DCEG	Division of Cancer Epidemiology and Genetics
DCTD	Division of Cancer Treatment and Diagnosis
OD	Office of the Director
OD-OCG	Office of the Director - Office of Cancer Genomics
OD-CRCHD	Office of the Director - Center to Reduce Cancer Health Disparities
OD-OHAM	Office of the Director - Office of HIV and AIDS Malignancy
OD-CSSI	Office of the Director - Center for Strategic Scientific Initiatives
OD-OBBR	Office of the Director - Office of Biorepositories and Biospecimen Research
OD-SBIRDC	Office of the Director - Small Business Innovation Research Development Center
TRANS-1	NCI (DCCPS, DCB), Trans-NIH
TRANS-2	NCI (DCCPS, DCP), Trans-NIH

* Indicates co-funding among NCI Divisions/Offices/Centers.

Supporting Peer Review Consultants

Ensuring that highly qualified individuals are available for expert review of grant applications and contract proposals requires an efficient administrative support system. The DEA's **Scientific Review and Evaluation Activities (SREA)** unit, residing within the NCI **Committee Management Office (CMO)**, supports the NCI peer review process by compensating consultants for their services on the NCI IRG Subcommittees and SEPs and by reimbursing them for their travel and other expenses (**Appendixes C and D**). The SREA staff also approves and/or processes payments for other activities related to review, including hotel contracts, teleconferencing services, and contract-supported ticketing services.

The NCI SREA unit is a multi-million dollar management program. SREA staff members oversee the successful reconciliation of peer review costs charged against the SREA account, identify erroneous charges, and maintain an extensive tracking system of all costs related to approximately 179 peer review associated meetings to successfully manage the budget. CMO is able to provide the DEA Director with a clear picture of funds spent against the SREA budget throughout the year to ensure sufficient funds are available to cover all NCI peer review activities.

On October 1, 2013, the U.S. Federal Government shut down for 16 days, due to the absence of either an FY 2014 appropriation or a Continuing Resolution for the Department of Health and Human Services (HHS). This had a significant impact on NCI DEA. During this period, 16 peer review meetings were cancelled and the DEA was responsible for contacting consultants participating in each peer review meeting and alerting them that meetings were cancelled, contacting hotels to cancel lodging and meeting space and contacting World Travel Service (WTS) to cancel consultant travel arrangements. Immediately upon the reopening of the Federal Government, SREA provided SROs with guidance on what was required for amending and renegotiating hotel contracts,

Federal Register Notices, and consultant travel for their rescheduled meetings. SROs faced unfamiliar situations with amendments of their hotel contracts. Factors included (1) need for a change in the location due to unavailable lodging and meeting space for the rescheduled meeting date(s); (2) change in U.S. General Services Administration (GSA) *per diem* rate for lodging due to meeting(s) being held in a different month; (3) prior approved AEA Memos; and (4) decrease or increase in the number of meeting attendees. SREA worked closely with the DEA Director, Associate Director, ORRPC, SROs, and the Committee Management Officer to ensure the rescheduled review meetings were still held during the current review cycle and prior to the scheduled January 2014 Council Round to ensure that the original funding obligations were appropriately used and there was no interruption of NCI funding or stoppage of critical research efforts of external Investigators.

During FY2014, approximately 2,400 expert consultants were reimbursed honoraria and flat-rate payment for serving at more than 179 peer review meetings (**Appendix D**). The SREA staff works diligently to reimburse reviewers in a timely manner or contact those reviewers with an unpaid or returned reimbursement status. The SREA staff also assists reviewers in completing their Secure Payee Registration System (SPRS) registration. Due to these proactive efforts by the SREA staff, only 20 out of the 3,737 (0.5%) instances of honoraria and flat-rate payments to NCI peer review consultants were not paid in FY2014.

Throughout the year, the SREA staff ensures the timely review and submission of hotel contracts for processing to secure lodging and meeting room space for face-to-face peer review meetings. In FY2014, 106 hotel contracts were processed by the SREA staff. The SREA also is responsible for ensuring all meeting logistic invoices (i.e., hotels, World Travel Service, and teleconference services charges) are accurate and valid before being processed for payment. All discrepancies

are immediately addressed with the appropriate vendor and a revised invoice is requested.

The CMO received and responded to several requests from the NIH Freedom of Information Act (FOIA) office. SREA staff was instrumental in the collection and review of one request that involved pulling approximately 601 rosters from the Committee Management IMPACII module and reviewing each to see if the roster met the criteria of the FOIA request. The SREA staff was able to complete this task in 14 calendar days.

The SREA staff collaborates with the Associate Director, ORRPC, NCI DEA Branch Chiefs, CMO, and SROs on the development of NCI SREA policies and procedures. On an ongoing basis, they monitor and evaluate current SREA activities and initiate changes and improvements when warranted.

In addition, CMO and SREA collaborates with the Program and Review Extramural Staff Training

Office (PRESTO) staff to ensure the training needs of DEA review and support staff are met for all aspects of CMO and SREA activities. SREA created new training materials and the following training sessions were conducted in FY2014:

- For Program Analysts (PAs) and Staff Assistants (SAs) – How to properly obtain, review, and process a BPA hotel contract for peer review meetings.
- For All Review Staff – How to prepare the Official Meeting File for FACA NCI peer review meetings.

All CMO and SREA documents related to peer review meeting activities are sent to PRESTO to be posted on the “NCI/DEA Peer Review Reference Guide for Staff Assistants” page on the PRESTO website. The documents are then utilized by NCI DEA SROs, PAs, and SAs. These training tools are imperative to the peer review process and the integrity of NCI’s mission.

DEA's Role in Advisory Activities

Beyond its central role in coordinating the referral of grants and peer review, perhaps the most far-reaching role that the DEA plays across the NCI is the coordination and administration of NCI's nine chartered Federal advisory committees ([Appendix C](#)). The memberships and activities of these advisory bodies are coordinated by the [Office of the Director](#), DEA, and the [Committee Management Office](#), DEA, in consultation with the [NCI Director](#). A primary responsibility of the DEA is coordination of the activities of the NCAB, whose members are appointed by the President and whose responsibilities include the second-level review of grant and cooperative agreement applications, as well as advising the NCI Director on policy for the conduct of the National Cancer Program. The DEA also coordinates administration of the BSA, the body responsible for the oversight and concept review of the extramural programs and initiatives of the NCI, and FNLAC, which reviews research activities of the FNLCR. Under the various chartered committees, working groups are formed to address and make recommendations on important areas of cancer research related to basic research, clinical trials, diverse populations, cancer advocacy, treatment, cancer control, drug development, prevention, communication, education, and so on. As such, the DEA plays a major role in the development and issuance of PAs, PARs, and RFAs, the major extramural program initiatives used by the NCI to fund extramural research. The DEA Director serves as Executive Secretary to the NCAB and the BSA. (See [Appendices A](#) and [B](#) for highlights of the activities of these Boards in FY2014 and [Appendix C](#) for a list of current chartered committee members.)

Major NCI Advisory Bodies Administered by the DEA

National Cancer Advisory Board (NCAB). NCI's principal advisory body is the presidentially appointed NCAB. The NCAB advises the HHS Secretary and the NCI Director on issues related to the entire National Cancer Program and provides a second level of review for grant applications

referred to the NCI and for the Food and Drug Administration (FDA) ([Appendix A](#)).

President's Cancer Panel (PCP). The PCP consists of three members appointed by the President, who by virtue of their training, experience, and background, are exceptionally qualified to appraise the National Cancer Program. At least two members of the Panel are distinguished scientists or physicians, and the third member is a nationally recognized cancer research advocate. The Panel monitors the development and execution of the activities of the National Cancer Program and reports directly to the President. Any delays or hindrances in the rapid execution of the Program are immediately brought to the attention of the President.

Board of Scientific Advisors (BSA). The BSA represents the scientific community's voice in NCI-supported extramural science. The BSA, composed of distinguished scientists from outside the NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The BSA evaluates NCI extramural programs and policies, and it reviews concepts for new research opportunities and solicitations to ensure that those concepts are meritorious and consistent with the Institute's mission ([Appendix B](#)).

Boards of Scientific Counselors (BSCs) for Basic Sciences, and for Clinical Sciences and Epidemiology. The two BSCs, managed through the Office of the Director (OD), NCI, advise the NCI leadership on the progress and future direction of NCI's Intramural Research Program residing in the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics (DCEG). The two BSCs, composed of scientific experts from outside the NCI, evaluate the performance and productivity of NCI Intramural Principal Investigators and Staff Scientists through periodic site visits to the intramural laboratories and provide evaluation and advice on the course of research for each Laboratory and Branch.

NCI Council of Research Advocates (NCRA). The NCRA, previously known as the Director's Consumer Liaison Group (DCLG), advises the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. To this end, the NCRA conducts these activities with the intent to identify new approaches, promote innovation, recognize unforeseen risks or barriers, and identify unintended consequences that could result from NCI decisions or actions. Additionally, the NCRA will provide insight into enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders.

Clinical Trials and Translational Research Advisory Committee (CTAC). The CTAC advises and makes recommendations to the NCI Director, NCI Deputy Directors, and the NCI Division/Office/Center (DOC) Directors on the NCI-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process. In addition, CTAC makes recommendations regarding the effectiveness of NCI's translational research management and administration program, including needs and opportunities across disease sites, patient populations, translational developmental pathways, and the range of molecular mechanisms responsible for cancer development. CTAC also will advise on the appropriate magnitude for dedicated translational research priorities and recommend allocation of translational research operations across organizational units, programs, disease sites, populations, developmental pathways, and molecular mechanisms. This responsibility encompasses oversight of all clinical trials, both extramural and intramural. The Committee provides broad scientific and programmatic advice on the investment of taxpayer dollars in clinical trials and related science.

Frederick National Laboratory Advisory Council (FNLAC). The FNLAC provides advice and makes recommendations to the Director, NCI, and the Associate Director, NCI-Frederick, on the optimal use of the NCI-Frederick facility to rapidly meet the most urgent needs of the Institute. The NCI facility in Frederick, Maryland, was established in

1972 as a Government-owned Contractor-operated facility. In 1975, the facility was designated as a Federally Funded Research and Development Center (FFRDC) to provide a unique national resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and AIDS. The FFRDC has been renamed as the Frederick National Laboratory for Cancer Research (FNLAC). FNLAC reviews new projects proposed to be performed at NCI-Frederick and advises the Director, NCI, and the Associate Director, NCI-Frederick, about the intrinsic merit of the projects and about whether they should be done at the Frederick facility.

NCI Initial Review Groups (IRGs). The NCI IRGs, composed of four active subcommittees, review grant applications for Cancer Centers, research projects, and Training, Education, and Career Development activities in the areas of cancer cause, prevention, diagnosis, treatment, and control. IRG members may be appointed as standing committee members with overlapping terms of up to 6 years, or as "temporary" *ad hoc* members. *Ad hoc* members have all of the rights and obligations of IRG committee membership, including the right to vote on recommendations in which the individual fully participated as a reviewer for a specific meeting. Consultants also may be invited to serve as special experts to provide information or advice. These individuals generally serve on site visit groups or work groups providing critical information to the chartered advisory subcommittees responsible for initial peer review.

NCI Special Emphasis Panels (SEPs). The SEPs advise the NCI Director and the DEA Director regarding research grant and cooperative agreement applications, contract proposals, and concept reviews relating to basic, preclinical, and clinical sciences, and applied research and development programs of special relevance to the NCI. Membership on a SEP is fluid, with experts designated to serve "as needed" for individual review meetings rather than for fixed terms. The SEP individuals have all of the rights and obligations of IRG committee membership, including the right to vote on recommendations.

Committee Management Activities

The NCI **Committee Management Office** (CMO) is critical to the continued success of all National Cancer Institute (NCI) Federal advisory committee activities, including Boards, Advisory Committees, subcommittees, working groups, and review panels. The CMO is located in the Office of the Director, Division of Extramural Activities (DEA), NCI. The CMO provides expert advice to the Director, NCI; Deputy Directors, NCI; the Director, DEA, NCI; and other senior-level Institute/Center/Client staff on all rules, regulations, guidelines, policies, and procedures governing the Federal Advisory Committee Act (FACA). The CMO is also an established Service Center for the management of other Institutes' Federal advisory committees. Currently, the CMO serves as the Service Center for the NIH Council of Councils (CoC) located in the Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The CMO began providing committee management support to NIAAA in April 2014. NIAAA has seven Federal Advisory committees, which include an Advisory Council, a BSC, four IRG Subcommittees, and a SEP.

The CMO is also responsible for providing logistical planning and support of the following: four NCAB meetings, three BSA meetings, and two NFAC meetings as well as numerous subcommittees and working groups. The office also continues to manage the Division's SREA Program, which includes reimbursement of thousands of peer review consultants, processing and payment of hotel contracts, teleconferences, and reconciliation of the SREA budget.

As a service center for the Office of the Director, NIH, and NIAAA, the CMO continued to provide exceptional service to these Client-Institutes on the management of their Federal advisory committees. The CMO effectively manages a comprehensive ethics program in support of CoC. Ethics services

include analysis and review of Special Government Employee OGE-450s of new CoC advisory committee members and preparation of recusal lists and waivers of current members. Additionally, the CMO prepares charter renewals, analyzes potential nominees, and prepares nomination slates, *Federal Register* notices, and annual and fiscal year reports for its Service Center Clients.

Highlights of CMO activities in FY2014 include the following:

- The NCI Director requested the names of two NCI Federal Advisory Committees be changed to better reflect their purpose. They were the Frederick National Laboratory Advisory Committee (formerly NCI-Frederick Advisory Committee) and NCI Council of Research Advocates (formerly the NCI Director's Consumer Liaison Group). The CMO worked expeditiously with the NIH OFACP and GSA to ensure that the charters of each advisory committee were processed quickly.
- At the request of the NCI Director, the CMO processed the appointment of a new NCRA member. This appointment required a very quick turnaround so that the NCI Director could make a formal announcement of the appointment at a White House press conference later that week. Total turnaround time on the nomination slate was 3 days.
- The following training sessions were given by the CMO to various Federal and non-Federal audiences over the course of the year:
 - 1) PAN Webinar Training to Public Affairs Specialists at various Universities/Institutions on the activities of the NCAB and BSA
 - 2) SRO Retreat Presentation to SROs on Committee Management and SREA Activities

- 3) Working Group Overview and Subcommittee Overview Training to newly assigned Designated Federal Officers (DFOs) working with various subcommittees and working
 - 4) Groups of the NCAB, BSA, FNLAC, NCRA, and CTAC.
- FACA Training to new NCRA and CoC Designated Federal Officials (DFOs).
 - **The 1810-1 NIH Manual Policy Issuance** titled “Procedures for Avoiding Conflict of Interest for Special Government and other Federal Employees Serving as Advisory Committee Members” was revised and released this year. The CMO participated in the OFACP Working Group to revise this policy. There were several major changes, including the SGE COI Update Schedule that was changed from updating on a meeting basis to a calendar year updating system.
 - **Freedom of Information Act (FOIA) Requests** – Received and responded to several requests from the NIH FOIA office. One request involved information regarding Special Emphasis Panel FACA meeting rosters for CY 2009-2013. The SREA staff pulled ~601 rosters from the Committee Management IMPAC II module and reviewed each roster to see if they met the criteria of the FOIA request.
 - Oversaw travel authorizations and vouchering of more than 100 SGE travel instances.
 - The Committee Management IMPAC II Module is an integral part of the day-to-day activities in the management of advisory committees. As such, the CMO continues to evaluate the current database system and provide feedback to the Committee Management Users Group Representative on potential modifications to the Module.
 - Responded to requests from senior NCI and Client staff on various non-FACA meetings and working group concerns.

Portfolio Tracking and Analysis

The DEA's **Research Analysis and Evaluation Branch** (RAEB) is the officially designated contact for scientific information on NCI-supported research. The NCI needs to collect and maintain consistent budget-linked scientific information across all of its scientific programs to analyze the Institute's research funding portfolio, make budget projections, and disseminate information about cancer. The DEA conducts analyses to project future NCI research expenditures and to provide budget justifications to Congress. The work of the RAEB allows the DEA to respond immediately to requests for information from NCI staff, the broader NIH community, and requesters nationally and worldwide regarding the NCI Funded Research Portfolio. The RAEB reviews both unfunded applications and funded extramural grants supported by the NCI to consistently link scientific categories to budget categories on all Institute programs. These capabilities are based on a sophisticated system of indexing in which research documentation staff members analyze grant applications to classify each project for its degree of relevance to Special Interest Category (SIC) and Organ Site Codes (SITE). SIC Codes are meant to describe in a consistent way the major scientific disciplines that are of stated or growing interest to the NIH, HHS, Congress, and the public. A critical characteristic of these data is comparability from one fiscal year to the next.

Trends in funding from FY2010 through FY2014 for selected organ sites and SIC Codes are presented in **Tables 15** and **16**. In addition, RAEB staff members serve as DEA or NCI representatives on NCI or NIH-wide scientific reporting initiatives. These groups and committees deal with various aspects of NIH grants and contracts or tracking and reporting on areas of special interest to the NIH, NCI, and/or Congress.

In FY2014, the RAEB provided numerous portfolio analyses, for example:

- Office of Government & Congressional Relations: Pancreatic Cancer Funding,

FY2010 – FY2013; Pediatric Cancer Funding, FY2010 – FY2013; Stomach Cancer Funding, FY2010 – FY2013. These reports were available at RAEB online on DEA's Intranet at <http://deaintranet/nci.nih.gov/>

- Exclusive Pediatric Cancer R01 Grant Applications, FY2007 – FY2013
- NCI Office of Budget and Finance: Pediatric Brain Cancer Funding, FY2003 – FY2013
- Supplied Office of the Director with funding data on NCI microbiome research
- Provided scientific indexing for NCI-funded and unfunded extramural projects and contracts.
- Supported the International Cancer Research Partners (ICRP), a group of international cancer research funding organizations, by coding NCI extramural projects and cancer grants funded by other NIH institutes to the Common Scientific Outline (CSO) and by participating in the ICRP.
- Continued coordination with the NCI Office of Budget and Finance (OBF) to update and align budget reporting categories.
- Chaired the NCI Accrual Working Group for biennial reporting of NCI compliance with congressional Health Disparities reporting requirements.
- Served as NCI subject matter expert on the NIH Inclusion Operating Procedures Working Group and its Policy subgroup.
- Served as DEA representative to the NCI Communications Committee.
- Served as DEA representative to the NCI Planning and Evaluation Special Interest Group (SIG).

Extramural Research by Foreign Research Institutions and Extramural NCI Research Grants With a Foreign Research Component

In FY2014, the NCI allocated \$15.1 million to support 42 grants and contracts received by foreign research institutions. These foreign grants are listed by country, mechanism, disease area, and total

funding support in **Table 17**. Canadian institutions received the most funding from the NCI, with 21 grants and contracts totaling \$9.5 million. R01s were the most common mechanisms funded, with 21 grants receiving \$6.3 million. Disease areas receiving the most NCI funding to foreign institutions were Not Site Specific (\$3.7 million), Breast (\$3.5 million), and Lung (\$1.9 million).

FY2014 Funding of Foreign Institutions

(See **Table 17** for more information.)

Country	Grants #	Funding \$
Canada	21	\$9,530,686
France	4	\$2,055,181
United Kingdom	6	\$1,578,337
Israel	4	\$974,929
Australia	3	\$402,672
Japan	1	\$209,449
India	1	\$189,801
Belgium	1	\$179,358
Sweden	1	\$48,190
Totals	42	\$15,168,603

In FY2014, the NCI supported 296 U.S. domestic grants with 509 foreign components. These grants are listed in **Table 18** by country, mechanism, and


number of grants. Because many grants have multiple foreign contributors, the total count is greater than the total number of grants. Institutions in Canada (74), the United Kingdom (47), Australia (33), Germany (33), and China (27) were the NCI’s most frequent collaborators. R01 is the most common funding mechanism used for collaborations, with 275 grants, followed by U24 (60) and U01 (58).

Success Rates of Extramural Science Categories

The RAEB assigns scientific indexing to both funded and unfunded applications, so it is possible to calculate success rates for funding in scientific categories. For example, the following graphs and tables illustrate FY2014 success rates for high incidence cancers (**Figure 9**) and for selected Special Interest Categories (SIC) (**Figure 10**). The highest incidence cancer rankings are from the SEER rank of top 15 cancer sites, 2004-2008, age-adjusted incidence for all races and sexes. Success rates were calculated by dividing the total number of newly funded applications in 2014 (Type 1 and 2 grants) for that research category (SIC or Organ Site) by the total number of applications for that research category (see **Figures 9** and **10**).

Figure 9. FY2014 Success Rates for Applications in High Incidence Cancers*


Sorted by Success Rate



Selected Oncology Sites	SEER Rank*	Types 1 & 2 Funded in 2014 for This Site	Total Applications Received in 2014 for This Site	2014 Success Rate for This Site	Total Funding for Types 1 & 2 in 2014 for This Site
Stomach	14	30	65	46.15%	\$4,016,544
Bladder	5	55	137	40.15%	\$8,846,964
Uterus	9	42	107	39.25%	\$4,629,183
Non-Hodgkins Lymphoma	7	124	370	33.51%	\$26,887,255
Kidney	8	51	155	32.90%	\$5,995,262
Leukemia	10	193	646	29.88%	\$68,151,644
Colon, Rectum	4	189	819	23.08%	\$43,958,523
Melanoma	6	116	518	22.39%	\$28,696,896
Pancreas	11	139	653	21.29%	\$37,955,513
Liver	15	75	377	19.89%	\$14,555,209
Lung	3	193	1,018	18.96%	\$53,847,501
Thyroid	12	15	83	18.07%	\$4,410,551
Prostate	1	166	982	16.90%	\$45,877,910
Breast	2	375	2,266	16.55%	\$125,678,774
Oral cavity and pharynx	13	13	88	14.77%	\$3,240,428

*SEER rank of top 15 cancer sites 2004-2008 age-adjusted incidence for all races and sexes.

Figure 10. FY2014 Success Rates for Applications in Selected Special Interest Categories (SIC)
Sorted by Success Rate



Special Interest Category	Type 1 & 2 Funded in 2014 for This SIC	Total Applications Received in 2014 for This SIC	2014 Success Rate for This SIC	Total Funding for Types 1 & 2 in 2014 for This SIC
Prevention	268	827	32.41%	\$140,401,111
Genomics	271	896	30.25%	\$77,305,241
Oncogene	373	1,276	29.23%	\$93,514,679
Inflammation	135	495	27.27%	\$25,408,709
Angiogenesis	75	312	24.04%	\$13,543,130
Biomarkers	364	1532	23.76%	\$82,283,928
Early Detection	163	721	22.61%	\$63,991,157
Therapy	1,060	4,910	21.59%	\$540,797,213
Obesity	56	266	21.05%	\$12,114,009
Metastasis	333	1,608	20.71%	\$83,900,498
Diagnosis	378	1,837	20.58%	\$164,017,364

Information Resources Management

The **Applied Information Systems Branch** (AISB) provides integrated computer support, information technology expertise, and information systems development for the DEA. The AISB maintains and monitors the DEA Internet and Intranet websites; designs, develops, and maintains Division-specific software applications; administers and maintains various DEA servers; provides help desk support; provides oversight of hardware and connectivity; and serves as a liaison with the NIH Center for Information Technology (CIT) and the NCI Center for Biomedical Informatics and Information Technology (CBIIT). Its mission is critical to the Division in communicating current information technology activities and new developments to all components of the NCI and NIH as well as to external reviewer and applicant communities.

DEA's Information Technology and Information Systems contracts are managed by the AISB. The AISB has a computer support team to track staff requests, manage the Division's computer equipment inventory, and provide computer-related training, as needed. Specific projects utilizing the technologies and services provided by the AISB are described under the appropriate functions of the DEA throughout this report.

For FY2014, specific AISB accomplishments are highlighted below.

System Administration and Desktop Support

- Secured 30 iPads for use as e-readers for NCAB closed sessions and an imaging cart to deploy and manage all 30 devices. The first rollout for a closed session was an overall success, which drastically reduced document duplication and a substantive reduction in overall costs.
- Awarded new software and systems support contracts for the DEA Information System (DEAIS) and Fiscal Linked Analysis of Research Emphasis (FLARE).
- Partnered with NCI's Center for Bioinformatics and Information Technology (CBIIT) to purchase Windows tablets for evaluation as possible substitution for laptops. Worked closely with the CBIIT imaging team and DEA staff to work through technical issues.
- Performed PC/laptop upgrades, bringing the DEA into compliance with a 3-year equipment refresh cycle.
- Developed new alliances and better working relationships with several CBIIT teams (Server Management, Equipment Imaging, Service Now Team) as a result of a newly established CBIIT liaison position.
- Set up and configured new servers for the FLARE production database, DEAIS configuration management, DEAIS Oracle production, and DEAIS production applications.
- Migrated local Oracle databases with eRA's change of the character set in the eRA/IMPAC II databases to UTF-8 (UCS Transformation Format – 8 bit) to support Unicode characters, primarily based on business requests to handle Greek characters.
- Upgraded the development and production databases to 11G, then 12C (installed Oracle software, created and configured databases, and loaded and tested data).
- Security Assessment and Authorization (SA&A)
 - Worked with NCI staff and contractors in support of SA&A packages for DEA GSS (General Support System) and FLARE, low and moderate applications respectively. Remediated deficiencies under AISB's control and documented NIH inherited controls. Documented responses to Plan of Actions and Milestones (POA&M). Documented changes for the Annual Assessment Review for control families, contingency plans, and participated in table-top exercises.
 - In addition to regular annual activity, the following reports and documentation were updated for DEA GSS and FLARE systems SA&A: Contingency Plan, CP Testing,

CP Training, Risk Assessment, Annual Assessment, System Security Plan, and E-Authentication/FIPS-199.

- Planned, organized, and worked with the Independent Validation and Verification team (IV&V) from the SRA contractor for FLARE's Re-Certification and FY2014 Annual Assessment requirements.

Application Development Projects

- After a successful pilot, the custom-developed Funding Patterns Summary and Blog website became fully operational. It readily manages funding report information and accepts and manages comments from the public. New content can be readily loaded while structured archives of both content and comments are retained and available.
- The Concept to Award Tracking System (CATS) notification implementation plan was developed and readied for deployment.
- All end-user requirements were incorporated, and the NCI Grant-Related Directory (NGRAD) application was promoted to full production.
- The Staff Listing application was adjusted to draw on the NIH Electronic Directory (NED) as the data source, provisioned with an administrative module, and updated to incorporate the DEA Web graphic user interface look and feel.
- Major revisions were made to the administrative and end-user modules of the Extramural Science Administrator Training – Tracking System (ESATTS).

User Training

- Developed a training workshop coupled with the preparation of an 83-page manual for the Cisco WebEx virtual meeting service. Presented the material to staff.
- Played a large role in transitioning NIH/AISB telecommunication towards a Cisco WebEx platform; helped PRESTO conduct

21 WebEx seminars and meetings, 5 webinars, and 10 training sessions.

DEA Website Development

- Implemented final changes to the new President's Cancer Panel (PCP) website and launched the PCP Annual Report. AISB provided essential management and input in the design and display of the PCP website, hosted on DEA's Internet.

Development and Support of Software Applications for the Research Analysis and Evaluation Branch (RAEB) Scientific Coding and Analysis

- Performed the following upgrades and maintenance to the FLARE system and environment:
 - Upgraded to Oracle 11G
 - Enhanced the Women's Health report (by subproject)
 - Ran FLARE under the NIH Login/PIV in the test environment
 - Allowed users to index non-NCI grants (duals and joint-funded) for FY2013 grants
 - Refined and enhanced reports (using 'BIRT' tool), which replaced the current Excel-based Crystal reports; met the goal of eliminating usage of the Crystal reports.
 - Completed development for version 1.0 production release of RAEB Online, to be initially available to internal NCI staff (Program Officers and SROs) for showing success rates and statistical analysis of RAEB disease coding data, which included a new menu, additional Division/Office/Center datasets, separation of grants and contracts in the charts, additional stacked charts, and numerous new features and bug fixes. Provided a demonstration to the new NCI CBIIT Director. An SPL demonstration is expected in 2015.

AISB Staff Involvement

Represented the needs and concerns of DEA staff through active participation in the following groups:

- Frederick Security Team
- CBIIT Process Improvement Team
- NCI Computer Upgrade Project – Technology Refresh Program
- NIH Mobile Device Policy Team
- NCI Conference Room Special Interest Group (SIG)
- Service Now SIG
- NCI Division IT Contacts Meeting
- Science Management Workspace (SMW)
- DEA Brown Bag seminars
- International Cancer Research Portfolio (ICRP) Data Meetings
- NCI BAD codes (Basic and Applied) Working Group
- NCI Coding QA/QC Team
- NIH eRA Technical Users Group (eTUG)
- Shady Grove IT and Server Consolidation Planning Team

Organizational Structure of the Division of Extramural Activities

Office of the Director

- Directs and administers the operations of the Division, including those activities relating to grant review and administration, contract review, referral and program coordination of FOAs, and Advisory Committee and Board activities.
- Directly coordinates and manages the NCAB and the BSA.
- Coordinates coding of NCI's grant portfolio.
- Initiates, coordinates, and implements Institute policies and procedures relating to grants and contracts reviews.
- Oversees the NCI's Committee Management Office.
- Implements NCI policies regarding extramural research integrity.
- Advises the Scientific Program Leadership (SPL) Committee, NCI, on extramural guidelines, review, advisory activities, and implementation strategies.
- Coordinates NCI extramural staff training requirements with the NIH.
- Represents the NCI on the NIH-wide Extramural Program Management Committee (EPMC) with responsibility for development of extramural policy and procedures across all NIH Institutes and Centers.
- Oversees inclusion of gender, minority, and children.
- Serves as the NCI Research Integrity Office.
- Coordinates, develops, and implements extramural policy.

Paulette Gray, Ph.D. **Director**
Vacant **Deputy Director**
Peter Wirth, Ph.D. **Assistant Director**
Dawn William **Senior Program Analyst**
Kathy Tiong **Program Analyst**
Judi Ziegler **Secretary**

DEA Processing and Distribution Unit (DPDU)*

- Provides services to DEA staff, including the coordination, consolidation, purchasing of supplies, tracking of expenditures, and preparation of meeting folders, Board book and orientation documents, and annual reports. In conjunction with the establishment of this unit, the number of DEA Purchase Cards was reduced from 15 to 6. This change has minimized hoarding of office supplies and overall reduction in dollar costs associated with the use of DEA Purchase Cards.

Ricardo Rawle **Special Assistant to the Director**
Clara Murphy **Program Specialist**
Adrian Bishop **Staff Assistant**
Sanjeeb Choudhry **Staff Assistant**
Robert Kruth **Staff Assistant**

*Established in February 2014.

Committee Management Office, OD

- Coordinates functionally related Federal advisory committee activities across the Institute and its client-Institutes. The office manages NCI advisory committees and serves as an NIH service center for the NIH Council of Councils, the NIH, and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to ensure that appropriate policies and procedures are in place to conduct the designated mission of each committee.
- Provides policy guidance to the NCI and client-Institute staff on administrative and technical aspects of Federal advisory committees; coordinates activities with all other NCI advisory committees; implements policies and procedures designed to avoid conflicts in the nomination, selection, and recruitment of board members; implements CM Module guidelines and procedures to ensure that all committee-related data are correctly entered into the database for preparation and submission of required annual reports to the President of the United States, HHS, and NIH; provides logistical support for NCAB, FNLAC, and BSA meetings, subcommittees, and work groups; and facilitates NCAB and BSA committee-related travel.
- Researches and evaluates conflict of interest and foreign activities issues for client-Institutes and provides advice on resolutions affecting advisory committee members serving as Special Government Employees.
- Provides administrative support for the peer review system by compensating consultants for their services on NCI IRG Subcommittees and SEPs, reimbursing consultants for travel and other expenses, and approving and processing payments for other activities related to review such as hotel contracts and teleconferencing.

Claire Harris	Committee Management Officer
Janet Craigie	Deputy Committee Management Officer
Malaika Staff	Senior Committee Management Specialist
Etsegenet Abebe	Committee Management Specialist
Natasha Copeland	Committee Management Specialist
Darnetta King	Committee Management Specialist
Alonda Lord	Committee Management Specialist
Rosalind Niamke*	Committee Management Specialist

*Joined in February 2014.

Program and Review Extramural Staff Training Office

- Develops and implements both broad-based and focused curricula for NCI Program and Review staff.
- Coordinates training for other extramural staff upon request.
- Identifies and develops resources (electronic and human) to facilitate learning and optimal individual, group, and organizational performance.
- Collaborates with NCI Divisions, Offices, Centers, and groups both internal and external to the NCI, to provide customized job-related training and career development opportunities.
- Tracks participation of extramural staff in NIH- and NCI-sponsored training activities.

Michael Small, Ph.D.	Chief
Scot Chen, Ph.D.,	Health Scientist Administrator
Ivan Ding, M.D.	Health Scientist Administrator
Gregory Jones	Program Analyst
Destiny Mercado	Program Analyst
Cecily Nelson, M.S*	Program Analyst
Denise Santeufemio	Program Analyst

*Left April 2014.

Office of Referral, Review, and Program Coordination

- Coordinates program concept development; publication functions; and receipt, referral, and assignment of all NCI applications.
- Coordinates review activities of the RTRB, RPRB, SRB, RTCRB, and PCR. B.

Shamala Srinivas, Ph.D.	Associate Director
Paul Gallourakis*	Special Assistant to the Associate Director
Catherine Battistone	Program Analyst
Linda Brown	Program Specialist
Linda Coleman †	Committee Management Specialist

*Moved to RTCRB in February 2014.

†Moved to NIH Clinical Center in 2014.

Special Review and Logistics Branch*

- Plans, manages, and assists in the scientific and technical merit review of applications received in response to RFAs, PAs, and PARs and contract proposals received in response to RFPs.
- Identifies and recommends appropriate review committee members as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.

Thomas Vollberg, Ph.D.†	Acting Chief
Kenneth Bielat, Ph.D.†	Scientific Review Officer
Eun-Ah Cho, Ph.D.‡	Scientific Review Officer
Donald Coppock, Ph.D.†	Scientific Review Officer
Jeffrey DeClue, Ph.D.†	Scientific Review Officer
Gerald Lovinger, Ph.D.†	Scientific Review Officer
Joyce Pegues, Ph.D.†	Scientific Review Officer
Marvin Salin, Ph.D. ‡	Scientific Review Officer
Ellen Schwartz, D.Ed.†	Scientific Review Officer
Viatcheslav Soldatenkov, Ph.D. ‡	Scientific Review Officer
Adriana Stoica, Ph.D.§	Scientific Review Officer
Thomas Winters Ph.D.‡	Scientific Review Officer
Zhiqiang Zou, Ph.D.‡	Scientific Review Officer
Thu Nguyen‡	Program Analyst
Rosalind Niamke**	Lead Staff Assistant
Donnell Wilson†	Lead Staff Assistant
Alicia Craig†	Staff Assistant
Bratati Chowdhury‡	Staff Assistant
Grace Hughitt (Tato)**	Staff Assistant
Hanh “Julie” Hoang†	Staff Assistant
Adrian Bishop‡‡	Mail and File Clerk
Sanjeeb Choudhry‡‡	Mail and File Clerk
Robert Kruth‡‡	Mail and File Clerk
Clara Murphy‡‡	Program Assistant

*Abolished in February 2014.

†Moved to RTCRB in February 2014.

‡Moved to SRB in February 2014.

§Moved to RTRB in February 2104.

**Moved to CMO in February 2014.

‡‡Moved to DPDU in February 2014.

Special Review Branch (SRB)*

- Plans, manages, and assists in the scientific and technical review of grant and cooperative agreement applications received in response to RFAs, PAs, and PARs
- Identifies and recommends appropriate review committee members as required for the review of assigned applications.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and cooperative agreements pending review by the Branch.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.

Eun-Ah Cho, Ph.D	Acting Chief
Marvin Salin, Ph.D.†	Scientific Review Officer
Cliff Schweinfest, Ph.D.	Scientific Review Officer
Viatcheslav Soldatenkov, Ph.D.	Scientific Review Officer
Thomas Winters Ph.D.	Scientific Review Officer
Zhiqiang Zou, Ph.D.	Scientific Review Officer
Thu Nguyen	Program Analyst
Bratati Chowdhury	Staff Assistant
Imela Gradington-Jones‡	Staff Assistant
Tonya Miller§	Lead Staff Assistant
Nakessha Mendez Modeste‡	Staff Assistant

*Established in February 2014.

†Retired in May 2014.

‡Joined in December 2014.

§Joined in August 2104.

Research Technology and Contract Review Branch (RTCRB)*

- Plans, manages, and assists in the scientific and technical merit review of grant and cooperative agreement applications received in response to RFAs and PARs and contract proposals received in response to RFPs.
- Identifies and recommends appropriate review committee members as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all technology-related grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.

Thomas Vollberg, Ph.D.	Chief
Kenneth Bielat, Ph.D.	Scientific Review Officer
Donald Coppock, Ph.D.	Scientific Review Officer
Jeffrey DeClue, Ph.D.	Scientific Review Officer
Gerald Lovinger, Ph.D.	Scientific Review Officer
Joyce Pegues, Ph.D.†	Scientific Review Officer
Ellen Schwartz, D.Ed.	Scientific Review Officer
Paul Gallourakis	Program Analyst
Donnell Wilson	Lead Staff Assistant
Alisha Craig	Staff Assistant
Hanh “Julie” Hoang	Staff Assistant
Lauren McLaughlin	Staff Assistant
Kimberly Millner‡	Staff Assistant

*Established in February 2014.

†Retired in July 2014.

‡Joined in December 2013.

Program Coordination and Referral Branch

- Serves as the information and coordination point within the NCI for the development, clearance, publication, and tracking of all NCI extramural program (funding) initiatives, which include all RFAs, PAs, and Notices submitted for publication in the *NIH Guide for Grants and Contracts*, and also on Grants.gov, which is a Federal-wide online portal for electronic submission of grant applications.
- Coordinates the development and periodic revision of referral (i.e., application assignment) guidelines within the NCI for both external and internal use.
- Coordinates the development of shared (referral) interest statements with other NIH Institutes and Centers (ICs) so that grant applications of possible or real mutual interest can be properly assigned for receipt, review, and/or funding.
- Serves as the liaison to the Center for Scientific Review (CSR), NIH, to ensure the appropriate referrals (i.e., assignments) of grant applications to the Institute and the transfers of grant applications between the NCI and other NIH ICs.
- Refers new (Type 1) applications to the appropriate cancer activity area(s) according to the NCI Internal Referral Guidelines that define the program interests of each of the 50 cancer activity areas (which typically represent program branches in the NCI extramural divisions).
- Semi-automatically refers resubmission (A1) and renewal (Type 2) applications to the cancer activity area that accepted the previously submitted application (with quality control measures performed to ensure the accuracy of referrals).
- Coordinates requests from Program staff for application status changes (including corrections of application assignments and numbers, which is done in collaboration with NCI Program staff, CSR referral staff, and referral staff of other ICs and agencies) and for acceptance of grant assignments.
- Serves as the NCI contact point and liaison to involved parties at the NIH for approval of the use of cooperative agreement mechanisms and for conversion of grants to cooperative agreements.
- Works with NCI Program and Review staff and with NIH referral liaisons to address unresolved referral and review issues with the CSR and other NIH ICs.
- Receives and distributes advance copies of applications to Review and Program staff.
- Receives Letters of Intent (LOI) from applicants (principal investigators) intending to submit large budget grants (including, but not limited to, program projects and cooperative agreements for clinical trials).
- By handling communications with applicants and NCI Program staff members, coordinates approvals (and disapprovals) of the NCI to sponsor the submission of individual conference (R13) grant applications.
- Serves as the primary point of contact and provides assistance at the NCI for applicants who want to apply for an Academic Research Enhancement Award (i.e., the NIH R15 AREA grant mechanism).
- Processes and tracks requests for submissions of large-budget grant applications that allow them to be received at the NIH, peer reviewed, and possibly awarded by the NCI.
- Maintains database records of prospective large-budget grant and conference grant applications for each council round.
- Serves as the primary NCI information and referral point for the extramural scientific community on a broad range of subjects, including grant guidelines, application information, new initiatives announced as RFAs or PAs, and the review process.

- Assists the extramural community in navigating the NIH and NCI Web pages to help users obtain current information, forms, and guidelines.
- Directs applicants to the appropriate SROs and Program Officers for information regarding the status of the review and award of their grant applications.
- Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes.
- Provides data and data analyses on funding opportunities and on the receipt and referral of grant applications to NCI senior staff members and committees.

Christopher L. Hatch, Ph.D.	Chief
David Contois	Referral Officer, NCI/NIH Referral Liaison
Anandarup Gupta, Ph.D.	RFA/PA Coordinator, Scientific Review Officer
Leota Hall	Referral Officer, NCI/NIH Referral Liaison
Bratin Saha, Ph.D.	Referral Officer, Scientific Review Officer
Jan Woynarowski, Ph.D.	RFA/PA Coordinator, Scientific Review Officer
Natacha P. Lassègue	Program Analyst
Dianne Johnson*	Staff Assistant

*Joined in August 2014.

Research Programs Review Branch

- Plans, coordinates, and manages the scientific merit review of program project grants, specialized centers, and other grant mechanisms, as necessary, by Special Emphasis Panels.
- Identifies and recommends appropriate review committee members for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers and other DEA Branches.

Caron Lyman, Ph.D.	Chief
Shakeel Ahmad, Ph.D.	Scientific Review Officer
Caterina Bianco Ph.D.	Scientific Review Officer
Majed Hamawy, Ph.D., M.B.A.	Scientific Review Officer
Wlodek Lopaczynski, M.D., Ph.D.	Scientific Review Officer
David Ransom, Ph.D.	Scientific Review Officer
Delia Tang, Ph.D.	Scientific Review Officer
Charles Choi	Program Analyst
Monica Congo*	Program Analyst
Shannon Harley†	Staff Assistant
Deneen Mattocks	Lead Staff Assistant
Kenneth Nock†	Staff Assistant

*Left in December 2013.

†Joined in September 2014.

Resources and Training Review Branch

- Plans, coordinates, and manages the scientific merit review of cancer center, training, education, and career development grant and cooperative agreement applications by chartered IRG committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments (site visits) of the research capabilities and facilities of selected applicants (i.e., Cancer Centers).
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, and research trends and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers, other DEA Branches, and the Center for Scientific Review.

Robert E. Bird, Ph.D.	Chief
Lynn Amende, Ph.D.*	Scientific Review Officer
Ilda Melo, Ph.D.	Scientific Review Officer
Timothy Meeker, M.D.	Scientific Review Officer
Sergei Radaev, Ph.D.	Scientific Review Officer
Sonya Roberson, Ph.D.	Scientific Review Officer
Adriana Stoica, Ph.D.†	Scientific Review Officer
Sheila Hester	Program Specialist
Linda Edwards	Staff Assistant
Gelia Holloway	Lead Staff Assistant
Leslie Kinney	Staff Assistant
Bridgette Wilson	Staff Assistant

*Retired in July 2014.

†Moved from SRLB to RTRB in February 2014.

Office of Extramural Applications

- Coordinates activities of the Research Analysis and Evaluation Branch (RAEB) and the Applied Information Systems Branch (AISB)
- Provides budget-linked research portfolio data and coordinates the information management of extramural NCI-supported research.

Amir Sahar-Khiz, Ph.D., M.B.A., PMP	Associate Director
Justin Rhoderick	Program Analyst

Research Analysis and Evaluation Branch (RAEB)

- Serves as the Institute’s officially designated, centralized source of scientific information and science-based budget information on NCI-supported research.
- Analyzes and classifies the science content of all Institute-supported research projects.
- Analyzes the distribution of funds among research areas; these analyses serve as a basis for budget projections.
- Reports and answers inquiries on the scientific and budgetary aspects of Institute-funded research, including research grants, center grants, training grants, and research contracts.
- Maintains liaisons with other organizations involved in related classification activities.
- Documents the need for proposed RFAs by comparing RFA concepts with existing NCI-supported research and with unsolicited applications.

Marilyn Gaston.....**Chief**
Edward Kyle.....**Deputy Chief**

Research Documentation

- Analyzes and indexes grants and contracts for the Branch’s computerized systems.
- Analyzes extramural projects for relevance to Special Interest Categories (SICs) and Anatomic Sites to determine the officially reported figures for Institute support and to provide a basis for budget projections.
- Maintains liaison with other offices within the Institute to ensure consistent reporting of data.
- Monitors the results of NCI’s grant-supported research.
- Assists other NCI organizations by indexing NCI research projects for attributes other than SICs and Sites, for example, Common Scientific Outline (CSO) Codes and AIDS Categories.

Edward Kyle..... **Lead Biologist/Team Leader**
Beth Buschling **Biologist**
Beverly Johnson, M.S* **Biologist**
Bernard Whitfield **Biologist**
Tyrone Wilson..... **Biologist**

*Left in June 2014.

Technical Operations, Inquiry, and Reporting

- Provides specialized data querying, archiving, and reporting functions for the Division and the Institute.
- Coordinates Institute data reporting with the NCI Office of Budget and Financial Management, NIH Population Tracking and Inclusion Committee, and others.
- Answers inquiries from Congress, the public, the press, and others concerning any phase of Institute-supported work.
- Conducts in-depth analyses of extramural research data, including trends analyses.
- Identifies emerging priority areas for data collection and analysis.
- Ensures that terms and categories for indexing are updated and reflect current trends in cancer research, and maintains a thesaurus of term definitions.

Organizational Structure of the Division of Extramural Activities _____

- Manages RAEB’s FLARE grants documentation and indexing database, ensuring reliability and completeness of its contents.
- Maintains and updates archival document files.
- Works with contractors and the AISB to refine RAEB’s computer applications to meet the Branch’s needs and resolve FLARE computer application problems for the Branch.
- Represents the DEA as its communications coordinator in the Office of Communications and Education Steering Committee.

Gail Blaufarb, M.S. Lead Biologist/Team Leader
William Clark, M.S. Biologist
Clarissa Douglas..... Program Specialist
Rajasri Roy, Ph.D. Epidemiologist

Applied Information Systems Branch (AISB)

- Fulfills the information technology (IT) requirements of the Division by coordinating information resources management (IRM) activities with other relevant NCI and NIH units, and by providing high-quality information analysis, design, development, and coordination of applications in support of the Division's business processes.
- Serves as the focal point for the Division in the development, deployment, and application of specialized software and databases required for the conduct of review, referral, coding, advisory, and other extramural applications.
- Serves as the liaison with the NCI Center for Biomedical Informatics and Information Technology (CBIIT) staff; NCI computer professionals; NCI units charged with execution of extramural IRM functions; trans-NIH functional units such as the CSR, Office of Policy for Extramural Research Administration (OPERA), and Office of Extramural Research (OER); and the IMPAC II and NIH eRA (electronic Research Administration) staff and systems.
- Supports connectivity and design of Internet and Intranet applications.
- Establishes, administers, and monitors commercial support contracts to provide design, production, and maintenance for microcomputer equipment and information storage and retrieval systems that are not covered by CBIIT.
- Formulates DEA-specific office automation policy.
- Provides staff/lead users with technical support and training for DEA IT applications.
- Coordinates general user support and training with NCI and NIH services.
- Provides Division-specific applications of video teleconferencing and audiovisual services in support of review and Board activities.
- Provides management with recommendations for establishing and implementing policies for conducting Division computer-assisted presentations, as necessary.
- Reviews user-created applications and recommends and/or designs changes to improve efficiency and effectiveness.

Gregory Fischetti..... **Chief**

Application Development Team

- Analyzes and coordinates life-cycle software development for the Division.
- Develops and designs applications to support the Division's business processes, including user guides.
- Coordinates security assessment and authorization for the Division's general support system applications.
- Develops, administers, and monitors contracts for acquisition, support, and maintenance of database systems.
- Formulates system development policy, and oversees eRA/IMPAC II operations for the Division.
- Coordinates internal user groups and training for specific DEA applications.

Todd Hardin..... **Team Leader**

Teresa Park..... **Information Technology Specialist**

Vivien Yeh..... **Information Technology Specialist**

Information Management Team

- Designs and maintains the Division's Intranet and Internet sites and pages, and identifies documents to be placed on the NCI website to make Division information more accessible to the public.
- Coordinates security assessment and authorization for systems and applications developed and implemented for the Research Analysis and Evaluation Branch (RAEB).
- Develops new Web-based software applications that will enhance the productivity and efficiency of extramural processes within the DEA and the distribution of Division information throughout the NCI.
- Coordinates application development and supports the RAEB in the areas of scientific coding and analysis.
- Administers and implements purchasing for the Division's computer hardware/software, maintenance, and supplies.
- Establishes partnerships and ongoing communications with staff and external customers to foster openness and collaboration in accomplishing the information initiatives of the Division.
- Works with DEA staff to ensure the current utility and linkages of documents placed on the Web.

Elaine Taylor..... Team Leader
Michael Hu..... Information Technology Specialist
Joshua Rhoderick..... Information Technology Specialist
Lorrie Smith..... Information Technology Specialist

Operations Team

- Administers and maintains the Division's application, database, and Web servers.
- Oversees and provides guidance for IT security policies and regulations.
- Coordinates and implements the Division's security assessment and authorization policies for the server environment.
- Manages the software application environment for development, testing, and production.
- Coordinates network connectivity for the Division with CBIIT.
- Provides user and technical support and training for desktop and laptop computers, office automation products, and applications.
- Plans and recommends purchases of all IT-related equipment for the Division.
- Maintains an accountable IT equipment inventory for the Division.
- Develops and maintains policies for the use of office automation technology.

Richard Florence..... Team Leader
Roderick James..... Information Technology Specialist
Raymond Vidal..... Information Technology Specialist

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2014
Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
10/25/2013	CA13-010	U54	Sub-Saharan African Collaborative HIV and Cancer Consortia	OHAM
10/30/2013	CA13-015	UH2, UH3	Cancer Detection, Diagnostic, and Treatment Technologies for Global Health	GCHR
11/4/2013	CA14-001	U54	Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data	DCCPS
11/8/2013	CA13-014	UM1	NCI Community Oncology Research Program (NCORP) - Minority/ Underserved Community Sites	DCP
	CA13-013	UM1	NCI Community Oncology Research Program (NCORP) - Community Sites	DCP
	CA13-012	UM1	NCI Community Oncology Research Program (NCORP) Research Bases	DCP
12/20/2013	CA14-003	R21	Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	CSSI
	CA14-004	R33	Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	CSSI
	CA14-005	R21	Early-Stage Development of Innovative Technologies for Biospecimen Science	CSSI
	CA14-006	R33	Validation and Advanced Development of Emerging Technologies for Biospecimen Science	CSSI
1/3/2014	CA14-007	R01	Using Social Media to Understand and Address Substance Use and Addiction	DCCPS
	CA14-009	R21	Using Social Media to Understand and Address Substance Use and Addiction	DCCPS
	CA14-008	R01	Using Social Media to Understand and Address Substance Use and Addiction	DCCPS
2/12/2014	CA14-002	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	SBIRDC
6/5/2014	CA14-501	U24	Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN)	DCTD
6/6/2014	CA14-010	U01	Molecular and Cellular Characterization of Screen-Detected Lesions	DCP
	CA14-011	U01	Molecular and Cellular Characterization of Screen-Detected Lesions - Coordinating Center and Data Management Group	DCP
7/17/2014	CA14-013	U54	Centers of Cancer Nanotechnology Excellence (CCNEs)	DCP
7/31/2014	CA14-012	U01	Cancer Intervention and Surveillance Modeling Network (CISNET)	DCCPS
8/8/2014	CA14-502	UM1	Limited Competition: AIDS Malignancy Clinical Trials Consortium	OHAM
9/4/2014	CA14-503	U01	Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program	DCB
9/5/2014	CA14-019	U01	Pediatric Preclinical Testing Consortium: Coordinating Center	DCTD
	CA14-018	U01	Pediatric Preclinical Testing Consortium: Research Programs	DCTD

Source: Office of Referral, Review and Program Coordination.

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2014
Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
CSSI	CA14-003	R21	Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	12/20/2013
	CA14-004	R33	Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	
	CA14-005	R21	Early-Stage Development of Innovative Technologies for Biospecimen Science	
	CA14-006	R33	Validation and Advanced Development of Emerging Technologies for Biospecimen Science	
DCB	CA14-503	U01	Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program	9/4/2014
DCCPS	CA14-001	U54	Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data	11/4/2013
	CA14-007	R01	Using Social Media to Understand and Address Substance Use and Addiction	1/3/2014
	CA14-008	R01		
	CA14-009	R21		
	CA14-012	U01	Cancer Intervention and Surveillance Modeling Network (CISNET)	7/31/2014
DCP	CA13-012	UM1	NCI Community Oncology Research Program (NCORP) Research Bases	11/8/2013
	CA13-013	UM1	NCI Community Oncology Research Program (NCORP) - Community Sites	
	CA13-014	UM1	NCI Community Oncology Research Program (NCORP) - Minority/Underserved Community Sites	
	CA14-010	U01	Molecular and Cellular Characterization of Screen-Detected Lesions	6/6/2014
	CA14-011	U01	Molecular and Cellular Characterization of Screen-Detected Lesions - Coordinating Center and Data Management Group	
	CA14-013	U54	Centers of Cancer Nanotechnology Excellence (CCNEs)	7/17/2014
DCTD	CA14-018	U01	Pediatric Preclinical Testing Consortium: Research Programs	9/5/2014
	CA14-019	U01	Pediatric Preclinical Testing Consortium: Coordinating Center	
	CA14-501	U24	Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN)	6/5/2014
GCHR	CA13-015	UH2, UH3	Cancer Detection, Diagnostic and Treatment Technologies for Global Health	10/30/2013
OHAM	CA13-010	U54	Sub-Saharan African Collaborative HIV and Cancer Consortia	10/25/2013
	CA14-502	UM1	Limited Competition: AIDS Malignancy Clinical Trials Consortium	8/8/2014
SBIRD	CA14-002	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization	2/12/2014

Source: Office of Referral, Review and Program Coordination.

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
12/4/2013	HG14-001	U54	BD2K-LINCS-Perturbation Data Coordination and Integration Center (DCIC)	ALL DIVISIONS	NIH
12/10/2013	RM14-001	R01	Computational Analyses Exploiting Reference Epigenomic Maps	ALL DIVISIONS	NIH-RM
12/13/2013	AI14-009	R01	U.S.-South Africa Program for Collaborative Biomedical Research	OHAM	NIH
	AI14-010	R21			
	HL14-031	U24	Development of an NIH Data Discovery Index Coordination Consortium	DCCPS	NIH
12/19/2013	RM13-015	U54	NIH Coordination and Evaluation Center for Enhancing the Diversity of the NIH-Funded Workforce Program	ALL DIVISIONS	NIH-RM
	RM13-016	U54	NIH Building Infrastructure Leading to Diversity (BUILD) Initiative		
	RM13-017	U54	NIH National Research Mentoring Network (NRMN)		
	RM13-020	R33	Validation and Advanced Development of Technologies for the Study of Biological Properties of Single Cells		
	RM13-021	R21	Exceptionally Innovative Tools and Technologies for Single Cell Analysis		
	RM13-022	R01	Revisions to Add Single Cell Analysis to Active Research Projects		
	RM13-023	U01			
1/15/2014	HG14-007	K01	Mentored Career Development Award in Biomedical Big Data Science for Clinicians and Doctorally Prepared Scientists	DCCPS	NIH
1/16/2014	HG14-008	R25	Courses for Skills Development in Biomedical Big Data Science		
	HG14-009	R25	Open Educational Resources for Biomedical Big Data		
1/17/2014	RM13-019	DP7	NIH Directors Biomedical Research Workforce Innovation Award: Broadening Experiences in Scientific Training (BEST)	ALL DIVISIONS	NIH-RM
1/24/2014	AI14-018	U01	U.S.-South Africa Program for Collaborative Biomedical Research	OHAM	NIH
2/12/2014	OD14-002	R01	Empirical Research on Ethical Issues Related to Central IRBs and Consent for Research Using Clinical Records and Data	DCCPS	NIH
	RM14-002	U01	Limited Competition: Renewal Applications for Technology Development for New Affinity Reagents Against the Human Proteome	ALL DIVISIONS	NIH-RM
4/18/2014	RM14-005	R21	Undiagnosed Diseases Gene Function Research		
4/22/2014	HG14-004	T32	Predocutorial Training in Biomedical Big Data Science	DCCPS	NIH
	HG14-005	T32	Revisions to Add Biomedical Big Data Training to Active Institutional Training Grants		

continued

Source: Office of Referral, Review and Program Coordination.

Table 2 (cont'd). NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
4/24/2014	OD14-004	SI2	Lasker Clinical Research Scholars Program	CCR	NIH
4/25/2014	OD14-005	U01	NIH Research Evaluation and Commercialization Hub (REACH) Awards	DCCPS	NIH
7/16/2014	AI14-057	R01	U.S.-China Program for Research Toward a Cure for HIV/AIDS	OHAM	NIAID
7/24/2014	RM14-003	R01	NIH Transformative Research Awards	ALL DIVISIONS	NIH-RM
8/7/2014	TW14-001	U01	Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) Research	DCCPS	NIH CDC
8/8/2014	TW14-002	U2R	Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) Research Training		
8/28/2014	GM15-006	R25	Training Modules to Enhance Data Reproducibility	CCT	NIH
9/24/2014	RM14-006	U54	Nuclear Organization and Function Interdisciplinary Consortium (NOFIC)	ALL DIVISIONS	NIH-RM
	RM14-007	U01	Nucleomics Tools		
	RM14-008	U01	Study of Nuclear Bodies and Compartments		
	RM14-009	U01	4D Nucleome Imaging Tools		
	RM14-010	U01	4D Nucleome Network Organizational Hub		
	RM14-011	U01	4D Nucleome Network Data Coordination and Integration Center		
9/26/2014	RM14-016	U54	Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN)	ALL DIVISIONS	NIH-RM
9/30/2014	RM14-012	R34	Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Structural, Analytical, and Interaction Data in the Context of Comparable Gene, Protein, and Lipid Data	ALL DIVISIONS	NIH-RM
	RM14-013	U01	Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and Their Functions		
	RM14-014	R21			
	RM14-015	U01	Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates		

Source: Office of Referral, Review and Program Coordination.

Table 3a. Program Announcements (PAs) Published by the NCI in FY2014
Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
10/17/2013	PAR13-371	P20	Planning for a National Center for Particle Beam Radiation Therapy Research	DCTD
10/21/2013	PA13-378	R21	Research on Malignancies in the Context of HIV/AIDS	DCB, OHAM, DCCPS
	PA13-377	R01		
11/7/2013	PAR13-386	P30	Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	OD
11/21/2013	PAR14-007	R03	NCI Small Grants Program for Cancer Research (NCI Omnibus)	ALL DIVISIONS
12/11/2013	PAR14-031	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	DCTD, DCP
1/9/2014	PAR14-067	U01	Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control	DCCPS
2/4/2014	PAR14-085	R01	Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy	DCB
	PAR14-086	U01		
	PAR14-087	P01		
2/19/2014	PAR14-013	R21	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	DCTD
2/26/2014	PAR14-116	U01	Quantitative Imaging for Evaluation of Response to Cancer Therapies	DCTD
3/10/2014	PAR14-152	P20	Feasibility Studies to Build Collaborative Partnerships in Cancer Research	CRCHD
3/19/2014	PAR14-160	U01	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	DCCPS
3/28/2014	PAR14-166	R01	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	DCTD
4/1/2014	PAR14-169	U54	Physical Sciences-Oncology Centers	DCB
	PAR14-239	U24	Oncology Models Forum	
5/30/2014	PAR14-240	R01	Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)	DCB
	PAR14-241	R01	Research Projects to Enhance Applicability of Mouse Models for Translational Research	
6/3/2014	PAR14-242	R01	Role of the Microflora in the Etiology of Gastro-Intestinal Cancer	DCB, DCP
6/16/2014	PAR14-260	R01	Interventions for Health Promotion and Disease Prevention in Native American Populations	DCCPS
6/18/2014	PAR14-261	333	Innovation Corps (I-Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp)	OSP
6/27/2014	PAR14-267	R35	Outstanding Investigator Award	DCB
7/17/2014	PAR14-285	U01	Innovative Research in Cancer Nanotechnology (IRCN)	CSSI
8/7/2014	PAR14-314	U01	New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers	DCB
9/26/2014	PAR14-353	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016	DCTD, DCP

Source: Office of Referral, Review and Program Coordination.

Table 3b. Program Announcements (PAs) Published by the NCI in FY2014
Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
ALL DIVISIONS	PAR14-007	R03	NCI Small Grants Program for Cancer Research (NCI Omnibus)	11/21/2013
CRCHD	PAR14-152	P20	Feasibility Studies to Build Collaborative Partnerships in Cancer Research	3/10/2014
CSSI	PAR14-285	U01	Innovative Research in Cancer Nanotechnology (IRCN)	7/17/2014
DCB	PAR14-085	R01	Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy	2/4/2014
	PAR14-086	U01		
	PAR14-087	P01	Physical Sciences-Oncology Centers	4/1/2014
	PAR14-169	U54		
	PAR14-239	U24	Oncology Models Forum	5/30/2014
	PAR14-240	R01	Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)	
	PAR14-241	R01	Research Projects to Enhance Applicability of Mouse Models for Translational Research	
	PAR14-267	R35	Outstanding Investigator Award	
PAR14-314	U01	New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers	8/7/2014	
DCB, DCCPS OHAM	PA13-377	R01	Research on Malignancies in the Context of HIV/AIDS	10/21/2013
	PA13-378	R21		
DCB, DCP	PAR14-242	R01	Role of the Microflora in the Etiology of Gastro-Intestinal Cancer	6/3/2014
DCCPS	PAR14-067	U01	Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control	1/9/2014
	PAR14-160	U01	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	3/19/2014
	PAR14-260	R01	Interventions for Health Promotion and Disease Prevention in Native American Populations	6/16/2014
	PAR13-371	P20	Planning for a National Center for Particle Beam Radiation Therapy Research	10/17/2013
DCTD	PAR14-013	R21	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	2/19/2014
	PAR14-116	U01	Quantitative Imaging for Evaluation of Response to Cancer Therapies	2/26/2014
	PAR14-166	R01	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	3/28/2014
DCTD DCP	PAR14-031	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	12/11/2013
	PAR14-353	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016	9/26/2014
OD	PAR13-386	P30	Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	11/7/2013
OSP	PAR14-261	333	Innovation Corps (I-Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp)	6/18/2014

Source: Office of Referral, Review and Program Coordination.

**Table 4. NCI Participation in Trans-NIH Program Announcements (PA/PARs)
in FY2014**

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
10/17/2013	PAR13-374	R01	Modeling Social Behavior	DCCPS	NIH
10/18/2013	PAR13-375	R01	Nutrigenetics and Nutrigenomics Approaches for Nutrition Research	DCP	NIH
10/24/2013	PA13-381	333	Administrative Supplements to NIH Awards for Validation Studies of Analytical Methods for Natural Products	DCP	NIH
10/30/2013	PAR13-382	R21	Analysis of Genome-Wide Gene-Environment (G x E) Interactions	DCCPS	NIH
11/13/2013	PAR13-390	R03	Indo-U.S. Collaborative Program on Affordable Medical Devices	CGH	NIH
11/14/2013	PA14-003	333	Collaborative Activities to Promote Metabolomics Research	DCB	NIH
12/6/2013	PA14-015	T32	Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent)	CCT	NIH
	PAR14-017	SC2	Support of Competitive Research (SCORE) Pilot Project Award	CRCHD	
	PAR14-019	SC1	Support of Competitive Research (SCORE) Research Advancement Award	CCT	
12/10/2013	PA14-024	333	NIH/PEPFAR Collaboration for Implementation Science	OHAM	NIAID
12/11/2013	PA14-027	333	Administrative Supplements for Research on Sex/Gender Differences	OD	NIH
	PAR14-028	R21	Mobile Health: Technology and Outcomes in Low and Middle Income Countries	DCCPS	
12/13/2013	PA14-040	333	Administrative Supplement to Existing NIH Directors Biomedical Research Workforce Innovation Award: Broadening Experiences in Scientific Training (BEST)	ALL DIVISIONS	NIH
12/17/2013	PAR14-041	P30	Centers for AIDS Research and Developmental Centers for AIDS Research	OHAM	NIAID
12/19/2013	PA14-042	K99, R00	NIH Pathway to Independence Award (Parent)	CCT	NIH
	PA14-046	K08	Mentored Clinical Scientist Research Career Development Award (Parent)		
	PA14-047	K24	Midcareer Investigator Award in Patient-Oriented Research (Parent)		
	PA14-048	K25	Mentored Quantitative Research Development Award (Parent)		
	PA14-049	K23	Mentored Patient-Oriented Research Career Development Award (Parent)		
1/17/2014	PA14-071	R43, R44	PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR)	SBIRDC	NIH CDC FDA ACF
	PA14-072	R41, R42	PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR)		
1/29/2014	PA14-078	777	Change of Grantee Organization (Type 7 Parent)	N/A	NIH

continued

Source: Office of Referral, Review and Program Coordination.

Table 4 (cont'd). NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
1/30/2014	PA14-077	333	Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp)	N/A	NIH
	PA14-079	666	Successor-in-Interest (Type 6 Parent)		
2/5/2014	PAR14-088	R44	Direct Phase II SBIR Grants to Support Biomedical Technology Development	SBIRDC	NIH
2/6/2014	PAR14-092	R01	Bioengineering Research Partnerships (BRP)	DCTD	NIH
2/24/2014	PA14-114	R01	Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care	DCCPS	NIH
3/5/2014	PA14-146	333	Additional Research Training Positions for NIAAA-, NIDA-, or NCI-Supported NRSA Institutional Training (T32) Grants	CCT DCCPS	NIH
	PA14-147	F31	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent)	CCT	
3/7/2014	PA14-148	F31	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent-Diversity)	CRCHD	NIH
	PA14-149	F32	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent)	CCT	
	PA14-150	F30	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral MD/PhD or Other Dual-Doctoral Degree Fellowship (Parent)		
	PA14-151	F33	Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellowship (Parent)		
3/14/2014	PA14-155	R01	Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science	DCB	NIH
	PA14-156	R01	Extended Development, Hardening and Dissemination of Technologies in Biomedical Computing, Informatics and Big Data Science		
4/24/2014	PAR14-191	U41	Genomic Resource Grants for Community Resource Projects	DCCPS	NIH / NCI
5/2/2014	PAR14-201	333	Administrative Supplements for Research on Dietary Supplements	DCP	NIH
5/12/2014	PAR14-210	UH2, UH3	Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules	DCTD	NIH FDA
	PAR14-211	UH3	Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules		
	PAR14-212	UH2, UH3	Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules		
	PAR14-213	X02	Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules		
5/15/2014	PAR14-225	R01	Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain	DCP	NIH
5/19/2014	PAR14-230	R21, R33	Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia	DCCPS	NIH
	PAR14-231	R33			

continued

Source: Office of Referral, Review and Program Coordination.

Table 4 (cont'd). NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
6/10/2014	PAR14-255	R01	Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection	DCB	NIH
7/10/2014	PA14-276	R01	Ethical, Legal, and Social Implications (ELSI) of Genomic Research Regular Research Program	DCCPS	NIH
	PA14-277	R03	Ethical, Legal, and Social Implications (ELSI) of Genomic Research Small Research Grant Program		
	PA14-278	R21			
7/11/2014	PAR14-279	R01	Discovery of <i>In Vivo</i> Chemical Probes	DCTD	NIH
7/17/2014	PAR14-283	R21	High Throughput Screening (HTS) to Discover Chemical Probes	DCTD	NIH
	PAR14-284	R01			
8/12/2014	PA14-320	333	Administrative Supplements for Tobacco Regulatory Research on the Role and Impact of Flavors in Cigarettes, Cigars, E-Cigarettes and Smokeless Tobacco (Admin Supp)	DCCPS	NIH
	PAR14-315	R01	Testing Interventions for Health-Enhancing Physical Activity		
	PAR14-321	R21, R33	Developing Interventions for Health-Enhancing Physical Activity		
8/28/2014	PA14-328	333	Administrative Supplements for U.S.-Brazil Biomedical Collaborative Research	OSPO	NIH
9/5/2014	PA14-334	R01	Advancing Interventions to Improve Medication Adherence	DCCPS	NIH
	PA14-335	R21			

Source: Office of Referral, Review and Program Coordination.

Table 5. Applications Received for Referral by the NCI/DEA in FY2014
Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by NCAB			Total Costs Requested First Year
			Jan	May	Oct	
International Training Grants in Epidemiology (FIC)	D43	16	16	0	0	\$5,996,762
NIH Director's Pioneer Award (NDPA)	DP1	2	0	2	0	\$5,000,000
NIH Director's New Innovator Awards	DP2	11	0	11	0	\$16,500,000
Early Independence Award	DP5	1	0	0	1	\$436,882
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA)	F30	121	33	41	47	\$0
Predoctoral Individual National Research Service Award	F31	414	136	150	128	\$0
Postdoctoral Individual National Research Service Award	F32	296	96	111	89	\$0
Research Scientist Development Award – Research and Training	K01	41	7	24	10	\$5,463,220
Research Scientist Award	K05	11	4	2	5	\$928,773
Academic/Teacher Award	K07	68	20	27	21	\$9,874,369
Clinical Investigator Award	K08	80	24	23	33	\$13,240,022
Physician Scientist Award (Program)	K12	6	6	0	0	\$1,819,891
Career Transition Award	K22	108	39	38	31	\$16,553,731
Mentored Patient-Oriented Research Development Award	K23	27	11	10	6	\$4,824,818
Midcareer Investigator Award in Patient-Oriented Research	K24	8	2	2	4	\$1,330,187
Mentored Quantitative Research Career Development	K25	10	0	5	5	\$1,471,092
Career Transition Award	K99	237	67	119	51	\$26,215,423
Research Program Projects	P01	57	14	26	17	\$121,582,570
Exploratory Grants	P20	24	2	0	22	\$7,317,108
Center Core Grants	P30	20	14	3	3	\$69,443,631
Biotechnology Resource Grant Program	P41	1	0	0	1	\$1,548,342
Specialized Center	P50	45	13	27	5	\$100,074,100
Research Project	R01	5,731	2,164	1,775	1,792	\$2,804,835,755
Small Research Grants	R03	703	218	259	226	\$54,987,129
Conferences	R13	100	37	31	32	\$3,140,328
Academic Research Enhancement Awards (AREA)	R15	287	104	106	77	\$118,549,825
Exploratory/Developmental Grants	R21	3,384	1,191	999	1,194	\$765,906,019
Education Projects	R25	55	21	25	9	\$15,191,443
Exploratory/Developmental Grants Phase II	R33	101	31	27	43	\$45,796,581
Method to Extend Research in Time (MERIT) Award	R37	3	3	0	0	\$1,025,126

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (413) were not included in the total count.

Table 5 (cont'd). Applications Received for Referral by the NCI/DEA in FY2014
Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by NCAB			Total Costs Requested First Year
			Jan	May	Oct	
Small Business Technology Transfer (STTR) Grants – Phase I	R41	216	67	70	79	\$43,851,480
Small Business Technology Transfer (STTR) Grants – Phase II	R42	27	6	12	9	\$13,686,641
Small Business Innovation Research Grants (SBIR) – Phase I	R43	801	252	269	280	\$160,134,426
Small Business Innovation Research Grants (SBIR) – Phase II	R44	202	52	62	88	\$114,976,092
High Priority, Short Term Project Award	R56	5	1	4	0	\$0
Research Enhancement Award	SC1	3	2	1	0	\$1,036,965
Pilot Research Project	SC2	1	0	0	1	\$134,250
Intramural Clinical Scholar Research Award	SI2	5	5	0	0	\$0
Institutional National Research Service Award	T32	68	29	24	15	\$30,384,707
Research Project (Cooperative Agreements)	U01	214	72	101	41	\$135,539,004
Research Program (Cooperative Agreement)	U19	22	1	21	0	\$24,769,925
Resource-Related Research Project (Cooperative Agreements)	U24	19	11	8	0	\$14,438,672
Resource-Related Research Multi-Component Projects and Centers Cooperative Agreements	U2C	1	1	0	0	\$3,199,868
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	13	13	0	0	\$2,409,844
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	2	2	0	0	\$1,405,981
Specialized Center (Cooperative Agreements)	U54	195	0	190	5	\$419,858,266
Clinical Research Cooperative Agreements – Single Project	UG1	53	0	53	0	\$150,436,624
Exploratory/Developmental Cooperative Agreement Phase I	UH2	94	0	94	0	\$46,231,288
Research Project With Complex Structure Cooperative Agreement	UM1	67	37	30	0	\$96,503,460
Pre-application	X02	12	0	12	0	\$0
Overall Totals		13,988	4,824	4,794	4,370	\$5,478,050,620

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (413) were not included in the total count.

Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2014
Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by NCAB			Total Costs Requested First Year
			Jan	Feb	Oct	
Research Scientist Development Award – Research and Training	K01	32	7	15	10	\$4,042,583
Research Scientist Award	K05	11	4	2	5	\$928,773
Academic/Teacher Award	K07	68	20	27	21	\$9,874,369
Clinical Investigator Award	K08	75	22	21	32	\$12,451,904
Physician Scientist Award (Program)	K12	6	6	0	0	\$1,819,891
Career Transition Award	K22	108	39	38	31	\$16,553,731
Mentored Patient-Oriented Research Development Award	K23	25	10	9	6	\$4,426,643
Midcareer Investigator Award in Patient-Oriented Research	K24	7	2	2	3	\$1,213,706
Mentored Quantitative Research Career Development	K25	9	0	5	4	\$1,332,277
Career Transition Award	K99	192	57	94	41	\$21,820,190
Research Program Projects	P01	57	14	26	17	\$121,582,570
Exploratory Grants	P20	24	2	0	22	\$7,317,108
Center Core Grants	P30	13	7	3	3	\$54,746,070
Specialized Center	P50	45	13	27	5	\$100,074,100
Research Project	R01	442	313	5	124	\$246,712,939
Small Research Grants	R03	620	194	239	187	\$47,857,000
Conferences	R13	67	19	26	22	\$1,739,481
Exploratory/Developmental Grants	R21	2,365	798	651	916	\$536,506,498
Education Projects	R25	37	18	10	9	\$11,709,657
Exploratory/Developmental Grants Phase II	R33	91	31	27	33	\$41,992,634
Small Business Innovation Research Grants (SBIR) – Phase II	R44	12	0	0	12	\$12,867,282
Institutional National Research Service Award	T32	64	26	24	14	\$24,404,267
Research Project (Cooperative Agreements)	U01	150	48	67	35	\$89,576,469
Research Program (Cooperative Agreement)	U19	1	1	0	0	\$3,979,423
Resource-Related Research Project (Cooperative Agreements)	U24	19	11	8	0	\$14,438,672
Resource-Related Research Multi-Component Projects and Centers Cooperative Agreements	U2C	1	1	0	0	\$3,199,868
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	13	13	0	0	\$2,409,844
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	2	2	0	0	\$1,405,981
Specialized Center (Cooperative Agreements)	U54	26	0	22	4	\$21,034,161
Clinical Research Cooperative Agreements – Single Project	UG1	53	0	53	0	\$150,436,624
Exploratory/Developmental Cooperative Agreement Phase I	UH2	94	0	94	0	\$46,231,288
Research Project With Complex Structure Cooperative Agreement	UM1	66	36	30	0	\$94,015,676
Overall Totals		4,795	1,714	1,525	1,556	\$1,708,701,679

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (181) were not included in the total count.

Table 7. Applications Reviewed by NCI IRG Subcommittees and Special Emphasis Panels (SEPs) in FY2014

NCI IRG Subcommittee	Types of Applications Reviewed	Number of Applications	Total Costs Requested First Year
A - Cancer Centers	P30	12	\$51,683,977
F - Institutional Training and Education	K12, R25, T32	105	\$37,382,041
I - Transition to Independence	K01, K22, K25, K99	247	\$30,213,522
J - Career Development	K05, K07, K08, K23, K24	183	\$28,406,471
Totals - NCI IRG Subcommittees		547	\$147,686,011
Total SEPs	K01, K07, K08, K22, K23, K4, K99, P01, P20, P30, P50, R01, R03, R13, R21, R33, R44, T32, U01, U19, U24, U2C, U43, U44, U54, UG1, UH2, UM1	4,248	\$1,561,015,668
TOTAL		4,795	\$1,708,701,679

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (204) were not included in the total count.

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed in FY2014

Type of Application	Applications by Board			FY 2014 Total
	February 2014	June 2014	September 2014	
New	5	10	8	23
Resubmitted New	0	0	1	1
Renewal	4	7	7	18
Resubmitted Renewal	5	6	1	12
Revisions	0	3	0	3
Total	14	26	17	57

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications.

Table 9. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2014

Program Division	Number of Applications	Total Costs Requested First Year	Total Costs for Requested Period
Division of Cancer Biology (DCB)	20	\$41,134,611	\$212,298,800
Division of Cancer Control and Population Sciences (DCCPS)	4	\$9,444,993	\$47,527,552
Division of Cancer Prevention (DCP)	5	\$14,272,467	\$72,099,538
Division of Cancer Treatment and Diagnosis (DCTD)	28	\$56,730,499	\$285,161,480
Total	57	\$121,582,570	\$617,087,370

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2014

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Jan	May	Oct	
Research Answers to NCI's Provocative Questions – Group A	CA12-015	R01	80	80	0	0	\$44,314,421
	CA13-016		13	0	0	13	\$6,906,813
	CA12-016	R21	54	54	0	0	\$11,994,564
	CA13-017		5	0	0	5	\$1,174,781
Research Answers to NCI's Provocative Questions – Group B	CA12-017	R01	73	73	0	0	\$40,790,389
	CA13-018		19	0	0	19	\$11,285,990
	CA12-018	R21	47	47	0	0	\$10,669,990
	CA13-019		9	0	0	9	\$1,969,850
Research Answers to NCI's Provocative Questions – Group C	CA12-019	R01	70	70	0	0	\$40,255,920
	CA13-020		14	0	0	14	\$8,223,059
	CA12-020	R21	46	46	0	0	\$10,379,608
	CA13-021		16	0	0	16	\$3,415,619
Research Answers to NCI's Provocative Questions – Group D	CA12-021	R01	84	84	0	0	\$42,605,451
	CA13-022		14	0	0	14	\$7,355,343
	CA12-022	R21	46	46	0	0	\$10,586,674
	CA13-023		7	0	0	7	\$1,687,224
Research Answers to NCI's Provocative Questions – Group E	CA13-024	R01	4	0	0	4	\$2,536,157
	CA13-025	R21	1	0	0	1	\$266,550
Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	CA13-001	R21	87	33	54	0	\$23,565,615
	CA14-003		55	0	0	55	\$14,258,122
Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	CA13-002	R33	45	24	21	0	\$20,321,499
	CA14-004		23	0	0	23	\$10,967,372
Early-Stage Development of Innovative Technologies for Biospecimen Science	CA13-003	R21	18	8	10	0	\$4,664,436
	CA14-005		11	0	0	11	\$3,213,706
Validation and Advanced Development of Emerging Technologies for Biospecimen Science	CA13-004	R33	13	7	6	0	\$6,110,563
	CA14-006		10	0	0	10	\$4,593,200
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN)	CA13-006	UM1	21	21	0	0	\$17,845,417
Collaborative Human Tissue Network (CHTN)	CA13-007	UM1	9	9	0	0	\$9,997,729
Person-Centered Outcomes Research Resource	CA13-008	U2C	1	1	0	0	\$3,199,868
Sub-Saharan African Collaborative HIV and Cancer Consortia	CA13-010	U54	16	0	16	0	\$11,878,740
NCI Community Oncology Research Program (NCORP) Research Bases	CA13-012	UG1	7	0	7	0	\$63,722,264
	CA13-012	UM1	3	0	3	0	\$12,958,674

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (127) were not included in the total count.

Table 10 (cont'd). Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2014

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Jan	May	Oct	
NCI Community Oncology Research Program (NCORP) – Community Sites	CA13-013	UG1	34	0	34	0	\$72,989,201
	CA13-013	UM1	11	0	11	0	\$15,149,099
NCI Community Oncology Research Program (NCORP) – Minority/Underserved Community Sites	CA13-014	UG1	12	0	12	0	\$13,725,159
	CA13-014	UM1	9	0	9	0	\$10,635,022
Cancer Detection, Diagnostic and Treatment Technologies for Global Health	CA13-015	UH2	94	0	94	0	\$46,231,288
Limited Competition: Adult Brain Tumor Consortium (ABTC)	CA13-501	UM1	1	1	0	0	\$2,000,000
Limited Competition: Pediatric Brain Tumor Consortium	CA13-502	UM1	1	1	0	0	\$2,590,000
Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data	CA14-001	U54	6	0	6	0	\$3,898,765
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization	CA14-002	R44	12	0	0	12	\$12,867,282
Using Social Media to Understand and Address Substance Use and Addiction	CA14-008	R01	58	0	0	58	\$31,476,085
	CA14-009	R21	57	0	0	57	\$12,099,069
Totals			1,216	605	283	328	\$687,376,578

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (127) were not included in the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2014

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Jan	May	Oct	
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants	PA11-184	T32	50	26	24	0	\$19,581,478
	PA14-015		14	0	0	14	\$4,822,789
Mentored Clinical Scientist Research Career Development Award	PA11-193	K08	39	18	21	0	\$6,322,887
	PA14-046		31	0	0	31	\$5,289,790
Mentored Patient-Oriented Research Career Development Award	PA11-194	K23	17	8	9	0	\$3,092,238
	PA14-049		4	0	0	4	\$694,811
Midcareer Investigator Award in Patient-Oriented Research	PA11-195	K24	4	2	2	0	\$752,172
	PA14-047		3	0	0	3	\$461,534
Mentored Quantitative Research Development Award	PA11-196	K25	5	0	5	0	\$726,757
	PA14-048		4	0	0	4	\$605,520
NIH Pathway to Independence Award	PA11-197	K99	151	57	94	0	\$17,243,262
	PA14-042		41	0	0	41	\$4,576,928
Research Project Grant	PA11-260	R01	4	4	0	0	\$3,914,171
	PA13-302		6	0	4	2	\$6,317,874
NIH Exploratory/Developmental Research Grant Program	PA11-261 PA13-303	R21	0	0	0	0	\$0
NIH Support for Conferences and Scientific Meeting	PA12-212	R13	19	19	0	0	\$442,103
	PA13-347		48	0	26	22	\$1,297,378
National Cancer Institute (NCI) Cancer Education and Career Development Program	PAR10-165	R25	10	10	0	0	\$4,054,481
	PAR12-049		27	8	10	9	\$7,655,176
Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR)	PAR10-286	U43	13	13	0	0	\$2,409,844
		U44	2	2	0	0	\$1,405,981
Cancer Prevention Research Small Grant Program	PAR11-079	R03	87	42	45	0	\$6,561,340
Quantitative Imaging for Evaluation of Responses to Cancer Therapies	PAR11-150	U01	38	11	18	9	\$25,603,615
Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	PAR11-167	UM1	11	4	7	0	\$22,839,735
National Cancer Institute Program Project Applications	PAR12-005	P01	14	14	0	0	\$32,209,610
		U19	1	1	0	0	\$3,979,423
		PAR13-321	P01	42	0	25	17
Small Grants Program for Cancer Epidemiology	PAR12-039	R03	104	35	35	34	\$8,225,908
NCI Mentored Research Scientist Development Award to Promote Diversity	PAR12-050	K01	32	7	15	10	\$4,042,583

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (77) were not included in the total count.

Table 11 (cont'd). Program Announcements (PAs) Reviewed by the NCI/DEA in FY2014

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Jan	May	Oct	
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	PAR12-051	K08	5	4	0	1	\$839,227
NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	PAR12-052	K23	4	2	0	2	\$639,594
Limited Competition: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)	PAR12-055	U54	4	0	0	4	\$5,256,656
The NCI Transition Career Development Award to Promote Diversity	PAR12-062	K22	15	7	4	4	\$2,219,119
NCI Established Investigator Award in Cancer Prevention and Control	PAR12-065	K05	11	4	2	5	\$928,773
Cancer Prevention, Control, Behavioral Sciences and Population Sciences Career Development Award	PAR12-067	K07	68	20	27	21	\$9,874,369
The NCI Transition Career Development Award	PAR12-121	K22	93	32	34	27	\$14,334,612
NCI Small Grants Program for Cancer Research (NCI Omnibus R03)	PAR12-144	R03	276	117	159	0	\$21,379,336
	PAR14-007		153	0	0	153	\$11,690,416
Revisions for Early-Stage Development of Informatics Technology	PAR12-286	R01	3	2	1	0	\$731,266
	PAR12-289	U01	3	2	1	0	\$835,388
Advanced Development of Informatics Technology	PAR12-287	U24	11	11	0	0	\$8,053,911
	PAR13-294		8	0	8	0	\$6,384,761
Early-Stage Development of Informatics Technology	PAR12-288	U01	31	8	23	0	\$12,444,442
Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	PAR12-296	P50	35	9	26	0	\$87,292,593
	PAR14-031		5	0	0	5	\$11,499,998
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	PAR12-298	P30	10	7	3	0	\$34,411,734
	PAR13-386		3	0	0	3	\$20,334,336
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research	PAR13-036	U01	30	13	0	17	\$18,929,419
Bridging the Gap Between Cancer Mechanism and Population Science	PAR13-081	U01	8	0	8	0	\$5,209,793
Planning for a National Center for Particle Beam Radiation Therapy Research	PAR13-096	P20	2	2	0	0	\$996,457
	PAR13-371		6	0	0	6	\$2,998,929
NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)	PAR13-146	R21	1,906	564	587	755	\$426,560,690
The Role of Microbial Metabolites in Cancer Prevention and Etiology	PAR13-159	U01	7	0	7	0	\$4,631,124
Revisions Applications to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	PAR13-170	P50	2	2	0	0	\$513,064

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (77) were not included in the total count.

Table 11 (cont'd). Program Announcements (PAs) Reviewed by the NCI/DEA in FY2014

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Jan	May	Oct	
Revision Applications to U01 Awards on Detection of Pathogen-Induced Cancer (DPIC)	PAR13-173	U01	1	1	0	0	\$231,750
Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	PAR13-174	P50	2	2	0	0	\$508,200
	PAR13-318		1	0	1	0	\$260,245
Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	PAR13-176	U01	2	1	1	0	\$507,388
Collaborative Research in Integrative Cancer Biology	PAR13-184	U01	21	12	9	0	\$15,287,617
Paul Calabresi Career Development Award for Clinical Oncology	PAR13-201	K12	6	6	0	0	\$1,819,891
Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	PAR13-317	P01	1	0	1	0	\$230,186
Opportunities for Collaborative Research at the NIH Clinical Center	PAR13-358	U01	9	0	0	9	\$5,895,933
Feasibility Studies to Build Collaborative Partnerships in Cancer Research	PAR14-152	P20	16	0	0	16	\$3,321,722
Totals			3,579	1,109	1,242	1,228	\$1,021,325,101

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (77) were not included in the total count.

Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2014*

Announcement/ Topic Number	Announcement Title	Work- load Round	No. of Proposals
Topic 326	Development of Novel Therapeutic Agents That Target Cancer Stem Cells	May-14	27
Topic 327 (Phase I & FastTrack)	Reformulation of Failed Chemotherapeutic Drugs	May-14	16 (1 FT)
Topic 328 (Phase I & FastTrack)	Validation of 3D Human Tissue Culture Systems That Mimic the Tumor Microenvironment	May-14	24 (3 FT)
Topic 329 (Phase I & FastTrack)	Proteomic Analysis of Single Cells Isolated From Solid Tumors	May-14	1
Topic 330 (Phase I & FastTrack)	Generation of Site-Specific Phospho-Threonine Protein Standards for Use in Cancer Assays	May-14	8
Topic 331 (Phase I & FastTrack)	Development of a Biosensor-Based Core Needle Tumor Biopsy Device	May-14	9
Topic 332 (Phase I & FastTrack)	Development of Radiation Modulators for Use During Radiotherapy	May-14	22 (5 FT)
Topic 333 (Phase I & FastTrack)	Software Tools for the Development of Environmental Measures Related to Cancer Health Behaviors and Resources	May-14	14 (1 FT)
Phase II Topics from Earlier Phase I Awards			
Topic 255	Development of Anticancer Agents	Oct-14	2
Topic 277	Development of Companion Diagnostics	Oct-14	2
Topic 300	Reformulation of Cancer Therapeutics Using Nanotechnology	Oct-14	2
Topic 312	Generation and Qualification of Site-Specific Post-Translationally Modified Proteins for Use as Calibrators in Pharmacodynamic (PD) Assays	Oct-14	1
Topic 291	Development of Radiation Modulators for Use During Radiotherapy	Oct-14	1
Topic 301	Probing Tumor Microenvironment Using <i>In Vivo</i> Nanotechnology-Based Sensors	Oct-14	2
Topic 305	Novel Digital X-ray Sources for Cancer Imaging Applications	Oct-14	1
Topic 306	Development of Innovative Algorithms for Processing & Analysis of <i>In Vivo</i> Images	Oct-14	2
Topic 307	Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment	Oct-14	5
Topic 308	Automated Collection, Storage, Analysis, and Reporting Systems for Dietary Images	Oct-14	3
Topic 309	Development of Low Cost, Small Sample Multi-Analyte Technologies for Cancer Diagnosis, Prognosis and Early Detection	Oct-14	5
Topic 314	Development of Human Tissue Culture Systems That Mimic the Tumor Microenvironment	Oct-14	2
Other Solicitations Reviewed in DEA			
N01 CO42400-80	Cancer Genomics Cloud Pilots	Oct-14	14
N01 CP41003-72	Support for Epidemiological Studies of Cancer Among Atomic Bomb Survivors (Sole Source)	Oct-14	1
L30 (OD13-081)	Loan Repayment Program for Clinical Researchers	Oct-14	267
L40 (OD13-083)	Loan Repayment Program for Pediatric Researchers	Oct-14	81
TOTAL			512

* The proposals were in response to SBIR Contract Solicitations - Phase I (111) and Fast Track-Phase I/II (10), Phase II (28), RFPs (N01) (15) and Loan Repayment (L30/L40) (348).

Source: Office of Referral, Review and Program Coordination.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2014*

Fund Type: Appropriated Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants		Competing Requested	Fiscal Year: 2014		
				Number	Dollars		Competing Awarded	Success Rate	
Research Project Grants									
Traditional Research Grants – R01/RL1	3,085	1,166,410,039	378,091	48.41%	38.1 %	3,849	578	15.02%	
Program Projects – P01	109	211,170,561	1,937,345	1.71%	6.9 %	54	18	33.33%	
Small Grants – R03	194	15,078,085	77,722	3.04%	0.49%	627	93	14.83%	
Exploratory/Developmental Research – R21	551	102,957,573	186,856	8.65%	3.36%	2,539	302	11.89%	
Phased Innovation Grant (Phase 2) – R33	0	0	0	0.0 %	0.0 %	0	0	0.0 %	
Pathway to Independence – R00	84	19,652,434	233,958	1.32%	0.64%	0	0	0.0 %	
Exploratory/Development Cooperative Agreements – UH2/UH3	1	627,224	627,224	0.02%	0.02%	0	0	0.0 %	
Merit Awards – R37	25	11,391,328	455,653	0.39%	0.37%	5	2	40.0 %	
NIH Director Pioneer Award (NDPA) – DP1	4	4,024,293	1,006,073	0.06%	0.13%	0	0	0.0 %	
NIH Director New Innovator Awards – DP2	3	7,488,829	2,496,276	0.05%	0.24%	3	3	100.0 %	
NIH Director's Early Independence Awards – DP5	6	2,317,871	386,312	0.09%	0.08%	0	0	0.0 %	
Academic Research Enhancement Awards (AREA) – R15	23	9,875,442	429,367	0.36%	0.32%	228	23	10.09%	
Multi-Component Research Project Cooperative Agreements – UM1	15	29,648,844	1,976,590	0.24%	0.97%	15	4	26.67%	
Cooperative Agreements – U01/U19	133	76,039,169	571,723	2.09%	2.48%	205	45	21.95%	
Request for Applications	263	96,030,511	365,135	4.13%	3.14%	959	119	12.41%	
Cooperative Agreements – RFA – U01/U19	101	105,070,580	1,040,303	1.58%	3.43%	55	20	36.36%	
Small Business Innovative Research – R43/R44	171	66,878,234	391,101	2.68%	2.18%	727	129	17.74%	
Small Business Technology Transfer – R41/R42	46	14,962,728	325,277	0.72%	0.49%	176	42	23.86%	
Program Evaluation – R01	0	72,936,000	72,936,000	0.0 %	2.38%	0	0	0.0 %	
Subtotal Research Project Grants	4,814	2,012,559,745	418,064	75.54%	65.73%	9,442	1,378	14.59%	
Other Research									
Clinical Cooperative Groups – U10/ UG1	102	263,347,218	2,581,835	1.6 %	8.6 %	135	101	74.81%	
Clinical Cooperative Groups – U10 Specials	0	3,800,000	3,800,000	0.0 %	0.12%	0	0	0.0 %	
Clinical Cooperative Groups – CCCT	0	4,487,361	4,487,361	0.0 %	0.15%	0	0	0.0 %	
Conference Grants – R13	54	758,248	14,042	0.85%	0.02%	63	42	66.67%	
International Research Training Grants Conference – D43	0	958,051	958,051	0.0 %	0.03%	0	0	0.0 %	
Continuing Education Training Grants – T15/RL9	1	100,323	100,323	0.02%	0.0 %	0	0	0.0 %	
Cancer Education Awards – R25	96	32,932,180	343,044	1.51%	1.08%	47	18	38.3 %	
Research/Resource Grant – R24/U24/ U2C	25	55,897,698	2,235,908	0.39%	1.83%	21	7	33.33%	
Invalid Budget Mechanism	0	6,000,000	6,000,000	0.0 %	0.2 %	0	0	0.0 %	
Subtotal Other Research	278	368,281,079	1,324,752	4.36%	12.03%	266	168	63.16%	

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

Source: Office of Extramural Finance and Information Analysis.

Table 13 (cont'd). Summary of NCI Grant Awards by Mechanism in FY2014*

Fund Type: Appropriated Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants		Fiscal Year: 2014		
				Number	Dollars	Competing Requested	Competing Awarded	Success Rate
Centers								
Core/Planing – P20/P30	86	276,579,866	3,216,045	1.35%	9.03%	39	23	58.97%
Core – CCCT	0	5,241,314	5,241,314	0.0 %	0.17%	0	0	0.0 %
Center for AIDS Research – CFAR – OHAM – P30	0	24,045	24,045	0.0 %	0.0 %	0	0	0.0 %
Invalid Budget Mechanism	0	1,084,000	1,084,000	0.0 %	0.04%	0	0	0.0 %
Spore Grants – P50	50	104,601,905	2,092,038	0.78%	3.42%	42	11	26.19%
Other P50/P20	11	18,203,343	1,654,849	0.17%	0.59%	0	0	0.0 %
Specialized Center (Cooperative Agreement)	111	138,509,205	1,247,831	1.74%	4.52%	25	13	52.0 %
Subtotal Centers	258	544,243,678	2,109,472	4.05%	17.78%	106	47	44.34%
National Research Service Awards (NRSA)								
NRSA Institution – T32/T35	139	49,704,248	357,585	2.18%	1.62%	61	28	45.9 %
NRSA Fellowships – F31/F32	485	19,512,900	40,233	7.61%	0.64%	680	196	28.82%
Subtotal NRSA	624	69,217,148	110,925	9.79%	2.26%	741	224	30.23%
Careers								
Mentored Clinical Scientist – K08	100	16,018,409	160,184	1.57%	0.52%	67	18	26.87%
Preventive Oncology Award – K07	59	8,745,014	148,221	0.93%	0.29%	66	12	18.18%
Mentored Career Award – K12	15	11,647,327	776,488	0.24%	0.38%	6	2	33.33%
Mentored Research Scientist Development Awards/Mentored Career Development/Temin – K01	49	6,243,040	127,409	0.77%	0.2 %	32	10	31.25%
Clinical Research Track – K22	27	4,481,622	165,986	0.42%	0.15%	114	15	13.16%
Mentored Patient-Oriented Research Career Dev A – K23	31	5,166,481	166,661	0.49%	0.17%	28	5	17.86%
Mid-Career Investigator in Patient- Oriented Research Award – K24	17	2,921,508	171,853	0.27%	0.1 %	5	4	80.0 %
Mentored Quantitative Research Career Development Award – K25	15	2,103,468	140,231	0.24%	0.07%	11	4	36.36%
Established Investigator Award in Cancer Prevention & Control – K05	15	1,787,792	119,186	0.24%	0.06%	8	3	37.5 %
Pathway to Independence – K99	71	8,410,172	118,453	1.11%	0.27%	179	46	25.7 %
Subtotal Careers	399	67,524,833	169,235	6.26%	2.21%	516	119	23.06%
Total:	6,373	3,061,826,483	480,437	100.0 %	100.0 %	11,071	1,936	17.49%

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

Source: Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2010 – FY2014

Budget Mechanism/ Division	FY 2010		FY 2011		FY 2012		FY 2013		FY 2014		Percent Change 2010 - 2014	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
R01 Average Cost of Award												
NCI Overall	3,655	362	3,648	365	3,526	374	3,306	358	3,085	378	-15.6 %	4.42%
DCB	1,783	313	1,748	317	1,660	323	1,555	312	1,441	330	-19.2 %	5.3 %
DCP	261	399	258	400	245	421	226	389	201	434	-23.0 %	8.9 %
DCTD	1,107	336	1,141	343	1,139	355	1,078	342	1,041	362	-6.0 %	7.8 %
DCCPS	486	561	485	553	468	559	436	521	391	542	-19.5 %	-3.5 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	18	911	16	901	14	924	11	1,221	11	1,343	-38.9 %	47.4 %
R01 Average Cost of Award												
NCI Overall	140	2,004	129	2,010	122	1,997	124	1,868	109	1,937	-22.14%	-3.34%
DCB	56	1,783	53	1,804	54	1,771	54	1,612	45	1,708	-19.6 %	-4.2 %
DCP	7	1,737	8	1,814	8	1,579	7	1,414	7	1,652	0.0 %	-4.9 %
DCTD	64	2,188	58	2,164	49	2,194	53	2,063	48	2,018	-25.0 %	-7.8 %
DCCPS	12	2,161	10	2,298	11	2,502	10	2,517	9	2,836	-25.0 %	31.2 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	1	2,576	0	638	0	306	0	155	0	343	-100.0 %	-86.7 %
R03 Average Cost of Award												
NCI Overall	181	78	127	76	172	76	199	77	194	78	7.18%	0.0 %
DCB	8	78	3	75	10	76	11	75	22	76	175.0 %	-2.8 %
DCP	56	78	38	75	61	78	63	77	48	78	-14.3 %	-0.7 %
DCTD	10	77	6	76	10	78	15	76	24	78	140.0 %	0.7 %
DCCPS	107	79	80	77	91	75	110	77	100	78	-6.5 %	-0.6 %
R21 Average Cost of Award												
NCI Overall	415	202	442	200	439	197	441	188	551	187	32.77%	-7.43%
DCB	77	188	79	181	80	187	90	185	138	188	79.2 %	0.0 %
DCP	50	187	51	183	54	188	54	181	44	172	-12.0 %	-8.3 %
DCTD	198	218	207	220	188	215	190	194	242	194	22.2 %	-10.9 %
DCCPS	82	185	80	178	89	176	78	179	93	174	13.4 %	-5.9 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	8	217	25	205	28	186	29	195	34	182	325.0 %	-15.8 %

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† In thousands.

Source: Office of Extramural Finance and Information Analysis.

Table 14 (cont'd). Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2010 – FY2014

Budget Mechanism/ Division	FY 2010		FY 2011		FY 2012		FY 2013		FY 2014		Percent Change 2010 - 2014	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
U01/U19 Average Cost of Award												
NCI Overall	131	1,091	130	1,062	132	989	115	1,093	79	988	-39.69%	-9.44%
DCB	28	776	29	721	28	714	28	665	1	1,065	-96.4 %	37.3 %
DCP	35	741	35	671	36	681	36	674	35	546	0.0 %	-26.3 %
DCTD	28	1,461	26	1,313	23	939	5	3,621	1	3,820	-96.4 %	161.6 %
DCCPS	23	1,598	23	1,752	22	1,761	22	1,593	16	1,570	-30.4 %	-1.8 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	17	1,039	17	1,135	23	1,119	24	1,235	26	1,113	52.9 %	7.1 %
R13 Average Cost of Award												
NCI Overall	95	76	92	65	64	89	57	15	54	14	-43.16%	-81.58%
DCB	36	9	35	4	22	6	24	5	22	6	-38.9 %	-33.6 %
DCP	8	12	9	15	5	19	6	18	3	34	-62.5 %	183.3 %
DCTD	19	12	16	11	14	14	15	8	18	6	-5.3 %	-44.8 %
DCCPS	17	20	17	14	11	21	7	19	8	21	-52.9 %	2.0 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	15	418	15	349	12	418	5	69	3	84	-80.0 %	-80.0 %
U10 Average Cost of Award												
NCI Overall	131	1,937	135	1,801	128	1,789	120	1,958	49	3,637	-62.6 %	87.76%
DCP	71	1,330	77	1,160	75	1,165	75	1,130	0	11,012	-100.0 %	728.0 %
DCTD	60	2,655	58	2,653	53	2,671	45	3,337	49	3,412	-18.3 %	28.5 %
P30 Average Cost of Award												
NCI Overall	66	4,446	66	4,168	67	4,134	68	3,823	68	4,098	3.03%	-7.83%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	66	4,446	66	4,168	67	4,133	68	3,823	68	4,098	3.0 %	-7.8 %
P50 Average Cost of Award												
NCI Overall	75	2,081	74	1,979	69	2,010	66	1,895	61	2,012	-18.67%	-3.32%
DCP	0	400	0	400	0	400	0	388	0	388	0.0 %	-3.0 %
DCTD	65	2,101	64	1,999	59	2,044	59	1,907	56	2,032	-13.8 %	-3.3 %
DCCPS	10	1,847	10	1,739	10	1,686	7	1,651	5	1,676	-50.0 %	-9.2 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	617	0	701	0	813	0	600	0	138	0.0 %	-77.6 %

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† In thousands.

Source: Office of Extramural Finance and Information Analysis.

Table 14 (cont'd). Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2010 – FY2014

Budget Mechanism/ Division	FY 2010		FY 2011		FY 2012		FY 2013		FY 2014		Percent Change 2010 - 2014	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
SBIR Average Cost of Award												
NCI Overall	180	411	123	587	151	422	132	444	171	391	-5.0 %	-4.87%
CRCHD	0	85	0	83	0	0	0	0	0	0	0.0 %	-100.0 %
DCTD	0	0	0	0	0	0	0	0	0	66	0.0 %	100.0 %
DCCPS	0	0	0	32	0	0	0	0	0	0	0.0 %	0.0 %
SBIRDC	180	411	123	586	151	422	132	444	171	391	-5.0 %	-4.9 %
STTR Average Cost of Award												
NCI Overall	27	431	21	562	39	350	27	469	46	325	70.37%	-24.59%
SBIRDC	0	0	21	562	39	350	27	469	46	325	100.0 %	100.0 %
STTRDC	27	431	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
U54 Average Cost of Award												
NCI Overall	93	1,453	101	1,523	103	1,709	106	1,316	99	1,268	6.45%	-12.73%
CRCHD	51	1,066	47	1,152	49	1,110	50	940	49	978	-3.9 %	-8.2 %
CSSI	18	2,776	21	2,468	21	3,630	21	2,155	9	2,343	-50.0 %	-15.6 %
DCB	20	1,492	22	1,400	22	1,441	24	1,343	30	1,288	50.0 %	-13.7 %
DCCPS	4	230	11	1,551	11	1,244	11	1,365	11	1,626	175.0 %	607.0 %

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† In thousands.

Source: Office of Extramural Finance and Information Analysis.

**Table 15. NCI Organ and Related Site-Specific Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Adrenal	Number of Grants	9	6	6	3	3	
	Relevant Grant Dollars	908,434	557,068	694,479	334,332	440,344	
	Total Count	9	6	6	3	3	
	Total Relevant Dollars	908,434	557,086	694,479	334,332	440,344	-8.54
Anus	Number of Grants	14	16	18	19	19	
	Relevant Grant Dollars	1,996,111	2,740,690	2,539,326	3,730,597	3,860,964	
	Number of Contracts	‡	3	‡	‡	‡	
	Relevant Contract Dollars	‡	446,435	‡	‡	‡	
	Total Count	14	19	18	19	19	
Total Relevant Dollars	1,996,111	3,187,125	2,539,326	3,730,597	3,860,964	22.44	
Bladder	Number of Grants	208	176	143	124	147	
	Relevant Grant Dollars	18,941,518	15,777,763	18,493,415	15,767,632	23,221,839	
	Number of Contracts	3	1	1	1	‡	
	Relevant Contract Dollars	25,113	176,266	749,947	561,614	‡	
	Total Count	211	177	144	125	147	
Total Relevant Dollars	18,966,631	15,954,029	19,243,362	16,329,246	23,221,839	7.95	
Bone Marrow	Number of Grants	92	76	55	67	40	
	Relevant Grant Dollars	13,124,422	17,343,897	8,938,608	8,109,194	6,186,065	
	Total Count	92	76	55	67	40	
	Total Relevant Dollars	13,124,422	17,343,897	8,938,608	8,109,194	6,186,065	-12.33
Bone, Cartilage	Number of Grants	98	90	72	68	54	
	Relevant Grant Dollars	18,014,359	14,539	10,824,238	7,034,582	4,313,783	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	98	90	72	68	54	
Total Relevant Dollars	18,014,359	14,539,162	10,824,238	7,034,582	4,313,783	-29.63	
Brain	Number of Grants	498	500	512	544	557	
	Relevant Grant Dollars	131,178,363	143,786,108	148,032,345	152,082,930	162,133,244	
	Number of Contracts	3	3	5	2	2	
	Relevant Contract Dollars	217,734	698,895	672,916	1,639,630	422,895	
	Total Count	501	503	517	546	559	
Total Relevant Dollars	131,396,097	144,485,003	148,705,261	153,722,560	162,556,139	5.50	
Breast	Number of Grants	1,934	1,859	1,835	1,792	1,811	
	Relevant Grant Dollars	569,062,367	552,999,395	536,444,140	501,581,607	478,792,611	
	Number of Contracts	32	20	25	20	10	
	Relevant Contract Dollars	7,908,595	9,370,644	12,810,843	11,117,661	5,422,635	
	Total Count	1,966	1,879	1,860	1,812	1,821	
Total Relevant Dollars	576,970,962	562,370,039	549,254,983	512,699,268	483,879,269	-4.27	
Central Nervous System	Number of Grants	43	35	51	59	48	
	Relevant Grant Dollars	6,255,071	5,370,246	4,169,107	3,630,469	1,739,620	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	43	35	51	59	48	
Total Relevant Dollars	6,255,071	5,770,246	4,169,107	3,630,469	1,739,620	-25.13	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Cervix	Number of Grants	298	295	298	283	305	
	Relevant Grant Dollars	61,579,940	60,341,462	58,198,274	50,597,621	52,183,192	
	Number of Contracts	5	4	3	1	1	
	Relevant Contract Dollars	4,759,619	4,729,585	3,366,401	2,280,313	740,476	
	Total Count	303	299	301	284	306	
	Total Relevant Dollars	66,339,559	65,071,047	61,564,675	52,877,934	52,923,668	-5.33
Childhood Leukemia	Number of Grants	148	157	178	151	159	
	Relevant Grant Dollars	49,924,922	33,329,128	51,786,291	51,230,678	36,743,720	
	Number of Contracts	‡	‡	‡	‡	1	
	Relevant Contract Dollars	‡	‡	‡	‡	45,000	
	Total Count	148	157	178	151	160	
	Total Relevant Dollars	49,924,922	33,291,283	51,786,291	51,230,678	36,788,720	-1.76
Colon, Rectum	Number of Grants	984	951	937	916	866	
	Relevant Grant Dollars	245,295,756	242,486,775	227,386,183	213,714,476	198,038,574	
	Number of Contracts	16	11	14	9	6	
	Relevant Contract Dollars	6,412,331	4,299,256	6,246,343	4,230,994	3,024,309	
	Total Count	1,000	962	951	925	872	
	Total Relevant Dollars	251,708,087	246,786,031	233,632,526	217,945,470	201,062,883	-5.44
Connective Tissue	Number of Grants	51	56	44	21	13	
	Relevant Grant Dollars	10,417,011	9,999,338	8,185,709	3,310,900	3,141,987	
	Total Count	51	56	44	21	13	
	Total Relevant Dollars	10,417,011	9,999,338	8,185,709	3,310,900	3,141,987	-21.70
Embryonic Tissue, Cells	Number of Grants	10	8	5	3	2	
	Relevant Grant Dollars	1,477,847	1,325,565	368,936	340,919	145,522	
	Total Count	10	8	5	3	2	
	Total Relevant Dollars	1,477,847	1,325,565	368,936	340,919	145,522	-36.85
Esophagus	Number of Grants	100	118	147	175	117	
	Relevant Grant Dollars	25,599,073	28,238,207	23,801,157	23,146,386	24,631,620	
	Number of Contracts	‡	1	2	1	‡	
	Relevant Contract Dollars	‡	20,000	229,905	12,726	‡	
	Total Count	100	119	149	176	117	
	Total Relevant Dollars	25,599,073	28,258,207	24,031,062	23,159,112	24,631,620	-0.46
Eye	Number of Grants	13	12	14	16	17	
	Relevant Grant Dollars	2,168,685	2,161,882	2,008,983	2,362,025	2,855,615	
	Total Count	13	12	14	16	17	
	Total Relevant Dollars	2,168,685	2,161,882	2,008,983	2,362,025	2,855,615	7.77
Gall Bladder	Number of Grants	1	16	2	2	2	
	Relevant Grant Dollars	212,356	199,485	156,086	146,805	‡	
	Total Count	1	16	2	2	2	
	Total Relevant Dollars	212,356	199,485	156,086	146,805	‡	-11.25
Gastrointestinal Tract	Number of Grants	51	48	50	45	35	
	Relevant Grant Dollars	8,649,596	8,306,179	9,181,848	7,398,956	5,831,855	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	51	48	50	45	35	
	Total Relevant Dollars	8,649,596	8,306,179	9,181,848	7,398,956	5,831,855	-8.51

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Genital System, Female	Number of Grants	12	19	38	43	74	
	Relevant Grant Dollars	1,255,368	1,708,702	2,136,318	2,875,521	1,800,605	
	Number of Contracts	5	1	‡	‡	‡	
	Relevant Contract Dollars	336,493	187,496	‡	‡	‡	
	Total Count	17	20	38	43	74	
	Total Relevant Dollars	1,591,861	1,896,198	2,136,318	2,875,521	1,800,605	7.25
Genital System, Male	Number of Grants	6	5	6	2	2	
	Relevant Grant Dollars	549,031	334,581	350,827	237,891	241,644	
	Number of Contracts	5	‡	‡	‡	‡	
	Relevant Contract Dollars	336,493	‡	‡	‡	‡	
	Total Count	11	5	6	2	2	
	Total Relevant Dollars	885,524	334,581	350,827	237,891	241,644	-21.99
Head and Neck	Number of Grants	204	201	217	248	226	
	Relevant Grant Dollars	41,468,691	39,623,318	37,034,455	33,677,355	33,439,973	
	Number of Contracts	7	3	7	5	3	
	Relevant Contract Dollars	1,897,174	1,337,385	4,032,932	717,810	1,733,390	
	Total Count	211	204	224	253	229	
	Total Relevant Dollars	43,365,865	40,960,703	41,067,387	34,395,165	35,173,363	-4.82
Heart	Number of Grants	15	16	12	10	7	
	Relevant Grant Dollars	2,148,483	1,737,287	1,971,428	1,792,289	1,344,822	
	Total Count	15	16	12	10	7	
	Total Relevant Dollars	2,148,483	1,737,287	1,971,428	1,792,289	1,344,822	-9.93
Hodgkins Lymphoma	Number of Grants	54	77	94	83	51	
	Relevant Grant Dollars	9,846,229	8,994,562	9,649,890	9,563,149	10,262,763	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	54	77	94	83	51	
	Total Relevant Dollars	9,846,229	8,994,562	9,649,890	9,563,149	10,262,763	1.26
Kaposi Sarcoma	Number of Grants	92	87	82	77	76	
	Relevant Grant Dollars	17,444,041	20,205,869	19,241,042	18,354,076	20,860,705	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	92	87	82	77	76	
	Total Relevant Dollars	17,444,041	20,205,869	19,241,042	18,354,076	20,860,705	5.03
Kidney	Number of Grants	226	241	246	250	237	
	Relevant Grant Dollars	26,734,935	29,194,089	32,449,153	31,320,199	21,146,275	
	Number of Contracts	2	2	‡	‡	‡	
	Relevant Contract Dollars	274,436	390,889	‡	‡	‡	
	Total Count	228	243	246	250	237	
	Total Relevant Dollars	27,009,371	29,584,978	32,449,153	31,320,199	21,146,275	-4.19
Larynx	Number of Grants	3	4	6	6	7	
	Relevant Grant Dollars	99,159	203,215	464,533	1,259,413	1,535,331	
	Total Count	3	4	6	6	7	
	Total Relevant Dollars	99,159	203,215	464,533	1,259,413	1,535,331	106.64

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Leukemia	Number of Grants	680	683	724	755	781	
	Relevant Grant Dollars	210,799,140	199,610,401	208,324,142	209,330,335	212,414,621	
	Number of Contracts	3	4	2	7	4	
	Relevant Contract Dollars	1,495,139	1,098,646	213,752	3,612,561	1,775,197	
	Total Count	683	687	726	762	785	
	Total Relevant Dollars	212,294,279	200,709,047	208,537,894	212,942,896	214,189,818	0.29
Liver	Number of Grants	294	302	322	321	306	
	Relevant Grant Dollars	60,616,338	54,071	52,508,097	48,910,887	49,666,458	
	Number of Contracts	‡	1	2	8	‡	
	Relevant Contract Dollars	‡	299,353	115,700	4,653,688	‡	
	Total Count	294	303	324	329	306	
	Total Relevant Dollars	60,616,338	54,370,763	52,623,797	53,564,575	49,666,458	-4.75
Lung	Number of Grants	965	968	993	1,003	977	
	Relevant Grant Dollars	243,602,747	260,155,893	268,028,541	243,708,636	219,322,515	
	Number of Contracts	23	16	26	21	11	
	Relevant Contract Dollars	7,815,307	4,919,129	12,146,630	11,323,702	6,163,921	
	Total Count	988	984	1,019	1,024	988	
	Total Relevant Dollars	251,418,054	265,075,022	280,175,171	255,032,338	225,486,436	-2.36
Lymph Node	Number of Grants	15	13	9	9	4	
	Relevant Grant Dollars	254,247	2,017,737	1,975,041	608,275	316,561	
	Total Count	15	13	9	9	4	
	Total Relevant Dollars	2,542,477	2,017,737	1,975,041	608,275	316,561	-34.98
Lymphatic System	Number of Grants	4	5	4	3	3	
	Relevant Grant Dollars	472,471	788,609	803,722	489,999	397,376	
	Total Count	4	5	4	3	3	
	Total Relevant Dollars	472,471	788,609	803,722	489,999	397,376	2.72
Melanoma	Number of Grants	457	435	423	474	502	
	Relevant Grant Dollars	85,429,532	96,537,993	99,713,846	101,678,996	106,822,745	
	Number of Contracts	4	1	2	2	‡	
	Relevant Contract Dollars	698,413	50,000	1,349,977	1,764,768	‡	
	Total Count	461	436	425	476	502	
Total Relevant Dollars	86,127,945	96,587,993	101,063,823	103,443,764	106,822,745	5.60	
Mesothelioma	Number of Grants	15	16	18	19	25	
	Relevant Grant Dollars	5,530,460	3,457,493	4,863,814	4,452,535	7,157,480	
	Total Count	15	16	18	19	25	
	Total Relevant Dollars	5,530,460	3,457,493	4,863,814	4,452,535	7,157,480	13.87
Muscle	Number of Grants	37	48	58	41	10	
	Relevant Grant Dollars	6,049,875	8,018,193	6,914,232	3,361,305	862,759	
	Total Count	37	48	58	41	10	
	Total Relevant Dollars	6,049,875	8,018,193	6,914,232	3,361,305	862,759	-26.74
Myeloma	Number of Grants	234	242	249	160	174	
	Relevant Grant Dollars	41,740,236	48,195,056	52,667,345	37,120,602	37,800,248	
	Number of Contracts	1	‡	1	‡	‡	
	Relevant Contract Dollars	199,860	‡	1,499,746	‡	‡	
	Total Count	235	242	250	160	174	
Total Relevant Dollars	41,940,096	48,195,056	54,167,091	37,120,602	37,800,248	-0.58	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Nervous System	Number of Grants	30	28	26	24	24	
	Relevant Grant Dollars	5,271,048	6,787,090	6,438,816	4,163,832	4,421,874	
	Number of Contracts	‡	1	‡	‡	‡	
	Relevant Contract Dollars	‡	8,250	‡	‡	‡	
	Total Count	30	29	26	24	24	
	Total Relevant Dollars	5,271,048	6,795,340	6,438,816	4,163,832	4,421,874	-1.37
Neuroblastoma	Number of Grants	98	98	105	99	104	
	Relevant Grant Dollars	17,861,575	20,974,714	24,697,656	16,492,753	21,130,521	
	Number of Contracts	‡	‡	1	‡	‡	
	Relevant Contract Dollars	‡	‡	299,993	‡	‡	
	Total Count	98	98	106	99	104	
	Total Relevant Dollars	17,861,575	20,974,714	24,997,649	16,492,753	21,130,521	7.68
Non-Hodgkins Lymphoma	Number of Grants	455	472	473	480	452	
	Relevant Grant Dollars	97,937,059	101,566,115	93,857,913	89,044,122	93,955,405	
	Number of Contracts	‡	1	1	1	‡	
	Relevant Contract Dollars	‡	1,500,000	125,000	749,986	‡	
	Total Count	455	473	474	481	452	
	Total Relevant Dollars	97,937,059	103,066,115	93,982,913	89,794,108	93,955,405	-0.85
Nose, Nasal Passages	Number of Grants	14	8	10	10	9	
	Relevant Grant Dollars	1,627,236	904,491	1,117,904	987,215	890,916	
	Total Count	14	8	10	10	9	
	Total Relevant Dollars	1,627,236	904,491	1,117,904	987,215	890,916	-10.57
Not Site Specific §	Number of Grants	2,079	1,952	1,889	1,727	1,747	
	Relevant Grant Dollars	608,746,346	573,631,342	572,734,563	495,343,572	621,155,734	
	Number of Contracts	162	166	192	201	181	
	Relevant Contract Dollars	191,360,124	192,657,199	187,026,369	205,498,650	212,411,501	
	Total Count	2,241	2,118	2,081	1,928	1,928	
Total Relevant Dollars	800,106,470	766,288,541	759,760,932	700,842,222	833,567,235	1.53	
Oral Cavity	Number of Grants	52	49	59	66	66	
	Relevant Grant Dollars	11,138,288	8,209,050	11,657,227	10,151,964	8,835,614	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	52	49	59	66	66	
Total Relevant Dollars	11,138,288	8,209,050	11,657,227	10,151,964	8,835,614	-2.54	
Ovary	Number of Grants	413	413	385	384	380	
	Relevant Grant Dollars	96,565,010	96,600,440	95,732,146	85,110,664	79,194,763	
	Number of Contracts	11	6	7	5	2	
	Relevant Contract Dollars	5,217,503	2,015,726	2,496,203	3,421,603	1,182,604	
	Total Count	424	419	392	389	382	
Total Relevant Dollars	101,782,513	98,616,166	98,228,349	88,532,267	80,377,367	-5.65	
Pancreas	Number of Grants	424	417	421	465	494	
	Relevant Grant Dollars	90,502,908	91,095,822	97,245,213	93,541,191	109,038,628	
	Number of Contracts	1	3	3	2	5	
	Relevant Contract Dollars	159,140	673,594	306,780	1,249,838	6,483,207	
	Total Count	425	420	424	467	499	
Total Relevant Dollars	90,662,048	91,769,416	97,551,993	94,791,029	115,521,835	6.64	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

§Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies. There is no cancer site focus; however, it is relevant to cancer research.)

Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Parathyroid	Number of Grants	2	1	2	2	3	
	Relevant Grant Dollars	‡	‡	216,587	199,513	401,380	
	Total Count	2	1	2	2	3	
	Total Relevant Dollars	‡	‡	216,587	199,513	401,380	46.65
Penis	Number of Grants	5	6	6	6	8	
	Relevant Grant Dollars	2,667,920	2,249,216	2,424,675	2,435,008	2,652,760	
	Total Count	5	6	6	6	8	
	Total Relevant Dollars	2,667,920	2,249,216	2,424,675	2,435,008	2,652,760	0.37
Pharynx	Number of Grants	14	18	74	63	25	
	Relevant Grant Dollars	1,521,576	1,692,375	3,427,507	4,442,944	1,881,045	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	14	18	74	63	25	
Total Relevant Dollars	1,521,576	1,692,375	3,427,507	4,442,944	1,881,045	21.43	
Pituitary	Number of Grants	7	7	5	6	4	
	Relevant Grant Dollars	627,219	1,032,440	695,788	649,567	458,773	
	Total Count	7	7	5	6	4	
	Total Relevant Dollars	627,219	1,032,440	695,788	649,567	458,773	-1.00
Prostate	Number of Grants	1,030	960	968	923	866	
	Relevant Grant Dollars	265,054,420	254,592,786	231,897,860	223,571,212	187,129,390	
	Number of Contracts	24	13	10	12	5	
	Relevant Contract Dollars	8,108,959	5,670,388	3,076,292	6,244,033	6,350,291	
	Total Count	1,054	973	978	935	871	
Total Relevant Dollars	273,163,379	260,263,174	234,974,152	229,815,245	193,479,681	-8.11	
Reticuloendothelial System	Number of Grants	24	23	12	9	8	
	Relevant Grant Dollars	4,220,047	4,207,337	3,007,301	1,097,687	1,318,507	
	Total Count	24	23	12	9	8	
Total Relevant Dollars	4,220,047	4,207,337	3,007,301	1,097,687	1,318,507	-18.05	
Respiratory System	Number of Grants	3	5	4	‡	‡	
	Relevant Grant Dollars	400,921	433,241	424,144	‡	‡	
	Total Count	3	5	4	‡	‡	
	Total Relevant Dollars	400,921	433,241	424,144	‡	‡	2.98
Retinoblastoma	Number of Grants	20	14	13	14	16	
	Relevant Grant Dollars	2,599,952	2,291,465	2,335,494	2,225,018	3,538,181	
	Total Count	20	14	13	14	16	
	Total Relevant Dollars	2,599,952	2,291,465	2,335,494	2,225,018	3,538,181	11.09
Salivary Glands	Number of Grants	5	2	3	3	2	
	Relevant Grant Dollars	281,931	122,931	582,113	515,075	45,316	
	Total Count	5	2	3	3	2	
	Total Relevant Dollars	281,931	122,931	582,113	515,075	45,316	53.60

continued

* Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific site.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Skin	Number of Grants	227	206	209	205	192	
	Relevant Grant Dollars	43,190,271	39,781,606	38,979,774	36,075,772	35,045,052	
	Number of Contracts	‡	1	1	1	‡	
	Relevant Contract Dollars	‡	999,000	299,993	608,798	‡	
	Total Count	227	207	210	206	192	
	Total Relevant Dollars	43,190,271	40,780,606	39,279,767	36,684,570	35,045,052	-5.08
Small Intestine	Number of Grants	19	21	22	19	13	
	Relevant Grant Dollars	2,154,757	2,523,663	2,601,072	2,440,030	1,954,527	
	Total Count	19	21	22	19	13	
	Total Relevant Dollars	2,154,757	2,523,663	2,601,072	2,440,030	1,954,527	-1.48
Spleen	Number of Grants	3	1	‡	‡	2	
	Relevant Grant Dollars	243,170	41,226	‡	‡	136,258	
	Total Count	3	1	‡	‡	2	
	Total Relevant Dollars	243,170	41,226	‡	‡	136,258	73.73
Stomach	Number of Grants	65	58	46	43	63	
	Relevant Grant Dollars	10,776,732	9,227,080	8,068,624	8,064,193	8,597,660	
	Number of Contracts	‡	‡	2	‡	‡	
	Relevant Contract Dollars	‡	‡	85,605	‡	‡	
	Total Count	65	58	48	43	63	
	Total Relevant Dollars	10,776,732	9,227,080	8,154,229	8,064,193	8,597,660	-5.12
Testis	Number of Grants	27	23	12	8	8	
	Relevant Grant Dollars	4,216,762	2,966,075	3,825,536	3,850,005	3,880,838	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	27	23	12	8	8	
	Total Relevant Dollars	4,216,762	2,966,075	3,825,536	3,850,005	3,880,838	0.19
Thymus	Number of Grants	4	4	4	5	5	
	Relevant Grant Dollars	397,192	504,940	615,252	609,747	449,070	
	Total Count	4	4	4	5	5	
	Total Relevant Dollars	397,192	504,940	615,252	609,747	449,070	5.43
Thyroid	Number of Grants	52	51	48	52	61	
	Relevant Grant Dollars	10,900,704	10,394,218	10,082,148	14,641,877	17,516,816	
	Number of Contracts	‡	‡	‡	1	‡	
	Relevant Contract Dollars	‡	‡	‡	95313	‡	
	Total Count	52	51	48	53	61	
	Total Relevant Dollars	10,900,704	10,394,218	10,082,148	14,737,190	17,516,816	14.35
Trachea, Bronchus	Number of Grants	2	4	3	3	3	
	Relevant Grant Dollars	112,364	927,176	707,722	523,065	279,944	
	Total Count	2	4	3	3	3	
	Total Relevant Dollars	112,364	927,176	707,722	523,065	279,944	157.23
Uterus	Number of Grants	80	90	107	104	101	
	Relevant Grant Dollars	12,006,415	13,617,358	16,911,090	15,653,222	13,467,035	
	Number of Contracts	‡	‡	‡	1	‡	
	Relevant Contract Dollars	‡	‡	‡	142712	‡	
	Total Count	80	90	107	105	101	
	Total Relevant Dollars	12,006,415	13,617,358	16,911,090	15,795,934	13,467,035	4.07

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Vagina	Number of Grants	4	5	5	4	4	
	Relevant Grant Dollars	275,471	284,762	336,623	317,026	286,298	
	Total Count	4	5	5	4	4	
	Total Relevant Dollars	275,471	284,762	336,623	317,026	286,298	1.52
Vascular	Number of Grants	55	48	40	30	19	
	Relevant Grant Dollars	3,792,626	3,166,418	2,563,467	1,341,539	3,843,112	
	Total Count	15	17	14	7	9	
	Total Relevant Dollars	3,792,626	3,166,418	2,563,467	1,341,539	3,843,112	25.81

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16. NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Adoptive Cell Immunotherapy	Number of Grants	249	226	231	216	211	
	Relevant Grant Dollars	71,169,780	68,415,543	64,459,206	55,186,231	52,024,707	
	Number of Contracts	‡	1	‡	1	‡	
	Relevant Contract Dollars	‡	247,568	‡	1,499,971	‡	
	Total Count	249	227	231	217	211	
	Total Relevant Dollars	71,169,780	68,663,021	64,459,206	56,686,202	52,024,707	-7.48
Advanced Manufacturing Technology	Number of Grants	15	13	10	7	8	
	Relevant Grant Dollars	3,285,087	2,770,889	2,945,075	2,460,945	2,295,195	
	Number of Contracts	1	‡	1	‡	‡	
	Relevant Contract Dollars	106,000	‡	498,626	‡	‡	
	Total Count	16	13	11	7	8	
	Total Relevant Dollars	3,391,087	2,770,889	3,443,701	2,460,945	2,295,195	-7.32
Aging	Number of Grants	1,066	854	689	577	420	
	Relevant Grant Dollars	113,349,368	99,438,832	79,998,304	69,649,282	57,171,560	
	Number of Contracts	7	5	2	1	1	
	Relevant Contract Dollars	2,424,616	631,073	82,113	27,250	31,046	
	Total Count	1,073	859	691	578	421	
	Total Relevant Dollars	115,773,984	100,069,905	80,080,417	69,676,532	57,202,606	-16.11
AIDS	Number of Grants	412	65	60	45	35	
	Relevant Grant Dollars	91,837,776	13,092,878	12,538,472	10,917,513	10,442,198	
	Number of Contracts	3	‡	‡	‡	‡	
	Relevant Contract Dollars	504,083	‡	‡	‡	‡	
	Total Count	415	65	60	45	35	
	Total Relevant Dollars	92,341,859	13,092,878	12,538,472	10,917,513	10,442,198	-26.83
Alternative Medicine, Direct	Number of Grants	373	347	343	304	317	
	Relevant Grant Dollars	89,420,040	83,106,708	73,033,996	57,639,318	52,792,542	
	Number of Contracts	2	‡	3	‡	2	
	Relevant Contract Dollars	1,149,412	‡	266,500	‡	3,552,516	
	Total Count	375	347	346	304	319	
	Total Relevant Dollars	90,569,452	83,106,708	73,300,496	57,639,318	56,345,058	-10.91
Alternative Medicine, Indirect	Number of Grants	44	47	31	23	24	
	Relevant Grant Dollars	8,714,472	8,363,143	6,981,196	4,798,508	4,098,399	
	Total Count	44	47	31	23	24	
	Total Relevant Dollars	8,714,472	8,363,143	6,981,196	4,798,508	4,098,399	-16.60
Alzheimers Dementia	Number of Grants	4	4	3	3	2	
	Relevant Grant Dollars	508,810	565,699	96,204	186,357	294,069	
	Total Count	4	4	3	3	2	
	Total Relevant Dollars	508,810	565,699	96,204	186,357	294,069	19.92
Arctic Research	Number of Grants	3	3	5	7	8	
	Relevant Grant Dollars	684,462	692,817	570,649	1,048,649	1,141,359	
	Number of Contracts	‡	‡	1	‡	‡	
	Relevant Contract Dollars	‡	‡	471,532	‡	‡	
	Total Count	3	3	6	7	8	
	Total Relevant Dollars	684,462	692,817	1,042,181	1,048,649	1,141,359	15.28

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Arthritis	Number of Grants	4	5	7	6	6	
	Relevant Grant Dollars	400,562	396,477	1,066,691	881,952	864,304	
	Total Count	4	5	7	6	6	
	Total Relevant Dollars	400,562	396,477	1,066,691	881,952	864,304	37.18
Asbestos	Number of Grants	11	12	13	13	12	
	Relevant Grant Dollars	3,428,084	2,591,109	3,609,082	2,872,753	2,937,531	
	Total Count	11	12	13	13	12	
	Total Relevant Dollars	3,428,084	2,591,109	3,609,082	2,872,753	2,937,531	-0.82
Ataxia Telangiectasia	Number of Grants	19	17	11	7	6	
	Relevant Grant Dollars	2,938,837	1,769,222	1,369,928	1,238,529	309,072	
	Total Count	19	17	11	7	6	
	Total Relevant Dollars	2,938,837	1,769,222	1,369,928	1,238,529	309,072	-36.75
Automimmune Diseases	Number of Grants	37	35	33	28	22	
	Relevant Grant Dollars	4,320,535	4,076,442	3,767,007	2,747,501	1,403,677	
	Total Count	37	35	33	28	22	
	Total Relevant Dollars	4,320,535	4,076,442	3,767,007	2,747,501	1,403,677	-22.30
Behavior Research	Number of Grants	1,104	1,098	1,106	1,093	1,032	
	Relevant Grant Dollars	314,205,359	322,649,017	328,483,291	288,411,741	239,765,778	
	Number of Contracts	10	12	18	19	5	
	Relevant Contract Dollars	3,248,062	7,177,481	7,750,198	11,278,961	3,018,920	
	Total Count	1,116	1,110	1,124	1,112	1,037	
Total Relevant Dollars	318,626,425	329,826,498	336,233,489	299,690,702	242,784,698	-6.10	
Bioengineering	Number of Grants	543	478	471	438	551	
	Relevant Grant Dollars	143,101,038	136,659,850	128,170,758	116,606,055	139,804,609	
	Number of Contracts	19	28	14	14	9	
	Relevant Contract Dollars	5,212,765	7,104,296	7,721,382	6,142,128	3,567,443	
	Total Count	562	506	485	452	560	
Total Relevant Dollars	148,313,803	143,764,146	135,892,140	122,748,183	143,372,052	-0.35	
Bioinformatics	Number of Grants	613	620	691	655	649	
	Relevant Grant Dollars	175,538,540	195,579,757	220,626,261	188,164,686	183,215,139	
	Number of Contracts	16	20	25	31	29	
	Relevant Contract Dollars	18,412,975	20,328,761	20,993,037	24,968,039	24,606,810	
	Total Count	629	640	716	686	678	
Total Relevant Dollars	193,951,515	215,908,518	241,619,298	213,132,725	207,821,949	2.24	
Biological Carcinogenesis, Non-Viral	Number of Grants	65	68	75	77	78	
	Relevant Grant Dollars	13,043,584	14,509,921	15,387,505	14,300,282	15,804,902	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	65	68	75	77	78	
Total Relevant Dollars	13,043,584	14,509,921	15,387,505	14,300,282	15,804,902	5.19	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Biologics/Biological Response Modifiers	Number of Grants	1,900	1,668	1,484	1,353	1,188	
	Relevant Grant Dollars	670,058,289	603,303,533	530,129,682	477,320,267	289,423,470	
	Number of Contracts	22	15	10	10	5	
	Relevant Contract Dollars	21,405,546	16,939,205	10,691,980	9,671,661	5,894,582	
	Total Count	1,922	1,683	1,494	1,363	1,193	
	Total Relevant Dollars	691,463,835	620,242,738	540,821,662	486,991,928	295,318,052	-18.10
Biomaterials Research	Number of Grants	141	114	104	94	84	
	Relevant Grant Dollars	21,212,069	17,519,246	15,414,009	12,137,705	14,254,502	
	Number of Contracts	4	‡	2	3	‡	
	Relevant Contract Dollars	1,548,783	‡	1,186,186	797,035	‡	
	Total Count	145	114	106	97	84	
	Total Relevant Dollars	22,760,852	17,519,246	16,600,195	12,934,740	14,254,502	-10.04
Biomedical Computing	Number of Grants	532	542	596	588	595	
	Relevant Grant Dollars	137,845,989	144,567,142	164,726,922	161,506,346	190,278,426	
	Number of Contracts	19	30	31	35	24	
	Relevant Contract Dollars	61,163,296	76,247,799	53,261,742	37,914,467	24,933,240	
	Total Count	551	572	627	623	619	
	Total Relevant Dollars	199,009,285	220,814,941	217,988,664	199,420,813	215,211,666	2.27
Birth Defects	Number of Grants	64	56	46	33	30	
	Relevant Grant Dollars	12,310,466	10,773,700	8,086,859	5,021,213	4,403,949	
	Total Count	64	56	46	33	30	
	Total Relevant Dollars	12,310,466	10,773,700	8,086,859	5,021,213	4,403,949	-21.91
Bone Marrow Transplantation	Number of Grants	140	146	112	130	115	
	Relevant Grant Dollars	54,507,621	50,005,537	37,328,235	39,871,538	35,750,541	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	140	146	112	130	115	
	Total Relevant Dollars	54,507,621	50,005,537	37,328,235	39,871,538	35,750,541	-9.28
Breast Cancer Detection	Number of Grants	498	458	441	411	385	
	Relevant Grant Dollars	99,759,605	91,023,962	88,105,336	81,666,201	75,065,760	
	Number of Contracts	13	15	12	4	1	
	Relevant Contract Dollars	3,632,816	6,478,783	5,863,578	3,543,475	1,100,000	
	Total Count	511	473	453	415	386	
	Total Relevant Dollars	103,392,421	97,502,745	93,968,914	85,209,676	76,165,760	-7.31
Breast Cancer Early Detection	Number of Grants	225	196	197	180	180	
	Relevant Grant Dollars	47,143,457	48,915,492	46,685,468	43,528,756	43,117,642	
	Number of Contracts	3	4	6	2	1	
	Relevant Contract Dollars	1,506,703	2,561,486	3,764,617	2,295,819	1,100,000	
	Total Count	228	200	203	182	181	
	Total Relevant Dollars	48,650,160	51,476,978	50,450,085	45,824,575	44,217,642	-2.21
Breast Cancer Education	Number of Grants	149	131	117	106	102	
	Relevant Grant Dollars	16,743,662	16,114,826	13,390,623	9,550,272	4,699,015	
	Total Count	149	131	117	106	102	
	Total Relevant Dollars	16,743,662	16,114,826	13,390,623	9,550,272	4,699,015	-25.03

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Breast Cancer Epidemiology	Number of Grants	189	195	215	219	210	
	Relevant Grant Dollars	64,674,588	67,767,559	79,021,942	74,082,885	65,139,979	
	Number of Contracts	5	1	2	6	1	
	Relevant Contract Dollars	336,493	1,620,669	1,728,711	3,348,609	125,000	
	Total Count	194	196	217	225	211	
	Total Relevant Dollars	65,011,081	69,388,228	80,750,653	77,431,494	65,264,979	0.82
Breast Cancer Genetics	Number of Grants	453	482	510	509	498	
	Relevant Grant Dollars	116,708,177	116,790,479	130,302,574	116,592,352	107,994,765	
	Number of Contracts	5	6	5	4	‡	
	Relevant Contract Dollars	2,418,766	2,277,691	2,143,190	2,739,232	‡	
	Total Count	458	488	515	513	498	
	Total Relevant Dollars	119,126,943	119,068,170	132,445,764	119,331,584	107,994,765	-2.05
Breast Cancer Prevention	Number of Grants	211	193	190	182	180	
	Relevant Grant Dollars	20,573,617	19,425,993	18,454,078	18,639,346	16,628,036	
	Number of Contracts	‡	2	1	1	1	
	Relevant Contract Dollars	‡	161,745	35,700	68,000	1,478,927	
	Total Count	211	195	191	183	181	
	Total Relevant Dollars	20,573,617	19,587,738	18,489,778	18,707,346	18,106,963	-3.11
Breast Cancer Rehabilitation	Number of Grants	165	180	169	160	130	
	Relevant Grant Dollars	23,414,402	23,491,341	23,354,588	19,304,588	16,034,148	
	Number of Contracts	‡	‡	‡	1	‡	
	Relevant Contract Dollars	‡	‡	‡	200,000	‡	
	Total Count	165	180	169	161	130	
	Total Relevant Dollars	23,414,402	23,491,341	23,354,588	19,504,588	16,034,148	-8.63
Breast Cancer Screening	Number of Grants	194	178	178	170	142	
	Relevant Grant Dollars	22,564,554	24,098,034	26,090,155	24,889,715	20,751,155	
	Number of Contracts	‡	1	1	1	1	
	Relevant Contract Dollars	‡	1,599,992	1,400,000	1,300,000	1,100,000	
	Total Count	194	179	179	171	143	
	Total Relevant Dollars	22,564,554	25,698,026	27,490,155	26,189,715	21,851,155	-0.11
Breast Cancer Treatment	Number of Grants	699	671	679	664	687	
	Relevant Grant Dollars	191,699,483	182,244,051	151,868,982	142,815,791	138,560,818	
	Number of Contracts	11	3	8	5	4	
	Relevant Contract Dollars	1,962,093	461,244	4,169,128	2,525,833	2,065,223	
	Total Count	710	674	687	669	691	
	Total Relevant Dollars	193,661,576	182,705,295	156,038,110	145,341,624	140,626,041	-7.59
Breast Cancer-Basic	Number of Grants	781	758	744	767	855	
	Relevant Grant Dollars	168,864,512	168,911,481	175,587,977	164,833,399	167,569,592	
	Number of Contracts	9	2	5	3	3	
	Relevant Contract Dollars	1,977,194	648,203	1,013,726	1,431,744	653,485	
	Total Count	790	760	749	770	858	
	Total Relevant Dollars	170,841,706	169,559,684	176,601,703	166,265,143	168,223,077	-0.32
Cancer Survivorship	Number of Grants	627	669	669	628	568	
	Relevant Grant Dollars	233,784,991	244,829,411	247,349,527	245,984,817	169,414,751	
	Number of Contracts	7	11	13	15	1	
	Relevant Contract Dollars	2,202,035	10,974,854	12,698,851	11,019,708	997,190	
	Total Count	634	680	682	643	569	
	Total Relevant Dollars	235,987,026	255,804,265	260,048,378	257,004,525	170,411,941	-6.20

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Carcinogenesis, Environmental	Number of Grants	1,316	1,237	1,163	1,116	1,041	
	Relevant Grant Dollars	395,790,431	384,795,833	367,617,534	313,980,620	273,042,396	
	Number of Contracts	19	9	13	17	11	
	Relevant Contract Dollars	7,165,859	3,411,768	4,057,751	5,565,513	3,879,202	
	Total Count	1,335	1,246	1,176	1,133	1,052	
	Total Relevant Dollars	402,956,290	388,207,601	371,675,285	319,546,133	276,921,598	-8.82
Cervical Cancer Education	Number of Grants	49	44	39	30	34	
	Relevant Grant Dollars	6,669,506	6,289,116	6,569,930	4,529,757	6,077,658	
	Total Count	49	44	39	30	34	
	Total Relevant Dollars	6,669,506	6,289,116	6,569,930	4,529,757	6,077,658	0.47
Chemoprevention	Number of Grants	554	513	521	490	429	
	Relevant Grant Dollars	110,809,302	110,334,008	106,270,652	97,428,457	84,243,372	
	Number of Contracts	9	9	9	6	6	
	Relevant Contract Dollars	14,907,908	12,224,778	7,745,895	8,399,689	15,066,511	
	Total Count	563	522	530	496	435	
	Total Relevant Dollars	125,717,210	122,558,786	114,016,547	105,828,146	99,309,883	-5.71
Chemoprevention, Clinical	Number of Grants	136	129	129	118	91	
	Relevant Grant Dollars	31,292,583	30,974,445	26,207,896	24,973,361	14,722,116	
	Number of Contracts	2	4	5	‡	‡	
	Relevant Contract Dollars	1,568,183	6,660,343	1,809,372	‡	‡	
	Total Count	138	133	134	118	91	
	Total Relevant Dollars	32,860,766	37,634,788	28,017,268	24,973,361	14,722,116	-15.73
Chemotherapy	Number of Grants	1,265	1,268	1,309	1,232	1,087	
	Relevant Grant Dollars	486,445,892	487,783,247	483,927,715	439,082,427	250,373,415	
	Number of Contracts	23	23	21	18	12	
	Relevant Contract Dollars	16,237,585	15,509,777	15,400,076	10,450,686	9,970,324	
	Total Count	1,288	1,291	1,330	1,250	1,099	
	Total Relevant Dollars	502,683,477	503,293,024	499,327,791	449,533,113	260,343,739	-13.18
Child Health	Number of Grants	180	146	132	123	122	
	Relevant Grant Dollars	35,485,301	30,619,348	29,367,355	23,265,126	24,830,888	
	Number of Contracts	1	1	3	5	2	
	Relevant Contract Dollars	100,000	500,000	632,000	2,181,318	177,670	
	Total Count	181	147	135	128	124	
	Total Relevant Dollars	35,585,301	31,119,348	29,999,355	25,446,444	25,008,558	-8.26
Childhood Cancers	Number of Grants	495	517	532	525	493	
	Relevant Grant Dollars	166,272,586	165,281,278	177,934,130	155,945,246	173,785,934	
	Number of Contracts	1	1	2	3	2	
	Relevant Contract Dollars	2,938,868	2,791,925	2,999,993	4,212,177	3,007,558	
	Total Count	496	518	534	528	495	
	Total Relevant Dollars	169,211,454	168,073,203	180,934,123	160,157,423	176,793,492	1.47
Chronic Myeloproliferative Disorders	Number of Grants	129	143	143	143	132	
	Relevant Grant Dollars	33,259,274	40,413,091	38,980,403	36,692,865	36,189,051	
	Total Count	129	143	143	143	132	
	Total Relevant Dollars	33,259,274	40,413,091	38,980,403	36,692,865	36,189,051	2.68

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Clinical Trials, Diagnosis	Number of Grants	158	157	142	136	146	
	Relevant Grant Dollars	49,365,161	50,104,212	38,090,132	30,815,744	45,889,734	
	Number of Contracts	14	3	2	3	1	
	Relevant Contract Dollars	21,295,518	4,929,393	2,264,053	1,651,880	1,728,293	
	Total Count	172	160	144	139	147	
	Total Relevant Dollars	70,660,679	55,033,605	40,354,185	32,467,624	47,618,027	-5.42
Clinical Trials, Other	Number of Grants	231	220	241	115	279	
	Relevant Grant Dollars	64,532,028	69,256,696	73,756,321	40,042,677	149,612,281	
	Number of Contracts	3	4	8	‡	3	
	Relevant Contract Dollars	2,199,778	5,627,105	4,870,009	‡	7,962,288	
	Total Count	234	224	249	115	282	
	Total Relevant Dollars	66,731,806	74,883,801	78,626,330	40,042,677	157,574,569	65.41
Clinical Trials, Prevention	Number of Grants	162	227	140	115	114	
	Relevant Grant Dollars	56,851,445	142,302,439	51,726,135	40,042,677	35,417,115	
	Number of Contracts	4	6	8	‡	4	
	Relevant Contract Dollars	10,044,105	11,401,878	2,682,866	‡	7,423,381	
	Total Count	166	233	148	115	118	
	Total Relevant Dollars	66,895,550	153,704,317	54,409,001	40,042,677	42,840,496	11.44
Clinical Trials, Therapy	Number of Grants	636	523	574	532	546	
	Relevant Grant Dollars	383,892,811	321,816,935	326,779,192	323,103,308	315,511,818	
	Number of Contracts	17	20	16	14	11	
	Relevant Contract Dollars	43,398,794	57,748,533	38,008,573	22,662,279	18,485,764	
	Total Count	653	543	590	546	557	
	Total Relevant Dollars	427,291,605	379,565,468	364,787,765	345,765,587	333,997,582	-5.92
Combined Treatment Modalities	Number of Grants	679	769	922	1,022	1,056	
	Relevant Grant Dollars	366,302,744	388,561,125	407,422,052	412,395,044	241,467,906	
	Number of Contracts	4	7	8	8	6	
	Relevant Contract Dollars	3,372,144	6,442,620	7,776,273	7,259,529	7,488,672	
	Total Count	683	776	930	1,030	1,062	
	Total Relevant Dollars	369,674,888	395,003,745	415,198,325	419,654,573	248,956,578	-6.91
Cost Effectiveness	Number of Grants	173	177	181	155	139	
	Relevant Grant Dollars	27,186,831	29,938,700	29,528,911	23,509,038	22,816,491	
	Number of Contracts	2	1	1	‡	‡	
	Relevant Contract Dollars	186,230	248,461	2,479,561	‡	‡	
	Total Count	175	178	182	155	139	
	Total Relevant Dollars	27,373,061	30,187,161	32,008,472	23,509,038	22,816,491	-3.30
Diabetes	Number of Grants	47	36	49	68	77	
	Relevant Grant Dollars	3,530,526	4,851,425	7,823,131	9,846,534	8,622,303	
	Number of Contracts	‡	‡	‡	1	‡	
	Relevant Contract Dollars	‡	‡	‡	207,952	‡	
	Total Count	47	36	49	69	77	
	Total Relevant Dollars	3,530,526	4,851,425	7,823,131	10,054,486	8,622,303	28.24
Diagnosis	Number of Grants	1,855	1,779	1,758	1,695	1,686	
	Relevant Grant Dollars	553,036,713	559,531,772	538,315,913	492,426,013	529,392,958	
	Number of Contracts	66	51	52	54	39	
	Relevant Contract Dollars	38,373,345	24,273,760	32,848,866	40,112,891	30,979,563	
	Total Count	1,921	1,830	1,810	1,749	1,725	
	Total Relevant Dollars	591,410,058	583,805,532	571,164,779	532,538,904	560,372,521	-1.25

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Diethylstilbestrol	Number of Grants	2	3	3	3	2	
	Relevant Grant Dollars	210,443	330,257	323,182	308,506	263,724	
	Number of Contracts	5	‡	‡	‡	‡	
	Relevant Contract Dollars	1,345,965	‡	‡	‡	‡	
	Total Count	7	3	3	3	2	
	Total Relevant Dollars	1,556,408	330,257	323,182	308,506	263,724	-24.99
Dioxin	Number of Grants	12	13	9	8	7	
	Relevant Grant Dollars	1,736,256	869,725	936,088	612,850	631,714	
	Total Count	12	13	9	8	7	
	Total Relevant Dollars	1,736,256	869,725	936,088	612,850	631,714	-18.43
DNA Repair	Number of Grants	600	555	540	512	494	
	Relevant Grant Dollars	128,813,944	122,952,777	111,276,907	102,121,375	99,797,181	
	Number of Contracts	2	‡	1	‡	‡	
	Relevant Contract Dollars	399,599	‡	999,596	‡	‡	
	Total Count	602	555	541	512	494	
Total Relevant Dollars	129,213,543	122,952,777	112,276,503	102,121,375	99,797,181	-6.21	
Drug Development	Number of Grants	2,091	2,095	2,233	2,310	2,393	
	Relevant Grant Dollars	550,899,818	582,044,480	593,685,849	583,484,075	604,291,255	
	Number of Contracts	82	84	69	64	39	
	Relevant Contract Dollars	50,932,059	44,439,383	58,367,271	43,062,404	36,749,532	
	Total Count	2,173	2,179	2,302	2,374	2,432	
Total Relevant Dollars	601,831,877	626,483,863	652,053,120	626,546,479	641,040,787	1.64	
Drug Discovery	Number of Grants	377	380	426	423	432	
	Relevant Grant Dollars	74,170,074	71,551,561	77,078,178	76,661,475	83,662,149	
	Number of Contracts	18	11	7	14	3	
	Relevant Contract Dollars	11,779,829	2,805,286	2,752,844	5,018,328	298,072	
	Total Count	395	391	433	437	435	
Total Relevant Dollars	85,949,903	74,356,847	79,831,022	81,679,803	83,960,221	-0.25	
Drug Resistance	Number of Grants	634	638	697	712	785	
	Relevant Grant Dollars	117,323,805	126,166,864	137,912,021	133,575,885	148,056,783	
	Number of Contracts	2	2	2	3	1	
	Relevant Contract Dollars	395,550	388,667	399,349	3,198,559	1,000,000	
	Total Count	636	640	699	715	786	
Total Relevant Dollars	117,719,355	126,555,531	138,311,370	136,774,444	149,056,783	6.17	
Drugs – Natural Products	Number of Grants	640	603	577	556	490	
	Relevant Grant Dollars	143,114,167	140,027,475	123,779,207	109,888,176	71,095,657	
	Number of Contracts	4	5	2	‡	‡	
	Relevant Contract Dollars	1,375,565	1,298,440	396,938	‡	‡	
	Total Count	644	608	579	556	490	
Total Relevant Dollars	144,489,732	141,325,915	124,176,145	109,888,176	71,095,657	-15.28	
Early Detection	Number of Grants	839	799	788	755	748	
	Relevant Grant Dollars	227,060,938	231,169,872	220,140,713	204,867,734	225,248,442	
	Number of Contracts	17	10	17	14	9	
	Relevant Contract Dollars	21,353,066	9,463,743	15,164,662	13,803,863	8,393,779	
	Total Count	856	809	805	769	757	
Total Relevant Dollars	248,414,004	240,633,615	235,305,375	218,671,597	233,642,221	-1.39	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Effectiveness Research	Number of Grants	199	241	329	318	296	
	Relevant Grant Dollars	59,933,366	88,645,132	95,620,963	90,764,479	80,220,580	
	Number of Contracts	2	2	7	8	1	
	Relevant Contract Dollars	560,081	303,094	5,463,193	12,172,772	10,500	
	Total Count	201	243	336	326	297	
	Total Relevant Dollars	60,493,447	88,948,226	101,084,156	102,937,251	80,231,080	10.11
Endocrinology	Number of Grants	716	669	619	572	539	
	Relevant Grant Dollars	144,586,939	134,691,456	127,583,367	111,913,229	107,069,679	
	Number of Contracts	5	2	4	1	1	
	Relevant Contract Dollars	1,345,965	365,780	813,140	1,307,520	1,478,552	
	Total Count	721	671	623	573	540	
	Total Relevant Dollars	145,932,904	135,057,236	128,396,507	113,220,749	108,548,231	-7.08
Energy Balance	Number of Grants	104	105	112	91	86	
	Relevant Grant Dollars	30,844,556	33,474,016	32,621,115	27,758,787	23,971,943	
	Number of Contracts	1	‡	‡	1	‡	
	Relevant Contract Dollars	4,885	‡	‡	31,250	‡	
	Total Count	105	105	112	92	86	
	Total Relevant Dollars	30,849,441	33,474,016	32,621,115	27,790,037	23,971,943	-5.65
Epidemiology	Number of Grants	238	248	257	245	233	
	Relevant Grant Dollars	58,955,769	58,456,327	75,023,578	76,193,758	81,439,737	
	Number of Contracts	12	9	19	42	33	
	Relevant Contract Dollars	7,967,822	6,370,296	13,162,987	42,219,232	38,502,206	
	Total Count	250	257	276	287	266	
	Total Relevant Dollars	66,923,591	64,826,623	88,186,565	118,412,990	119,941,943	17.12
Epidemiology, Biochemical	Number of Grants	544	513	525	516	495	
	Relevant Grant Dollars	207,004,532	196,371,213	200,458,114	183,330,345	169,955,392	
	Number of Contracts	9	10	10	4	1	
	Relevant Contract Dollars	22,230,209	27,302,955	32,063,034	12,320,111	2,160,252	
	Total Count	553	523	535	520	496	
	Total Relevant Dollars	229,234,741	223,674,168	232,521,148	195,650,456	172,115,644	-6.59
Epidemiology, Environmental	Number of Grants	487	442	402	380	336	
	Relevant Grant Dollars	169,765,154	158,195,340	146,924,987	117,386,653	107,915,202	
	Number of Contracts	16	10	14	6	5	
	Relevant Contract Dollars	24,953,396	22,833,401	27,082,561	13,262,667	3,754,701	
	Total Count	503	452	416	386	341	
	Total Relevant Dollars	194,718,550	181,028,741	174,007,548	130,649,320	111,669,903	-12.59
Epigenetics	Number of Grants	771	859	893	901	943	
	Relevant Grant Dollars	161,834,223	182,952,932	197,448,892	183,377,930	187,566,016	
	Number of Contracts	3	‡	1	1	‡	
	Relevant Contract Dollars	549,598	‡	80,000	80,000	‡	
	Total Count	774	859	894	902	943	
	Total Relevant Dollars	162,383,821	182,952,932	197,528,892	183,457,930	187,566,016	3.94
Gene Mapping, Human	Number of Grants	436	402	349	283	237	
	Relevant Grant Dollars	158,894,763	149,903,735	112,977,260	75,989,190	61,585,479	
	Total Count	436	402	349	283	237	
	Total Relevant Dollars	158,894,763	149,903,735	112,977,260	75,989,190	61,585,479	-20.50

continued

* Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific site.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Gene Mapping, Non-Human	Number of Grants	243	215	183	157	130	
	Relevant Grant Dollars	37,746,569	35,807,176	30,805,418	24,907,163	14,858,944	
	Total Count	243	215	183	157	130	
	Total Relevant Dollars	37,746,569	35,807,176	30,805,418	24,907,163	14,858,944	-19.65
Gene Transfer, Clinical	Number of Grants	28	33	28	23	22	
	Relevant Grant Dollars	8,086,568	8,242,594	6,398,890	5,731,303	4,272,656	
	Total Count	28	33	28	23	22	
	Total Relevant Dollars	8,086,568	8,242,594	6,398,890	5,731,303	4,272,656	-14.08
Genetic Testing Research, Human	Number of Grants	335	286	250	195	154	
	Relevant Grant Dollars	115,367,220	97,622,451	78,970,309	60,583,797	42,299,385	
	Number of Contracts	3	4	4	‡	1	
	Relevant Contract Dollars	1,325,744	1,531,022	2,838,423	‡	660,000	
	Total Count	338	290	254	195	155	
Total Relevant Dollars	116,692,964	99,153,473	81,808,732	60,583,797	42,959,385	-21.89	
Genomics	Number of Grants	837	936	1,090	1,113	1,182	
	Relevant Grant Dollars	276,653,749	312,504,344	355,990,253	315,909,113	323,758,372	
	Number of Contracts	9	10	9	8	2	
	Relevant Contract Dollars	2,573,478	3,992,902	3,769,491	3,463,628	972,912	
	Total Count	846	946	1,099	1,121	1,184	
Total Relevant Dollars	279,227,227	316,497,246	359,759,744	319,372,741	324,731,284	4.37	
Health Literacy	Number of Grants	93	104	107	106	98	
	Relevant Grant Dollars	21,151,000	23,322,845	25,702,360	20,195,573	18,558,771	
	Number of Contracts	1	1	1	1	‡	
	Relevant Contract Dollars	2,225,682	2,034,678	2,026,250	2,298,614	‡	
Total Count	94	105	108	107	98		
Total Relevant Dollars	23,376,682	25,357,523	27,728,610	22,494,187	18,558,771	-4.64	
Health Promotion	Number of Grants	535	492	459	434	378	
	Relevant Grant Dollars	156,169,759	158,653,454	152,900,603	125,530,387	107,111,437	
	Number of Contracts	12	5	9	6	7	
	Relevant Contract Dollars	8,239,835	4,853,740	5,078,162	7,193,454	4,712,166	
	Total Count	547	497	468	440	385	
Total Relevant Dollars	164,409,594	163,507,194	157,978,765	132,723,841	111,823,603	-8.92	
Health Care Delivery	Number of Grants	323	361	370	360	398	
	Relevant Grant Dollars	99,249,496	111,213,954	116,521,815	108,978,920	218,923,687	
	Number of Contracts	9	10	12	14	3	
	Relevant Contract Dollars	4,637,640	6,239,884	6,285,437	12,762,591	2,221,373	
Total Count	332	371	382	374	401		
Total Relevant Dollars	103,887,136	117,453,838	122,807,252	121,741,511	221,145,060	24.60	
Helicobacter	Number of Grants	34	33	32	31	29	
	Relevant Grant Dollars	8,078,008	8,081,826	7,685,880	6,972,140	6,799,315	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	34	33	32	31	29	
Total Relevant Dollars	8,078,008	8,081,826	7,685,880	6,972,140	6,799,315	-4.15	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Hematology	Number of Grants	1,472	1,423	1,440	1,411	1,336	
	Relevant Grant Dollars	466,847,932	464,441,339	454,740,603	428,144,424	432,281,168	
	Number of Contracts	6	6	7	9	4	
	Relevant Contract Dollars	1,967,879	2,797,458	3,100,209	5,851,583	1,775,197	
	Total Count	1,478	1,429	1,447	1,420	1,340	
	Total Relevant Dollars	468,815,811	467,238,797	457,840,812	433,996,007	434,056,365	-1.89
Hematopoietic Stem Cell Research	Number of Grants	396	465	449	431	397	
	Relevant Grant Dollars	113,380,226	122,611,326	105,983,734	101,488,276	87,079,722	
	Number of Contracts	1	‡	‡	‡	‡	
	Relevant Contract Dollars	999,936	‡	‡	‡	‡	
	Total Count	397	465	449	431	397	
	Total Relevant Dollars	114,380,162	122,611,326	105,983,734	101,488,276	87,079,722	-6.20
Hormone Replacement Therapy	Number of Grants	33	31	23	21	17	
	Relevant Grant Dollars	3,175,346	3,987,675	2,695,611	2,396,798	1,621,562	
	Total Count	33	31	23	21	17	
	Total Relevant Dollars	3,175,346	3,987,675	2,695,611	2,396,798	1,621,562	-12.56
Hospice	Number of Grants	45	33	34	31	26	
	Relevant Grant Dollars	9,344,380	8,276,000	7,183,290	5,960,311	6,718,944	
	Number of Contracts	1	‡	‡	‡	‡	
	Relevant Contract Dollars	999,998	‡	‡	‡	‡	
	Total Count	46	33	34	31	26	
	Total Relevant Dollars	10,344,378	8,276,000	7,183,290	5,960,311	6,718,944	-9.37
Human Genome	Number of Grants	533	631	762	831	889	
	Relevant Grant Dollars	224,387,803	262,277,096	303,194,306	285,048,104	288,232,403	
	Number of Contracts	2	2	4	6	2	
	Relevant Contract Dollars	2,260,666	1,398,722	1,744,057	2,922,371	972,912	
	Total Count	535	633	766	837	891	
	Total Relevant Dollars	226,648,469	263,675,818	304,938,363	287,970,475	289,205,315	6.71
Iatrogenesis	Number of Grants	257	247	264	240	255	
	Relevant Grant Dollars	61,577,955	62,271,326	70,740,383	63,359,024	62,665,069	
	Number of Contracts	5	3	4	15	16	
	Relevant Contract Dollars	1,345,965	487,983	1,406,258	9,252,324	11,590,700	
	Total Count	262	250	268	255	271	
	Total Relevant Dollars	62,923,920	62,759,309	72,146,641	72,611,348	74,255,769	4.40
Imaging	Number of Grants	1,045	1012	1,014	977	1,020	
	Relevant Grant Dollars	298,744,722	309,142,019	287,214,478	262,826,270	303,333,609	
	Number of Contracts	32	20	14	18	15	
	Relevant Contract Dollars	21,851,672	7,316,896	7,351,691	13,479,943	9,601,975	
	Total Count	1,077	1032	1,028	995	1,035	
	Total Relevant Dollars	320,596,394	316,458,915	294,566,169	276,306,213	312,935,584	-0.29
Immunization	Number of Grants	442	449	469	443	432	
	Relevant Grant Dollars	116,267,543	122,814,703	127,780,151	108,339,472	104,548,325	
	Number of Contracts	‡	4	1	5	4	
	Relevant Contract Dollars	‡	3,429,651	1,996,084	8,810,556	4,894,582	
	Total Count	442	453	470	448	436	
	Total Relevant Dollars	116,267,543	126,244,354	129,776,235	117,150,028	109,442,907	-1.23

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Inflammation	Number of Grants	418	467	532	594	611	
	Relevant Grant Dollars	81,746,863	99,553,973	113,039,549	107,278,269	109,966,955	
	Number of Contracts	‡	‡	‡	1	3	
	Relevant Contract Dollars	‡	‡	‡	318,141	3,652,516	
	Total Count	418	467	532	595	614	
	Total Relevant Dollars	81,746,863	99,553,973	113,039,549	107,596,410	113,619,471	9.03
Information Dissemination	Number of Grants	861	835	787	755	739	
	Relevant Grant Dollars	231,787,714	237,305,178	247,159,725	224,368,430	217,876,571	
	Number of Contracts	38	36	56	22	8	
	Relevant Contract Dollars	72,642,039	70,246,091	76,556,706	19,915,843	14,567,395	
	Total Count	899	871	843	777	747	
	Total Relevant Dollars	304,429,753	307,551,269	323,716,431	244,284,273	232,443,966	-5.78
Metastasis	Number of Grants	1,527	1,534	1,543	1,550	1,545	
	Relevant Grant Dollars	361,870,802	381,229,457	370,139,067	339,242,680	340,009,556	
	Number of Contracts	7	6	6	6	3	
	Relevant Contract Dollars	1,325,290	1,024,332	3,434,990	2,322,483	961,421	
	Total Count	1,534	1,540	1,549	1,556	1,548	
	Total Relevant Dollars	363,196,092	382,253,789	373,574,057	341,565,163	340,970,977	-1.42
Mind/Body Research	Number of Grants	75	83	83	78	59	
	Relevant Grant Dollars	17,883,028	16,149,064	18,436,251	13,881,407	11,783,092	
	Number of Contracts	‡	‡	2	‡	‡	
	Relevant Contract Dollars	‡	‡	89,759	‡	‡	
	Total Count	75	83	85	78	59	
	Total Relevant Dollars	17,883,028	16,149,064	18,526,010	13,881,407	11,783,092	-8.79
Molecular Disease	Number of Grants	4,962	4,879	4,945	5,158	5,466	
	Relevant Grant Dollars	1,670,263,492	1,660,747,605	1,646,243,216	1,611,962,239	1,679,313,384	
	Number of Contracts	31	35	34	49	45	
	Relevant Contract Dollars	9,144,621	14,337,338	19,893,543	30,025,697	30,765,834	
	Total Count	4,993	4,914	4,979	5,207	5,511	
	Total Relevant Dollars	1,679,408,113	1,675,084,943	1,666,136,759	1,641,987,936	1,710,079,218	0.48
Molecular Imaging	Number of Grants	650	701	724	672	620	
	Relevant Grant Dollars	164,707,342	181,500,075	184,280,121	160,435,399	152,907,543	
	Number of Contracts	15	15	4	5	3	
	Relevant Contract Dollars	4,042,324	5,602,005	798,078	2,940,739	1,942,675	
	Total Count	665	716	728	677	623	
	Total Relevant Dollars	168,749,666	187,102,080	185,078,199	163,376,138	154,850,218	-1.79
Molecular Targeted Prevention	Number of Grants	252	248	269	260	232	
	Relevant Grant Dollars	39,235,184	47,765,297	47,214,496	48,209,422	44,556,081	
	Number of Contracts	1	1	2	2	2	
	Relevant Contract Dollars	74,750	248,461	212,500	1,647,216	2,979,162	
	Total Count	253	249	271	262	234	
	Total Relevant Dollars	39,309,934	48,013,758	47,426,996	49,856,638	47,535,243	5.35
Molecular Targeted Therapy	Number of Grants	1,515	1,577	1,775	1,888	2,044	
	Relevant Grant Dollars	407,096,513	442,319,529	475,531,951	470,992,018	523,857,998	
	Number of Contracts	21	18	18	12	12	
	Relevant Contract Dollars	6,175,491	7,588,080	12,174,642	8,499,344	8,863,954	
	Total Count	1,536	1,595	1,793	1,900	2,056	
	Total Relevant Dollars	413,272,004	449,907,609	487,706,593	479,491,362	532,721,952	6.67

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Nanotechnology	Number of Grants	461	444	480	476	455	
	Relevant Grant Dollars	122,072,696	119,336,493	121,450,044	109,920,780	111,516,643	
	Number of Contracts	20	11	14	6	5	
	Relevant Contract Dollars	7,338,362	5,161,598	7,104,793	2,045,407	5,326,115	
	Total Count	481	455	494	482	460	
	Total Relevant Dollars	129,411,058	124,498,091	128,554,837	111,966,187	116,842,758	-2.27
Neurofibromatosis	Number of Grants	34	15	15	11	8	
	Relevant Grant Dollars	7,560,557	2,915,817	2,745,637	1,584,767	1,376,362	
	Total Count	34	15	15	11	8	
	Total Relevant Dollars	7,560,557	2,915,817	2,745,637	1,584,767	1,376,362	-30.68
Nursing Research	Number of Grants	54	49	45	37	35	
	Relevant Grant Dollars	13,918,717	11,599,142	11,366,624	9,407,781	8,475,918	
	Total Count	54	49	45	37	35	
	Total Relevant Dollars	13,918,717	11,599,142	11,366,624	9,407,781	8,475,918	-11.45
Nutrition-Fiber	Number of Grants	19	19	13	10	7	
	Relevant Grant Dollars	2,058,728	3,019,322	1,881,369	1,147,521	1,084,354	
	Number of Contracts	‡	‡	1	‡	‡	
	Relevant Contract Dollars	‡	‡	56,250	‡	‡	
	Total Count	19	19	14	10	7	
	Total Relevant Dollars	2,058,728	3,019,322	1,937,619	1,147,521	1,084,354	-8.86
Nutrition	Number of Grants	830	779	735	698	638	
	Relevant Grant Dollars	198,165,748	201,597,394	176,394,674	152,339,204	131,807,340	
	Number of Contracts	14	5	19	9	9	
	Relevant Contract Dollars	13,792,873	9,069,226	12,900,479	11,924,668	4,372,361	
	Total Count	844	784	754	707	647	
	Total Relevant Dollars	211,958,621	210,666,620	189,295,153	164,263,872	136,179,701	-10.27
Nutrition Monitoring	Number of Grants	45	42	36	30	30	
	Relevant Grant Dollars	11,311,406	15,194,549	9,995,060	10,354,902	8,955,163	
	Number of Contracts	‡	‡	7	2	3	
	Relevant Contract Dollars	‡	‡	1,107,515	1,277,146	2,210,544	
	Total Count	45	42	43	32	33	
	Total Relevant Dollars	11,311,406	15,194,549	11,102,575	11,632,048	11,165,707	2.04
Obesity	Number of Grants	251	251	258	283	290	
	Relevant Grant Dollars	47,992,367	58,308,346	63,008,280	62,423,989	63,637,392	
	Number of Contracts	‡	3	4	‡	1	
	Relevant Contract Dollars	‡	689,394	1,012,349	‡	1,478,927	
	Total Count	251	254	262	283	291	
	Total Relevant Dollars	47,992,367	59,006,740	64,020,629	62,423,989	65,116,319	8.32
Occupational Cancer	Number of Grants	57	49	42	36	27	
	Relevant Grant Dollars	10,901,093	8,727,377	7,737,704	6,712,701	6,625,987	
	Number of Contracts	2	‡	‡	‡	‡	
	Relevant Contract Dollars	224,000	‡	‡	‡	‡	
	Total Count	59	49	42	36	27	
	Total Relevant Dollars	11,125,093	8,727,377	7,737,704	6,712,701	6,625,987	-11.86

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

**Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Oncogenes	Number of Grants	2,031	1,934	1,883	1,828	1,784	
	Relevant Grant Dollars	515,190,558	498,144,267	473,323,034	413,130,527	404,601,468	
	Number of Contracts	3	5	8	6	1	
	Relevant Contract Dollars	2,074,867	1,072,456	2,534,277	5,307,498	111,706	
	Total Count	2,034	1,939	1,891	1,834	1,785	
	Total Relevant Dollars	517,265,425	499,216,723	475,857,311	418,438,025	404,713,174	-5.88
Organ Transplant Research	Number of Grants	182	194	164	175	151	
	Relevant Grant Dollars	66,404,117	67,155,158	49,923,229	55,542,375	48,657,932	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	182	194	164	175	151	
	Total Relevant Dollars	66,404,117	67,155,158	49,923,229	55,542,375	48,657,932	-6.42
Osteoporosis	Number of Grants	8	6	6	5	7	
	Relevant Grant Dollars	411,172	317,668	925,324	722,771	1,471,815	
	Total Count	8	6	6	5	7	
	Total Relevant Dollars	411,172	317,668	925,324	722,771	1,471,815	62.57
Pain	Number of Grants	147	152	154	159	132	
	Relevant Grant Dollars	16,468,439	16,300,996	18,155,638	17,703,099	12,405,393	
	Number of Contracts	2	‡	‡	1	‡	
	Relevant Contract Dollars	1,299,610	‡	‡	100,000	‡	
	Total Count	149	152	154	160	132	
	Total Relevant Dollars	17,768,049	16,300,996	18,155,638	17,803,099	12,405,393	-7.28
Palliative Care	Number of Grants	161	153	153	152	129	
	Relevant Grant Dollars	20,897,707	21,247,383	21,916,672	18,689,924	15,149,837	
	Number of Contracts	2	1	1	1	1	
	Relevant Contract Dollars	2,198,445	52,655	21,000	53,991	10,500	
	Total Count	163	154	154	153	130	
	Total Relevant Dollars	23,096,152	21,300,038	21,937,672	18,743,915	15,160,337	-9.62
Pap Testing	Number of Grants	106	105	111	98	81	
	Relevant Grant Dollars	10,627,523	11,695,680	11,312,785	10,168,380	5,542,465	
	Number of Contracts	1	‡	‡	‡	‡	
	Relevant Contract Dollars	45,000	‡	‡	‡	‡	
	Total Count	107	105	111	98	81	
	Total Relevant Dollars	10,672,523	11,695,680	11,312,785	10,168,380	5,542,465	-12.32
Pediatric Research	Number of Grants	685	581	636	681	623	
	Relevant Grant Dollars	212,337,590	146,844,741	179,363,922	193,100,899	209,529,822	
	Number of Contracts	7	2	5	8	4	
	Relevant Contract Dollars	4,384,833	3,291,925	3,631,993	6,488,808	3,185,228	
	Total Count	692	583	641	689	627	
	Total Relevant Dollars	216,722,423	150,136,666	182,995,915	199,589,707	212,715,050	1.70
Personalized Health Care	Number of Grants	630	638	685	661	664	
	Relevant Grant Dollars	183,230,229	180,445,101	184,951,025	164,974,350	155,335,886	
	Number of Contracts	21	17	20	12	1	
	Relevant Contract Dollars	37,543,010	32,351,821	37,283,739	8,158,581	224,999	
	Total Count	651	655	705	673	665	
	Total Relevant Dollars	220,773,239	212,796,922	222,234,764	173,132,931	155,560,885	-7.86

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Pesticides	Number of Grants	12	13	10	4	1	
	Relevant Grant Dollars	531,371	471,294	460,087	59,725	§	
	Number of Contracts	2	‡	‡	‡	‡	
	Relevant Contract Dollars	224,000	‡	‡	‡	‡	
	Total Count	14	13	10	4	1	
	Total Relevant Dollars	755,371	471,294	460,087	59,725	§	-42.33
Pharmacogenetics	Number of Grants	312	276	266	248	226	
	Relevant Grant Dollars	53,813,379	52,795,552	54,346,257	49,570,728	41,541,959	
	Number of Contracts	‡	1	2	‡	‡	
	Relevant Contract Dollars	‡	193,637	670,000	‡	‡	
	Total Count	312	277	268	248	226	
	Total Relevant Dollars	53,813,379	52,989,189	55,016,257	49,570,728	41,541,959	-5.95
Prevention	Number of Grants	1,246	1,220	1,235	1,240	1,221	
	Relevant Grant Dollars	324,621,692	332,988,470	338,729,425	324,824,552	366,837,607	
	Number of Contracts	20	23	35	27	23	
	Relevant Contract Dollars	28,993,208	30,211,780	25,780,603	30,875,471	32,958,496	
	Total Count	1,266	1,243	1,270	1,267	1,244	
	Total Relevant Dollars	353,614,900	363,200,250	364,510,028	355,700,023	399,796,103	3.26
Proteomics	Number of Grants	564	648	718	700	680	
	Relevant Grant Dollars	105,713,144	128,504,517	143,749,069	133,187,112	132,200,036	
	Number of Contracts	13	12	8	14	3	
	Relevant Contract Dollars	3,710,715	2,364,169	3,506,652	5,364,611	465,439	
	Total Count	577	660	726	714	683	
	Total Relevant Dollars	109,423,859	130,868,686	147,255,721	138,551,723	132,665,475	5.49
Radiation, Electromagnetic Fields	Number of Grants	5	5	2	1	1	
	Relevant Grant Dollars	794,902	274,880	208,400	195,214	207,149	
	Total Count	5	5	2	1	1	
	Total Relevant Dollars	794,902	274,880	208,400	195,214	207,149	-22.45
Radiation, Ionizing	Number of Grants	137	118	109	99	91	
	Relevant Grant Dollars	24,942,689	22,587,580	20,437,132	15,415,636	13,527,344	
	Number of Contracts	‡	‡	1	1	1	
	Relevant Contract Dollars	‡	‡	91,808	95,313	209,449	
	Total Count	137	118	110	100	92	
	Total Relevant Dollars	24,942,689	22,587,580	20,528,940	15,510,949	13,736,793	-13.61
Radiation, Ionizing Diagnosis	Number of Grants	284	288	297	291	301	
	Relevant Grant Dollars	67,228,830	83,355,570	78,440,948	69,835,784	67,671,200	
	Number of Contracts	2	6	4	6	3	
	Relevant Contract Dollars	1,127,414	3,682,723	2,664,706	4,565,381	4,153,185	
	Total Count	286	294	301	297	304	
	Total Relevant Dollars	68,356,244	86,038,293	81,105,654	74,401,165	71,824,385	2.10
Radiation, Ionizing Radiotherapy	Number of Grants	605	594	595	578	510	
	Relevant Grant Dollars	197,773,842	215,668,304	178,645,894	168,829,680	105,995,072	
	Number of Contracts	3	6	6	14	1	
	Relevant Contract Dollars	226,116	852,523	1,860,053	7,299,204	1,499,978	
	Total Count	608	600	601	592	511	
	Total Relevant Dollars	197,999,958	216,520,827	180,505,947	176,128,884	107,495,050	-12.17

continued

* Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific site.

‡ Coding not required or requested.

§ No Cost Extension.

Source: Research Analysis and Evaluation Branch.

**Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for
FY2010 – FY2014 – Annual Percent Change***

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Radiation, Low-Level Ionizing	Number of Grants	16	15	11	8	7	
	Relevant Grant Dollars	3,564,004	2,684,415	2,790,815	1,703,359	760,210	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	16	15	11	8	7	
	Total Relevant Dollars	3,564,004	2,684,415	2,790,815	1,703,359	760,210	-28.76
Radiation, Magnetic Resonance Imaging	Number of Grants	309	311	316	302	322	
	Relevant Grant Dollars	71,053,694	72,516,747	66,373,621	71,059,404	83,520,731	
	Number of Contracts	2	3	4	3	‡	
	Relevant Contract Dollars	625,760	810,966	1,649,709	813,452	‡	
	Total Count	311	314	320	305	322	
	Total Relevant Dollars	71,679,454	73,327,713	68,023,330	71,872,856	83,520,731	4.23
Radiation, Mammography	Number of Grants	211	186	183	173	153	
	Relevant Grant Dollars	26,824,376	30,249,026	29,124,083	27,564,637	23,148,908	
	Number of Contracts	1	2	1	1	1	
	Relevant Contract Dollars	999,985	1,845,486	1,400,000	1,300,000	1,100,000	
	Total Count	212	188	184	174	154	
	Total Relevant Dollars	27,824,361	32,094,512	30,524,083	28,864,637	24,248,908	-2.74
Radiation, Non-Ionizing	Number of Grants	167	160	149	129	130	
	Relevant Grant Dollars	26,918,563	26,910,915	25,283,118	21,566,717	24,739,055	
	Number of Contracts	3	1	1	‡	‡	
	Relevant Contract Dollars	476,414	999,000	137,350	‡	‡	
	Total Count	170	161	150	129	130	
	Total Relevant Dollars	27,394,977	27,909,915	25,420,468	21,566,717	24,739,055	-1.87
Radiation, Non-Ionizing Diagnosis	Number of Grants	471	467	491	469	474	
	Relevant Grant Dollars	125,702,669	131,948,820	126,670,584	114,249,805	130,723,063	
	Number of Contracts	9	5	6	6	3	
	Relevant Contract Dollars	1,675,452	1,260,269	2,735,231	4,045,191	679,250	
	Total Count	480	472	497	475	477	
	Total Relevant Dollars	127,378,121	133,209,089	129,405,815	118,294,996	131,402,313	1.05
Radiation, Non-Ionizing Radiotherapy	Number of Grants	195	190	187	187	193	
	Relevant Grant Dollars	40,077,552	48,439,155	45,869,628	42,314,931	51,128,011	
	Number of Contracts	3	‡	1	2	5	
	Relevant Contract Dollars	599,386	‡	1,499,896	1,573,324	1,044,592	
	Total Count	198	190	188	189	198	
	Total Relevant Dollars	40,676,938	48,439,155	47,369,524	43,888,255	52,172,603	7.10
Radiation, UV	Number of Grants	149	144	133	121	114	
	Relevant Grant Dollars	23,686,597	24,555,465	23,909,838	20,530,426	22,589,958	
	Number of Contracts	3	1	1	‡	‡	
	Relevant Contract Dollars	476,414	‡	137,350	‡	‡	
	Total Count	152	145	134	121	114	
	Total Relevant Dollars	24,163,011	25,554,465	24,047,188	20,530,426	22,589,958	-1.18
Radon	Number of Grants	2	3	5	4	4	
	Relevant Grant Dollars	48,624	326,441	490,407	399,608	417,728	
	Total Count	2	3	5	4	4	
	Total Relevant Dollars	48,624	326,441	490,407	399,608	417,728	151.90

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Rare Diseases	Number of Grants	140	119	100	73	62	
	Relevant Grant Dollars	29,192,350	23,592,946	18,712,924	12,159,075	10,866,928	
	Number of Contracts	‡	‡	‡	1	1	
	Relevant Contract Dollars	‡	‡	‡	74,592	312,912	
	Total Count	140	119	100	74	63	
	Total Relevant Dollars	29,192,350	23,592,946	18,712,924	12,233,667	11,179,840	-20.78
Rehabilitation	Number of Grants	221	230	234	229	210	
	Relevant Grant Dollars	38,584,600	40,748,671	45,308,533	40,076,940	47,474,572	
	Number of Contracts	2	1	1	4	2	
	Relevant Contract Dollars	76,452	52,655	21,000	475,141	1,007,690	
	Total Count	223	231	235	233	212	
	Total Relevant Dollars	38,661,052	40,801,326	45,329,533	40,552,081	48,482,262	6.41
Rural Populations	Number of Grants	103	103	100	91	118	
	Relevant Grant Dollars	35,157,309	34,658,560	31,874,931	28,293,909	51,131,320	
	Number of Contracts	12	10	8	‡	‡	
	Relevant Contract Dollars	10,416,108	8,535,867	7,269,316	‡	‡	
	Total Count	115	113	108	91	118	
	Total Relevant Dollars	45,573,417	43,194,427	39,144,247	28,293,909	51,131,320	9.60
Sexually Transmitted Diseases	Number of Grants	183	185	175	154	130	
	Relevant Grant Dollars	30,488,788	29,789,110	28,189,148	21,439,368	17,283,985	
	Number of Contracts	2	1	1	‡	‡	
	Relevant Contract Dollars	4,439,576	3,836,717	870,317	‡	‡	
	Total Count	185	186	176	154	130	
	Total Relevant Dollars	34,928,364	33,625,827	29,059,465	21,439,368	17,283,985	-15.73
Sleep Disorders	Number of Grants	70	64	54	46	48	
	Relevant Grant Dollars	9,183,149	7,810,486	6,729,657	5,420,968	6,930,386	
	Number of Contracts	‡	‡	1	3	1	
	Relevant Contract Dollars	‡	‡	300,000	550,000	78,195	
	Total Count	70	64	55	49	49	
	Total Relevant Dollars	9,183,149	7,810,486	7,029,657	5,970,968	7,008,581	-5.66
Small Molecules	Number of Grants	407	416	513	556	609	
	Relevant Grant Dollars	70,693,138	81,708,151	100,631,305	95,910,356	109,485,605	
	Number of Contracts	10	9	4	6	4	
	Relevant Contract Dollars	2,203,593	3,726,105	1,449,375	1,140,627	1,389,150	
	Total Count	417	425	517	562	613	
	Total Relevant Dollars	72,896,731	85,434,256	102,080,680	97,050,983	110,874,755	11.50
Smokeless Tobacco	Number of Grants	34	19	24	33	29	
	Relevant Grant Dollars	6,896,702	4,743,669	5,175,673	4,087,588	1,359,152	
	Number of Contracts	1	1	1	1	1	
	Relevant Contract Dollars	453,965	385,000	385,000	332,500	420,000	
	Total Count	35	20	25	34	30	
	Total Relevant Dollars	7,350,667	5,128,669	5,560,673	4,420,088	1,779,152	-25.52
Smoking, Passive	Number of Grants	24	15	14	18	20	
	Relevant Grant Dollars	3,459,579	2,250,884	2,491,604	3,160,590	3,771,941	
	Number of Contracts	1	1	1	1	1	
	Relevant Contract Dollars	453,965	385,000	385,000	332,500	420,000	
	Total Count	25	16	15	19	21	
	Total Relevant Dollars	3,913,544	2,635,884	2,876,604	3,493,090	4,191,941	4.48

continued

* Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific site.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Structural Biology	Number of Grants	1,337	1,242	1,199	1,103	1,048	
	Relevant Grant Dollars	269,191,027	258,099,045	235,455,633	206,932,623	196,164,921	
	Number of Contracts	11	15	3	4	‡	
	Relevant Contract Dollars	1,512,388	1,522,607	615,101	1,595,591	‡	
	Total Count	1,348	1,257	1,202	1,107	1,048	
	Total Relevant Dollars	270,703,415	259,621,652	236,070,734	208,528,214	196,164,921	-7.69
Surgery	Number of Grants	327	333	328	326	300	
	Relevant Grant Dollars	72,591,577	85,655,815	76,917,479	77,598,007	48,740,495	
	Number of Contracts	2	2	3	5	‡	
	Relevant Contract Dollars	1,200,000	373,417	545,979	2,527,184	‡	
	Total Count	329	335	331	331	300	
	Total Relevant Dollars	73,791,577	86,029,232	77,463,458	80,125,191	48,740,495	-7.28
Taxol	Number of Grants	305	285	273	270	222	
	Relevant Grant Dollars	73,441,347	70,198,681	60,447,024	52,963,267	17,879,201	
	Number of Contracts	1	‡	1	‡	‡	
	Relevant Contract Dollars	50,000	‡	199,714	‡	‡	
	Total Count	306	285	274	270	222	
	Total Relevant Dollars	73,491,347	70,198,681	60,646,738	52,963,267	17,879,201	-24.25
Telehealth	Number of Grants	351	311	292	288	283	
	Relevant Grant Dollars	83,738,070	76,191,259	76,478,419	65,169,688	64,593,337	
	Number of Contracts	10	11	7	7	6	
	Relevant Contract Dollars	12,502,513	11,912,660	9,755,606	9,541,363	10,473,269	
	Total Count	361	322	299	295	289	
	Total Relevant Dollars	96,240,583	88,103,919	86,234,025	74,711,051	75,066,606	-5.87
Therapy	Number of Grants	3,668	3,626	3,738	3,838	4,057	
	Relevant Grant Dollars	1,289,919,675	1,295,238,778	1,293,761,000	1,246,559,964	1,366,836,549	
	Number of Contracts	102	94	92	104	67	
	Relevant Contract Dollars	97,314,391	93,641,732	88,810,315	71,823,475	80,749,732	
	Total Count	3,770	3,720	3,830	3,942	4,124	
	Total Relevant Dollars	1,387,234,066	1,388,880,510	1,382,571,315	1,318,383,439	1,447,586,281	1.21
Tobacco	Number of Grants	470	449	416	417	381	
	Relevant Grant Dollars	121,389,946	127,614,366	122,594,345	98,441,413	80,787,427	
	Number of Contracts	8	4	4	8	5	
	Relevant Contract Dollars	2,479,840	1,419,652	1,302,350	2,268,519	1,335,500	
	Total Count	478	453	420	425	386	
	Total Relevant Dollars	123,869,786	129,034,018	123,896,695	100,709,932	82,122,927	-9.25
Tobacco Use Behavior	Number of Grants	250	239	259	276	274	
	Relevant Grant Dollars	81,176,603	83,456,895	87,985,064	73,128,257	64,136,938	
	Number of Contracts	4	2	4	6	5	
	Relevant Contract Dollars	1,868,571	1,320,000	1,302,350	2,066,485	1,335,500	
	Total Count	254	241	263	282	279	
	Total Relevant Dollars	83,045,174	84,776,895	89,287,414	75,194,742	65,472,438	-5.33
Tropical Diseases	Number of Grants	29	25	21	16	15	
	Relevant Grant Dollars	6,535,704	5,619,635	5,588,012	2,226,158	2,968,168	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	29	25	21	16	15	
	Total Relevant Dollars	6,535,704	5,619,635	5,588,012	2,226,158	2,968,168	-10.35

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Tumor Markers	Number of Grants	731	626	508	393	298	
	Relevant Grant Dollars	189,955,095	161,691,676	124,259,866	88,015,396	59,605,975	
	Number of Contracts	12	4	3	‡	‡	
	Relevant Contract Dollars	4,365,645	2,569,530	2,693,245	‡	‡	
	Total Count	743	630	511	393	298	
	Total Relevant Dollars	194,320,740	164,531,206	126,953,111	88,015,396	59,605,975	-25.28
Underserved Populations	Number of Grants	607	595	585	556	610	
	Relevant Grant Dollars	210,560,355	210,385,470	216,074,187	189,290,919	245,809,745	
	Number of Contracts	21	16	16	2	‡	
	Relevant Contract Dollars	12,245,405	10,306,244	11,469,992	2,354,483	‡	
	Total Count	628	611	601	558	610	
	Total Relevant Dollars	222,805,760	220,691,714	227,544,179	191,645,402	245,809,745	3.66
Vaccine Development	Number of Grants	163	159	151	130	112	
	Relevant Grant Dollars	21,218,754	21,105,678	20,714,291	17,452,232	15,119,199	
	Number of Contracts	‡	1	‡	1	1	
	Relevant Contract Dollars	‡	199,988	‡	739,425	458,635	
	Total Count	163	160	151	131	113	
	Total Relevant Dollars	21,218,754	21,305,666	20,714,291	18,191,657	15,577,834	-7.23
Vaccine Production	Number of Grants	8	6	3	2	1	
	Relevant Grant Dollars	1,046,919	661,049	589,530	152,239	‡	
	Number of Contracts	‡	1	‡	1	‡	
	Relevant Contract Dollars	‡	1,499,001	‡	739,425	‡	
	Total Count	8	7	3	3	1	
	Total Relevant Dollars	1,046,919	2,160,050	589,530	891,664	‡	28.29
Vaccine Research	Number of Grants	201	195	183	167	149	
	Relevant Grant Dollars	33,377,072	34,117,779	31,279,880	25,866,062	25,518,109	
	Number of Contracts	1	2	1	3	‡	
	Relevant Contract Dollars	23,100	1,502,003	1,996,084	5,831,735	‡	
	Total Count	202	197	184	170	149	
	Total Relevant Dollars	33,400,172	34,619,782	33,275,964	31,697,797	25,518,109	-6.12
Vaccine Testing	Number of Grants	130	111	101	82	70	
	Relevant Grant Dollars	21,759,604	18,745,944	17,217,816	13,797,753	14,265,015	
	Number of Contracts	1	1	1	‡	3	
	Relevant Contract Dollars	4,394,576	3,836,717	870,317	‡	4,435,947	
	Total Count	131	112	102	82	73	
	Total Relevant Dollars	26,154,180	22,582,661	18,088,133	13,797,753	18,700,962	-5.44
Virus Cancer Research	Number of Grants	541	505	481	458	442	
	Relevant Grant Dollars	153,628,908	142,438,045	133,815,083	123,611,800	124,977,046	
	Number of Contracts	3	1	4	2	1	
	Relevant Contract Dollars	4,549,461	3,836,717	4,066,305	2,478,454	740,476	
	Total Count	544	506	485	460	443	
	Total Relevant Dollars	158,178,369	146,274,762	137,881,388	126,090,254	125,717,522	-5.53
Virus – Epstein-Barr	Number of Grants	110	104	96	81	75	
	Relevant Grant Dollars	24,362,117	24,499,924	22,756,337	20,096,683	17,304,516	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	110	104	96	81	75	
	Total Relevant Dollars	24,362,117	24,499,924	22,756,337	20,096,683	17,304,516	-8.03

continued

* Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

† Relevant Dollars = portion of the funded amount relevant to a specific site.

‡ Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Virus – Genital Herpes	Number of Grants	4	4	3	‡	‡	
	Relevant Grant Dollars	379,575	372,188	290,654	‡	‡	
	Total Count	4	4	3	‡	‡	
	Total Relevant Dollars	379,575	372,188	290,654	‡	‡	-11.93
Virus – Hepatitis B	Number of Grants	51	50	42	39	39	
	Relevant Grant dollars	11,337,066	6,370,613	4,928,799	3,929,183	4,816,519	
	Total Count	51	50	42	39	39	
	Total Relevant Dollars	11,337,066	6,370,613	4,928,799	3,929,183	4,816,519	-16.03
Virus – Hepatitis C	Number of Grants	34	31	40	39	34	
	Relevant Grant Dollars	5,719,779	4,600,379	5,332,014	3,990,130	3,507,767	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	34	31	40	39	34	
Total Relevant Dollars	5,719,779	4,600,379	5,332,014	3,990,130	3,507,767	-10.23	
Virus – Herpes	Number of Grants	206	190	182	163	157	
	Relevant Grant Dollars	47,274,246	48,127,519	44,080,597	41,683,291	42,315,552	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	206	190	182	163	157	
Total Relevant Dollars	47,274,246	48,127,519	44,080,597	41,683,291	42,315,552	-2.63	
Virus – HHV8	Number of Grants	87	78	74	66	65	
	Relevant Grant Dollars	18,532,843	17,725,584	15,764,211	18,719,752	19,671,059	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	87	78	74	66	65	
Total Relevant Dollars	18,532,843	17,725,584	15,764,211	18,719,752	19,671,059	2.10	
Virus – HTLV-I	Number of Grants	22	24	22	20	22	
	Relevant Grant Dollars	6,183,612	6,171,762	6,563,215	3,679,947	4,627,662	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	22	24	22	20	22	
Total Relevant Dollars	6,183,612	6,171,762	6,563,215	3,679,947	4,627,662	-3.01	
Virus – HTLV-II	Number of Grants	‡	2	1	1	1	
	Relevant Grant Dollars	‡	2,000	171,471	160,325	151,718	
	Total Count	‡	2	1	1	1	
	Total Relevant Dollars	‡	2,000	171,471	160,325	151,718	2820.56
Virus – Papilloma	Number of Grants	169	168	165	162	176	
	Relevant Grant Dollars	46,214,177	43,559,761	41,276,749	40,445,208	43,808,063	
	Number of Contracts	1	1	3	2	1	
	Relevant Contract Dollars	4,394,576	3,836,717	3,866,401	2,478,454	740,476	
	Total Count	170	169	168	164	177	
Total Relevant Dollars	50,608,753	47,396,478	45,143,150	42,923,662	44,548,539	-3.06	

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

†Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Virus – Papova	Number of Grants	207	200	190	185	196	
	Relevant Grant Dollars	55,528,827	52,541,742	49,415,531	49,217,700	50,340,929	
	Number of Contracts	2	1	3	2	1	
	Relevant Contract Dollars	4,544,576	3,836,717	3,866,401	2,478,454	740,476	
	Total Count	209	201	193	187	197	
	Total Relevant Dollars	60,073,403	56,378,459	53,281,932	51,696,154	51,081,405	-3.95
Virus – SV40	Number of Grants	29	25	21	15	7	
	Relevant Grant Dollars	5,171,617	5,163,432	3,525,677	3,313,239	356,763	
	Total Count	29	25	21	15	7	
	Total Relevant Dollars	5,171,617	5,163,432	3,525,677	3,313,239	356,763	-31.78
Vitamin A	Number of Grants	66	55	42	40	31	
	Relevant Grant Dollars	8,863,103	9,150,008	6,336,364	6,714,906	4,342,551	
	Number of Contracts	1	1	‡	‡	‡	
	Relevant Contract Dollars	391,285	99,917	‡	‡	‡	
	Total Count	67	56	42	40	31	
	Total Relevant Dollars	9,254,388	9,249,925	6,336,364	6,714,906	4,342,551	-15.23
Vitamin C	Number of Grants	21	15	16	11	7	
	Relevant Grant Dollars	1,843,823	1,106,973	1,323,825	1,327,243	993,313	
	Total Count	21	15	16	11	7	
	Total Relevant Dollars	1,843,823	1,106,973	1,323,825	1,327,243	993,313	-11.32
Vitamin D	Number of Grants	45	70	76	70	81	
	Relevant Grant Dollars	11,837,723	20,457,495	20,791,513	17,759,137	17,167,368	
	Number of Contracts	‡	‡	1	1	‡	
	Relevant Contract Dollars	‡	‡	56,250	918,685	‡	
	Total Count	45	70	77	71	81	
	Total Relevant Dollars	11,837,723	20,457,495	20,847,763	18,677,822	17,167,368	14.06
Vitamins, Other	Number of Grants	55	44	25	15	8	
	Relevant Grant Dollars	12,310,882	10,076,781	6,252,528	4,252,163	3,199,595	
	Number of Contracts	‡	‡	1	‡	‡	
	Relevant Contract Dollars	‡	‡	56,250	‡	‡	
	Total Count	55	44	26	15	8	
	Total Relevant Dollars	12,310,882	10,076,781	6,308,778	4,252,163	3,199,595	-28.22

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 17. NCI Funding of Foreign Research Grants in FY2014*(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)*

Country/ Cancer Site	Mechanism									Totals
	N01	R01	R03	R21	R37	U01	U10	U24	UM1	
AUSTRALIA										
Grants & Contracts #	1	1			1					2
Funding \$	45,000	134,377			223,295					402,672
Breast		134,377								134,377
Hodgkins Lymphoma					37,960					37,960
Leukocytes					111,648					111,648
Myeloma					35,727					35,727
Childhood Leukemia	45,000									45,000
Non-Hodgkins Lymphoma					37,960					37,960
BELGIUM										
Grants & Contracts #							1			1
Funding \$							179,358			179,358
Bone, Cartilage							4,679			4,679
Brain							3,119			3,119
Breast							51,467			51,467
Central Nervous System							1,560			1,560
Cervix							3,119			3,119
Childhood Leukemia							21,835			21,835
Colon, Rectum							6,238			6,238
Esophagus							1,560			1,560
Head and Neck							1,560			1,560
Kidney							3,119			3,119
Leukemia							21,835			21,835
Liver							1,560			1,560
Lung							12,477			12,477
Neuroblastoma							3,119			3,119
Non-Hodgkins Lymphoma							1,560			1,560
Not Site Specific*							12,477			12,477
Ovary							4,679			4,679
Pancrea							1,560			1,560
Pharynx							1,560			1,560
Prostate							17,156			17,156
Uterus							3,119			3,119

continued

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.)

Source: Research Analysis and Evaluation Branch.

Table 17 (cont'd). NCI Funding of Foreign Research Grants in FY2014*(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)*

Country/ Cancer Site	Mechanism									
CANADA	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts #	1	13	1	2		1	1	1	1	21
Funding \$	798,409	4,046,552	68,062	348,173		257,249	3,314,493	296,351	401,397	9,530,686
Bladder		19,836					165,725			185,561
Brain							165,725			165,725
Breast		1,211,738	68,062				1,325,796			2,605,596
Cervix							82,862			82,862
Childhood Leukemia		159,959								159,959
Colon, Rectum							132,580			132,580
Esophagus							66,290			66,290
Head and Neck							165,725			165,725
Kidney							165,725			165,725
Leukemia		727,096					124,293			851,389
Liver							33,145			33,145
Lung		808,094					165,725			973,819
Myeloma							82,862			82,862
Non-Hodgkins Lymphoma							124,293			124,293
Not Site Specific*	798,409	745,785		103,360				296,351	401,397	2,345,302
Ovary						257,249	165,725			422,974
Pancreas				244,813			66,290			311,103
Prostate		374,044					165,725			539,769
Stomach							33,145			33,145
Uterus							82,862			82,862
FRANCE	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts #				1		3				4
Funding \$				126,247		1,928,934				2,055,181
Bladder						124,289				124,289
Kidney				126,247		329,259				455,506
Lung						895,370				895,370
Not Site Specific*						580,016				580,016
INDIA	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts #		1								1
Funding \$		189,801								189,801
Breast		189,801								189,801
ISRAEL	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts #		3			1					4
Funding \$		753,516			221,413					974,929
Breast		48,482			221,413					269,895
Colon, Rectum		48,482								48,482
Lung		48,482								48,482
Not Site Specific*		459,899								459,899
Ovary		99,689								99,689
Skin		48,482								48,482

continued

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.)

Source: Research Analysis and Evaluation Branch.

Table 17 (cont'd). NCI Funding of Foreign Research Grants in FY2014*(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)*

Country/ Cancer Site	Mechanism									Totals
	N01	R01	R03	R21	R37	U01	U10	U24	UM1	
JAPAN										
Grants & Contracts #	1									1
Funding \$	209,449									209,449
Not Site Specific*	209,449									209,449
SWEDEN										
Grants & Contracts #			1							1
Funding \$			48,190							48,190
Bone, Cartilage			4,819							4,819
Brain			4,819							4,819
Childhood Leukemia			4,819							4,819
Leukemia			4,819							4,819
Liver			4,819							4,819
Neuroblastoma			4,819							4,819
Non-Hodgkins Lymphoma			4,819							4,819
Retinoblastoma			4,819							4,819
Sarcoma, Soft Tissue			4,819							4,819
Wilms Tumor			4,819							4,819
UNITED KINGDOM										
Grants & Contracts #	1	3				1		1		6
Funding \$	50,218	1,188,279				97,149		242,691		1,578,337
Breast		215,945								215,945
Eye		380,739								380,739
Melanoma		380,739								380,739
Myeloma		210,856								210,856
Not Site Specific*	50,218					97,149				147,367
Thyroid								242,691		242,691
Total Grants & Contracts	4	21	2	3	2	5	2	2	1	42
Total \$ Per Grant & Contract type	1,103,076	6,312,525	116,252	474,420	444,708	2,283,332	3,493,851	539,042	401,397	15,168,603

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.)

Source: Research Analysis and Evaluation Branch.

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2014*(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)*

Country	Funding Mechanism																Sub-Total									
	F30	F31	F32	K01	K05	K07	K08	K23	K99	P01	R00	R01	R03	R13	R21	R25		R37	R43	R44	U01	U24	U54	UG1	UH2	UM1
Africa (unspecified)											1															1
Argentina				1							1										1					3
Asia (unspecified)											2	1														3
Australia				1	1						22		2							3	3			1		33
Austria											1						1				1					3
Bangladesh											1															1
Belgium											2										1					3
Benin											1															1
Botswana																							1			1
Brazil											2		1	1						1	1			1		7
Cameroon											1															1
Canada					1					1	43		6	6	2		1	1	8	3		1		1		74
Caribbean (unspecified)											1															1
Central America (unspecified)											1															1
Chile											1															1
China		1				1					13	3	2						2	2			3		27	
Columbia											2		1								1		1		5	
Costa Rica																				1					1	
Czech Republic																				1	1					2
Denmark			1								7		1							1	1				11	
Egypt											1										1				2	
El Salvador											1														1	
Europe (unspecified)											1	1													2	
Finland											2									1	1				4	
France											7	2	2						5	1					17	
Germany									1		24		1						4	2		1			33	
Greece											3														3	
Honduras												1													1	
Hungary																					2				2	
Iceland																				1					1	
India			1		1						5	1									1		1		10	
Iran																					1				1	
Ireland											1										2				3	
Israel		1								1	7				1	1		1	1	2					15	
Italy		1			1						8	1							2	2					15	
Jamaica													1												1	
Japan											9	1	1								1				12	
Kenya		1									4									1		1			7	
Kuwait																					1				1	
Malawi											1		1									1			3	

continued

Source: Research Analysis and Evaluation Branch.

Table 18 (cont'd). Foreign Components of U.S. Domestic Research Grants in FY2014*(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)*

Country	Funding Mechanism																				Sub-Total						
	F30	F31	F32	K01	K05	K07	K08	K23	K99	P01	R00	R01	R03	R13	R21	R25	R37	R43	R44	U01		U24	U54	UG1	UH2	UM1	
Malaysia																						1					1
Mexico				1								4			2							1					8
Middle East (unspecified)												1															1
Netherlands		1								1		11			1		1				5	1					21
New Zealand												3			1								3				7
Nicaragua												1															1
Nigeria															1										1		2
North America (unspecified)												1															1
Norway												6	2									3					11
Oceania (unspecified)												1															1
Pakistan																							1				1
Panama																							1				1
Paraguay															1												1
Peru												1													1		2
Philippines																									1		1
Poland												1											1				2
Portugal												1											1				2
Romania																						1					1
Russia																						1	1				2
Rwanda																								1			1
Saudi Arabia																							1				1
Singapore									1			6	1										1			1	10
Slovenia																							1				1
South Africa																						1	2		1		4
South America (unspecified)												1															1
South Korea												1											1				2
Spain												7			1	1							2				11
Sweden												6										4	2				12
Switzerland												1										1	2				10
Taiwan												4											1				5
Tanzania												1												1			2
Thailand												2															2
Turkey		1	1									1											1				4
Uganda			1						1			3										1		3			9
United Kingdom			1									30	3		3	1						8	1				47
Uruguay																							1				1
Venezuela																								1			1
Vietnam												1															1
Zambia												2															2
Zimbabwe																						1					1
Totals	3	6	2	3	4	1	1	1	2	2	1	275	20	8	27	6	2	2	2	2	58	60	8	1	8	6	509*

* Because many grants and contracts have multiple foreign contributors, the total count (509) is greater than the total number of grants and contracts (296).

Source: Research Analysis and Evaluation Branch.

Appendix A: Activities of the National Cancer Advisory Board

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 18 members who are appointed by the President and 12 nonvoting *ex officio* members. The NCAB advises, assists, consults with, and makes recommendations to the Secretary, HHS, and to the NCI Director with respect to the activities carried out by and through the Institute and on policies pertaining to these activities. It is authorized to recommend support for grants and cooperative agreements following technical and scientific peer review. The Director of the DEA serves as Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all peer reviewed applications, the Board reviewed a total of 6,712 applications in FY2014 requesting \$2,752,500,251 in direct costs with appropriated funds from a total of 13,071 applications requesting \$3,792,650,570.

The Board heard presentations, discussed, and provided advice on a variety of topics and NCI activities in FY2014, such as:

- NCI Director's Report
- President's Cancer Panel Report
- Legislative Update
- Report on Study of Cancer Center Budgets
- Annual Delegations of Authority
- Overview of NCI Tobacco Control Research Investment and Partnerships
- Surgeon General's Tobacco Report
- Pathophysiology of Tobacco-Induced Cancers
- New Directions in Cessation of Tobacco Uses: A 2014 Update
- E-Cigarettes: Unanswered Questions
- Global Tobacco Control
- FDA Regulation and the FDA-NIH Regulatory Science Partnership

- Final Report: Cancer Centers Working Group
- Clinical Trials Reporting Policy
- SPORE Program Working Group Report
- Use of Aspirin for Prevention and Treatment of Cancers
- NCI and the Common Fund
- Pediatric Oncology
- Intramural Program: Review of NCI Report to the NIH
- Impact of the New NCI Clinical Trials System
- Cancer Genomics
- Update: Electronic Cigarette
- Reducing the Number of Types of K Awards
- Modular Grants
- Perspective on Cancer Prevention Research and Implementation

As part of its mandate for oversight of NCI activities, the NCAB receives regular updates from the NCI Director, the NCI Office of Legislation and Congressional Activities, and the President's Cancer Panel.

Another major role of the Board is to monitor the overall advisory and oversight activities of the NCI as a whole. In that regard, it annually reviews the site visit outcomes of intramural review and the extramural RFA and RFP concepts acted on by the BSA. The NCAB also participates in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities as expressed by the allocation of the annual operating budget.

The full text of recent NCAB meeting summaries is available on the NCI website at <http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm>

Appendix B: Activities of the Board of Scientific Advisors

The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of NCI's extramural research programs, and concept review of extramural program initiatives.

In addition to approving a number of extramural program initiatives (see below), the BSA also heard presentations on the following in FY2014:

- Report of the NCI Director
- Cancer Genomics
- Clinical Trials Reporting Policy
- Final Report Cancer Centers Working Group
- SPORE Program Working Group Report
- NCI and the Common Fund
- Pediatric Oncology
- Update: Electronic Cigarettes
- Reducing the Types of K Awards
- Modular Grants
- Perspective on Cancer Prevention Research and Implementation

RFA Concept Approved

Division of Cancer Control and Population Sciences

- Using Social Media to Understand and Address Substance Use and Addiction Effort with NIDA and NIAAA

RFP Concept Approved

Division of Cancer Treatment and Diagnosis

- A Prospective Randomized Trial of Carbon Ion Versus Conventional Radiation Therapy for Locally Advanced, Unresectable Pancreatic Cancer

RFA/Cooperative Agreements Approved

Division of Cancer Treatment and Diagnosis

- Biospecimens Banks to Support NCI-Clinical Trials Network (NCTN)

Division of Cancer Prevention

- Chronic Pancreatitis and Pancreatic Cancer Clinical Research or Consortium of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CSCPPC)

Division of Cancer Prevention and Division of Cancer Biology

- Molecular Characterization of Screen-Detected Lesions

RFA/Cooperative Agreements Re-Issuances

Office of the Director

- Innovative Molecular Analysis Technologies (IMAT)
- AIDS Malignancy Clinical Trials Consortium (AMC)
- Centers of Cancer Nanotechnology Excellence
- Research Answers to NCI Provocative Questions

Division of Cancer Treatment and Diagnosis

- Pediatric Preclinical Testing Program (PPTP)

Division of Cancer Control and Population Sciences

- Cancer Intervention and Surveillance Modeling Network (CISNET)
- Breast Cancer and the Environment Research Program

Division of Cancer Prevention

- The Early Detection Network (EDRN)

Division of Cancer Biology

- IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Appendix C: List of Chartered Committees

President’s Cancer Panel

Chair

Barbara K. Rimer, Dr.P.H., M.P.H. The University of North Carolina at Chapel Hill

Members

Hill Harper, J.D. Author, Actor, Philanthropist
Owen N. Witte, M.D. University of California, Los Angeles

Executive Secretary

Abby B. Sandler, Ph.D. National Cancer Institute, NIH

National Cancer Advisory Board

Chair

Tyler E. Jacks, Ph.D. Massachusetts Institute of Technology

Members

Victoria L. Champion, Ph.D., R.N., F.A.A.N. Indiana University
David C. Christiani, M.D., M.P.H. Harvard Medical School
Marcia R. Cruz-Correa, M.D., Ph.D. University of Puerto Rico
Kevin J. Cullen, M.D. University of Maryland, Baltimore
Judy E. Garber, M.D., M.P.H. Harvard Medical School
William H. Goodwin, Jr., M.B.A. CCA Industries, Inc.
Waun K. Hong, M.D. The University of Texas MD Anderson Cancer Center
Elizabeth M. Jaffee, M.D. Johns Hopkins University
Beth Y. Karlan, M.D. University of California, Los Angeles
Ms. Mary Vaughan Lester University of California, San Francisco Foundation
H. Kim Lyerly, M.D. Duke University
Olufunmilayo F. Olopade, M.B.B.S., F.A.C.P. The University of Chicago
Jennifer A. Pietenpol, Ph.D. Vanderbilt University
Mack Roach III, M.D., F.A.C.R. University of California, San Francisco
Jonathan M. Samet, M.D., M.S. University of Southern California
Charles L. Sawyers, M.D. Weill Cornell Medical College of Cornell University
William R. Sellers, M.D. Novartis Institutes for BioMedical Research, Inc.

Ex Officio Members of the National Cancer Advisory Board

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. National Institute of Environmental Health Sciences, NIH
The Honorable Sylvia M. Burwell..... U.S. Department of Health and Human Services
Francis S. Collins, M.D., Ph.D. National Institutes of Health
Margaret A. Hamburg, M.D. U.S. Food and Drug Administration

John P. Holdren, Ph.D.	Office of Science and Technology Policy
John Howard, M.D., M.P.H., J.D., L.L.M. .	National Institute for Occupational Safety and Health
Gina McCarthy, M.S.	U.S. Environmental Protection Agency
The Honorable Thomas E. Perez	U.S. Department of Labor
Robert A. Petzel, M.D.	U.S. Department of Veterans Affairs
The Honorable Kathleen Sebelius, M.P.A.	U.S. Department of Health and Human Services
Inez Tenenbaum, M.Ed.	U.S. Consumer Product Safety Commission
Sharlene Weatherwax, Ph.D.	U.S. Department of Energy
Jonathan Woodson, M.D.	U.S. Department of Defense

Alternates to *Ex Officio* Members of the National Cancer Advisory Board

Robert T. Anderson, Ph.D.	U.S. Department of Energy
Michael A. Babich, Ph.D.	U.S. Consumer Product Safety Commission
Patricia Bray, M.D., M.P.H.	OSHA/U.S. Department of Labor
Vincent J. Cogliano, Ph.D.	U.S. Environmental Protection Agency
Michael Kelley, M.D., F.A.C.P.	U.S. Department of Veterans Affairs
Aubrey Miller, M.D.	National Institute of Environmental Health Sciences, NIH
Richard Pazdur, M.D., F.A.C.P.	U.S. Food and Drug Administration
Craig D. Shriver, M.D., F.A.C.S., COL., M.C.	U.S. Department of Defense
Kerry Souza, Sc.D., M.P.H.	National Institute for Occupational Safety and Health
Michael Stebbins, Ph.D.	Office of Science and Technology Policy
Lawrence A. Tabak, D.D.S., Ph.D.	National Institutes of Health
Richard J. Thomas, M.D., M.P.H.	OSHA/U.S. Department of Labor

Executive Secretary

Paulette S. Gray, Ph.D.	National Cancer Institute, NIH
------------------------------	--------------------------------

Frederick National Laboratory Advisory Committee to NCI

(formerly the NCI-Frederick Advisory Committee)

Chair

Joe W. Gray, Ph.D.	Oregon Health & Science University
-------------------------	------------------------------------

Members

J. Carl Barrett, Ph.D.	AstraZeneca Pharmaceuticals LP
Gail A. Bishop, Ph.D.	The University of Iowa College of Medicine
David Botstein, Ph.D.	Princeton University
Vicki L. Colvin, Ph.D.	Brown University
Levi A. Garraway, M.D., Ph.D.	Harvard Medical School
Beatrice H. Hahn, M.D.	University of Pennsylvania
Monica J. Justice, Ph.D.	The HSC Pediatric Center
Lawrence J. Marnett, Ph.D.	Vanderbilt University Medical Center
Jill P. Mesirov, Ph.D.	The Broad Institute of MIT and Harvard University
Garry P. Nolan, Ph.D.	Stanford University
Kenneth J. Pienta, M.D.	Johns Hopkins University
Steven T. Rosen, M.D., F.A.C.P.	City of Hope National Medical Center

Representatives

- Elizabeth M. Jaffee, M.D. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
- Alexandra L. Joyner, Ph.D. Memorial Sloan Kettering Cancer Center
- Cheryl Willman, M.D. The University of New Mexico

Ex Officio Members of the Frederick National Laboratory Advisory Committee to the NCI

- Stephen J. Chanook, M.D. National Cancer Institute, NIH
- James H. Doroshow, M.D. National Cancer Institute, NIH
- Paulette S. Gray, Ph.D. National Cancer Institute, NIH
- Douglas R. Lowy, M.D. National Cancer Institute, NIH
- Alan S. Rabson, M.D. National Cancer Institute, NIH
- Craig W. Reynolds, Ph.D. National Cancer Institute, NIH
- Robert H. Wiltrout, Ph.D. National Cancer Institute, NIH

Executive Secretary

- Thomas M. Vollberg, Sr., Ph.D. National Cancer Institute, NIH

NCI Board of Scientific Advisors

Chair

- Todd R. Golub, M.D. The Broad Institute of MIT and Harvard University

Members

- Francis Ali-Osman, D.Sc. Duke University Medical Center
- Kenneth C. Anderson, M.D., Ph.D. Dana-Farber Cancer Institute
- Dafna Bar-Sagi, Ph.D. New York University School of Medicine
- Ethan M. Basch, M.D., M.Sc. The University of North Carolina at Chapel Hill
- Sangeeta N. Bhatia, M.D., Ph.D. Massachusetts Institute of Technology
- Andrea Califano, Ph.D. Columbia University Medical Center
- Arul M. Chinnaiyan, M.D., Ph.D. University of Michigan
- Curt I. Civin, M.D. University of Maryland, Baltimore
- Graham A. Colditz, M.D., Dr.P.H. Washington University in St. Louis
- Chi V. Dang, M.D., Ph.D. University of Pennsylvania
- Joseph M. DeSimone, Ph.D. The University of North Carolina at Chapel Hill
- Daniel C. DiMaio, M.D., Ph.D. Yale University
- Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S. University of Pennsylvania
- Brian J. Druker, M.D. Oregon Health & Science University
- Karen M. Emmons, Ph.D. Kaiser Foundation Research Institute
- Betty R. Ferrell, Ph.D., R.N., F.A.A.N. City of Hope National Medical Center
- Kathleen M. Foley, M.D. Memorial Sloan Kettering Cancer Center
- Stanton L. Gerson, M.D. Case Western Reserve University
- Joe W. Gray, Ph.D. Oregon Health & Science University
- Chanita Hughes-Halbert, Ph.D. Medical University of South Carolina
- Joshua LaBaer, M.D., Ph.D. Arizona State University

Theodore S. Lawrence, M.D., Ph.D.	University of Michigan
Mr. Donald Listwin.....	Canary Foundation
Maria E. Martinez, M.P.H., Ph.D.	University of California, San Diego
Luis F. Parada, Ph.D.	The University of Texas Southwestern Medical Center
Diane Z. Quale, J.D.	Bladder Cancer Advisory Network
Martine F. Roussel (Sherr), Ph.D.	St. Jude Children’s Research Hospital
Kevin M. Shannon, M.D.	University of California, San Francisco
Mary L. Smith, J.D., M.B.A.	Research Advocacy Network
Lincoln Stein, M.D., Ph.D.	Ontario Institute for Cancer Research
Bruce W. Stillman, Ph.D.	Cold Spring Harbor Laboratory
Frank M. Torti, M.D., M.P.H.	University of Connecticut Health Center
Gregory L. Verdine, Ph.D.	Harvard University
Cheryl L. Walker, Ph.D., A.T.S., F.A.A.A.S.	Texas A&M Health Science Center
Irving L. Weissman, M.D.	Stanford University
Eileen P. White, Ph.D.	Rutgers Cancer Institute of New Jersey
Kevin P. White, Ph.D.	The University of Chicago

Executive Secretary

Paulette S. Gray, Ph.D.	National Cancer Institute, NIH
------------------------------	--------------------------------

Clinical Trials and Translational Research Advisory Committee

Chair

James L. Abbruzzese, M.D., F.A.C.P.Duke University

Members

Susan G. Arbuck, M.D., M.Sc., F.A.C.P. Susan G. Arbuck M.D., LLC
 David F. Arons, J.D. National Brain Tumor Society
 Susan M. Blaney, M.D. Texas Children’s Hospital
 Monica M. Bertagnolli, M.D. Dana-Farber Cancer Institute
 Curt I. Civin, M.D. University of Maryland, Baltimore
 Kevin J. Cullen, M.D. University of Maryland, Baltimore
 Walter J. Curran, M.D., Ph.D. Emory University
 Nancy E. Davidson, M.D. University of Pittsburgh
 J. Philip Kuebler, M.D., Ph.D. Columbus Oncology Associates, Inc.
 Michael L. LeBlanc, Ph.D. University of Washington
 Scott M. Lippman, M.D. University of California, San Diego
 David A. Mankoff, M.D., Ph.D. University of Pennsylvania
 Mary S. McCabe, R.N., M.A. Memorial Sloan Kettering Cancer Center
 Edith P. Mitchell, M.D., F.A.C.P. Thomas Jefferson University
 Nikhil C. Munshi, M.D. Harvard Medical School
 Lisa A. Newman, M.D., M.P.H., F.A.C.S. University of Michigan
 Peter G. Shields, M.D. The Ohio State University
 George W. Sledge, Jr., M.D. Stanford University
 Chris H. Takimoto, M.D., Ph.D., F.A.C.P. Janssen Pharmaceuticals, Inc.
 Gillian M. Thomas, M.D., F.R.C.P.C., F.R.C.R. University of Toronto
 Frank M. Torti, M.D., M.P.H. University of Connecticut Health Center
 Miguel A. Villalona-Calero, M.D. The Ohio State University
 George J. Weiner, M.D. The University of Iowa

Ex Officio Members

James H. Doroshow, M.D. National Cancer Institute, NIH
 Paulette S. Gray, Ph.D. National Cancer Institute, NIH
 Rosemarie B. Hakim, Ph.D., M.S. U.S. Centers for Medicare and Medicaid Services
 Lee J. Helman, M.D. National Cancer Institute, NIH
 Michael J. Kelley, M.D., F.A.C.P. U.S. Department of Veterans Affairs
 Richard Pazdur, M.D., F.A.C.P. U.S. Food and Drug Administration
 Alan S. Rabson, M.D. National Cancer Institute, NIH

Executive Secretary

Sheila A. Prindiville, M.D., M.P.H. National Cancer Institute, NIH

Board of Scientific Counselors for Clinical Sciences and Epidemiology, NCI

Chair

Louis M. Weiner, M.D. Georgetown University Medical Center

Members

Edgar Ben-Josef, M.D. University of Pennsylvania
 Jonine L. Bernstein, Ph.D. Memorial Sloan Kettering Cancer Center
 Arthur W. Blackstock, Jr., M.D. Wake Forest University
 E. Julie Buring, Sc.D. Brigham and Women's Hospital
 Tim Byers, M.D., M.P.H. University of Colorado Cancer Center
 Nicola J. Camp, M.D., Ph.D. University of Utah
 Graham Casey, Ph.D. University of Southern California
 Susan L. Cohn, M.D. The University of Chicago
 Laurence J.N. Cooper, M.D., Ph.D. The University of Texas MD Anderson Cancer Center
 John F. DiPersio, M.D., Ph.D., F.A.C.P. Washington University in St. Louis
 Kojo S.J. Elenitoba-Johnson, M.D. University of Michigan Medical School
 Elizabeth T. H. Fontham, Dr.P.H., M.P.H. Louisiana State University Health Science Center
 Michael L. Freeman, Ph.D. Vanderbilt University
 Marc T. Goodman, Ph.D, M.P.H. Cedars-Sinai Medical Center
 Nancy Goodman, J.D. Kids V Cancer
 Bernard Harlow, Ph.D. University of Minnesota
 Carl June, M.D. University of Pennsylvania
 Karen L. Kelly, M.D. University of California, Davis
 Hongzhe Lee, Ph.D. University of Pennsylvania
 Alexandra M. Levine, M.D., M.A.C.P. City of Hope National Medical Center
 Sanford Markowitz, M.D., Ph.D. Case Western Reserve University
 David A. Norris, M.D. University of Colorado
 Augusto Ochoa, M.D. Louisiana State University
 Kenneth Offit, M.D., M.P.H. Memorial Sloan Kettering Cancer Center
 Raphael E. Pollock, M.D., Ph.D. The Ohio State University
 David Poplack, M.D. Baylor College of Medicine
 Alfredo Quinones-Hinojosa, M.D. Johns Hopkins University
 Jeremy N. Rich, M.D., M.H.Sc. Case Western Reserve University
 Thomas Rohan, M.D., Ph.D. Albert Einstein College of Medicine of Yeshiva University
 A. Oliver Sartor, M.D. Tulane University Medical School
 Darryl K. Shibata, M.D. The University of Southern California
 Walter M. Stadler, M.D., F.A.C.P. The University of Chicago Medical Center
 Elizabeth Ward, Ph.D. American Cancer Society
 George Wilding, M.D. University of Wisconsin, Madison
 Cheryl L. Willman, M.D. The University of New Mexico Cancer Research Facility

Executive Secretary

Brian E. Wojcik, Ph.D. National Cancer Institute, NIH

Board of Scientific Counselors for Basic Sciences, NCI

Chair

Joan W. Conaway, Ph.D. Stowers Institute for Medical Research

Members

Amnon Altman, Ph.D. La Jolla Institute for Allergy and Immunology
 Paul D. Bieniasz, Ph.D. The Rockefeller University
 John C. Cambier, Ph.D. University of Colorado, Denver
 Lawrence Corey, M.D. Fred Hutchinson Cancer Research Center
 Sara A. Courtneidge, Ph.D. Sanford Burnham Prebys Medical Discovery Institute
 Alan D'Andrea, Ph.D. Dana-Farber Cancer Institute
 Norman Drinkwater, Ph.D. University of Wisconsin, Madison
 Errol Friedberg, M.D. The University of Texas Southwestern Medical Center
 Joanna Groden, Ph.D. The Ohio State University
 Daria J. Hazuda, Ph.D. Merck & Company Inc.
 Eric Hunter, Ph.D. Emory University
 Stephen D. Hursting, Ph.D., M.P.H. The University of Texas at Austin
 Alexandra L. Joyner, Ph.D. Memorial Sloan Kettering Cancer Center
 Marcelo G. Kazanietz, Ph.D. University of Pennsylvania
 Brian C. Lewis, Ph.D. University of Massachusetts Medical School
 Robert E. Lewis, Ph.D. University of Nebraska Medical Center
 Jonathan D. Licht, M.D. Northwestern University Feinberg School of Medicine
 Sergio A. Lira, M.D., Ph.D. Icahn School of Medicine at Mount Sinai
 Ian G. Macara, Ph.D. Vanderbilt University Medical Center
 Roeland Nusse, Ph.D. Stanford University
 Suzanne Ostrand-Rosenberg, Ph.D. University of Maryland, Baltimore County
 Thomas L. Poulos, Ph.D. University of California, Irvine
 Kenneth L. Rock, M.D. University of Massachusetts Medical School
 Daniel Romo, Ph.D. Texas A&M University
 James A. Wells, Ph.D. University of California, San Francisco
 Tzzy-Choou Wu, M.D., Ph.D., M.P.H. Johns Hopkins University
 Wayne M. Yokoyama, M.D. Washington University in St. Louis
 Virginia A. Zakian, Ph.D. Princeton University
 Dong-Er Zhang, Ph.D. University of California, San Diego

Executive Secretary

Mehrdad Tondravi, Ph.D. National Cancer Institute, NIH

NCI Council of Research Advocates

(formerly NCI Director’s Consumer Liaison Group)

Chair

Max N. Wallace, J.D. Accelerate Brain Cancer Cure

Members

- David F. Arons, J.D. National Brain Tumor Society
- Gregory H. Aune, M.D., Ph.D. The University of Texas Health Science Center
- Susan G. Braun, M.A. The V Foundation for Cancer Research
- Adam M. Clark, Ph.D. U.S. Department of Health and Human Services
- Martha E. Gaines, J.D., LL.M. University of Wisconsin Law School
- Joya D. Harris, M.P.H. American Cancer Society
- Linda S. House, R.N., B.S.N., M.S.M. Cancer Support Community
- Jeffrey A. Kaufman, M.B.A, M.I.A. Adenoid Cystic Carcinoma Research Foundation
- Ms. Mila McCurrach The Lustgarten Foundation
- Michelle T. McMurry-Heath, M.D., Ph.D. U.S. Food and Drug Administration
- Shelley F. Nasso, M.P.P. National Coalition for Cancer Survivorship
- Senaida F. Poole, Ph.D. University of California
- Jon G. Retzlaff, M.P.A., M.B.A. American Association for Cancer Research
- Mr. Josh Sommer The Chordoma Foundation
- Andrea E. Ferris Stern, M.B.A. LUNGevity Foundation
- Regina M. Vidaver, Ph.D. National Lung Cancer Partnership

Executive Secretary

Kelley Landy, M.P.A. National Cancer Institute, NIH

NCI Initial Review Group Scientific Review Committees

Subcommittee A—Cancer Centers

Chair

Timothy L. Ratliff, Ph.D. Purdue University

Members

Lucile L. Adams-Campbell, Ph.D. Georgetown University
 Alex A. Adjei, M.D., Ph.D., F.A.C.P. Roswell Park Cancer Institute
 Terrance L. Albrecht, Ph.D. Wayne State University
 Howard H. Bailey, M.D. University of Wisconsin, Madison
 Donald J. Buchsbaum, Ph.D. The University of Alabama at Birmingham
 William E. Carson III, M.D. The Ohio State University
 Moon S. Chen, Jr., Ph.D., M.P.H. University of California, Davis
 Margie L. Clapper, Ph.D. Fox Chase Cancer Center
 Robert S. DiPaola, M.D. Rutgers Biomedical and Health Sciences
 S. Gail Eckhardt, M.D. University of Colorado, Denver
 Dennis E. Hallahan, M.D., F.A.S.T.R.O. Washington University in St. Louis
 Helen E. Heslop, M.D. Baylor College
 Roy A. Jensen, M.D. University of Kansas
 Karen E. Knudsen, Ph.D. Thomas Jefferson University
 King C. Li, M.D., M.B.A. Wake Forest University Health Sciences & Baptist Medical Center
 Beverly S. Mitchell, M.D. Stanford University
 Alfred W. Rademaker, Ph.D. Northwestern University
 Jerome Ritz, M.D. Dana-Farber Cancer Institute
 Victor M. Santana, M.D. St. Jude Children’s Research Hospital
 Victoria L. Seewaldt, M.D. Duke University
 Richard L. Seither, Ph.D., M.B.A. Albert Einstein College of Medicine of Yeshiva University
 Eric J. Small, M.D. University of California, San Francisco
 Eduardo M. Sotomayor, M.D. H. Lee Moffit Cancer Center & Research Institute
 Ian M. Thompson, Jr., M.D. The University of Texas Health Science Center at San Antonio
 Barnarese Wheatley, Dr.Ed., M.P.H. BPW Consulting Services
 Patti Wiley, M.B.A. On the Wings of Angels Pediatric Cancer Foundation

Scientific Review Officer

Sonya V. Roberson, Ph.D. National Cancer Institute, NIH

Subcommittee F—Institutional Training & Education

Chair

Nipun B. Merchant, M.D., F.A.C.S. Vanderbilt University

Members

Lisa K. Denzin, Ph.D. Rutgers, The State University of New Jersey
 Marlene L. Hauck, D.V.M., Ph.D. North Carolina State University
 Jennifer J. Hu, Ph.D. University of Miami Miller School of Medicine
 Aminah Jatoi, M.D. Mayo Clinic
 Molly F. Kulesz-Martin, Ph.D. Oregon Health & Science University
 Primo N. Lara Jr., M.D. University of California, Davis
 Stephen L. Lessnick, M.D., Ph.D. University of Utah
 Jesse D. Martinez, Ph.D. The University of Arizona
 Deborah B. McGuire, Ph.D., R.N., F.A.A.N. Virginia Commonwealth University
 Karen M. Meneses, Ph.D., R.N., F.A.A.N. The University of Alabama at Birmingham
 Funda Meric-Bernstam, M.D. The University of Texas MD Anderson Cancer Center
 Shiraz I. Mishra, M.B.B.S., Ph.D. The University of New Mexico
 Polly A. Newcomb, Ph.D. University of Washington
 Daniel P. Normolle, Ph.D. University of Pittsburgh
 Fiemu E. Nwariaku, M.D. The University of Texas Southwestern Medical Center
 Mark P. Pfeifer, M.D. University of Louisville
 Gavin P. Robertson, Ph.D. The Pennsylvania State University
 Kathryn H. Schmitz, Ph.D., M.P.H. University of Pennsylvania
 Danny R. Welch, Ph.D. University of Kansas Medical Center
 Gayle E. Woloschak, Ph.D. Northwestern University

Scientific Review Officer

Timothy C. Meeker, M.D. National Cancer Institute, NIH

Subcommittee I—Transition to Independence

Chair

Neil Osheroff, Ph.D. Vanderbilt University Medical Center

Members

Emmanuel T. Akporiaye, Ph.D. Providence Portland Medical Center
 Deepak Bastia, Ph.D. Medical University of South Carolina
 Lawrence H. Boise, Ph.D. Emory University
 Amy H. Bouton, Ph.D. University of Virginia
 Jennifer P. Clarke, Ph.D. University of Nebraska–Lincoln
 Andrei Goga, M.D., Ph.D. University of California, San Francisco
 Charles Keller, M.D. Oregon Health & Science University
 Kenneth A. Krohn, Ph.D. University of Washington
 Sophie A. Lelievre, D.V.M., Ph.D., LL.M(PH) Purdue University
 Anna E. Lokshin, Ph.D. University of Pittsburgh
 Adhip P. N. Majumdar, D.Sc., Ph.D. Wayne State University
 Daniela E. Matei, M.D. Indiana University–Purdue University Indianapolis
 Keith D. Paulsen, Ph.D. Dartmouth College
 Rajagopal Ramesh, Ph.D. University of Oklahoma Health Science Center
 Edward A. Sausville, M.D., Ph.D., F.A.C.P. University of Maryland, Baltimore
 Tiffany N. Seagroves, Ph.D. The University of Tennessee Health Science Center
 David B. Solit, M.D. Memorial Sloan Kettering Cancer Center
 Bakhos A. Tannous, Ph.D. Harvard Medical School
 E. Aubrey Thompson, Ph.D. Mayo Clinic, Jacksonville
 Shizhen E. Wang, Ph.D. City of Hope National Medical Center
 Michael A. White, Ph.D. The University of Texas
 Robert A. Winn, M.D. University of Illinois at Chicago
 Wen-Cheng Xiong, Ph.D. Medical College of Georgia
 Yu-Chung Yang, Ph.D. Case Western Reserve University

Scientific Review Officer

Sergei Radaev, Ph.D. National Cancer Institute, NIH

Subcommittee J—Career Development

Chair

Christopher H. Lowrey, M.D. Dartmouth-Hitchcock Medical Center

Members

Virginia F. Borges, M.D., M.M.Sc. University of Colorado Denver
 Deborah W. Bruner, Ph.D., R.N. Emory University
 John C. Byrd, M.D. The Ohio State University
 Fernando A. Ferrer, M.D. University of Connecticut School of Medicine
 Christopher R. Friese, Ph.D., R.N., A.O.C.N. University of Michigan
 Michael E. Hagensee, M.D., Ph.D. Louisiana State University
 Heather S.L. Jim, Ph.D. H. Lee Moffitt Cancer Center & Research Institute
 Santosh Kesari M.D., Ph.D. University of California, San Diego
 Alexander S. Krupnick, M.D. Washington University in Saint Louis
 Gertraud Maskarinec, M.D., Ph.D., M.P.H. University of Hawaii
 Chaya S. Moskowitz, Ph.D. Memorial Sloan Kettering Cancer Center
 Daniel C. Mullins, Ph.D. University of Maryland, Baltimore
 Scott A. Waldman, M.D., Ph.D. Thomas Jefferson University
 Zuo-Feng Zhang, M.D., Ph.D. University of California, Los Angeles

Scientific Review Officer

Ilda F.S. Melo, Ph.D. National Cancer Institute, NIH

Appendix D: NCI Initial Review Group Consultants

1. Consultants Serving as Temporary Members on IRG Subcommittees in FY2014

A

Andersen, Bogi, M.D. University of California, Irvine
Arceci, Robert J., M.D., Ph.D. The University of Arizona
Axelrod, David E., Ph.D. Rutgers, The State University of New Jersey

B

Bae-Jump, Victoria L., M.D., Ph.D. The University of North Carolina
Basu, Sujit, M.D., Ph.D. The Ohio State University
Baumgartner, Kathy B., Ph.D. University of Louisville
Behbod, Fariba, Pharm.D., Ph.D. University of Kansas Medical Center
Berwick, Marianne, Ph.D., M.P.H. The University of New Mexico
Bjornsti, Mary-Ann, Ph.D. The University of Alabama at Birmingham
Brock, Malcolm V., M.D. Johns Hopkins University
Buchsbaum, Donald J., Ph.D. The University of Alabama at Birmingham
Byers, Stephen W., Ph.D. Georgetown University

C

Cannon, Martin J., Ph.D. University of Arkansas for Medical Sciences
Chen, Moon S., Ph.D., M.P.H. University of California, Davis
Chiao, Elizabeth, M.D., M.P.H. Baylor College of Medicine
Coleman, William B., Ph.D. The University of North Carolina at Chapel Hill
Cooney, Kathleen A., M.D. University of Michigan
Corey, Seth J., M.D., M.P.H. Northwestern University
Corry, Peter M., Ph.D. University of Arkansas for Medical Sciences
Creighton, Chad, Ph.D. Baylor College of Medicine

D

Datta, Kaustubh, Ph.D. University of Nebraska Medical Center
Davis, Ian J., M.D., Ph.D. The University of North Carolina at Chapel Hill
Davis, Scott C., Ph.D. Dartmouth College

F

Figlin, Robert A., M.D. Cedars-Sinai Medical Center

G

Garza, Mary A., M.D. Yale University
Girardi, Michael, M.D. Yale University

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2014

Goydos, James S., M.D. Rutgers Cancer Institute of New Jersey
Graves, Kristi D., Ph.D. Georgetown University

H

Hackett, Lauren, M.P.A. Vanderbilt University
Hawkins, William G., M.D. Washington University in St. Louis
Hezel, Aram F., M.D. University of Rochester
Hohl, Raymond J., M.D., Ph.D. Penn State Milton S. Hershey Medical Center
Hong, Chi-Chen, Ph.D. Roswell Park Cancer Institute
Hwang, Rosa F., M.D. The University of Texas MD Anderson Cancer Center

J

Jim, Heather S.L., Ph.D. H. Lee Moffitt Cancer Center & Research Institute
Jones, Kevin B., M.D. University of Utah

K

Kalinski, Pawel, M.D., Ph.D. University of Pittsburgh
Kalyanaraman, Balaraman, Ph.D. Medical College of Wisconsin
Kazak, Anne E., Ph.D. Nemours Alfred I. duPont Hospital for Children
Kesler, Shelli R., Ph.D. The University of Texas MD Anderson Cancer Center
Kessel, David, Ph.D. Wayne State University
Khan, Shafiq A., Ph.D. Clark Atlanta University
Kline, Justin P., M.D. The University of Chicago
Krohn, Kenneth, Ph.D. University of Washington

L

Lannigan, Deborah, Ph.D. Vanderbilt University
Loffredo, Christopher A., Ph.D. Georgetown University

M

Ma, Xiaomei, Ph.D. Yale University
Majumdar, Adhip P. N., D.Sc., Ph.D. Wayne State University
Malafa, Mokenge P., M.D. H. Lee Moffitt Cancer Center & Research Institute
Malkas, Linda H., Ph.D. City of Hope National Medical Center
Manjili, Masoud H., D.V.M., Ph.D. Virginia Commonwealth University
Martinez, Jesse D., Ph.D. The University of Arizona
Matthay, Katherine K., M.D. University of California, San Francisco
Mermelstein, Robin J., Ph.D. University of Illinois at Chicago
Michor, Franziska, Ph.D. Dana-Farber Cancer Institute
Morel, Penelope A., M.D. University of Pittsburgh
Mortimer, Joanne E., M.D. City of Hope National Medical Center
Mukhtar, Hasan, Ph.D. University of Wisconsin, Madison

N

Neugut, Alfred I., M.D., Ph.D., M.P.H. Columbia University

O

O'Connor, Kathleen L., Ph.D. University of Kentucky

O'Dorisio, M. Sue, M.D., Ph.D. The University of Iowa

Olshan, Andrew, Ph.D. The University of North Carolina at Chapel Hill

P

Pagel, John M., M.D., Ph.D. Fred Hutchinson Cancer Research Center

Patankar, Manish S., Ph.D. Eastern Virginia Medical School

Paterson, Yvonne J., Ph.D. University of Pennsylvania

Q

Quarles, Christopher C., Ph.D. Vanderbilt University

R

Rall, Glenn F., Ph.D. Fox Chase Cancer Center

Rathmell, Wendy K., M.D., Ph.D. The University of North Carolina

Reginato, Mauricio J., Ph.D. Drexel University College of Medicine

Reid, Mary E., Ph.D. Roswell Park Cancer Institute

Ritz, Jerome, M.D. Dana-Farber Cancer Institute

Rubenstein, James L., M.D., Ph.D. University of California, San Francisco

S

Sausville, Edward A., M.D., Ph.D. University of Maryland, Baltimore

Scaglioni, Pier P., M.D. The University of Texas Southwestern Medical Center at Dallas

Schmidt, Edward E., Ph.D. Montana State University, Bozeman

Spruck, Charles H., Ph.D. Sanford Burnham Prebys Medical Discovery Institute

Steel, Jennifer L., Ph.D. University of Pittsburgh

Steidl, Ulrich G., M.D., Ph.D. Albert Einstein College of Medicine of Yeshiva University

Sweet-Cordero, Eric A., M.D. Stanford University School of Medicine

Syngal, Sapna, M.D., M.P.H. Dana-Farber Cancer Institute

T

Tan, Ming T., Ph.D. Georgetown University

Thomas, Douglas D., Ph.D. University of Illinois at Chicago

Tsai, Kenneth Y., M.D., Ph.D. The University of Texas MD Anderson Cancer Center

Tunnell, James W., Ph.D. The University of Texas at Austin

U

Uittenbogaart, Christel H., M.D. University of California, Los Angeles

W

Walter, Roland B., M.D., Ph.D. Fred Hutchinson Cancer Research Center

Wang, Shizhen E., Ph.D. City of Hope National Medical Center

Watson, Dennis K., Ph.D. Medical University of South Carolina

Welch, Danny R., Ph.D. University of Kansas Medical Center

White, Michael A., Ph.D. The University of Texas Southwestern Medical Center at Dallas

White, Rebekah, M.D. Duke University

Williams, Karen P., Ph.D. Michigan State University

Y

Yamashiro, Darrell J., M.D., Ph.D. Columbia University Medical Center

Z

Zhang, Rugang, Ph.D. The Wistar Institute

Zhang, Ruiwen, M.D., Ph.D. Texas Tech University Health Sciences Center

Zhang, Yanping, Ph.D. The University of North Carolina at Chapel Hill

Zheng, Lei, M.D., Ph.D. Johns Hopkins University

Total Number of Reviewers: 97

2. Consultants Serving as *Ad Hoc* Committee Members on IRG Site Visit Teams in FY2014

A

Abate-Shen, Cory, Ph.D. Columbia University Medical Center
Adams-Campbell, Lucile L., Ph.D. Georgetown University
Agarwal, Rajesh, Ph.D. University of Colorado Denver
Ahn, Chul W., Ph.D. The University of Texas Southwestern Medical Center
Albertson, Donna G., Ph.D. New York University

B

Bastani, Roshan, Ph.D. University of California, Los Angeles
Beckwith, Barbara J., M.A. The Ohio State University
Berwick, Marianne, Ph.D. M.P.H. The University of New Mexico
Bhatia, Smita, M.D., M.P.H. City of Hope National Medical Center
Bjornsti, Mary-Ann, Ph.D. The University of Alabama at Birmingham
Boffetta, Paolo, M.D., M.P.H. Icahn School of Medicine at Mount Sinai
Bond, Jeffrey P., Ph.D. University of Vermont and State Agricultural College
Bondy, Melissa L., Ph.D. Baylor College of Medicine
Bowen, Deborah J., Ph.D. Boston University Medical Campus
Brentjens, Renier J., M.D., Ph.D. Memorial Sloan Kettering Cancer Center

C

Chaudhary, Preet M., M.D., Ph.D. University of Southern California
Chen-Kiang, Selina Y., Ph.D. Weill Cornell Medical College
Chernoff, Jonathan D., M.D., Ph.D. Fox Chase Cancer Center
Chu, Edward, M.D. University of Pittsburgh
Cody, Vivian, Ph.D. Hauptman-Woodward Medical Research Institute
Cooney, Kathleen A., M.D. University of Michigan

D

Debinski, Waldemar, M.D., Ph.D. Wake Forest University Health Sciences &
Baptist Medical Center
Deininger, Michael W., M.D., Ph.D. The University of Texas MD Anderson Cancer Center
Djeu, Julie Y., Ph.D. H. Lee Moffitt Cancer Center & Research Institute
Dowlati, Afshin, M.D. Case Western Reserve University
Duckett, Colin S., Ph.D. University of Michigan
Duli, Anne, M.P.A. Case Western Reserve University

E

Earp, Henry S., M.D. The University of North Carolina at Chapel Hill
Eaton, Kathryn A., D.V.M., Ph.D. University of Michigan
El-Deiry, Wafik S., M.D., Ph.D. Fox Chase Cancer Center

F

Ferris, Robert L., M.D., Ph.D. University of Pittsburgh
 Ferrone, Soldano, M.D., Ph.D. Massachusetts General Hospital
 Formenti, Silvia C., M.D. New York University School of Medicine
 Friedman, Debra L., M.D., R.N. Fred Hutchinson Cancer Research Center
 Futscher, Bernard W., Ph.D. The University of Arizona

G

Gao, Allen C., M.D., Ph.D. University of California, Davis
 Gapstur, Susan M., Ph.D., M.P.H. American Cancer Society, Inc.
 Gerlach, Robert W., M.P.A. Dartmouth College
 Gewirtz, David A., Ph.D. Virginia Commonwealth University
 Gillanders, William E., M.D. Washington University in St. Louis
 Gimotty, Phyllis A., Ph.D. University of Pennsylvania
 Ginder, Gordon D., M.D. Virginia Commonwealth University
 Gmitro, Arthur F., Ph.D. The University of Arizona
 Gruber, Stephen B., M.D., Ph.D., M.P.H. University of Southern California

H

Hackett, Lauren, M.P.A. Vanderbilt University
 Harrison, Anita L., M.P.A. Medical University of South Carolina
 Heguy, Adriana, Ph.D. New York University School of Medicine
 Hoopes, Jack, D.V.M., Ph.D. Dartmouth College
 Houghton, Janet A., Ph.D. Cleveland Clinic Lerner College of Medicine
 Huang, Tim H., Ph.D. The University of Texas Health Science Center at San Antonio
 Hung, Mien-Chie, Ph.D. The University of Texas MD Anderson Cancer Center
 Hussain, Maha H., M.D. University of Michigan
 Hyslop, Terry, Ph.D. Duke University

J

Jensen, Roy A., M.D. University of Kansas
 Jeraj, Robert, Ph.D. University of Wisconsin, Madison
 Jones, David A., Ph.D. Oklahoma Medical Research Foundation
 Jones, Richard J., M.D. Johns Hopkins University

K

Kane, Madeleine A., M.D., Ph.D. University of Colorado Denver
 Kelley, Mark R., Ph.D. Indiana University–Purdue University Indianapolis
 Kerr, William G., Ph.D. State University of New York Upstate Medical University
 Keyomarsi, Khandan, Ph.D. The University of Texas MD Anderson Cancer Center
 Khuri, Fadlo R., M.D. Emory University
 Kinney, Anita Y., Ph.D., R.N. The University of New Mexico Health Sciences Center
 Knudsen, Karen E., Ph.D. Thomas Jefferson University
 Kumar, Nagi B., Ph.D. H. Lee Moffitt Cancer Center & Research Institute

L

Lang, Frederick F., M.D. The University of Texas MD Anderson Cancer Center
 Le Beau, Michelle M., Ph.D. The University of Chicago
 Lenkinski, Robert E., Ph.D. The University of Texas Southwestern Medical Center at Dallas
 Lubaroff, David M., Ph.D. The University of Iowa
 Lynch, Thomas J., M.D. Yale University

M

Malkas, Linda H., Ph.D. City of Hope National Medical Center
 Mao, Li, M.D. University of Maryland, Baltimore
 Marzluff, William F., Ph.D. The University of North Carolina at Chapel Hill
 Mayne, Susan T., Ph.D. Yale University
 McCarthy, James B., Ph.D. University of Minnesota
 McWeeney, Shannon K., Ph.D. Oregon Health & Science University
 Meneses, Karen M., Ph.D., R.N. The University of Alabama at Birmingham
 Mermelstein, Robin J., Ph.D. University of Illinois at Chicago
 Mikkelsen, Tom, M.D. Henry Ford Health System
 Moley, Jeffrey F., M.D. Washington University in St. Louis
 Mori, Motomi, Ph.D. Oregon Health & Science University
 Munster, Pamela N., M.D. University of California, San Francisco

O

O'Connor, Kathleen L., Ph.D. University of Kentucky
 O'Malley, Michael S., Ph.D. The University of North Carolina at Chapel Hill
 Oeffinger, Kevin Charles, M.D. Memorial Sloan Kettering Cancer Center
 Olshan, Andrew, Ph.D. The University of North Carolina at Chapel Hill

P

Partridge, Edward E., M.D. The University of Alabama at Birmingham
 Pasche, Boris, M.D., Ph.D. Wake Forest University Health Sciences & Baptist Medical Center
 Perez, Raymond P., M.D. University of Kansas Medical Center
 Piazza, Gary A., Ph.D. University of South Alabama
 Pieper, Russell O., Ph.D. University of California, San Francisco
 Platanius, Leonidas C., M.D., Ph.D. Northwestern University
 Porter, Peggy L., M.D. Fred Hutchinson Cancer Research Center
 Prossnitz, Eric R., Ph.D. The University of New Mexico Health Sciences Center

Q

Quaranta, Vito, M.D. University of Pennsylvania

R

Redmond, Carol K., Sc.D., Ph.D. University of Pittsburgh
 Resnicow, Ken A., Ph.D. University of Michigan

Rosner, Marsha R., Ph.D. The University of Chicago

S

Schwartz, Ann G., Ph.D., M.P.H. Wayne State University
 Serody, Jonathan S., M.D. The University of North Carolina at Chapel Hill
 Shea, Thomas C., M.D. The University of North Carolina at Chapel Hill
 Shyr, Yu, Ph.D. Vanderbilt University
 Singh, Rakesh K., Ph.D. University of Nebraska Medical Center
 Sotomayor, Eduardo M., M.D. H. Lee Moffitt Cancer Center & Research Institute
 Stauffacher, Cynthia V., Ph.D. Purdue University
 Stein, Gary S., Ph.D. University of Vermont and State Agricultural College

T

Tanzer, Linda L., B.S. Rutgers Biomedical and Health Sciences
 Tycko, Benjamin, M.D., Ph.D. Gordon Research Conferences

V

Van Breemen, Richard B., Ph.D. University of Illinois at Chicago
 Van Etten, Richard A., M.D., Ph.D. University of California, Irvine
 Vertino, Paula M., Ph.D. Emory University
 Vuori, Kristiina, M.D., Ph.D. Sanford Burnham Prebys Medical Discovery Institute

W

Weiner, George J., M.D. The University of Iowa
 Weiss, Geoffrey R., M.D. University of Virginia
 Welch, Danny R., Ph.D. University of Kansas Medical Center
 Wilburn, Louella S., M.S. People Living With Cancer

Z

Zhang, Zhong-Yin, Ph.D. Indiana University–Purdue University Indianapolis
 Zutter, Mary M., M.D. Vanderbilt University

Total Number of Reviewers: 118

3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

A

Abdulkadir, Sarki A., M.D., Ph.D.	Northwestern University
Abounader, Roger, M.D., Ph.D.	University of Virginia
Abraham, George N., M.D., Ph.D.	University of Rochester
Abrams, Scott I., Ph.D.	Roswell Park Cancer Institute
Acharya, Raj S., Ph.D.	The Pennsylvania State University
Acharya, Samir, Ph.D.	The Ohio State University
Achilefu, Samuel, Ph.D.	Washington University in St. Louis
Acosta, Michelle C., Ph.D.	National Development and Research Institutes
Adams-Campbell, Lucile L., Ph.D.	Georgetown University
Adebamowo, Clement A., Sc.D.	University of Maryland, Baltimore
Adejare, Adeboye, Ph.D.	University of the Sciences
Adjei, Alex A., M.D., Ph.D., F.A.C.P.	Roswell Park Cancer Institute
Adler, Adam J., Ph.D.	University of Connecticut School of Dental Medicine
Aft, Rebecca L., M.D., Ph.D.	Washington University in St. Louis
Agah, Masoud, Ph.D.	Virginia Polytechnic Institute and State University
Agarwal, Rajesh, Ph.D.	University of Colorado Denver
Ahmed, Khalil, Ph.D.	University of Minnesota
Ahsan, Habibul, M.D.	The University of Chicago
Akabani, Gamal, Ph.D.	Texas A&M University
Akbari, Omid, Ph.D.	University of Southern California
Al'Absi, Mustafa N., Ph.D.	University of Minnesota
Albertson, Donna G., Ph.D.	New York University
Albrecht, Terrance L., Ph.D.	Wayne State University
Aldape, Kenneth D., M.D.	University Health Network
Alexandrakis, Georgios, Ph.D.	The University of Texas at Arlington
Alexandrow, Mark G., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Almasan, Alexandru, Ph.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Altman, Norman H., V.M.D.	University of Miami Miller School of Medicine
Altomare, Deborah A., Ph.D.	University of Central Florida
Alvarez, Ronald D., M.D.	The University of Alabama at Birmingham
Amaravadi, Ravi K., M.D.	University of Pennsylvania
Amatruda, James F., M.D., Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Amos, Christopher I., Ph.D.	Dartmouth College
Anant, Shrikant, Ph.D.	University of Kansas Medical Center
Anchordoquy, Thomas, Ph.D.	University of Colorado Denver
Andersen, M. Robyn, Ph.D., M.P.H.	Fred Hutchinson Cancer Research Center
Anderson, Carolyn J., Ph.D.	University of Pittsburgh
Anderson, James R., Ph.D.	University of Florida
Anderson, Karen S., M.D., Ph.D.	Arizona State University, Tempe
Andrews, Judy A., Ph.D.	Oregon Research Institute
Andrisani, Ourania M., Ph.D.	Purdue University

Androphy, Elliot J., M.D.	Indiana University–Purdue University, Indianapolis
Anton-Culver, Hoda A., Ph.D.	University of California, Irvine
Antony, Veena B., M.D.	The University of Alabama at Birmingham
Aparicio, Oscar M., Ph.D.	University of Southern California
Appelhans, Bradley M., Ph.D.	Rush University Medical Center
Applegate, Brian E., Ph.D.	Texas A&M University
Archer, Kellie J., Ph.D.	Virginia Commonwealth University
Arcila, Maria E., M.D.	Memorial Hospital for Cancer & Allied Diseases
Ardehali, Hossein, M.D., Ph.D.	Northwestern University
Armstrong, Deborah K., M.D.	Johns Hopkins University
Armstrong, Floyd D., Ph.D.	University of Miami Miller School of Medicine
Armstrong, Gregory, M.D.	St. Jude Children’s Research Hospital
Arnold, Connie L., Ph.D.	Louisiana State University Health Science Center, Shreveport
Arnold, Robert D., Ph.D.	Auburn University at Auburn
Arslan, Alan A., M.D.	New York University School of Medicine
Artman, Michael, M.D.	The Children’s Mercy Hospitals and Clinics
Ashendel, Curtis L., Ph.D.	Purdue University
Ashktorab, Hassan, Ph.D.	Howard University
Athar, Mohammad, Ph.D.	The University of Alabama at Birmingham
Atkins, Michael B., M.D.	Georgetown University
Atkins, William M., Ph.D.	University of Washington
Attisano, Liliana, Ph.D.	University of Toronto
Au, Jessie L. S., Pharm.D., Ph.D.	Optimum Therapeutics, LLC
Audrain-McGovern, Janet E., Ph.D.	University of Pennsylvania
Auerbach, Robert, Ph.D.	University of Wisconsin, Madison
Augenlicht, Leonard H., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Avantaggiati, Maria L., M.D., Ph.D.	Georgetown University
Avery, Anne C., V.M.D., Ph.D.	Colorado State University-Fort Collins
Avis, Nancy E., Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Awasthi, Vibhudutta, Ph.D.	The University of Oklahoma Health Sciences Center
Axelrod, David E., Ph.D.	Rutgers, The State University of New Jersey
Ayala, Gustavo, M.D.	The University of Texas Health Science Center at Houston
Ayer, Donald E., Ph.D.	The University of Utah
Azcarate-Peril, M. Andrea, Ph.D.	The University of North Carolina at Chapel Hill

B

Babensee, Julia E., Ph.D.	Georgia Institute of Technology
Bae-Jump, Victoria L., M.D., Ph.D.	The University of North Carolina at Chapel Hill
Bagiella, Emilia, Ph.D.	The Mount Sinai Hospital
Bahary, Nathan, M.D., Ph.D.	University of Pittsburgh
Bai, Mingfeng, Ph.D.	University of Pittsburgh
Bailey, Ryan C., Ph.D.	University of Illinois at Urbana-Champaign
Baker, Amanda F., Pharm.D., Ph.D.	The University of Arizona
Baker, Julie C., Ph.D.	Stanford University
Baker, Sharyn D., Pharm.D., Ph.D.	St. Jude Children’s Research Hospital
Baker, Tamara A., Ph.D.	University of Kansas
Bakitas, Marie A., D.N.Sc., A.P.R.N., F.A.A.N.	The University of Alabama at Birmingham

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014 _____

Balgley, Brian M., Ph.D.	Bioproximity, LLC
Ballesteros-Tato, Andre, Ph.D.	The University of Alabama at Birmingham
Ballman, Karla V., Ph.D.	Mayo Clinic
Balusu, Ramesh, Ph.D.	University of Kansas Medical Center
Bambot, Shabbir B., Ph.D.	LumaMed, LLC
Band, Vimla, Ph.D.	University of Nebraska Medical Center
Bandera, Elisa V., M.D., Ph.D.	Rutgers Biomedical and Health Sciences
Banerjee, Sushanta K., Ph.D.	Kansas City VA Medical Center
Bantum, Erin O., Ph.D.	University of Hawaii at Manoa
Bao, Ting, M.D., D.A.B.M.A.	Memorial Sloan Kettering Cancer Center
Baranova, Anna V., Ph.D.	George Mason University
Baranowski, Tom, Ph.D.	Baylor College of Medicine
Barcellos-Hoff, Mary H., Ph.D.	New York University School of Medicine
Bareli, Menashe, Ph.D.	The University of Texas MD Anderson Cancer Center
Barlow, William E., Ph.D.	University of Washington, Seattle
Barocas, Daniel A., M.D., M.P.H.	Vanderbilt University
Barrett, Michael T., Ph.D.	Translational Genomics Research Institute
Barrick, Christopher G., Ph.D.	State University of New York at Buffalo
Barth, Rolf F., M.D.	The Ohio State University
Barton, Debra L., Ph.D., R.N., A.O.C.N., F.A.A.N.	University of Michigan
Bass, Adam J., M.D.	Dana-Farber Cancer Institute
Bastia, Deepak, Ph.D.	Medical University of South Carolina
Basu, Hirak S., Ph.D.	University of Wisconsin, Madison
Basu, Sujit, M.D., Ph.D.	The Ohio State University
Batra, Surinder K., Ph.D.	University of Nebraska Medical Center
Batt, Carl A., Ph.D.	Cornell University
Bearden, James D., M.D.	Spartanburg Regional Medical Center
Beauchamp, Robert D., M.D.	Vanderbilt University
Bechara, Antoine, Ph.D.	University of Southern California
Becich, Michael J., M.D., Ph.D.	University of Pittsburgh
Beck, George R., Ph.D.	Emory University
Beck, John R., M.D.	Fox Chase Cancer Center
Beck, William T., Ph.D.	University of Illinois at Chicago
Becker, Dorothea, Ph.D.	University of Pittsburgh
Becker, Michael W., M.D.	University of Rochester
Beebe, Laura A., Ph.D., M.P.H.	The University of Oklahoma Health Sciences Center
Belani, Chandra, M.D.	Penn State Milton S. Hershey Medical Center
Belbin, Thomas J., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Belinsky, Steven A., Ph.D.	Lovelace Biomedical Environmental Research Institute
Bell, Ronny A., Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Bellamy, Scarlett L., Sc.D.	University of Pennsylvania
Bellgrau, Donald, Ph.D.	University of Colorado Denver
Benbrook, Doris M., Ph.D.	The University of Oklahoma Health Sciences Center
Beningo, Karen A., Ph.D.	Wayne State University
Ben-Jonathan, Nira, Ph.D.	University of Cincinnati
Bennett, Gary J., Ph.D.	McGill University
Berg, Stacey L., M.D.	Baylor College of Medicine
Bergan, Raymond C., M.D.	Northwestern University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Bergen, Harold R., Ph.D.	Mayo Clinic
Berger, Nathan A., M.D.	Case Western Reserve University School
Bergers, Gabriele, Ph.D.	University of California, San Francisco
Berliner, Lawrence J., Ph.D.	University of Denver
Bernstam, Elmer V., M.D.	The University of Texas Health Science Center at Houston
Bernstein, Emily, Ph.D.	The Mount Sinai Hospital
Berry, Donna L., Ph.D.	Dana-Farber Cancer Institute
Bertino, Joseph R., M.D.	Rutgers Biomedical Health Sciences
Bhansali, Shekhar, Ph.D.	Florida International University
Bhatia, Ravi, M.D.	City of Hope National Medical Center
Bhaumik, Sukesh R., Ph.D.	Southern Illinois University, Carbondale
Bhowmick, Neil A., Ph.D.	Cedars-Sinai Medical Center
Bhujwalla, Zaver M., Ph.D.	Johns Hopkins University
Bickell, Nina A., M.D., M.P.H.	The Mount Sinai Hospital
Bilby, Curt, Ph.D.	Terapio Corporation
Binder, Robert J., Ph.D.	University of Pittsburgh
Birt, Diane F., Ph.D.	Iowa State University
Bissell, Mina, Ph.D.	Lawrence Berkeley National Laboratory
Biswal, Shyam, Ph.D.	Johns Hopkins University
Black, Jennifer D., Ph.D.	University of Nebraska Medical Center
Blair, Sarah L., M.D.	University of California, San Diego
Bland, Kirby I., M.D.	The University of Alabama at Birmingham
Blaney, Susan M., M.D.	Baylor College of Medicine
Blankenberg, Francis G., M.D.	Stanford University
Bloom, Joan R., Ph.D.	University of California, Berkeley
Bobashev, Georgiy, Ph.D.	RTI International
Bocchetta, Maurizio, Ph.D.	Loyola University, Chicago
Bock, Beth C., Ph.D.	The Miriam Hospital
Bock, Cathryn H., Ph.D., M.P.H.	Wayne State University
Bogart, Jeffrey A., M.D.	State University of New York Upstate Medical University
Bohn, Robert, Ph.D.	National Institute of Standards and Technology
Boise, Lawrence H., Ph.D.	Emory University
Bokar, Joseph A., M.D, Ph.D.	University Hospitals Case Medical Center
Bold, Richard J., M.D.	University of California, Davis
Bollard, Catherine M., M.D.	Children's National Medical Center
Boman, Bruce M., M.D., Ph.D.	Christiana Care Health Services, Inc.
Bonavida, Benjamin, Ph.D.	University of California, Los Angeles
Bondy, Melissa L., Ph.D.	Baylor College of Medicine
Boockvar, John A., M.D.	Weill Cornell Medical College of Cornell University
Bookman, Michael A., M.D.	The University of Arizona
Booth, Robert E., Ph.D.	University of Colorado Denver
Borad, Mitesh, M.D.	Mayo Clinic, Arizona
Borch, Richard F., M.D., Ph.D.	Purdue University
Borden, Ernest C., M.D.	Cleveland Clinic
Borges, Virginia F., M.D.	University of Colorado Denver
Bosenberg, Marcus W., M.D., Ph.D.	Yale University
Bourguignon, Lilly Y.W., Ph.D.	Northern California Institute of Research Education
Boussiotis, Vassiliki A., M.D., Ph.D.	Beth Israel Deaconess Medical Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014 _____

Bouton, Amy H., Ph.D.	University of Virginia
Bouvet, Michael, M.D.	University of California, San Diego
Bovbjerg, Dana H., Ph.D.	University of Pittsburgh
Bowers, Daniel C., M.D.	The University of Texas Southwestern Medical Center at Dallas
Boyd, Douglas D., Ph.D.	The University of Texas MD Anderson Cancer Center
Boyd, Jeffrey, Ph.D.	Fox Chase Cancer Center
Boyer, Jean D., Ph.D.	University of Pennsylvania
Boysen, Gunnar, Ph.D.	University of Arkansas for Medical Sciences
Brace, Christopher L., Ph.D.	University of Wisconsin, Madison
Braden, Carrie J., Ph.D.	The University of Texas Health Science Center at San Antonio
Bradner, James E., M.D.	Dana-Farber Cancer Institute
Braithwaite, Dejana K., Ph.D.	University of California, San Francisco
Brandt, Heather M., Ph.D.	The University of South Carolina, Columbia
Brat, Daniel J., M.D., Ph.D.	Emory University
Brattain, Michael G., Ph.D.	University of Nebraska Medical Center
Braun, Benjamin, M.D., Ph.D.	University of California, San Francisco
Braunlin, Elizabeth, M.D., Ph.D.	University of Minnesota
Braziel, Rita M., M.D.	Oregon Health & Science University
Breit, Jeffrey, Ph.D.	Bend Research, Inc.
Brem, Steven, M.D.	H. Lee Moffitt Cancer Center & Research Institute
Brenowitz, Michael D., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Brewer, Molly A., D.V.M., M.D.	University of Connecticut Health Center
Bright, Robert K., Ph.D.	Texas Tech University Health Sciences Center
Brock, Kristy, Ph.D.	University of Michigan
Brody, James P., Ph.D.	University of California, Irvine
Bromberg, Jacqueline F., M.D., Ph.D.	Memorial Sloan Kettering Cancer Center
Brooks, James D., M.D.	Stanford University
Brown, John M., Ph.D.	Stanford University
Brown, Stuart M., Ph.D.	New York University School Medicine
Browning, Christopher R., Ph.D.	The Ohio State University
Bruchez, Marcel P., Ph.D.	Carnegie Mellon University
Brufsky, Adam M., M.D., Ph.D.	University of Pittsburgh
Bruner, Deborah W., Ph.D., R.N., F.A.A.N.	Emory University
Buatti, John M., M.D.	The University of Iowa
Buchsbaum, Donald J., Ph.D.	The University of Alabama at Birmingham
Bui, Jack D., M.D., Ph.D.	University of California, San Diego
Buller, David B., Ph.D.	Klein Buendel, Inc.
Bullock, Timothy N., Ph.D.	University of Virginia
Buolamwini, John K., Ph.D.	Rosalind Franklin University of Medicine and Science
Burchiel, Scott W., Ph.D.	The University of New Mexico Health Sciences Center
Burdette, Everette C., Ph.D.	Acoustic MedSystems, Inc.
Burk, Robert D., M.D.	Albert Einstein College of Medicine of Yeshiva University
Burnham, Nancy, Ph.D.	Worcester Polytechnic Institute
Burns, Charles P., M.D.	The University of Iowa
Burns, Linda J., M.D.	University of Minnesota
Burtness, Barbara, M.D.	Yale University
Businelle, Michael S., Ph.D.	The University of Texas Health Science Center at Houston
Butler, Lesley M., Ph.D.	University of Pittsburgh

Butterfield, Lisa H., Ph.D. University of Pittsburgh
 Buttyan, Ralph, Ph.D. The University of British Columbia
 Byers, Stephen W., Ph.D. Georgetown University

C

Cabot, Myles C., Ph.D. East Carolina University
 Caffrey, Michael S., Ph.D. University of Illinois at Chicago
 Calderwood, David A., Ph.D. Yale University
 Callas, Peter, Ph.D. The University of Vermont and State Agricultural College
 Calvi, Laura M., M.D. University of Rochester
 Camarero, Julio A., Ph.D. The University of Southern California
 Cameron, Carrie A., Ph.D. The University of Texas MD Anderson Cancer Center
 Campbell, Patrick K., M.D., Ph.D. St. Jude Children’s Research Hospital
 Canman, Christine E., Ph.D. University of Michigan
 Cantor, Sharon B., Ph.D. University of Massachusetts Medical School
 Cao, Caroline G.L., Ph.D. Wright State University
 Carducci, Michael A., M.D. Johns Hopkins University
 Carey, Robert, M.B.A. RPC Associates, Inc.
 Carlin, Bradley P., Ph.D. University of Minnesota
 Caron, Marc G., Ph.D. Duke University
 Carrier, France, Ph.D. University of Maryland, Baltimore
 Carroll, Kathleen M., Ph.D. Yale University
 Carson, James A., Ph.D. University of South Carolina, Columbia
 Carter, Kenneth C., Ph.D. Noble Life Sciences, Inc.
 Casillas, Jacqueline, M.D. University of California, Los Angeles
 Cassidy, Pamela B., Ph.D. Oregon Health & Science University
 Castilla, Lucio H., Ph.D. University of Massachusetts Medical School
 Castro, Maria G., Ph.D. University of Michigan
 Celebi, Julide T., M.D. The Mount Sinai Hospital
 Celi, Francesco S., M.D. Virginia Commonwealth University
 Celis, Esteban, M.D., Ph.D. Georgia Regents University
 Cesarman, Ethel, M.D., Ph.D. Weill Cornell Medical College of Cornell University
 Chagpar, Anees B., M.D., M.P.H. Yale University
 Chaillet, J. Richard, M.D., Ph.D. University of Pittsburgh
 Chak, Amitabh, M.D. Case Western Reserve University
 Chalmers, Jeffrey J., Ph.D. The Ohio State University
 Chamberlain, Marc C., M.D. University of Washington
 Champlin, Richard E., M.D. The University of Texas MD Anderson Cancer Center
 Chan, Andrew T., M.D., M.P.H. Massachusetts General Hospital
 Chan, Cliburn C., Ph.D. Duke University
 Chandra, Joya, Ph.D. The University of Texas MD Anderson Cancer Center
 Chang, Chawnshang, Ph.D. University of Rochester
 Chang, Eric C., Ph.D. Baylor College of Medicine
 Chang, Shine, Ph.D. The University of Texas MD Anderson Cancer Center
 Chao, Nelson J., M.D. Duke University
 Chaplin, David D., M.D., Ph.D. The University of Alabama at Birmingham
 Chapman, Paul B., M.D. Memorial Sloan Kettering Cancer Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Chauhan, Abhay S., Ph.D.	Concordia University Wisconsin
Chellappan, Srikumar P., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Chen, Chin-Tu, Ph.D.	The University of Chicago
Chen, Herbert, M.D.	University of Wisconsin, Madison
Chen, Jason J., Ph.D.	University of Massachusetts Medical School
Chen, John W., M.D., Ph.D.	Massachusetts General Hospital
Chen, Kuang Y., Ph.D., M.P.H.	Rutgers, The State University of New Jersey
Chen, Lin-Feng, Ph.D.	University of Illinois at Urbana-Champaign
Chen, Ming-Hui, Ph.D.	University of Connecticut, Storrs
Chen, Ru, Ph.D.	University of Washington
Chen, Shu-Hsia, Ph.D.	The Mount Sinai Hospital
Chen, Suzie, Ph.D.	Rutgers, The State University of New Jersey
Chen, Thomas C., M.D., Ph.D.	University of Southern California
Chen, Wenyong, Ph.D.	City of Hope National Medical Center
Chen, Xinbin, D.V.M., Ph.D.	University of California, Davis
Chen, Ying Q., Ph.D.	Fred Hutchinson Cancer Research Center
Chen, Yong Q., Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Chen, Yu, Ph.D.	New York University School of Medicine
Chen, Yuan, Ph.D.	City of Hope National Medical Center
Chen, Yuhchyau, M.D., Ph.D.	University of Rochester
Chen, Zheng W., M.D., Ph.D.	University of Illinois at Chicago
Cheng, Jin Q., M.D., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Cheng, Leo L., Ph.D.	Massachusetts General Hospital
Cheng, Liang, M.D.	Indiana University
Cheng, Shi-Yuan, Ph.D.	Northwestern University
Cher, Michael L., M.D.	Wayne State University
Chesney, Jason A., M.D., Ph.D.	University of Louisville
Chia, David S., Ph.D.	University of California, Los Angeles
Chiang, Cheng-Ming, Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Chiasson, Mary A., Dr.P.H.	Columbia University Mailman School of Public Health
Chigurupati, Radhika, D.D.S.	Boston University Medical Campus
Chiles, Thomas C., Ph.D.	Boston College
Cho, Clifford, M.D.	University of Wisconsin, Madison
Cho, Hyunyi, Ph.D.	Purdue University
Choi, Hak S., Ph.D.	Beth Israel Deaconess Medical Center
Choi, Won S., Ph.D., M.P.H.	University of Kansas Medical Center
Chow, Wong-Ho, Ph.D., M.P.H.	The University of Texas MD Anderson Cancer Center
Choy, Hak, M.D.	The University of Texas Southwestern Medical Center at Dallas
Christensen, Brock C., Ph.D.	Dartmouth College
Christensen, Merrill, Ph.D.	Brigham Young University
Christie, Debra W., M.B.A.	The University of Mississippi Medical Center
Chung, Dai H., M.D.	Vanderbilt University
Chung, Fung-Lung, Ph.D.	Georgetown University
Chung, Leland W.K., Ph.D.	Cedars-Sinai Medical Center
Ciccarone, Daniel H., M.D., M.P.H.	University of California, San Francisco
Cittadine, Andrew J., M.B.A.	Diagnostic Photonics, Inc.
Civitelli, Roberto, M.D.	Washington University in St. Louis
Claffey, Kevin P., Ph.D.	University of Connecticut Health Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Clarke, Jennifer G., M.D., M.P.H.	Rhode Island Hospital
Clarke, Robert R., D.Sc., Ph.D.	Georgetown University
Claudio, Pier P., M.D., Ph.D.	Marshall University
Clawson, Gary A., M.D., Ph.D.	Penn State Milton S. Hershey Medical Center
Cleary, Kevin R., Ph.D.	Children's Research Institute
Cleary, Margot P., Ph.D.	University of Minnesota
Cleary, Sean D., Ph.D., M.P.H.	George Washington University
Cleeland, Charles S., Ph.D.	The University of Texas MD Anderson Cancer Center
Clunie, David A., M.B.B.S.	PixelMed Publishing, LLC
Cobb, Melanie H., Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Cochran, Brent H., Ph.D.	Tufts University
Cody, Vivian, Ph.D.	Hauptman-Woodward Medical Research Institute
Cohen, Trevor, Ph.D.	The University of Texas Health Science Center at Houston
Coker, Ann L., Ph.D., M.P.H.	University of Kentucky
Colcher, David M., Ph.D.	City of Hope National Medical Center
Cole, Michael D., Ph.D.	Dartmouth College
Comai, Lucio, Ph.D.	University of Southern California
Conaway, Mark R., Ph.D.	University of Virginia
Connell, Philip P., M.D.	The University of Chicago
Contag, Christopher H., Ph.D.	Stanford University
Conzen, Suzanne D., M.D.	The University of Chicago
Cook, Jeanette G., Ph.D.	The University of North Carolina at Chapel Hill
Cooley, Philip C., M.S.	RTI International
Cooper, Gregory S., M.D.	Case Western Reserve University
Cooper, Michael K., M.D.	Vanderbilt University
Copelan, Edward A., MD.	Cleveland Clinic Taussig Cancer Institute
Copland, John A., Ph.D.	Mayo Clinic, Jacksonville
Corey, Seth J., M.D., M.P.H.	Northwestern University
Cormack, Robert A., Ph.D.	Brigham and Women's Hospital
Cote, Gerard L., Ph.D.	BioTex Medical, Inc.
Cote, Gilbert J., Ph.D.	The University of Texas MD Anderson Cancer Center
Cote, Michele L., Ph.D., M.P.H.	Wayne State University
Couch, Marion E., M.D., Ph.D.	The University of Vermont and State Agriculture College
Cowan, Morton, M.D.	University of California, San Francisco
Cowan, Ronald L., M.D., Ph.D.	Vanderbilt University
Cox, Adrienne D., Ph.D.	The University of North Carolina at Chapel Hill
Cox, Dianne, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Cozen, Wendy, D.O., M.P.H.	University of Southern California
Cragle, Donna L., Ph.D.	Oak Ridge Institute for Science and Education
Crane, Lori A., Ph.D., M.P.H.	University of Colorado Denver
Crano, William D., Ph.D.	The University of Arizona
Crawford, Jeffrey, M.D.	Duke University
Crawford, Sybil L., Ph.D.	University of Massachusetts Medical School
Cress, Anne E., Ph.D.	The University of Arizona
Croghan, Ivana T., Ph.D.	Mayo Clinic
Cronan, Thereasa A., Ph.D.	San Diego State University
Cropsey, Karen L., Psy.D.	The University of Alabama at Birmingham
Cruciani, Ricardo A., M.D., Ph.D.	Capital Health Medical Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014 _____

Cukierman, Edna, Ph.D. Fox Chase Cancer Center
 Cunningham, John M., M.D. The University of Chicago
 Cutler, Stephen J., M.D., Ph.D. The University of Vermont
 Czerniak, Bogdan A., M.D., Ph.D. The University of Texas MD Anderson Cancer Center
 Czyzyk-Krzeska, Maria F., M.D., Ph.D. University of Cincinnati

D

D'Ambrosio, Steven M., PhD. The Ohio State University
 D'Onofrio, Carol N., Dr.P.H. University of California, Berkeley
 D'Orazio, John A., M.D., Ph.D. University of Kentucky
 D'Souza, Warren D., Ph.D. University of Maryland, Baltimore
 Daaka, Yehia, Ph.D. University of Florida
 Dahiya, Rajvir, Ph.D. Northern California Institute of Research & Education
 Daly, Mary B., M.D., Ph.D. Fox Chase Cancer Center
 Damodaran, Chendil, Ph.D. University of Louisville
 Dang, Nam H., M.D., Ph.D. University of Florida
 Daniel, Larry W., Ph.D. Wake Forest University Health Sciences & Baptist Medical Center
 Daniulaityte, Raminta, Ph.D. Wright State University
 Das, Gokul M., Ph.D. Roswell Park Cancer Institute
 Dasgupta, Ramanuj, Ph.D. New York University School of Medicine
 Dash, Srikanta, Ph.D. Tulane University
 Daskalakis, Constantine, Sc.D. Thomas Jefferson University
 Datta, Kamal, M.D. Georgetown University
 Datta, Kaustubh, Ph.D. University of Nebraska Medical Center
 Davalos, Rafael V., Ph.D. Virginia Polytechnic Institute and State University
 Dave, Sandeep, M.D. Duke University
 Davidoff, Andrew M., M.D. St. Jude Children's Research Hospital
 Davidson, Kelly M., M.D. University of Virginia
 Davies, Joanna D., Ph.D. San Diego Biomedical Research Institute
 Davis, Michael J., Ph.D. University of Missouri
 Day, Roger S., Sc.D. University of Pittsburgh
 Day, Stephen P., Ph.D. Hologic, Inc.
 de Bono, Johann S., M.D., Ph.D. The Institute of Cancer Research
 De Leon, Marino, Ph.D. Loma Linda University
 de Winter, Alex, Ph.D. General Electric Healthcare Ventures
 Deapen, Dennis M., Dr.P.H. University of Southern California
 Dearling, Jason L., Ph.D. Boston Children's Hospital
 Debinski, Waldemar, M.D., Ph.D. Wake Forest University Health Sciences &
 Baptist Medical Center
 Debnath, Asim K., Ph.D. New York Blood Center
 DeClerck, Yves A., M.D. University of Southern California
 DeCoster, Mark A., Ph.D. Louisiana Tech University
 Deiner, Stacie, M.D. The Mount Sinai Hospital
 Deininger, Prescott L., Ph.D. Tulane University
 Del Fabbro, Egidio, M.D. Virginia Commonwealth University
 Delnevo, Cristine D., Ph.D., M.P.H. Rutgers Biomedical and Health Sciences
 Delong, Robert K., Ph.D. Kansas State University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Delva, Jorge, Ph.D.	University of Michigan
Demaria, Sandra, M.D.	New York University School of Medicine
Demore, Nancy K., M.D.	Medical University of South Carolina
Deng, Yibin, M.D., Ph.D.	University of Minnesota
Denis, Gerald V., Ph.D.	Boston University Medical Campus
Denko, Nicholas C., M.D., Ph.D.	The Ohio State University
Dennis, Leslie K., Ph.D.	The University of Arizona
Dent, Paul, Ph.D.	Virginia Commonwealth University
Dewhirst, Mark W., D.V.M., Ph.D.	Duke University
Diamond, Alan, Ph.D.	University of Illinois at Chicago
Diaz, Manuel O., M.D.	Loyola University, Chicago
Di Carlo, Dino, Ph.D.	University of California, Los Angeles
Dicker, Adam P., M.D., Ph.D.	Thomas Jefferson University
Diehl, Michael R., Ph.D.	Rice University
Diergaarde, Brenda B., Ph.D.	University of Pittsburgh
Dignan, Mark B., Ph.D., M.P.H.	University of Kentucky
Diller, Lisa R., M.D.	Dana-Farber Cancer Institute
Dimri, Goberdhan P., Ph.D.	George Washington University
Ding, Han-Fei, Ph.D.	Georgia Regents University
Dingli, David J., M.D., Ph.D.	Mayo Clinic
Dino, Geri A., Ph.D.	West Virginia University
Dinov, Ivo D., Ph.D.	University of Michigan
DiPersio, C. Michael, Ph.D.	Albany Medical College
DiSilvestro, Paul A., M.D.	Women and Infants Hospital of Rhode Island
Distelhorst, Clark W., M.D.	Case Western Reserve University
Divgi, Chaitanya R., M.D.	Columbia University Health Sciences
Divine, George W., Ph.D.	Henry Ford Health System
Djaballah, Hakim, Ph.D.	Memorial Sloan Kettering Cancer Center
Djeu, Julie Y., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Djuric, Zora, Ph.D.	University of Michigan
Doherty, Gerard M., M.D.	Boston University Medical Campus
Dong, Lei, Ph.D.	Scripps Research Institute
Donovan, Heidi S., Ph.D., R.N.	University of Pittsburgh
Dooley, William C., M.D.	The University of Oklahoma Health Sciences Center
Dorgan, Joanne F., Ph.D., M.P.H.	University of Maryland, Baltimore
Dorresteijn, Pieter C., Ph.D.	University of California, San Diego
Dorsey, Susan G., Ph.D., R.N., F.A.A.N.	University of Maryland, Baltimore
Dou, Qing P., Ph.D.	Wayne State University
Dovat, Sinisa, M.D., Ph.D.	Penn State Milton S. Hershey Medical Center
Dowlati, Afshin, M.D.	Case Western Reserve University
Downs, Stephen M., M.D.	Indiana University–Purdue University, Indianapolis
Doyley, Marvin M., Ph.D.	University of Rochester
Drabkin, Harry A., M.D.	Medical University of South Carolina
Drake, Richard R., Ph.D.	Medical University of South Carolina
Dritschilo, Anatoly, M.D.	Georgetown University
Dubbs, Robert M., J.D.	Obermayer Rebmann Maxwell & Hippel LLP
Dubeau, Louis, M.D., Ph.D.	University of Southern California
Duda, Dan G., D.M.D., Ph.D.	Massachusetts General Hospital

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014 _____

Dudley, Andrew C., Ph.D. The University of North Carolina at Chapel Hill
 Duerksen-Hughes, Penelope J., Ph.D. Loma Linda University
 Duffy, David C., Ph.D. Quanterix Corporation
 Dunbar, Cynthia E., M.D. National Heart, Lung, and Blood Institute
 Dunkel, Ira J., M.D. Memorial Sloan Kettering Cancer Center
 Dunn, William A., Ph.D. University of Florida
 Dunton, Genevieve F., Ph.D., M.P.H. University of Southern California
 Dupont, William D., Ph.D. Vanderbilt University
 Dupuy, Adam J., Ph.D. The University of Iowa
 Dwinell, Michael B., Ph.D. Medical College of Wisconsin

E

Earle, Craig C., M.D. Sunnybrook Health Sciences Centre
 Eary, Janet F., M.D. The University of Alabama at Birmingham
 Eckelman, William C., Ph.D., M.P.H. Molecular Tracer, LLC
 Eckhart, Walter, Ph.D. Salk Institute for Biological Studies
 Edelen, Maria O., Ph.D. RAND Corporation
 Edil, Barish H., M.D. University of Colorado Denver
 Edwards, D. Scott, Ph.D. SciFluor Life Sciences, LLC
 Edwards, Jeremy S., Ph.D. The University of New Mexico
 Ehemann, Christie R., Ph.D. U.S. Centers for Disease Control and Prevention
 Eib, Lynn A., B.A. Consultant
 Eibl, Guido E. M., M.D. University of California, Los Angeles
 Eischen, Christine M., Ph.D. Vanderbilt University
 Eiseman, Julie L., Ph.D. University of Pittsburgh
 Eklund, Elizabeth A., M.D. Northwestern University
 Elashoff, David, Ph.D. University of California, Los Angeles
 El-Ashry, Dorraya, Ph.D. University of Miami Miller School of Medicine
 El-Bayoumy, Karam E., Ph.D. Penn State Milton S. Hershey Medical Center
 El-Deiry, Wafik S., M.D., Ph.D. Fox Chase Cancer Center
 Elemento, Olivier, Ph.D. Weill Cornell Medical College of Cornell University
 Eley, John W., M.D., M.P.H. Emory University
 Eliason, James F., Ph.D. Wayne State University
 Ellenson, Lora H., M.D. Weill Cornell Medical College of Cornell University
 Elliott, John T., Ph.D. National Institute of Standards & Technology
 Elliott, Thomas E., M.D. HealthPartners Institute
 Ellis, Nathan A., Ph.D. The University of Arizona
 El-Rifai, Wael, M.D., Ph.D. Vanderbilt University
 El-Sayed, Ivan H., M.D. University of California, San Francisco
 Eltoum, Isameldin A., M.D. The University of Alabama at Birmingham
 El-Zein, Randa A., M.D., Ph.D. The University of Texas MD Anderson Cancer Center
 Emanuel, Peter D., M.D. University of Arkansas for Medical Sciences
 Emelianov, Stanislav Y., Ph.D. The University of Texas at Arlington
 Emens, Leisha A., M.D., Ph.D. Johns Hopkins University
 Emerson, Jane, M.D., Ph.D. University of Southern California
 Engelman, Jeffrey A., M.D., Ph.D. Massachusetts General Hospital
 Epplein, Meira, Ph.D. Vanderbilt University

Epstein, Alan L., M.D., Ph.D. University of Southern California
 Epstein, Jennifer A., Ph.D. Weill Cornell Medical College of Cornell University
 Erdei, Esther, Ph.D., M.P.H. The University of New Mexico Health Sciences Center
 Erdman, Susan E., D.V.M., M.P.H. Massachusetts Institute of Technology
 Erickson, David, Ph.D. Cornell University
 Esser, Karyn A., Ph.D. University of Kentucky
 Essner, Jeffrey J., Ph.D. Iowa State University
 Etkin, Amit, M.D., Ph.D. Palo Alto Veterans Institute for Research
 Evans, Conor L., Ph.D. Massachusetts General Hospital
 Evers, Bernard M., M.D. University of Kentucky
 Ewing, James R., Ph.D. Henry Ford Health System
 Exner, Agata A., Ph.D. Case Western Reserve University

F

Faddegon, Bruce, Ph.D. University of California, San Francisco
 Fan, Guang, M.D., Ph.D. Oregon Health & Science University
 Fan, Hung Y., Ph.D. University of California, Irvine
 Fan, Rong, Ph.D. Yale University
 Fan, Weimin, M.D., M.P.H. Medical University of South Carolina
 Fan, Z. Hugh, Ph.D. University of Florida
 Farag, Sherif S., M.D., Ph.D. Indiana University–Purdue University, Indianapolis
 Fatatis, Alessandro, M.D., Ph.D. Drexel University
 Fearon, Eric R., M.D., Ph.D. University of Michigan
 Fedorov, Andriy, Ph.D. Brigham and Women’s Hospital
 Felding, Brunhilde, Ph.D. Scripps Research Institute
 Feleppa, Ernest J., Ph.D. Riverside Research Institute
 Fennessy, Fiona, M.D., Ph.D. Harvard Medical School
 Fernander, Anita F., Ph.D. University of Kentucky
 Ferrance, Jerome P., Ph.D. J2F-Engineering
 Ferrari, Anna C., M.D. New York University School of Medicine
 Ferrone, Soldano, M.D., Ph.D. Massachusetts General Hospital
 Festinger, David S., Ph.D. Treatment Research Institute, Inc.
 Feusner, James, M.D. Children’s Hospital & Research Center at Oakland
 Figlin, Robert A., M.D. Cedars-Sinai Medical Center
 Figueiredo, Jane C., Ph.D. University of Southern California
 Fisher, Brian D., Ph.D. Simon Fraser University
 Fisher, Christopher, Ph.D. NanoVir, LLC
 Fisher, Gary J., Ph.D. University of Michigan
 Fisher, Joy D., M.A. Johns Hopkins University
 Fisher, Susan G., Ph.D. Temple University
 Fishman, David A., M.D. The Mount Sinai Hospital
 Fitzgerald-Bocarsly, Patricia, Ph.D. Rutgers Biomedical and Health Sciences
 Flaherty, Lawrence E., M.D. Wayne State University
 Flaig, Thomas W., M.D. University of Colorado Denver
 Flaumenhaft, Robert C., M.D., Ph.D. Beth Israel Deaconess Medical Center
 Fleming, Jason B., M.D. The University of Texas MD Anderson Cancer Center
 Fleming, Jonathan J., M.P.A. Oxford Bioscience Partners

Flemington, Erik K., Ph.D.	Tulane University
Florez, Karen R., Dr.P.H.	RAND Corporation
Fong, Yiu-Liang, Ph.D.	Abbott Laboratories
Fonseca, Rafael, M.D.	Mayo Clinic, Arizona
Ford, Eric C., Ph.D.	University of Washington
Ford, James M., M.D.	Stanford University
Ford, Jean G., M.D.	Johns Hopkins University
Forero, Andres, M.D.	The University of Alabama at Birmingham
Forrest, Marcus L., Ph.D.	University of Kansas
Forsyth, Peter A., M.D.	University of South Florida
Fortina, Paolo M., M.D., Ph.D.	Thomas Jefferson University
Foty, Ramsey A., Ph.D.	Rutgers Biomedical and Health Science
Fraass, Benedick A., Ph.D.	Cedars-Sinai Medical Center
Francesconi, Lynn C., Ph.D.	Hunter College
Franklin, Wilbur A., M.D.	University of Colorado Denver
Freedland, Stephen J., M.D.	Duke University
Freeman, James W., Ph.D.	The University of Texas Health Science Center at San Antonio
Freeman, Michael R., Ph.D.	Cedars-Sinai Medical Center
Freitas, Michael A., Ph.D.	The Ohio State University
Freyer, David R., D.O.	Children's Hospital Los Angeles
Freyer, James P., Ph.D.	The University of New Mexico
Fridley, Brooke L., Ph.D.	University of Kansas Medical Center
Friedman, Debra L., M.D., R.N.	Fred Hutchinson Cancer Research Center
Fritsche, Herbert A., Ph.D.	The University of Texas MD Anderson Cancer Center
Fu, Haian, Ph.D.	Emory University
Fu, Jianping, Ph.D.	University of Michigan
Fu, Mei R., Ph.D., R.N., A.C.N.S.-B.C., F.A.A.N.	New York University
Fu, Pingfu, Ph.D.	Case Western Reserve University
Fu, Rongwei, Ph.D.	Oregon Health & Science University
Fu, Yang-Xin, M.D., Ph.D.	The University of Chicago
Fueyo, Juan, M.D.	The University of Texas MD Anderson Cancer Center
Fujita, Mayumi, M.D., Ph.D.	University of Colorado Denver
Fukumura, Dai, M.D., Ph.D.	Massachusetts General Hospital
Fuloria, Jyotsna, M.B.B.S.	Ochsner Clinic Foundation
Fulton, Amy M., Ph.D.	University of Maryland, Baltimore
Furdui, Cristina, Ph.D.	Wake Forest University Health Sciences

G

Gabrielson, Edward W., M.D.	Johns Hopkins University
Gabrilovich, Dmitry I., M.D., Ph.D.	The Wistar Institute
Gajjar, Amar, M.D.	St. Jude Children's Research Hospital
Galban, Craig J., Ph.D.	University of Michigan
Galbraith, David W., Ph.D.	The University of Arizona
Galipeau, Jacques, M.D.	Emory University
Gallagher, Carla J., Ph.D.	Penn State Milton S. Hershey Medical Center
Gallick, Gary E., Ph.D.	The University of Texas MD Anderson Cancer Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Galloway, Robert L., Ph.D.	Vanderbilt University
Ganapathy, Vadivel, Ph.D.	Georgia Regents University
Ganju, Ramesh K., Ph.D.	The Ohio State University
Ganz, Patricia A., M.D.	University of California, Los Angeles
Gao, Feng, Ph.D.	Washington University in St. Louis
Gao, Nan, Ph.D.	Rutgers, The State University of New Jersey
Gao, Shou-Jiang, Ph.D.	University of Southern California
Gao, Xiaohu, Ph.D.	University of Washington
Garbow, Joel R., Ph.D.	Washington University in St. Louis
Garcia, Jose M., M.D., Ph.D.	Baylor College of Medicine
Gartel, Andrei L., Ph.D.	The University of Illinois at Chicago
Gartenhaus, Ronald B., M.D.	University of Maryland, Baltimore
Gascoyne, Peter R. C., Ph.D.	The University of Texas MD Anderson Cancer Center
Gaspar, Laurie E., M.D.	University of Colorado Denver
Gaston, Sandra M., Ph.D.	Beth Israel Deaconess Medical Center
Gatenby, Robert A., M.D.	H. Lee Moffitt Cancer Center & Research Institute
Gatsonis, Constantine A., Ph.D.	Brown University
Gau, Vincent, Ph.D.	GeneFluidics, Inc.
Gavai, Ashvinikumar, Ph.D.	Bristol-Myers Squibb Pharmaceutical Research
Geacintov, Nicholas E., Ph.D.	New York University Langone Medical Center
Gebreyes, Wondwossen A., D.V.M., Ph.D.	The Ohio State University
Gee, James C., Ph.D.	University of Pennsylvania
Gelmann, Edward P., M.D.	Columbia University Health Sciences
Gelovani, Juri G., M.D., Ph.D.	Wayne State University
Genkinger, Jeanine M., Ph.D.	Columbia University Health Sciences
George, Steven C., M.D., Ph.D.	Washington University in St. Louis
Gerend, Mary A., Ph.D.	Northwestern University
Gerig, Guido, Ph.D.	University of Utah
Gestwicki, Jason E., Ph.D.	University of California, San Francisco
Gewirtz, Abigail, Ph.D.	University of Minnesota
Ghandehari, Hamid, Ph.D.	University of Utah
Ghobrial, Irene M., M.D.	Dana-Farber Cancer Institute
Ghosh, Paramita M., Ph.D.	University of California, Davis
Ghoshal, Kalpana, Ph.D.	The Ohio State University
Giaccia, Amato J., Ph.D.	Stanford University
Giaccone, Giuseppe, M.D., Ph.D.	Georgetown University
Giam, Chou-Zen, Ph.D.	U.S. Uniformed Services University of the Health Sciences
Giardina, Charles A., Ph.D.	University of Connecticut, Storrs
Gibson, Raymond E., Ph.D.	Gibson Consulting
Giger, Maryellen L., Ph.D.	The University of Chicago
Giguere, Jeffrey K., M.D.	Greenville Health System
Gilbert, David M., Ph.D.	Florida State University
Gilchrist, Gerald S., M.D.	Mayo Clinic
Gill, Steven R., Ph.D.	University of Rochester
Gillanders, William E., M.D.	Washington University in St. Louis
Gillespie, G. Yancy, Ph.D.	The University of Alabama at Birmingham
Gillies, Robert J., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Gimotty, Phyllis A., Ph.D.	University of Pennsylvania

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014 _____

Girotti, Albert, Ph.D.	Medical College of Wisconsin
Giuliano, Anna R., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Gius, David, M.D., Ph.D.	Northwestern University
Given, Barbara A., Ph.D., R.N., F.A.A.N.	Michigan State University
Glatstein, Eli J., M.D.	University of Pennsylvania
Glazer, Peter M., M.D., Ph.D.	Yale University
Glorioso, Joseph C., Ph.D.	University of Pittsburgh
Glunde, Kristine, Ph.D.	Johns Hopkins Hospital
Gmeiner, William H., Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Gmitro, Arthur F., Ph.D.	The University of Arizona
Goel, Ajay, Ph.D.	Baylor University Medical Center
Goetz, Matthew P., M.D.	Mayo Clinic
Goga, Andrei, M.D., Ph.D.	University of California, San Francisco
Gold, David V., Ph.D.	Garden State Cancer Center
Gold, Ellen B., Ph.D.	University of California, Davis
Goldkorn, Amir, M.D.	University of Southern California
Goldman, Radoslav, Ph.D.	Georgetown University
Goldsmith, Elizabeth J., Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Golemis, Erica A., Ph.D.	Fox Chase Cancer Center
Gomer, Charles J., Ph.D.	Children’s Hospital Los Angeles
Gooding, Lori, Ph.D.	University of Kentucky
Goodwin, Edwin H., Ph.D.	New Mexico Consortium, Inc.
Goodwin, Pamela J., M.D.	University of Toronto
Gopalakrishnan, Vidya, Ph.D.	The University of Texas MD Anderson Cancer Center
Gospodarowicz, Mary K., M.D.	Princess Margaret Hospital
Gottesfeld, Joel M., Ph.D.	Scripps Research Institute
Gottschalk, Stephen, M.D.	Baylor College of Medicine
Govindan, Ramaswamy, M.D.	Washington University in St. Louis
Grady, William M., M.D.	Fred Hutchinson Cancer Research Center
Grandis, Jennifer R., M.D.	University of Pittsburgh
Grant, Marcia L., R.N., D.N.Sc.	City of Hope National Medical Center
Grant, Steven, M.D.	Virginia Commonwealth University
Gravekamp, Claudia, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Graves, Edward E., Ph.D.	Stanford University
Gray, Robert J., Ph.D.	Dana-Farber Cancer Institute
Graziano, Stephen L., M.D.	State University of New York Upstate Medical University
Grdina, David J., Ph.D.	The University of Chicago
Grzelishvili, Valery Z., Ph.D.	The University of North Carolina at Charlotte
Green, Mark A., Ph.D.	Indiana University–Purdue University, Indianapolis
Greenberg, Daniel J., B.A.	Media Rez, LLC
Gregg, Jeffrey P., M.D.	University of California, Davis
Gregory, Richard I., Ph.D.	Children’s Hospital Corporation
Griffin, Robert J., Ph.D.	University of Arkansas for Medical Sciences
Griffin, Timothy J., Ph.D.	University of Minnesota
Grimes, H. Leighton, Ph.D.	Cincinnati Children’s Hospital Medical Center
Grippio, Paul J., Ph.D.	University of Illinois at Chicago

Grobin, Adam W., Ph.D.	Allergan Inc.
Grochow, Louise B., M.D., F.A.C.P.	Johns Hopkins Hospital
Groden, Joanna L., Ph.D.	The Ohio State University
Gronemeyer, Suzanne A., Ph.D.	St. Jude Children’s Research Hospital
Gross, Cynthia R., Ph.D.	University of Minnesota
Gross, Mitchell E., M.D., Ph.D.	University of Southern California
Gross, Myron D., Ph.D.	University of Minnesota
Grossniklaus, Hans E., M.D.	Emory University
Groutas, William C., Ph.D.	Wichita State University
Gruber, Stephen B., M.D., Ph.D., M.P.H.	University of Southern California
Grufferman, Seymour, M.D., Dr.P.H.	The University of New Mexico
Grundfest, Warren S., M.D.	University of California, Los Angeles
Gu, Li-Qun, Ph.D.	University of Missouri
Gu, Xiaohui, Ph.D.	North Carolina State University
Gu, Xinbin, M.D., Ph.D.	Howard University
Guan, Jun-Lin, Ph.D.	University of Cincinnati
Guda, Chittibabu, Ph.D.	University of Nebraska Medical Center
Gudkov, Andrei V., D.Sc., Ph.D.	Roswell Park Cancer Institute
Guha, Chandan, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Guidry, Jeffrey J., Ph.D.	Texas A&M University
Gulley, Margaret L., M.D.	The University of North Carolina at Chapel Hill
Guo, Grace L., Ph.D.	Rutgers, The State University of New Jersey
Gupta, Sanj ay, Ph.D.	Case Western Reserve University
Gutkind, J. Silvio, Ph.D.	National Institute of Dental and Craniofacial Research
Gutmann, David H., M.D., Ph.D.	Washington University in St. Louis
Guttridge, Denis C., Ph.D.	The Ohio State University

H

Haab, Brian B., Ph.D.	Van Andel Research Institute
Haase, Volker H., M.D.	Vanderbilt University
Habelhah, Hasem, Ph.D.	The University of Iowa
Hahn, Elizabeth A., M.A.	Northwestern University
Hahn, William C., M.D., Ph.D.	Dana-Farber Cancer Institute
Haimovitz-Friedman, Adriana, Ph.D.	Memorial Sloan Kettering Cancer Center
Haines, Dale S., Ph.D.	Temple University
Halabi, Susan, Ph.D.	Duke University
Hambardzumyan, Dolares, Ph.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Hamburger, Anne W., Ph.D.	University of Maryland, Baltimore
Hamilton, Ann S., Ph.D.	University of Southern California
Hamilton, Stanley R., M.D.	The University of Texas MD Anderson Cancer Center
Hamilton, Thomas C., Ph.D.	Fox Chase Cancer Center
Hammer, Daniel A., Ph.D.	University of Pennsylvania
Hammond, Scott M., Ph.D.	The University of North Carolina at Chapel Hill
Hammons, George J., Ph.D.	Philander Smith College
Han, Sang M., Ph.D.	The University of New Mexico
Hansen, Kirk C., Ph.D.	University of Colorado Denver

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Hansen, Laura A., Ph.D.	Creighton University
Hansen, Marc F., Ph.D.	University of Connecticut School of Dental Medicine
Hardman, Wanda E., Ph.D.	Marshall University
Hardy, Jerry L.	Us TOO International, Inc.
Harhaj, Edward W., Ph.D.	Johns Hopkins University
Harismendy, Olivier, Ph.D.	University of California, San Diego
Harpole, David H., M.D.	Duke University
Harrington, Maureen A., Ph.D.	Indiana University School of Medicine
Harris, Eleanor E., M.D.	East Carolina University
Hartford, Alan C., M.D., Ph.D.	Dartmouth-Hitchcock Medical Center
Hartshorn, Kevan L., M.D.	Boston Medical Center
Haura, Eric B., M.D.	H. Lee Moffitt Cancer Center & Research Institute
Hawkins, Douglas S., M.D.	Seattle's Children's Hospital
Hawley, Sarah T., Ph.D., M.P.H.	University of Michigan
Hazle, John D., Ph.D.	The University of Texas MD Anderson Cancer Center
Hazlehurst, Lori A., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
He, Jiang, Ph.D.	University of Virginia
Heckman, Carolyn J., Ph.D.	Fox Chase Cancer Center
Hel, Zdenek, Ph.D.	The University of Alabama at Birmingham
Held, Jason M., Ph.D.	Washington University in St. Louis
Held, Kathryn D., Ph.D.	Massachusetts General Hospital
Hellstrom, Ingegerd E., M.D., Ph.D.	University of Washington
Helzlsouer, Kathy J., M.D.	Mercy Health Services
Henikoff, Steven, Ph.D.	Fred Hutchinson Cancer Research Center
Herbst, Roy S., M.D., Ph.D., M.P.H.	Yale University
Herlyn, Meenhard F., D.V.M., D.Sc.	The Wistar Institute
Gonzalez Hernandez, Graciela, Ph.D.	Arizona State University, Tempe
Hernando, Eva, Ph.D.	New York University School of Medicine
Herring, Amy H., Sc.D.	The University of North Carolina at Chapel Hill
Herrinton, Lisa J., Ph.D.	Kaiser Foundation Research Institute
Hersch, Rebekah K., Ph.D.	Isa Associates, Inc.
Hesketh, Peter J., Ph.D.	Georgia Institute of Technology
Heslop, Helen E., M.D.	Baylor College
Heston, Warren D., Ph.D.	Cleveland Clinic Foundation
Hettich, Robert L., Ph.D.	The University of Tennessee-Oak Ridge National Laboratory
Heymach, John V., M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Hiatt, Robert A., M.D., Ph.D.	University of California, San Francisco
Hickey, Robert J., Ph.D.	City of Hope National Medical Center
Higgins, Paul J., Ph.D.	Albany Medical College
Hilakivi-Clarke, Leena A., Ph.D.	Georgetown University
Hill, David E., Ph.D.	Dana-Farber Cancer Institute
Hill, Elizabeth G., Ph.D.	Medical University of South Carolina
Hillhouse, Joel J., Ph.D.	East Tennessee State University
Hinds, Philip W., Ph.D.	Tufts University
Hirschowitz, Edward A., M.D.	University of Kentucky
Hlatky, Lynn, Ph.D.	Genesys Research Institute, Inc.
Hlavacek, William S., Ph.D.	Los Alamos National Laboratory
Ho, Alan L., M.D., Ph.D.	Memorial Sloan Kettering Cancer Center

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Ho, Shuk-Mei, Ph.D.	University of Cincinnati
Hockenbery, David M., M.D.	Fred Hutchinson Cancer Research Center
Hodi, Frank S., M.D.	Dana-Farber Cancer Institute
Hoering, Antje, Ph.D.	Cancer Research and Biostatistics
Hoffman, Amy J., Ph.D., R.N.	Michigan State University
Hogan, Michael E., Ph.D.	GMSbiotech, Inc.
Hohl, Raymond J., M.D., Ph.D.	Penn State Milton S. Hershey Medical Center
Hohmann, Andrea G., Ph.D.	Indiana University, Bloomington
Holford, Theodore R., Ph.D.	Yale University
Holiday, David B., Ph.D.	RTI International
Holl, Mark R., Ph.D.	Arizona State University, Tempe
Hollenbach, Andrew D., Ph.D.	Louisiana State University Health Sciences Center
Holmen, Sheri L., Ph.D.	The University of Utah
Holsworth, Daniel, Ph.D.	Stemnext, LLC
Holt, Jeffrey T., M.D.	Commonwealth Medical College
Hong, Yang, Ph.D.	University of Pittsburgh
Hooper, Douglas C., Ph.D.	Thomas Jefferson University
Hoopes, Jack, D.V.M., Ph.D.	Dartmouth College
Hoque, Ashraful, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Hord, Norman G., Ph.D., M.P.H.	Michigan State University
Hortobagyi, Gabriel N., M.D.	The University of Texas MD Anderson Cancer Center
Houchen, Courtney W., M.D.	The University of Oklahoma Health Sciences Center
Houghton, A. McGarry, M.D.	Fred Hutchinson Cancer Research Center
Houghton, JeanMarie, M.D., Ph.D.	University of Massachusetts Medical School
Houghton, Peter J., Ph.D.	St. Jude Children's Research Hospital
Houlette, Judy K., M.A.	Friend for Life Cancer Support Network
Howe, Louise R., Ph.D.	Weill Cornell Medical College of Cornell University
Howell, Gillian M., Ph.D.	University of Nebraska Medical Center
Hoyo, Cathrine, Ph.D., M.P.H.	North Carolina State University
Hsiang, David, M.D.	University of California, Irvine
Hsieh, Jer-Tsong, Ph.D.	The University of Texas Southwestern Medical Center
Hsu, Chun-Nan, Ph.D.	University of California, San Diego
Hu, Guanghui, Ph.D.	Merck & Co, Inc.
Hu, Jennifer J., Ph.D.	University of Miami Miller School of Medicine
Huang, Emina H., M.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Huang, Suyun, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Huang, Wei, Ph.D.	Oregon Health & Science University
Hubel, Allison, Ph.D.	University of Minnesota
Hughes, Dennis P., M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Huh, Warner K., M.D.	The University of Alabama at Birmingham
Hundley, William G., M.D.	Wake Forest University Health Sciences
Hung, Chien-Fu, Ph.D.	Johns Hopkins University
Hung, Mien-Chie, Ph.D.	The University of Texas MD Anderson Cancer Center
Hunt, C. Anthony, Ph.D.	University of California, San Francisco
Hurdle, John F., M.D., Ph.D.	University of Utah
Hurwitz, Herbert I., M.D.	Duke University
Husain, Aliya N., M.B.B.S.	The University of Chicago

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Hussong, Andrea M., Ph.D. The University of North Carolina at Chapel Hill
 Huth, James F., M.D. The University of Texas Southwestern Medical Center at Dallas
 Hutt-Fletcher, Lindsey M., Ph.D. Louisiana State University Health Science, Shreveport
 Hwang, Rosa F., M.D. The University of Texas MD Anderson Cancer Center
 Hylemon, Phillip B., Ph.D. Virginia Commonwealth University
 Hyslop, Terry, Ph.D. Duke University

I

Iavarone, Antonio, M.D. Columbia University Health Sciences
 Iftimia, Nicusor, Ph.D. Physical Sciences, Inc.
 Inaba, Hiroto, M.D., Ph.D. St. Jude Children’s Research Hospital
 Isom, Harriet C., Ph.D. Penn State Milton S. Hershey Medical Center
 Issa, Jean-Pierre J., M.D. Temple University of the Commonwealth
 Ittmann, Michael M., M.D., Ph.D. Baylor College of Medicine
 Iversen, Edwin S., Ph.D. Duke University

J

Jabado, Nada, M.D., Ph.D. McGill University
 Jackson, Mark W., Ph.D. Case Western Reserve University
 Jacobs, Lisa K., M.D. Johns Hopkins University
 Jacobs, Michael A., Ph.D. Johns Hopkins University
 Jacobsen, Paul B., Ph.D. University of South Florida
 Jacobson, Geraldine M., M.D., M.P.H. West Virginia University
 Jadvar, Hossein, M.D., Ph.D. University of Southern California
 Jaffray, David A., Ph.D. University of Toronto
 Jain, Maneesh, Ph.D. University of Nebraska Medical Center
 James, Charles D., Ph.D. Northwestern University
 Jamner, Larry D., Ph.D. University of California, Irvine
 Jarrard, David F., M.D. University of Wisconsin, Madison
 Jay, Daniel G., Ph.D. Tufts University
 Jay, Michael, Ph.D. NanoMed Pharmaceuticals, Inc.
 Jeffe, Donna B., Ph.D. Washington University in St. Louis
 Jeffery, Elizabeth H., Ph.D. University of Illinois at Urbana-Champaign
 Jeffrey, Stefanie S., M.D. Stanford University
 Jelicks, Linda A., Ph.D. Albert Einstein College of Medicine of Yeshiva University
 Jensen, Todd R., Ph.D. Jensen Informatics LLC
 Jermaine, Christopher, Ph.D. Rice University
 Jernigan, David, Ph.D. Johns Hopkins University
 Jerry, D. Joseph, Ph.D. University of Massachusetts, Amherst
 Jewell, William R., M.D. University of Kansas Medical Center
 Ji, Hanlee, M.D. Stanford University
 Jia, Shidong, Ph.D. Genentech, Inc.
 Jiang, Binghua, Ph.D. Thomas Jefferson University
 Jiang, Feng, M.D., Ph.D. University of Maryland, Baltimore
 Jiang, Yi, Ph.D. Georgia State University
 Jimeno, Antonio, M.D., Ph.D. University of Colorado Denver

Johnson, David G., Ph.D. The University of Texas MD Anderson Cancer Center
 Johnson, Gary L., Ph.D. The University of North Carolina at Chapel Hill
 Johnson, Mark E., Ph.D. Mark E. Johnson Consulting, LLC
 Johnson, Michael D., Ph.D. Georgetown University
 Johnson, William E., Ph.D. Boston University Medical Campus
 John-Stewart, Grace C., M.D., Ph.D., M.P.H. University of Washington
 Jones, David A., Ph.D. Oklahoma Medical Research Foundation
 Jones, Elizabeth C., M.D. National Institutes of Health, Clinical Center
 Jones, Kevin B., M.D. University of Utah
 Jones, Resa M., Ph.D., M.P.H. Virginia Commonwealth University
 Joshi, Amit, Ph.D. Baylor College of Medicine
 Joshi, Karuna, Ph.D. University of Maryland, Baltimore
 Ju, Jingfang, Ph.D. The State University New York at Stony Brook
 Judge, Andrew R., Ph.D. University of Florida
 Junghans, Richard P., M.D., Ph.D. Tufts Medical Center

K

Kable, Joseph W., Ph.D. University of Pennsylvania
 Kadlubar, Susan A., Ph.D. Roswell Park Cancer Institute
 Kahl, Brad, M.D. University of Wisconsin, Madison
 Kahn, Jessica A., M.D., M.P.H. Cincinnati Children’s Hospital Medical Center
 Kahn, Michael, Ph.D. University of Southern California
 Kai, Mihoko, Ph.D. Johns Hopkins University
 Kakar, Sham S., Ph.D. University of Louisville
 Kalinski, Pawel, M.D., Ph.D. University of Pittsburgh
 Kalluri, Raghu, M.D., Ph.D. The University of Texas MD Anderson Cancer Center
 Kalpathy-Cramer, Jayashree, Ph.D. Massachusetts General Hospital
 Kaminski, Joseph M., M.D. Medical College of Georgia
 Kandarian, Susan, Ph.D. Boston University
 Kane, Madeleine A., M.D., Ph.D. University of Colorado Denver
 Kane, Susan E., Ph.D. City of Hope National Medical Center
 Kang, Duck-Hee, Ph.D., R.N., F.A.A.N. The University of Texas Health Science Center
 at Houston
 Kang, Min H., Pharm.D. Texas Tech University Health Sciences Center
 Kang, Yibin, Ph.D. Princeton University
 Kao, Joseph P. Y., Ph.D. University of Maryland, Baltimore
 Kaplan, Alan, Ph.D. University of Kentucky
 Kapur, Reuben, Ph.D. Indiana University–Purdue University, Indianapolis
 Kar, Koushik, Ph.D. Rensselaer Polytechnic Institute
 Karchin, Rachel, Ph.D. Johns Hopkins University
 Karczmar, Gregory S., Ph.D. The University of Chicago
 Karellas, Andrew, Ph.D. University of Massachusetts Medical School
 Karlseder, Jan, Ph.D. Salk Institute for Biological Studies
 Karnad, Anand, M.D. The University of Texas Health Science Center at San Antonio
 Kasid, Usha N., Ph.D. Georgetown University
 Kasper, Susan, Ph.D. University of Cincinnati
 Katsanis, Emmanuel, M.D. The University of Arizona

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Katz, Steven J., M.D., M.P.H.	University of Michigan
Kaufman, David J., Ph.D.	Baylor College of Medicine
Kaumaya, Pravin T.P., Ph.D.	The Ohio State University
Kaur, Balveen, Ph.D.	The Ohio State University
Kaur, Judith S., M.D.	Mayo Clinic
Kay, Brian K., Ph.D.	University of Illinois at Chicago
Kaye, Kenneth M., M.D.	Harvard Medical School
Keith, Scott W., Ph.D.	Thomas Jefferson University
Keller, Evan T., D.V.M., Ph.D., M.P.H.	University of Michigan
Kelley, Amy S., M.D.	The Mount Sinai Hospital
Kelley, Mark R., Ph.D.	Indiana University–Purdue University, Indianapolis
Kelley, William, Ph.D.	Dartmouth College
Kemper, Kathi J., M.D., M.P.H.	The Ohio State University
Kern, Scott E., M.D.	Johns Hopkins University
Kerr, William G., Ph.D.	State University of New York Upstate Medical University
Kershaw, Trace S., Ph.D.	Yale University
Keshavarzian, Ali, M.D.	The University of Chicago
Kesler, Shelli R., Ph.D.	The University of Texas MD Anderson Cancer Center
Kessel, David, Ph.D.	Wayne State University
Kessler, Larry G., D.Sc.	University of Washington
Kester, Mark, Ph.D.	University of Virginia
Khaled, Annette R., Ph.D.	University of Central Florida
Khalili, Kamel, Ph.D.	Temple University
Khan, Seema A., M.D.	Northwestern University
Khare, Sharad, Ph.D.	Harry S. Truman Memorial Veteran’s Hospital
Khong, Hung T., M.D.	University of Utah
Khuri, Fadlo R., M.D.	Emory University
Kieber-Emmons, Thomas, Ph.D.	University of Arkansas for Medical Sciences
Kiem, Hans-Peter, M.D., Ph.D.	Fred Hutchinson Cancer Research Center
Killackey, Maureen A., M.D.	Memorial Sloan Kettering Cancer Center
Kilmer, Beau G., Ph.D.	RAND Corporation
Kim, Hyeong-Reh C., Ph.D.	Wayne State University
Kim, Jae H., M.D., Ph.D.	Henry Ford Health System
Kim, Nancy S., Ph.D.	Northeastern University
Kim, William Y., M.D.	The University of North Carolina at Chapel Hill
Kim, Young-In J., M.D.	University of Toronto
Kimmel, Marek, Sc.D., Ph.D.	Rice University
King, Michael R., Ph.D.	Cornell University
King, Peter H., M.D.	The University of Alabama at Birmingham
Kingham, T. Peter, M.D.	Memorial Sloan Kettering Cancer Center
Kinney, Anita Y., Ph.D., R.N.	The University of New Mexico Health Sciences Center
Kinter, Michael T., Ph.D.	Oklahoma Medical Research Foundation
Kipke, Michele D., Ph.D.	University of Southern California
Kirkwood, John M., M.D.	University of Pittsburgh
Kirschner, Marvin A., M.D.	Rutgers, The State University of New Jersey
Kisseleva, Tatiana, M.D., Ph.D.	University of California, San Diego
Kissil, Joseph, Ph.D.	Scripps Research Institute, Florida
Kitajewski, Jan K., Ph.D.	Columbia University Health Sciences

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Klassen, Ann C., Ph.D.	Drexel University
Klein, Alison P., Ph.D.	Johns Hopkins University
Klein, Hannah L., Ph.D.	New York University School of Medicine
Klesges, Robert C., Ph.D.	The University of Tennessee Health Science Center
Kline, Justin P., M.D.	The University of Chicago
Klingelhutz, Aloysius J., Ph.D.	The University of Iowa
Klosky, James, Ph.D.	St. Jude Children's Research Hospital
Kluger, Harriet M., M.D.	Yale University
Knipp, Gregory T., Ph.D.	Purdue University
Knoepfler, Paul S., Ph.D.	University of California, Davis
Knudsen, Beatrice S., M.D., Ph.D.	Cedars-Sinai Medical Center
Kobayashi, Susumu, M.D., Ph.D.	Beth Israel Deaconess Medical Center
Kogelnik, Andreas M., M.D., Ph.D.	Open Medicine Institute, Inc.
Koh, James, Ph.D.	Duke University
Komanduri, Krishna V., M.D.	University of Miami Miller School of Medicine
Konjeti, Sekhar R., Ph.D.	Vanderbilt University
Koochekpour, Shahriar, M.D., Ph.D.	Roswell Park Cancer Institute
Koopman, James S., M.D., M.P.H.	University of Michigan
Kopelman, Raoul, Ph.D.	University of Michigan
Korbelik, Mladen, Ph.D.	British Columbia Cancer Agency
Korngold, Robert, Ph.D.	Hackensack University Medical Center
Kosorok, Michael R., Ph.D.	The University of North Carolina at Chapel Hill
Koul, Hari K., Ph.D.	Louisiana State University Health Science Center, Shreveport
Koumenis, Constantinos, Ph.D.	University of Pennsylvania
Kovari, Ladislau C., Ph.D.	Wayne State University
Kowalski, Jeanne, Ph.D.	Emory University
Koya, Richard C., M.D., Ph.D.	Roswell Park Cancer Institute
Kramer, Fred R., Ph.D.	Public Health Research Institute
Kratzke, Robert A., M.D.	University of Minnesota
Kresty, Laura A., Ph.D.	Medical College of Wisconsin
Kricka, Larry J., B.A.	University of Pennsylvania
Kridel, Steven J., Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Krishnamurthi, Smitha, M.D.	University Hospitals of Cleveland
Krishnan, Sunil, M.D.	The University of Texas MD Anderson Cancer Center
Krishnaswamy, Venkataramanan, Ph.D.	Dartmouth College
Krizman, David B., Ph.D.	Expression Pathology, Inc.
Krohn, Kenneth A., Ph.D.	University of Washington
Krolewski, John J., M.D., Ph.D.	University of Rochester
Kron, Stephen J., M.D., Ph.D.	The University of Chicago
Krop, Ian E., M.D., Ph.D.	Dana-Farber Cancer Institute
Krupinski, Elizabeth A., Ph.D.	The University of Arizona
Krymskaya, Vera P., M.B.A., Ph.D.	University of Pennsylvania
Kudrolli, Haris, Ph.D.	Radiation Monitoring Devices, Inc.
Kufe, Donald W., M.D.	Dana-Farber Cancer Institute
Kulasingam, Shalini L., Ph.D., M.P.H.	University of Minnesota
Kulesz-Martin, Molly F., Ph.D.	Oregon Health & Science University
Kumar, Addanki P., Ph.D.	The University of Texas Health Science Center at San Antonio
Kumar, Ajit, Ph.D.	George Washington University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Kumar, Challa S., Ph.D. Louisiana State University Agricultural & Mechanical College
 Kumar, Deepak, Ph.D. The University of the District of Columbia
 Kumar, Nagi B., Ph.D. H. Lee Moffitt Cancer Center & Research Institute
 Kumar, Naresh, Ph.D. University of Miami Miller School of Medicine
 Kumar, Santosh, Ph.D. University of Memphis
 Kumar, Shaji K., M.D. Mayo Clinic
 Kunicki, Thomas J., Ph.D. Children’s Hospital of Orange County
 Kuo, Macus T., Ph.D. The University of Texas MD Anderson Cancer Center
 Kuwana, Tomomi, M.D., Ph.D. La Jolla Institute for Allergy & Immunology
 Kuzel, Timothy M., M.D. Northwestern University
 Kwiatkowski, David J., M.D., Ph.D. Brigham and Women’s Hospital
 Kwock, Lester, Ph.D. The University of North Carolina at Chapel Hill
 Kwon, Glen S., Ph.D. University of Wisconsin, Madison
 Kyprianou, Iacovos S., Ph.D. U.S. Food and Drug Administration
 Kyprianou, Natasha, Ph.D. University of Kentucky

L

LaBarge, Mark A., Ph.D. Lawrence Berkeley National Laboratory
 LaFramboise, William A., Ph.D. University of Pittsburgh
 Lackner, Jeffrey M., Psy.D. The State University of New York at Buffalo
 Lacy, Maureen A., Ph.D. The University of Chicago
 Laderoute, Keith R., Ph.D. SRI International
 Lai, Jonathan, Ph.D. Albert Einstein College of Medicine of Yeshiva University
 Lai, Yi-Chen, M.D. Baylor College of Medicine
 Laiyemo, Adeyinka O., M.P.H. Howard University
 Lake-Bakaar, Gerond V., M.D. Beth Israel Deaconess Medical Center
 Lal, Ratneshwar, Ph.D. University of California, San Diego
 Lam, Kit S., M.D., Ph.D. University of California, Davis
 Lam, Wan L., Ph.D. British Columbia Cancer Research Centre
 Lambert, William J., Ph.D. MedImmune, Inc.
 Lampe, Paul D., Ph.D. Fred Hutchinson Cancer Research Center
 Lancaster, Jack R., Ph.D. The University of Alabama at Birmingham
 Landgraf, Ralf, Ph.D. University of Miami Miller School of Medicine
 Landowski, Terry H., Ph.D. University of Arizona
 Landsittel, Douglas P., Ph.D. University of Pittsburgh
 Landsman, David, Ph.D. National Library of Medicine
 Lane, Andrew N., Ph.D. University of Kentucky
 Lane, Timothy F., Ph.D. University of California, Los Angeles
 Lang, James C., Ph.D. The Ohio State University
 Langer, Mark P., M.D. Indiana University–Purdue University, Indianapolis
 Langer, Steve G., Ph.D. Mayo Clinic
 Languino, Lucia R., Ph.D. Thomas Jefferson University
 Lanier, Keith S., M.D. Providence Portland Medical Center
 Lannigan, Deborah, Ph.D. Vanderbilt University
 Lanza-Jacoby, Susan P., Ph.D. Thomas Jefferson University
 Larner, Andrew C., M.D., Ph.D. Virginia Commonwealth University
 Larson, Andrew C., Ph.D. Northwestern University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Lash, Timothy L., D.Sc., M.P.H.	Emory University
Lattime, Edmund C., Ph.D.	Rutgers Biomedical and Health Sciences
Lau, Ching C., M.D., Ph.D.	Baylor College of Medicine
Laudenslager, Mark L., Ph.D.	University of Colorado Denver
Law, Brian K., Ph.D.	University of Florida
Lawson, Michael J., M.D.	Kaiser Permanente
Lazarova, Darina L., Ph.D.	Commonwealth Medical College
Lazo, John S., Ph.D.	University of Virginia
Lazovich, Deann, Ph.D., M.P.H.	University of Minnesota
Leach, Robin J., Ph.D.	The University of Texas Health Science Center at San Antonio
Lee, Adrian V., Ph.D.	University of Pittsburgh
Lee, Amy S., Ph.D.	University of Southern California
Lee, Brian K., Ph.D.	Drexel University
Lee, Chung, Ph.D.	University of California, Irvine
Lee, Ethan, M.D., Ph.D.	Vanderbilt University
Lee, Francis Y., M.D., Ph.D.	Columbia University
Lee, Hongzhe, Ph.D.	University of Pennsylvania
Lee, Jae K., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Lee, James C., Ph.D.	The University of Texas Medical Branch at Galveston
Lee, Jeannette Y., Ph.D.	University of Arkansas for Medical Sciences
Lee, Ji-Hyun, Dr.P.H.	The University of New Mexico Health Sciences Center
Lee, Marion M., Ph.D., M.P.H.	University of California, San Francisco
Lee, Nancy Y., M.D.	Memorial Sloan Kettering Cancer Center
Lee, Peter P., M.D.	City of Hope National Medical Center
Lee, Robert J., Ph.D.	The Ohio State University
Lee, Zhenghong, Ph.D.	Case Western Reserve University
Lehman, John M., Ph.D.	East Carolina University
Leiby, Benjamin, Ph.D.	Jefferson University
Leifer, Cynthia A., Ph.D.	Cornell University
Leighton, John K., Ph.D.	U.S. Food and Drug Administration
Lemasters, John J., M.D., Ph.D.	Medical University of South Carolina
Lengerich, Eugene J., V.M.D.	Penn State Milton S. Hershey Medical Center
Leong, Stephen, M.D.	University of Colorado Denver
Leopold, Judith S., Ph.D.	University of Michigan
Lerman, Caryn, Ph.D.	University of Pennsylvania
Lesinski, Gregory B., Ph.D., M.P.H.	The Ohio State University
Lesniak, Maciej S., M.D.	The University of Chicago
Leung, Wing, Ph.D.	St. Jude Children's Research Hospital
Leung, Yuet-Kin, Ph.D.	University of Cincinnati
Levenson, Richard M., M.D.	University of California, Davis
Levine, Alexandra M., M.D.	University of California, Los Angeles
Levine, Ellis G., M.D.	Roswell Park Cancer Institute
Lewis, Crystal F., Ph.D., M.P.H.	Columbia University Medical Center
Lewis, Michael T., Ph.D.	Baylor College of Medicine
Li, Changqing, Ph.D.	University of California, Merced
Li, Chi, Ph.D.	University of Louisville
Li, Christopher I., M.D., Ph.D., M.P.H.	Fred Hutchinson Cancer Research Center
Li, Ellen, Ph.D.	The State University of New York at Stony Brook

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Li, Hong-Yu, Ph.D.	The University of Arizona
Li, Jian J., M.D., Ph.D.	University of California, Davis
Li, Li, M.D., Ph.D., M.P.H.	Case Western Reserve University
Li, Rong, Ph.D.	The University of Texas Health Science Center at San Antonio
Li, Xin, Ph.D.	New York University
Li, Xingde, Ph.D.	Johns Hopkins University
Liang, Jie, Ph.D.	University of Illinois at Chicago
Lichtenberger, Lenard M., Ph.D.	The University of Texas Health Science Center at Houston
Lichter, Terence R., M.D., Ph.D.	Rush University Medical Center
Liddy, Elizabeth D., Ph.D.	Syracuse University
Lieberman, Howard B., Ph.D.	Columbia University Health Sciences Campus
Lieberman, Paul M., Ph.D.	The Wistar Institute
Liesveld, Jane L., M.D.	University of Rochester
Lightdale, Charles J., M.D.	Columbia University Medical Center
Lilja, Hans, M.D., Ph.D.	Memorial Sloan Kettering Cancer Center
Lillard, James W., Ph.D.	Morehouse School of Medicine
Lin, Chia-Ying J., Ph.D.	University of Cincinnati
Lin, Haifan, Ph.D.	Yale University
Lin, Hui-Kuan, Ph.D.	The University of Texas MD Anderson Cancer Center
Lin, Jiayuh, Ph.D.	Nationwide Children’s Hospital
Lin, Ming-Fong, Ph.D.	University of Nebraska Medical Center
Lin, Qiao, Ph.D.	Columbia University
Lin, Steven H., M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Lin, Sue-Hwa, Ph.D.	The University of Texas MD Anderson Cancer Center
Lin, Yan, Ph.D.	University of Pittsburgh
Ling, Kun, Ph.D.	Mayo Clinic
Link, Brian K., M.D.	The University of Iowa
Liotta, Lance A., M.D., Ph.D.	George Mason University
Liphardt, Jan T., Ph.D.	Stanford University
Lipkin, Steven M., M.D., Ph.D.	Weill Cornell Medical College of Cornell University
Lipshultz, Steven E., M.D.	Wayne State University
Lisetti, Christine L., Ph.D.	Florida International University
Liu, Chunming, Ph.D.	University of Kentucky
Liu, Gilbert C., M.D.	University of Louisville
Liu, Jonathan T., Ph.D.	University of Washington
Liu, Pengyuan, Ph.D.	Medical College of Wisconsin
Liu, Song, Ph.D.	Roswell Park Cancer Institute
Liu, Yunlong, Ph.D.	Indiana University–Purdue University, Indianapolis
Lo, Hui-Wen, Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Lo, Yu-Hwa, Ph.D.	University of California, San Diego
Loba, Elizabeth G., Ph.D.	North Carolina State University, Raleigh
Locher, Julie L., Ph.D.	The University of Alabama at Birmingham
Locker, Joseph D., M.D., Ph.D.	University of Pittsburgh
Loeb, Lawrence A., M.D., Ph.D.	University of Washington
Loehrer, Patrick J., M.D.	Indiana University–Purdue University, Indianapolis
Loffredo, Christopher A., Ph.D.	Georgetown University
Logothetis, Christopher J., M.D.	The University of Texas MD Anderson Cancer Center
Lokeshwar, Balakrishna L., Ph.D.	University of Miami Miller School of Medicine

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Lokeshwar, Vinata B., Ph.D.	University of Miami Miller School of Medicine
Lokshin, Anna E., Ph.D.	University of Pittsburgh
London, Jack W., Ph.D.	Thomas Jefferson University
Long, Jirong, Ph.D.	Vanderbilt University
Lonsdale, John T., Ph.D.	National Disease Research Interchange
Lord, Edith M., Ph.D.	University of Rochester Medical Center
Lorusso, Patricia M., D.O.	Yale University
Loscalzo, Matthew J., L.C.S.W.	City of Hope National Medical Center
Lothstein, Leonard, Ph.D.	The University of Tennessee Health Science Center
Lounsbury, David W., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Lowe, Anson W., M.D.	Stanford University
Lu, Chang, Ph.D.	Virginia Polytechnic Institute and State University
Lu, Jianming, Ph.D.	Immuphargen, LLC
Lu, Karen H., M.D.	The University of Texas MD Anderson Cancer Center
Lubaroff, David M., Ph.D.	The University of Iowa
Lue, Neal F., M.D., Ph.D.	Weill Cornell Medical College of Cornell University
Luebeck, Georg E., Ph.D.	Fred Hutchinson Cancer Research Center
Lum, Lawrence, Ph.D.	The University of Texas Southwestern Medical Center
Lum, Lawrence G., M.D.	Wayne State University
Lunyak, Victoria, Ph.D.	Buck Institute for Research on Aging
Luo, Juhua, Ph.D.	Indiana University, Bloomington
Luo, Jun-Li, M.D., Ph.D.	Scripps Research Institute
Luo, Yuling, Ph.D.	Advanced Cell Diagnostics, Inc.
Luque, John S., Ph.D., M.P.H.	Georgia Southern University
Lutters, Wayne G., Ph.D.	University of Maryland, Baltimore
Lv, Qin, Ph.D.	University of Colorado Boulder
Lyman, Gary H., M.D., M.P.H.	Fred Hutchinson Cancer Research Center
Lynch, John P., M.D., Ph.D.	University of Pennsylvania
Lyon, Debra E., Ph.D.	University of Florida

M

Ma, Cynthia X., M.D., Ph.D.	Washington University in St. Louis
Ma, Grace X., Ph.D.	Temple University
Ma, Haiching, Ph.D.	Reaction Biology Corp.
Ma, Patrick C., M.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Macoska, Jill A., Ph.D.	University of Massachusetts, Boston
Madabhushi, Anant, Ph.D.	Case Western Reserve University
Maggard-Gibbons, Melinda A., M.D.	University of California, Los Angeles
Mahadevan-Jansen, Anita, Ph.D.	Vanderbilt University
Mai, Volker, Ph.D.	University of Florida
Maihle, Nita J., Ph.D.	Georgia Health Sciences University
Maizels, Nancy, Ph.D.	University of Washington
Majumdar, Adhip P.N., D.Sc., Ph.D.	Wayne State University
Majumder, Sadhan, Ph.D.	The University of Texas MD Anderson Cancer Center
Makriyannis, Alexandros, Ph.D.	Northeastern University
Maley, Carlo, Ph.D.	University of California, San Francisco

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014 _____

Malkas, Linda H., Ph.D.	City of Hope National Medical Center
Malone, Kathleen E., Ph.D., M.P.H.	Fred Hutchinson Cancer Research Center
Manak, Mark M., Ph.D.	Henry M. Jackson Foundation
Manfredi, James J., Ph.D.	The Mount Sinai Hospital
Mani, Sridhar, M.D.	Albert Einstein College of Medicine of Yeshiva University
Manjili, Masoud H., D.V.M., Ph.D.	Virginia Commonwealth University
Mankoff, David A., Ph.D.	University of Pennsylvania
Manne, Upender, Ph.D.	The University of Alabama at Birmingham
Mansbridge, Jonathan N., Ph.D.	Advanced Tissue Sciences, Inc.
Mansur, David B., M.D.	Case Western Reserve University
Mao, Junhao, Ph.D.	University of Massachusetts Medical School
Mao, Li, M.D.	University of Maryland, Baltimore
Mapes, James P., Ph.D.	Myriad Rules-Based Medicine, Inc.
Marchetti, Dario, Ph.D.	Baylor College of Medicine
Marcucci, Guido, M.D.	The Ohio State University
Marcus, Stevan, Ph.D.	The University of Alabama College of Arts and Sciences
Mareci, Thomas H., Ph.D.	University of Florida
Marians, Kenneth J., Ph.D.	Memorial Sloan Kettering Cancer Center
Marini, Frank C., Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Maris, John M., M.D.	Children’s Hospital of Philadelphia
Markert, James M., M.D., M.P.H.	The University of Alabama at Birmingham
Marks, Jeffrey R., Ph.D.	Duke University
Marr, David W.M., Ph.D.	Colorado School of Mines
Martin, MaryBeth, Ph.D.	Georgetown University
Martinez, Iveris L., Ph.D.	Florida International University
Maskarinec, Gertraud, M.D., Ph.D., M.P.H.	University of Hawaii at Manoa
Master, Viraj, M.D., Ph.D.	Emory Healthcare
Matei, Daniela E., M.D.	Indiana University–Purdue University, Indianapolis
Mato, Anthony R., M.D.	Hackensack University Medical Center
Matsui, William H., M.D.	Johns Hopkins University
Matthews, Dwight E., Ph.D.	The University of Vermont and State Agricultural College
Matthews, Ellyn E., Ph.D.	University of Colorado Denver
Mattingly, Raymond R., Ph.D.	Wayne State University
Matusik, Robert J., Ph.D.	Vanderbilt University
Maurer, Barry J., M.D., Ph.D.	Texas Tech University Health Sciences Center
Mawlawi, Osama, Ph.D.	The University of Texas MD Anderson Cancer Center
Maxwell, George L., M.D.	Inova Fairfax Hospital
May, William A., M.D.	Children’s Hospital of Los Angeles
Mayo, Kevin H., Ph.D.	University of Minnesota
Mayo, Lindsey D., Ph.D.	Indiana University–Purdue University, Indianapolis
Mayr, Christine, M.D., Ph.D.	Memorial Sloan Kettering Cancer Center
McBride, William H., D.Sc., Ph.D.	University of California, Los Angeles
McCabe, George P., Ph.D.	Purdue University
McCarthy, James B., Ph.D.	University of Minnesota
McCarthy, Timothy J., Ph.D.	Pfizer, Inc.
McClure, Samuel M., Ph.D.	Stanford University
McConkey, David J., Ph.D.	The University of Texas MD Anderson Cancer Center
McCormick, Tyler, Ph.D.	University of Washington

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

McDaid, Hayley M., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
McDonald, Brenna C., Psy.D., M.B.A.	Indiana University–Purdue University, Indianapolis
McInerney, Marcia F., Ph.D.	Vanderbilt University
McKeon, Frank D., Ph.D.	The Jackson Laboratory
McLafferty, Sara L., Ph.D.	Hunter College
McMahon, Steven B., Ph.D.	Thomas Jefferson University
McMillan, Minnie, Ph.D.	The University of Southern California
McMillen, Janey S., Ph.D.	3C Institute
McNeel, Douglas G., M.D., Ph.D.	University of Wisconsin, Madison
McNeely, Margaret, Ph.D.	University of Alberta
McNitt-Gray, Michael F., Ph.D.	University of California, Los Angeles
McQueen, Amy, Ph.D.	Washington University in St. Louis
McTiernan, Anne M., M.D., Ph.D.	Fred Hutchinson Cancer Research Center
Medhora, Meetha M., Ph.D.	Medical College of Wisconsin
Mehta, Anand S., Ph.D.	Drexel University
Mehta, Rajendra G., Ph.D.	IIT Research Institute
Mendonca, Paulo R., Ph.D.	General Electric Global Research Center
Mermelstein, Robin J., Ph.D.	University of Illinois at Chicago
Meroueh, Samy, Ph.D.	Indiana University–Purdue University, Indianapolis
Mesri, Enrique A., Ph.D.	University of Miami Miller School of Medicine
Messersmith, Wells A., M.D.	University of Colorado Denver
Metallo, Christian M., Ph.D.	University of California, San Diego
Metzger, Gregory J., Ph.D.	University of Minnesota
Meyer, Charles R., Ph.D.	University of Michigan
Meyer, Laurence J., M.D., Ph.D.	University of Utah
Meyerand, Mary E., Ph.D.	University of Wisconsin, Madison
Meyers, Craig M., Ph.D.	Penn State Milton S. Hershey Medical Center
Meyskens, Frank L., M.D.	University of California, Irvine
Meza, Jane, Ph.D.	University of Nebraska Medical Center
Michaelson, Dror, M.D., Ph.D.	Massachusetts General Hospital
Michalek, Arthur M., Ph.D.	The State University of New York at Buffalo
Michaud, Dominique S., Sc.D.	Brown University
Miesfeldt, Susan, M.D.	Maine Medical Center
Mikhael, Joseph R., M.D.	Mayo Clinic
Mikkelsen, Ross B., Ph.D.	Virginia Commonwealth University
Miller, Brenda A., Ph.D.	Pacific Institute for Research and Evaluation
Miller, Christopher J., Ph.D.	University of California, Davis
Miller, Jeffrey S., M.D.	University of Minnesota
Miller, Norman G., Ph.D.	Stanford University
Minden, Mark D., M.D., Ph.D.	University Health Network
Minna, John D., M.D.	The University of Texas Southwestern Medical Center at Dallas
Miranti, Cynthia K., Ph.D.	Van Andel Research Institute
Mishra, Lopa, M.D.	The University of Texas MD Anderson Cancer Center at Dallas
Miskimins, Keith W., Ph.D.	Sanford Research
Mitchell, Edith P., M.D.	Thomas Jefferson University
Mitchell, Malcolm S., M.D.	Wayne State University
Mitra, Sankar, Ph.D.	Southern Research Institute
Mitsiades, Constantine S., M.D., Ph.D.	Dana-Farber Cancer Institute

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Mittal, Vivek, Ph.D.	Weill Cornell Medical College of Cornell University
Miyake, Akira, Ph.D.	University of Colorado Boulder
Miyamoto, Shigeki, Ph.D.	University of Wisconsin, Madison
Miyamoto, Suzanne, Ph.D.	University of California, Davis
Mo, Yin-Yuan, Ph.D.	The University of Mississippi Medical Center
Moasser, Mark M., M.D.	University of California, San Francisco
Mohammad, Ramzi M., Ph.D.	Wayne State University
Mohler, James L., M.D.	Roswell Park Cancer Institute
Moinpour, Carol M., Ph.D.	Fred Hutchinson Cancer Research Center
Mojica, Wilfrido D., M.D.	The State University of New York at Buffalo
Moley, Kelle H., M.D.	Washington University in St. Louis
Montagna, Cristina, Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Monteiro, Alvaro N.A., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Monti, Stefano, Ph.D.	Boston University Medical Campus
Mooney, Kathleen H., Ph.D.	University of Utah
Moore, Melissa, Ph.D.	Sofie Biosciences, LLC
Moraru, Ion I., M.D., Ph.D.	University of Connecticut School of Dental Medicine
Moritz, Robert L., Ph.D.	Institute for Systems Biology
Moros, Eduardo G., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Morris, David R., Ph.D.	University of Washington
Morris, Elizabeth A., M.D.	Memorial Sloan Kettering Cancer Center
Morris, Wanda M., Ph.D.	University of Washington
Morrow, Gary R, Ph.D.	University of Rochester
Morse, David L., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Morse, Douglas E., Ph.D.	New York University
Morton, Kathryn A., M.D.	University of Utah
Mosavel, Maghboeba, Ph.D.	Virginia Commonwealth University
Moseley, Martin A., Ph.D.	Duke University
Moses, Ashlee V., Ph.D.	Oregon Health & Science University
Moses, Harold L., M.D.	Vanderbilt University
Motamedi, Massoud, Ph.D.	The University of Texas Medical Branch at Galveston
Mourant, Judith R., Ph.D.	Los Alamos National Laboratory
Mu, David, Ph.D.	Eastern Virginia Medical School
Muddiman, David C., Ph.D.	North Carolina State University, Raleigh
Muench, Frederick J., Ph.D.	The Feinstein Institute for Medical Research
Muise-Helmericks, Robin C., Ph.D.	Medical University of South Carolina
Mukherjee, Bhramar, Ph.D.	University of Michigan
Mukherjee, Pinku, Ph.D.	The University of North Carolina at Charlotte
Mukherjee, Priyabrata, Ph.D.	The University of Oklahoma Health Sciences Center
Mukherji, Bijay, M.D.	University of Connecticut School of Dental Medicine
Mukhopadhyay, Debabrata, Ph.D.	Mayo Clinic
Mukhtar, Hasan, Ph.D.	University of Wisconsin, Madison
Mullan, Patricia B., Ph.D.	University of Michigan
Mullen, Craig A., M.D., Ph.D.	University of Rochester
Muller, Carolyn Y., M.D.	The University of New Mexico
Mullersman, Jerald E., M.D., Ph.D., M.P.H.	East Tennessee State University
Mullins, David W., Ph.D.	Dartmouth College
Mulloy, James C., Ph.D.	Cincinnati Children's Hospital Medical Center

Mulshine, James L., M.D.	Rush University Medical Center
Mulvihill, John J., M.D.	The University of Oklahoma Health Sciences Center
Munden, Reginald F., M.D.	The Methodist Hospital Research Institute
Munger, Karl, Ph.D.	Tufts University
Munshi, Hidayatullah G., M.D.	Northwestern University
Murgo, Anthony J., M.D.	U.S. Food and Drug Administration
Murphy, Barbara A., M.D.	Vanderbilt University
Murphy, Robert L., M.D.	Northwestern University
Murphy, Sheigla B., Ph.D.	Scientific Analysis Corporation
Murphy, William J., Ph.D.	University of Nevada, Reno
Murray, John J., M.D., Ph.D.	Meharry Medical College
Murtaugh, Lewis C., Ph.D.	University of Utah
Mustian, Karen M., Ph.D., M.P.H.	University of Rochester
Muthusamy, Natarajan, Ph.D.	The Ohio State University
Muthuswamy, Senthil K., Ph.D.	Cold Spring Harbor Laboratory
Myers, Jeffrey N., Ph.D.	The University of Texas MD Anderson Cancer Center
Myers, Leann, Ph.D.	Tulane University
Myers, Valerie H., Ph.D.	Klein Buendel, Inc.

N

Nabors, Louis B., M.D.	The University of Alabama at Birmingham
Nagarkatti, Mitzi, Ph.D.	University of South Carolina, Columbia
Nagle, Dale G., Ph.D.	The University of Mississippi
Nagrath, Sunitha, Ph.D.	University of Michigan
Naidu, Mamta D., Ph.D.	GeneSys Research Institute
Najavits, Lisa M., Ph.D.	Treatment Innovations, LLC
Nakagawa, Mayumi, M.D., Ph.D.	Type IV Technologies, Inc.
Nakshatri, Harikrishna, Ph.D.	Indiana University–Purdue University, Indianapolis
Nana-Sinkam, Serge P., M.D.	The Ohio State University
Napolitano, Melissa A., Ph.D.	George Washington University
Nathanson, Katherine L., M.D.	University of Pennsylvania
Naughton, Michelle J., Ph.D., M.P.H.	The Ohio State University
Navone, Nora M., Ph.D.	The University of Texas MD Anderson Cancer Center
Nelson, Celeste M., Ph.D.	Princeton University
Nelson, Sarah J., Ph.D.	University of California, San Francisco
Nemenoff, Raphael A., Ph.D.	University of Colorado Denver
Nephew, Kenneth P., Ph.D.	Indiana University–Purdue University, Indianapolis
Ness, Scott A., Ph.D.	The University of New Mexico Health Sciences Center
Neuhouser, Marian L., Ph.D.	Fred Hutchinson Cancer Research Center
Neuwelt, Edward A., M.D.	Vanderbilt University
Newcomb, Polly A., Ph.D., M.P.H.	Fred Hutchinson Cancer Research Center
Nichol, Peter F., M.D., Ph.D.	University of Wisconsin, Madison
Nickerson, Jeffrey A., Ph.D.	University of Massachusetts Medical School
Nickoloff, Jac A., Ph.D.	Colorado State University
Nicosia, Santo V., M.D.	University of South Florida
Nieva, Jorge J., M.D.	The University of Southern California
Nikiforov, Mikhail, Ph.D.	Roswell Park Cancer Institute

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Nikitin, Alexander Y., M.D., Ph.D. Cornell University
 Nishikawa, Robert M., Ph.D. University of Pittsburgh
 Nishimura, Michael I., Ph.D. Loyola University, Chicago
 Nishioka, Gary M., Ph.D. H & N Instruments, Inc.
 Nonn, Larisa, Ph.D. University of Illinois at Chicago
 Norian, Lyse A., Ph.D. The University of Iowa
 Normolle, Daniel P., Ph.D. University of Pittsburgh
 Norris, Jeremy L., Ph.D. Vanderbilt University
 Novina, Carl D., M.D., Ph.D. Dana-Farber Cancer Institute
 Nucifora, Giuseppina, D.Sc., Ph.D. The University of Chicago
 Nusse, Roeland, Ph.D. Stanford University
 Nygaard, Peter, Ph.D. Pacific Institute for Research and Evaluation

O

O'Bryan, John P., Ph.D. University of Illinois at Chicago
 O'Connor, Kathleen L., Ph.D. University of Kentucky
 O'Connor, Richard J., Ph.D. Roswell Park Cancer Institute
 O'Hara, Michael D., Ph.D. U.S. Food and Drug Administration
 O'Neill, Brian P., M.D. Mayo Clinic
 Ochs, Michael F., Ph.D. The College of New Jersey
 Odedina, Folakemi T., Ph.D. University of Florida
 Oesterle, Sabrina, Ph.D. University of Washington
 Ogretmen, Besim, Ph.D. Medical University of South Carolina
 Okada, Craig Y., M.D., Ph.D. Oregon Health & Science University
 Okcu, Mehmet F., M.D., M.P.H. The University of Texas MD Anderson Cancer Center
 Oleinick, Nancy L., Ph.D. Case Western Reserve University
 Oliver, Janet M., Ph.D. The University of New Mexico Health Sciences Center
 Omenn, Gilbert S., M.D., Ph.D. University of Michigan
 Onar-Thomas, Arzu, Ph.D. St. Jude Children's Research Hospital
 Ondrey, Frank G., M.D., Ph.D. University of Minnesota
 Onyuksel, Hayat, Ph.D. University of Illinois at Chicago
 Opferman, Joseph T., Ph.D. St. Jude Children's Research Hospital
 Orłowski, Robert Z., M.D., Ph.D. The University of Texas MD Anderson Cancer Center
 Orsulic, Sandra, Ph.D. Cedars-Sinai Medical Center
 Osheroff, Neil, Ph.D. Vanderbilt University
 Ostrowski, Michael C., Ph.D. The Ohio State University
 Ota, David M., M.D. Duke University
 Ou, James J.-H., Ph.D. University of Southern California
 Ouchi, Toru, Ph.D. Roswell Park Cancer Institute
 Owen, Jason E., Ph.D., M.P.H. Veterans Administration Palo Alto Health Care System
 Oyajobi, Babatunde O., Ph.D. The University of Texas Health Science Center at San Antonio
 Ozbun, Michelle A., Ph.D. The University of New Mexico Health Sciences Center

P

Padilla, Geraldine V., Ph.D. University of California, San Francisco
 Pagel, Mark D., Ph.D. The University of Arizona

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Pajonk, Frank, M.D., Ph.D.	University of California, Los Angeles
Pal, Soumitro, Ph.D.	Children's Hospital Corporation
Palecek, Sean P., Ph.D.	University of Wisconsin, Madison
Palsson, Bernhard O., Ph.D.	University of California, San Diego
Pan, Xiaochuan, Ph.D.	The University of Chicago
Pan, Zhen-Qiang, Ph.D.	Icahn School of Medicine at Mount Sinai
Pandita, Tej K., Ph.D.	The Methodist Hospital Research Institute
Panepinto, Julie A., M.D.	Medical College of Wisconsin
Pankratz, V. Shane, Ph.D.	The University of New Mexico Health Sciences Center
Pankuch, Mark, Ph.D.	Procure Treatment Centers, Inc.
Pannell, Lewis K., Ph.D.	University of South Alabama
Panyam, Jayanth, Ph.D.	University of Minnesota
Papineni, Rao V.L., Ph.D.	Precision X-Ray, Inc.
Parangi, Sareh, M.D.	Massachusetts General Hospital
Park, Ben H., M.D., Ph.D.	Johns Hopkins University
Park, Jason Y., M.D., Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Parker, Laurie L., Ph.D.	University of Minnesota
Parra-Medina, Deborah M., Ph.D., M.P.H.	The University of Texas Health Science Center at San Antonio
Parsa, Andrew T., M.D., Ph.D.	Northwestern University
Parsons, Barbara L., Ph.D.	U.S. Food and Drug Administration
Parsons, Ramon E., M.D., Ph.D.	Icahn School of Medicine at Mount Sinai
Partridge, Savannah C., Ph.D.	University of Washington
Parvin, Bahram A., Ph.D.	University of California, Berkeley
Pasa-Tolic, Ljiljana, Ph.D.	Pacific Northwest National Laboratory
Pasick, Rena J., M.P.H.	University of California, San Francisco
Paskett, Electra D., Ph.D.	The Ohio State University
Patel, Alpa V., Ph.D., M.P.H.	American Cancer Society, Inc.
Patel, Tushar, M.B., Ch.B.	Mayo Clinic, Jacksonville
Paternostro, Giovanni, M.D., Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Paulos, Chrystal M., Ph.D.	Medical University of South Carolina
Paulovich, Amanda G., M.D., Ph.D.	Fred Hutchinson Cancer Research Center
Paulsen, Keith D., Ph.D.	Dartmouth College
Pavlidis, Ioannis, Ph.D.	The University of Houston
Pearcey, Robert G., M.D.	University of Alberta
Pearse, Roger N., M.D., Ph.D.	Weill Cornell Medical College of Cornell University
Pearson, Jennifer L., Ph.D., M.P.H.	American Legacy Foundation
Pechmann, Cornelia, Ph.D.	University Of California, Irvine
Peehl, Donna M., Ph.D.	Stanford University School of Medicine
Pegram, Mark D., M.D.	Stanford University
Peikert, Tobias, M.D.	Mayo Clinic
Pellecchia, Maurizio, Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Pence, Barbara C., Ph.D.	Texas Tech University Health Sciences Center
Peng, Guangyong, M.D., Ph.D.	Saint Louis University School of Medicine
Perelman, Lev T., Ph.D.	Beth Israel Deaconess Medical Center
Perera, Ranjan J., Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Perez, Raymond P., M.D.	University of Kansas Medical Center
Perez-Perez, Guillermo I., D.Sc.	New York University School of Medicine

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Perez-Soler, Roman, M.D.	Albert Einstein College of Medicine of Yeshiva University
Perkins, Susan M., Ph.D.	Indiana University
Perucho, Manuel, Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Peters, Edward S., D.M.D., Sc.D.	Louisiana State University Health Sciences Center
Petersen, Gloria M., Ph.D.	Mayo Clinic, Rochester
Peterson, Douglas E., D.M.D., Ph.D.	University of Connecticut School of Dental Medicine
Petricoin, Emanuel F., Ph.D.	U.S. Food and Drug Administration
Petros, John A., M.D.	Emory University
Petros, William P., Pharm.D.	West Virginia University
Petroski, Matthew, Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Petry, Nancy M., Ph.D.	University of Connecticut School of Dental Medicine
Peyton, Shelly R., Ph.D.	University of Massachusetts, Amherst
Pfeffer, Lawrence M., Ph.D.	The University of Tennessee, Memphis
Phillippy, Adam M., Ph.D.	University of Maryland, College Park
Phillips, Scott T., Ph.D.	The Pennsylvania State University, University Park
Piantadosi, Steven, M.D., Ph.D.	Cedars-Sinai Medical Center
Piazza, Gary A., Ph.D.	University of South Alabama
Piccioni, David E., M.D., Ph.D.	University of California, San Diego
Piedrahita, Jorge A., Ph.D.	North Carolina State University, Raleigh
Pieper, Russell O., Ph.D.	University of California, San Francisco
Pili, Roberto, M.D.	Roswell Park Cancer Institute
Pilz, Renate B., M.D.	University of California, San Diego
Pirisi-Creek, Lucia A., M.D.	University of South Carolina, Columbia
Platanias, Leonidas C., M.D., Ph.D.	Northwestern University
Plattner, Rina, Ph.D.	University of Kentucky
Pleasure, David E., M.D.	University of California, Davis
Plymate, Stephen R., M.D.	University of Washington
Poisson, Laila M., Ph.D.	Henry Ford Health System
Pollock, Bradley H., Ph.D., M.P.H.	The University of Texas Health Science Center at San Antonio
Pop, Mihai, Ph.D.	University of Maryland, College Park
Poplin, Elizabeth, M.D.	Rutgers, The State University of New Jersey
Pore, Nabendu, Ph.D.	MedImmune, LLC
Porter, Marc D., Ph.D.	University of Utah
Porter, Weston W., Ph.D.	Texas A&M University
Postolache, Teodor T., M.D.	University of Maryland, Baltimore
Powell, Charles A., M.D.	Icahn School of Medicine at Mount Sinai
Powell, Marianne B., Ph.D., M.P.H.	Stanford University
Prabhakar, Bellur S., Ph.D.	University of Illinois at Chicago
Pramanik, Sakti, Ph.D.	Michigan State University
Prendergast, George C., Ph.D.	Lankenau Institute for Medical Research
Priebe, Waldemar, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Prins, Gail S., Ph.D.	University of Illinois at Chicago
Prins, Jan F., Ph.D.	The University of North Carolina at Chapel Hill
Prior, Fred W., Ph.D.	Washington University in St. Louis
Prossnitz, Eric R., Ph.D.	The University of New Mexico Health Sciences Center
Prywes, Ron M., Ph.D.	Columbia University
Przytycka, Teresa M., Ph.D.	National Library of Medicine

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Puduvalli, Vinay K., M.D. The Ohio State University
Pulsipher, Michael A., M.D. University of Utah
Pumiglia, Kevin M., Ph.D. Albany Medical College

Q

Qian, Wei, Ph.D. The University of Texas at El Paso
Quaranta, Vito, M.D. University of Pennsylvania
Quarles, Christopher C., Ph.D. Vanderbilt University
Quintero, Gilbert A., Ph.D. The University of Montana
Quintiliani, Lisa M., Ph.D. Boston Medical Center

R

Raber, Jacob, Ph.D. Gladstone Institutes
Radhakrishnan, Ravi, Ph.D. University of Pennsylvania
Radich, Jerald P., M.D. Fred Hutchinson Cancer Research Center
Radisky, Derek C., Ph.D. Mayo Clinic, Jacksonville
Rae, James M., Ph.D. University of Michigan
Raffel, Glen D., M.D., Ph.D. University of Massachusetts Medical School
Rafii, Shahin, M.D. Weill Cornell Medical College of Cornell University
Raghavan, Derek, M.D., Ph.D. Carolinas Healthcare System
Rahimi, Nader, Ph.D. Boston University Medical Campus
Rajasekaran, Ayyappan K., Ph.D. Lankenau Institute for Medical Research
Ramakrishnan, Viswanathan, Ph.D. Medical University of South Carolina
Ramesh, Rajagopal, Ph.D. University of Oklahoma Health Sciences Center
Rampersaud, Arfaan, Ph.D. Columbus NanoWorks, Inc.
Rangnekar, Vivek M., Ph.D. University of Kentucky
Ransohoff, David F., M.D. The University of North Carolina at Chapel Hill
Rao, Chinthalapally V., Ph.D. University of Oklahoma Health Sciences Center
Rao, Dinesh S., M.D., Ph.D. University of California, Los Angeles
Rapkin, Bruce D., Ph.D. Albert Einstein College of Medicine of Yeshiva University
Ratajczak, Mariusz Z., M.D., Ph.D. University of Louisville
Ratliff, Timothy L., Ph.D. Purdue University
Ratnam, Manohar, Ph.D. Wayne State University
Ratner, Lee, M.D., Ph.D. Washington University in St. Louis
Raubitschek, Andrew A., M.D. City of Hope National Medical Center
Rauscher, Frank J., Ph.D. The Wistar Institute
Ray, Krishanu, Ph.D. University of Maryland, Baltimore
Ray, Ratna B., Ph.D. Saint Louis University School of Medicine
Raychaudhuri, Pradip, Ph.D. University of Illinois at Chicago
Reader, Steven, Ph.D. University of South Florida
Redd, William H., Ph.D. Icahn School of Medicine at Mount Sinai
Reddy, Kaladhar B., Ph.D. Wayne State University
Reddy, Sakamuri V., Ph.D. Medical University of South Carolina
Redmond, Carol K., Sc.D. University of Pittsburgh
Reecy, James M., Ph.D. Iowa State University
Reich, Daniel H., Ph.D. Johns Hopkins University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Rejniak, Katarzyna A., Sc.D., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Relling, Mary V., Pharm.D.	St. Jude Children’s Research Hospital
Remick, Scot C., M.D.	West Virginia University
Renne, Rolf F., Ph.D.	University of Florida
Retterer, Scott T., Ph.D.	UT-Battelle, LLC
Revzin, Alexander, Ph.D.	University of California, Davis
Reynolds, Brady A., Ph.D.	University of Kentucky
Reynolds, Brent, Ph.D.	University of Florida
Rich, Jeremy N., M.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Richards, Nigel G., Ph.D.	Indiana University–Purdue University Indianapolis
Richardson, Adam D., Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Richardson, Christine A., Ph.D.	The University of North Carolina at Charlotte
Richmond, Ann, Ph.D.	Vanderbilt University
Ridner, Sheila H., Ph.D.	Vanderbilt University
Riethman, Harold, Ph.D.	The Wistar Institute
Riggins, Gregory J., M.D., Ph.D.	Johns Hopkins University
Rigoutsos, Isidore, Ph.D.	Temple University
Riley, Barth B., Ph.D.	University of Illinois at Chicago
Riley, James L., Ph.D.	University of Pennsylvania
Rimm, David L., M.D., Ph.D.	Yale University
Risch, Harvey A., M.D., Ph.D.	Yale University
Robbiani, Melissa J., Ph.D.	The Population Council, Inc.
Robek, Michael D., Ph.D.	Yale University
Roberson, Noma L., Ph.D.	Roberson Consulting International
Roberson, Paula K., Ph.D.	University of Arkansas for Medical Sciences
Roberts, John D., M.D.	Yale University
Rocco, James W., M.D., Ph.D.	Massachusetts General Hospital
Roden, Richard B., Ph.D.	Johns Hopkins University
Rodland, Karin D., Ph.D.	Pacific Northwest National Laboratory
Roe, Denise J., Dr.P.H.	The University of Arizona
Roess, Amira A., Ph.D.	George Washington University
Rogatko, Andre, Ph.D.	Cedars-Sinai Medical Center
Rogers, Laura Q., M.D., M.P.H.	The University of Alabama at Birmingham
Rogers, Rick, Ph.D.	Harvard School of Public Health
Rohr, Jurgen T., Ph.D.	University of Kentucky
Rollins, Nancy K., M.D.	The University of Texas Southwestern Medical Center at Dallas
Romkes, Marjorie, Ph.D.	University of Pittsburgh
Rosenberg, Naomi, Ph.D.	Tufts University School of Medicine
Rosenfeld, Steven S., M.D., Ph.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Rosenman, Julian G., M.D., Ph.D.	The University of North Carolina at Chapel Hill
Rosi, Susanna, Ph.D.	University of California, San Francisco
Rossi, John J., Ph.D.	City of Hope National Medical Center
Roth, Kevin A., M.D., Ph.D.	The University of Alabama at Birmingham
Rothstein, Mark A., J.D.	University of Louisville
Roukes, Michael L., Ph.D.	California Institute of Technology
Routes, John M., M.D.	Medical College of Wisconsin

Rowan, Brian G., Ph.D.	Tulane University
Roy, Hemant K., M.D.	Boston Medical Center
Royston, Thomas J., Ph.D.	University of Illinois at Chicago
Rozek, Laura, Ph.D.	University of Michigan
Rubnitz, Jeffrey E., M.D., Ph.D.	St. Jude Children's Research Hospital
Rudd, Brian D., Ph.D., M.P.H.	Cornell University
Ruppert, John M., M.D., Ph.D.	West Virginia University
Rushton, Gerard, Ph.D.	The University of Iowa
Russo, Jose, M.D.	Fox Chase Cancer Center
Rutter, Jared P., Ph.D.	University of Utah

S

Sabbadini, Roger A., Ph.D.	Lpath, Inc.
Safa, Ahmad R., Ph.D.	Indiana University–Purdue University, Indianapolis
Said, Jonathan W., M.D.	University of California, Los Angeles
Saigal, Christopher, M.D., M.P.H.	University of California, Los Angeles
Sakr, Wael A., M.D.	Wayne State University
Salgado, Roberto, M.D.	GasthuisZusters Antwerpen Hospital
Salomon, Arthur R., Ph.D.	Brown University
Saltz, Joel H., M.D., Ph.D.	The State University of New York at Stony Brook
Salvesen, Guy S., Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Salz, Talya, Ph.D.	Memorial Sloan Kettering Cancer Center
Sanderson, Maureen, Ph.D., M.P.H.	Meharry Medical College
Sandison, George A., Ph.D.	University of Washington
Santangelo, Philip J., Ph.D.	Georgia Institute of Technology
Sargent, James D., M.D.	Dartmouth College
Sarkar, Fazlul H., Ph.D.	Wayne State University
Savage, Cary R., Ph.D.	University of Kansas Medical Center
Savaraj, Niramol, M.D.	University of Miami Miller School of Medicine
Sayeski, Peter P., Ph.D.	University of Florida
Scarpinato, Karin D., Ph.D.	University of Miami Miller School of Medicine
Schad, Peter A., Ph.D.	Digital Infuzion, Inc.
Schechter, Clyde, M.D.	Albert Einstein College of Medicine of Yeshiva University
Scheidt, Karl A., Ph.D.	Northwestern University
Schensul, Jean J., Ph.D.	Institute for Community Research
Scheurer, Michael E., Ph.D., M.P.H.	Baylor College of Medicine
Schildkraut, Joellen M., Ph.D., M.P.H.	Duke University
Schmaier, Alvin H., M.D.	Case Western Reserve University
Schmainda, Kathleen M., Ph.D.	Medical College of Wisconsin
Schmeler, Kathleen, M.D.	The University of Texas MD Anderson Cancer Center
Schmidt, Edward E., Ph.D.	Montana State University, Bozeman
Schmidt, Jeanette P., Ph.D.	Affymetrix, Inc.
Schmitz, Kathryn H., Ph.D., M.P.H.	University of Pennsylvania
Schneider, Stefan, Ph.D.	University of Southern California
Schoen, Robert E., M.D., M.P.H.	University of Pittsburgh
Schootman, Mario, Ph.D.	Saint Louis University
Schultz, Kirk R., M.D.	University of British Columbia

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Schwabe, Robert F., M.D.	Columbia University Health Sciences
Schwartz, Ann G., Ph.D., M.P.H.	Wayne State University
Schwartz, Cindy L., M.D., M.P.H.	The University of Texas MD Anderson Cancer Center
Schwartz, Joel L., D.M.D., D.Med.Sc.	University of Illinois at Chicago
Schwartz, Randy H., M.S.P.H.	American Cancer Society
Schwartz, Russell S., Ph.D.	Carnegie Mellon University
Schwertfeger, Kathryn L., Ph.D.	University of Minnesota
Scroggins, Mary J., M.A.	Consultant
Seagroves, Tiffany N., Ph.D.	The University of Tennessee Health Science Center
Seay, Thomas E., M.D., Ph.D.	St. Joseph's Hospital
Seeger, Robert C., M.D.	University of Southern California
Seewaldt, Victoria L., M.D.	Duke University
Segall, Jeffrey E., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Seiden, Michael V., M.D., Ph.D.	Fox Chase Cancer Center
Seo, Youngho, Ph.D.	University of California, San Francisco
Sepulveda, Antonia R., M.D., Ph.D.	Columbia University Medical Center
Serody, Jonathan S., M.D.	The University of North Carolina at Chapel Hill
Servan-Schreiber, Edouard, Ph.D.	MongoDB, Inc.
Seth, Prem, Ph.D.	NorthShore University HealthSystem
Sevilla, Michael D., Ph.D.	Oakland University
Sgouros, George, Ph.D.	Johns Hopkins University
Shacham, Enbal, Ph.D.	Saint Louis University
Shah, Manish A., M.D.	Weill Cornell Medical College of Cornell University
Shah, Priti R., Ph.D.	University of Michigan
Shankar, Sharmila, Ph.D.	Kansas City VA Medical Center
Shannon, Jackilen, Ph.D., M.P.H.	Oregon Health & Science University
Shao, Yiping, Ph.D.	The University of Texas MD Anderson Cancer Center
Shapiro, Erik, Ph.D.	Michigan State University
Sharifi, Nima, M.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Sharlow, Elizabeth R., Ph.D.	University of Virginia
Sharma, Dipali, Ph.D.	Johns Hopkins University
Sharma, Sherven, Ph.D.	VA Greater Los Angeles Healthcare System
Sharma, Vijay, Ph.D.	Washington University in St. Louis
Sharp, John G., Ph.D.	University of Nebraska Medical Center
Shaw, Leslie M., Ph.D.	University of Massachusetts Medical School, Worcester
Shay, Jerry W., Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Sheffer, Christine E., Ph.D.	City College of New York
Sheikh, M. Saeed, M.D., Ph.D.	The State University of New York Upstate Medical University
Shen, Lanlan, M.D., Ph.D.	Baylor College of Medicine
Shen, Zhiyuan, M.D., Ph.D.	Rutgers Biomedical and Health Sciences
Sheng, Shijie, Ph.D.	Wayne State University
Shi, Huidong, Ph.D.	Georgia Health Sciences University
Shi, Xianglin, Ph.D.	University of Kentucky
Shibata, Darryl K., M.D.	University of Southern California
Shibata, David, M.D.	H. Lee Moffitt Cancer Center & Research Institute
Shields, Anthony F., M.D., Ph.D.	Wayne State University
Shih, Ie-Ming, M.D., Ph.D.	Johns Hopkins University

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Shih, Wan Y., Ph.D.	Drexel University
Shillitoe, Edward J., Ph.D.	The State University of New York Upstate Medical University
Shin, Dong-Guk, Ph.D.	University of Connecticut, Storrs
Shin, Dong M., M.D.	Emory University
Shinohara, Russell T., Ph.D.	University of Pennsylvania
Shiramizu, Bruce T., M.D.	University of Hawaii at Manoa
Shively, John E., Ph.D.	City of Hope National Medical Center
Showe, Louise C., Ph.D.	The Wistar Institute
Shreffler, Wayne G., M.D., Ph.D.	Massachusetts General Hospital
Shroyer, Kenneth R., M.D., Ph.D.	The State University of New York at Stony Brook
Shuler, Michael L., Ph.D.	Cornell University
Shureiqi, Imad, M.D.	The University of Texas MD Anderson Cancer Center
Sibinga, Erica M.S., M.D.	Johns Hopkins University
Siegfried, Jill M., Ph.D.	University of Minnesota
Sill, Alan F., Ph.D.	Texas Tech University
Silver, Robert B., Ph.D.	Syracuse University
Simard, Edgar P., Ph.D., M.P.H.	Columbia University Medical Center
Simberg, Dimitri, Ph.D.	University of Colorado Denver
Singh, Karan P., Ph.D.	The University of Alabama at Birmingham
Singh, Keshav K., Ph.D.	The University of Alabama at Birmingham
Singh, Shailesh, Ph.D.	Morehouse School of Medicine
Singh, Shivendra, Ph.D.	University of Pittsburgh
Sinko, Patrick J., Ph.D.	Rutgers, The State University of New Jersey
Sirover, Michael A., Ph.D.	Temple University
Siu, Lillian L., M.D.	University Health Network
Slager, Susan L., Ph.D.	Mayo Clinic
Slattery, Martha L., Ph.D., M.P.H.	Signature HealthCare
Sloan, Andrew E., M.D.	Case Western Reserve University
Sloan, Jeff S., Ph.D.	Mayo Clinic
Slovin, Susan F., M.D., Ph.D.	Memorial Sloan Kettering Cancer Center
Small, Eric J., M.D.	University of California, San Francisco
Smalley, Keiran, Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Smela, Elisabeth, Ph.D.	University of Maryland, College Park
Smith, Franklin O., M.D.	University of Cincinnati
Smith, Jennifer S., Ph.D., M.P.H.	The University of North Carolina at Chapel Hill
Smith, Kevin M., Ph.D.	Louisiana State University
Smithgall, Thomas E., Ph.D.	University of Pittsburgh
Smogorzewska, Agata, M.D., Ph.D.	Rockefeller University
Soellner, Matthew B., Ph.D.	University of Michigan
Sofou, Stavroula, Ph.D.	Rutgers, The State University of New Jersey
Soh, Hyongsok T., Ph.D.	University of California, Santa Barbara
Sohn, Lydia L., Ph.D.	University of California, Berkeley
Soker, Shay, Ph.D.	Wake Forest University Health Sciences Center
Soliman, Amr, M.D., Ph.D., M.P.H.	University of Nebraska Medical Center
Song, Chang W., Ph.D.	University of Minnesota
Soper, Steven A., Ph.D.	The University of North Carolina at Chapel Hill
Sorkin, Alexander D., Ph.D.	University of Pittsburgh
Sowers, Lawrence C., Ph.D.	The University of Texas Medical Branch at Galveston

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Sparano, Joseph A., M.D.	Albert Einstein College of Medicine of Yeshiva University
Sparreboom, Alexander, Ph.D.	St. Jude Children’s Research Hospital
Spiegelman, Vladimir S., M.D., Ph.D.	University of Wisconsin, Madison
Spitz, Douglas R., Ph.D.	The University of Iowa
Spring, Bonnie, Ph.D.	Northwestern University at Chicago
Spruck, Charles H., Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Srivastava, Rakesh K., Ph.D.	University of Kansas Medical Center
Srivastava, Sanjay K., Ph.D.	Texas Tech University Health Sciences Center
Stadler, Walter M., M.D.	The University of Chicago
Staff, Nathan P., M.D., Ph.D.	Mayo Clinic
Staley, Charles A., M.D.	Emory University
Stampfer, Meir, M.D., M.P.H.	Harvard School of Public Health
Standish, Leanna J., Ph.D.	Bastyr University
Staveley-O’Carroll, Kevin F., M.D., Ph.D.	Penn State Milton S. Hershey Medical Center
Stein, Gary S., Ph.D.	The University of Vermont and State Agricultural College
Steinle, Nanette I., M.D.	University of Maryland, Baltimore
Stern, David F., Ph.D.	Yale University
Stern, Mariana C., Ph.D.	University of Southern California
Stevens, Victoria L., Ph.D.	American Cancer Society, Inc.
Stewart, Clinton F., Pharm.D.	St. Jude Children’s Research Hospital
Stiff, Patrick J., M.D.	Loyola University, Chicago
Stiles, Bangyan, Ph.D.	University of California, Los Angeles
Stoecker, William V., M.D.	Stoecker & Associates
Stone, Michael P., Ph.D.	Vanderbilt University
Stoner, Gary, Ph.D.	Medical College of Wisconsin
Stork, Linda C., M.D.	Oregon Health & Science University
Storkus, Walter J., Ph.D.	University of Pittsburgh
Strasser, Andrew, Ph.D.	University of Pennsylvania
Strome, Scott E., M.D.	University of Maryland, Baltimore
Strongin, Robert M., Ph.D.	Portland State University
Studzinski, George P., M.D., Ph.D.	Rutgers Biomedical and Health Sciences
Stupack, Dwayne G., Ph.D.	University of California, San Diego
Sturgeon, Susan R., M.P.H.	University of Massachusetts, Amherst
Sudarshan, Tirumalai S., Ph.D.	Materials Modification, Inc.
Sumner, Susan J., Ph.D.	RTI International
Sun, Duxin, Ph.D.	University of Michigan
Sun, Wei, Ph.D.	The University of North Carolina at Chapel Hill
Sun, Xiankai, Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Sunderland, John, Ph.D.	The University of Iowa
Sutcliffe, Julie L., Ph.D.	University of California, Davis
Sutkowski, Natalie A., Ph.D.	Medical University of South Carolina
Suto, Mark J., Ph.D.	Omneuron, Inc.
Suva, Larry J., Ph.D.	University of Arkansas for Medical Sciences
Swaminathan, Sankar, M.D.	University of Utah
Swamy, Manjunath N., M.D.	Texas Tech University Health Sciences Center
Swanson, Basil I., M.D., Ph.D.	Los Alamos National Laboratory
Swanson, Kristin R., Ph.D.	Northwestern University
Swartz, Harold M., M.D., Ph.D.	Dartmouth College

Sweasy, Joann B., Ph.D. University of Washington
 Swinnen, Lode, M.D. Johns Hopkins University
 Syeda-Mahmood, Tanveer F., Ph.D. IBM Research, Almaden
 Synold, Timothy W., Pharm.D. City of Hope National Medical Center

T

Tackett, Alan J., Ph.D. University of Arkansas for Medical Sciences
 Taichman, Russell S., D.M.D., D.M.Sc. University of Michigan
 Taioli, Emanuela, M.D., Ph.D. Icahn School of Medicine at Mount Sinai
 Tamimi, Rulla M., Sc.D. Brigham and Women’s Hospital
 Tan, Ming, M.D., Ph.D. University of South Alabama
 Tan, Ming T., Ph.D. Georgetown University
 Tang, Keqi, Ph.D. Pacific Northwest National Laboratory
 Tanjasiri, Sora P., M.P.H. California State University, Fullerton
 Tannenbaum, Charles S., Ph.D. Cleveland Clinic Lerner College of Medicine
 of Case Western Reserve University
 Tannous, Bakhos A., Ph.D. Massachusetts General Hospital
 Tautz, Lutz, Ph.D. Sanford Burnham Prebys Medical Discovery Institute
 Taxman, Faye S., Ph.D. George Mason University
 Taylor, Jeremy M.G., Ph.D. University of Michigan
 Tearney, Guillermo J., M.D., Ph.D. Massachusetts General Hospital
 Tekmal, Rajeshwar R., Ph.D. The University of Texas Health Science Center at San Antonio
 Telleria, Carlos M., Ph.D. University of South Dakota
 Tempst, Paul, Ph.D. Memorial Sloan Kettering Cancer Center
 Ten Haken, Randall K., Ph.D. University of Michigan
 Terrazas, Alejandro, Ph.D. Nielsen Engineering and Research, Inc.
 Terry, Mary B., Ph.D. Columbia University Medical Center
 Teter, Kenneth R., Ph.D. University of Colorado Denver
 Tew, Kenneth D., D.Sc., Ph.D. Medical University of South Carolina
 Tewari, Muneesh, M.D., Ph.D. University of Michigan
 Thaler, Joshua P., M.D., Ph.D. University of Washington
 Thangaraju, Muthusamy, Ph.D. Georgia Health Sciences University
 Thiagalingam, Sam, Ph.D. Boston University Medical Campus
 Thomas, David B., M.D. Fred Hutchinson Cancer Research Center
 Thomas, Douglas D., Ph.D. University of Illinois at Chicago
 Thomas-Tikhonenko, Andrei, Ph.D. Children’s Hospital of Philadelphia
 Thompson, Cheryl L., Ph.D. Case Western Reserve University
 Thompson-Carino, Patricia A., Ph.D. Stony Brook University School of Medicine
 Thorburn, Andrew M., Ph.D. University of Colorado Denver
 Thorne, Leigh B., M.D. The University of North Carolina at Chapel Hill
 Threadgill, David W., Ph.D. Texas A&M University Health Science Center
 Tilley, Barbara C., Ph.D. The University of Texas Health Science Center at Houston
 Titler, Marita G., Ph.D. University of Michigan
 Toker, Alex, Ph.D. Beth Israel Deaconess Medical Center
 Tolcher, Anthony W., M.D. South Texas Accelerated Research Therapeutics
 Tomar, Scott L., M.P.H. University of Florida
 Tomlin, Claire J., Ph.D. Stanford University

Tomlinson, Gail E., M.D., Ph.D. The University of Texas Health Science Center at Houston
 Torres-Vazquez, Jesus, Ph.D. New York University School of Medicine
 Towner, Rheal A., Ph.D. Oklahoma Medical Research Foundation
 Tran, Phuoc T., M.D., Ph.D. Johns Hopkins University
 Travis, Lois B., M.D. University of Rochester
 Triche, Timothy J., M.D., Ph.D. Children’s Hospital of Los Angeles
 Troester, Melissa A., Ph.D., M.P.H. University of Massachusetts, Amherst
 Trojanowska, Maria T., Ph.D. Boston University Medical Campus
 Tropsha, Alexander, Ph.D. The University of North Carolina at Chapel Hill
 Trudeau, Kimberlee J., Ph.D. Inflexxion, Inc.
 True, Lawrence D., M.D. University of Washington
 Tumiel-Berhalter, Laurene M., Ph.D. The State University of New York at Buffalo
 Turchi, John J., Ph.D. Indiana University
 Turker, Mitchell S., Ph.D. Oregon Health & Science University
 Turner, Jessica, Ph.D. Georgia State University
 Turner, Stephen W., Ph.D. Pacific Biosciences of California, Inc.
 Tuthill, Theresa A., Ph.D. University of Michigan
 Tyner, Angela L., Ph.D. University of Illinois at Chicago
 Tyner, Jeffrey W., Ph.D. Oregon Health & Science University
 Tyson, John J., Ph.D. Virginia Polytechnic Institute and State University

V

Vadaparampil, Susan T., Ph.D., M.P.H. H. Lee Moffitt Cancer Center & Research Institute
 Vadlamudi, Ratna K., Ph.D. The University of Texas Health Science Center at Houston
 Valenzuela, Manuel S., Ph.D. Meharry Medical College
 Van Besien, Koen W., M.D., Ph.D. Weill Cornell Medical College of Cornell University
 Van Breemen, Richard B., Ph.D. University of Illinois at Chicago
 Vanderah, Todd W., Ph.D. The University of Arizona
 Vanderheyden, Jean-Luc E., Ph.D. JLVMI Consulting
 Van Meir, Erwin G., Ph.D. Emory University
 Vannier, Michael W., M.D. The University of Chicago
 Varghese, Sheelu, Ph.D. University of Maryland, Baltimore
 Varki, Nissi M., M.D. University of California, San Diego
 Vaughan, Andrew T., Ph.D. University of California, Davis
 Vaughan, Thomas L., M.D., M.P.H. Fred Hutchinson Cancer Research Center
 Venook, Alan P., M.D. University of California, San Francisco
 Vera, David R., Ph.D. University of California, San Diego
 Verardi, Paulo H., Ph.D. University of Connecticut
 Verbridge, Scott S., Ph.D. Virginia Polytechnic Institute and State University
 Verma, Amit, M.D. Albert Einstein College of Medicine of Yeshiva University
 Vernon, Sally W., Ph.D. The University of Texas Health Science Center at Houston
 Verschraegen, Claire F., M.D. The University of Vermont and State Agricultural College
 Vessella, Robert L., Ph.D. University of Washington
 Viator, John A., Ph.D. Duquesne University
 Vile, Richard G., Ph.D. Mayo Clinic
 Villinger, Francois J., Ph.D. Emory University
 Vogel, Carl-Wilhelm E., M.D., Ph.D. University of Hawaii at Manoa

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Volk, Robert J., Ph.D. The University of Texas MD Anderson Cancer Center
von Gunten, Charles F., M.D., Ph.D. OhioHealth Research Institute
Von Roenn, Jamie H., M.D. American Society of Clinical Oncology

W

Wachsman, William, M.D., Ph.D. University of California, San Diego
Wagner, David H., Ph.D. University of Colorado Denver
Wagner, Kay-Uwe, Ph.D. University of Nebraska Medical Center
Wahl, Richard L., M.D. Johns Hopkins University
Walker, Joan L., M.D. University of Oklahoma Health Sciences Center
Waller, Edmund K., M.D., Ph.D. Emory University
Walton, S. Patrick., Sc.D. Michigan State University
Wan, Yu-Jui Y., Ph.D. University of California, Davis
Wang, Chun, Ph.D. University of Minnesota
Wang, Denong, Ph.D. SRI International
Wang, Edwin, Ph.D. National Research Council Canada
Wang, Hong-Gang, Ph.D. Penn State Milton S. Hershey Medical Center
Wang, Judy H., Ph.D. Georgetown University
Wang, Kenneth K., M.D. Mayo Clinic
Wang, Liang, Ph.D. Medical College of Wisconsin
Wang, Lisa L., M.D. Baylor College of Medicine
Wang, Qiming J., Ph.D. University of Pittsburgh
Wang, Rong, Ph.D. Illinois Institute of Technology
Wang, Shaopeng, Ph.D. Arizona State University, Tempe
Wang, Sophia S., Ph.D. City of Hope National Medical Center
Wang, Tian-Li, Ph.D. Johns Hopkins University
Wang, Tza-Huei, Ph.D. Johns Hopkins University
Wang, Xiao-Fan, Ph.D. Duke University
Wang, Yingxiao, Ph.D. University of California, San Diego
Wang, Zhenghe, Ph.D. Case Western Reserve University
Ward, Dianne S., Ed.D. The University of North Carolina at Chapel Hill
Ward, John H., M.D. University of Utah
Ware, Carl F., Ph.D. Sanford Burnham Prebys Medical Discovery Institute
Warren, Christopher L., Ph.D. Florida International University
Warren, Graham W., M.D., Ph.D. Medical University of South Carolina
Washington, Mary K., M.D., Ph.D. Vanderbilt University
Wasik, Mariusz A., M.D. University of Pennsylvania
Watkins, Stephanie K., Ph.D. Loyola University, Chicago
Watson, Dennis K., Ph.D. Medical University of South Carolina
Wattenberg, Brian W., Ph.D. University of Louisville
Weaver, Alissa M., M.D., Ph.D. Vanderbilt University
Webb, Tonya J., Ph.D. University of Maryland, Baltimore
Weber, Michael J., Ph.D. University of Virginia
Weber, Patricia C., Ph.D. Imiplex, LLC
Weekes, Colin, M.D., Ph.D. University of Colorado Denver
Wei, Alexander, Ph.D. Purdue University
Weidhaas, Joanne B., M.D., Ph.D. University of California, Los Angeles

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Weier, Heinz-Ulrich G., Ph.D.	Lawrence Berkeley National Laboratory
Weinberg, Armin D., Ph.D.	Life Beyond Cancer Foundation
Weinberg, David S., M.D., M.Sc.	Fox Chase Cancer Center
Weiner, George J., M.D.	The University Of Iowa
Weiner, Louis M., M.D.	Georgetown University
Weiner, Roy S., M.D.	Tulane University
Weinmann, Sheila A., Ph.D., M.P.H.	Kaiser Foundation Research Institute
Weiss, Eta B., Ed.D.	The University of Alabama at Birmingham
Weiss, Geoffrey R., M.D.	University of Virginia
Weiss, Gregory A., Ph.D.	University of California, Irvine
Weiss, Heidi L., Ph.D.	University of Kentucky
Weiss, Stephen M., Ph.D.	University of Miami Miller School of Medicine
Weiss, William A., M.D., Ph.D.	University of California, San Francisco
Weissfeld, Joel L., M.D., M.P.H.	University of Pittsburgh
Welch, Danny R., Ph.D.	University of Kansas Medical Center
Wells, Alan, M.D.	University of Pittsburgh
Wellstein, Anton, M.D., Ph.D.	Georgetown University
Welsh, Joellen, Ph.D.	The State University of New York at Albany
Werahera, Priya N., Ph.D.	University of Colorado Denver
West, Dee W., Ph.D.	Public Health Institute
West, Robert B., M.D., Ph.D.	Stanford University
Wetzler, Meir, M.D.	Roswell Park Cancer Institute
Whang, Young E., M.D., Ph.D.	The University of North Carolina at Chapel Hill
Whartenby, Katharine A., Ph.D.	Johns Hopkins University
Wheeler, Barbara L., Ph.D.	Molloy College
White, Forest M., Ph.D.	Massachusetts Institute of Technology
deVere White, Ralph W., M.D.	University of California, Davis
White, Richard M., M.D., Ph.D.	Memorial Sloan Kettering Cancer Center
Whiteside, Theresa L., Ph.D.	University of Pittsburgh
Whitley, Richard J., M.D.	The University of Alabama at Birmingham
Whitt, Michael A., Ph.D.	The University of Tennessee Health Science Center
Whittemore, Alice, Ph.D.	Stanford University
Wieder, Robert, M.D., Ph.D.	Rutgers, The State University of New Jersey
Wigdahl, Brian, Ph.D.	Drexel University College of Medicine
Willett, Christopher G., M.D.	Duke University
Willett, Walter C., M.D., M.P.H.	Harvard School of Public Health
Willey, James C., M.D.	University of Toledo Medical Center
Williams, David A., M.D.	Children’s Hospital Corporation
Williams, Donna L., M.P.H.	Louisiana State University Health Sciences Center, New Orleans
Williams, John C., Ph.D.	City of Hope National Medical Center
Williams, Scott M., Ph.D.	Dartmouth College
Williamson, Jeffrey F., Ph.D.	Virginia Commonwealth University
Williamson, Stephen K., M.D.	University of Kansas Medical Center
Wilson, Brian C., Ph.D.	University of Toronto
Wilson, James N., Ph.D.	University of Miami Miller School of Medicine
Wilson, Thaddeus A., Ph.D.	The University of Tennessee Health Science Center
Windle, Jolene J., Ph.D.	Virginia Commonwealth University
Wingard, John R., M.D.	University of Florida

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Winter, Stuart S., M.D.	The University of New Mexico
Wish, Eric D., Ph.D.	University of Maryland, College Park
Wisnivesky, Juan P., M.D., M.P.H.	Icahn School of Medicine at Mount Sinai
Wolf, Wendy A., Ph.D.	Children's Hospital Corporation
Wollenweber, Scott D., Ph.D.	Wake Forest University Health Sciences & Baptist Medical Center
Woloschak, Gayle E., Ph.D.	Northwestern University
Wondrak, Georg T., Ph.D.	The University of Arizona
Wong, David T., D.M.D., D.M.Sc.	University of California, Los Angeles
Wong, Lee-Jun C., Ph.D.	Baylor College of Medicine
Wong, Lucas, M.D.	Scott and White Memorial Hospital
Wong, Richard J., M.D.	Memorial Sloan Kettering Cancer Center
Wood, Marie E., M.D.	The University of Vermont and State Agricultural College
Woods, Erik J., Ph.D.	General Biotechnology, LLC
Woods, William G., M.D.	Children's Healthcare of Atlanta, Inc.
Woodward, Wendy A., M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Worsham, Maria J., Ph.D.	Henry Ford Health System
Woster, Patrick M., Ph.D.	Medical University of South Carolina
Wright, Dennis L., Ph.D.	University of Connecticut, Storrs
Wu, Catherine J., M.D.	Dana-Farber Cancer Institute
Wu, Dianqing, Ph.D.	Yale University
Wu, Gen S., Ph.D.	Wayne State University
Wu, Guojun, Ph.D.	Wayne State University
Wu, Jennifer D., Ph.D.	Medical University of South Carolina
Wu, Mingming, Ph.D.	Cornell University
Wu, Thomas D., M.D., Ph.D.	Genentech, Inc.
Wu, Tzyy-Choou, M.D., Ph.D., M.P.H.	Johns Hopkins University
Wu, Xifeng, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Wyatt, Michael D., Ph.D.	University of South Carolina

X

Xi, Yaguang, M.D., Ph.D.	University of South Alabama
Xiao, Gutian, Ph.D.	University of Pittsburgh
Xiao, Hua, M.D., Ph.D.	Michigan State University
Xie, Jingwu, Ph.D.	Indiana University–Purdue University, Indianapolis
Xie, Keping, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Xu, Dong, Ph.D.	University of Missouri
Xu, Liang, M.D., Ph.D.	University of Kansas
Xu, Xiangxi M., Ph.D.	University of Miami Miller School of Medicine
Xu, Xiaowei, M.D., Ph.D.	University of Pennsylvania
Xu, Yan, Ph.D.	Indiana University–Purdue University, Indianapolis
Xuan, Jason J., Ph.D.	Virginia Polytechnic Institute and State University

Y

Yamamoto, Masato, M.D., Ph.D.	University of Minnesota
Yamashiro, Darrell J., M.D., Ph.D.	Columbia University Health Sciences Campus

Yamashita, Yukiko, Ph.D.	University of Michigan
Yan, Hai, M.D., Ph.D.	Duke University
Yang, Chung S., Ph.D.	Rutgers, The State University of New Jersey
Yang, Hu, Ph.D.	Virginia Commonwealth University
Yang, Lily, M.D., Ph.D.	Emory University
Yang, Vincent W., M.D., Ph.D.	The State University of New York at Stony Brook
Yang, Wancai, M.D.	University of Illinois at Chicago
Yang, Xiaowei, Ph.D.	Bayessoft, Inc.
Yannelli, John R., Ph.D.	University of Kentucky
Ybarra, Michele, Ph.D., M.P.H.	Center for Innovative Public Health Research
Yee, Douglas, M.D.	University of Minnesota
Yeh, Jen J., M.D.	The University of North Carolina at Chapel Hill
Yen, Yun, M.D., Ph.D.	City of Hope National Medical Center
Yeo, Yoon, Ph.D.	Purdue University
Yeudall, William A., Ph.D.	Virginia Commonwealth University
Yi, Qing, M.D., Ph.D.	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Yi, Richard, Ph.D.	University of Maryland, College Park
Ying, Shao-Yao, Ph.D.	University of Southern California
Yothers, Greg, Ph.D.	University of Pittsburgh
Young, Damian W., Ph.D.	Baylor College of Medicine
Young, James W., M.D.	Memorial Sloan Kettering Cancer Center
Young, Jeanne P., B.A.	Childhood Brain Tumor Foundation
Yu, Cedric X., D.Sc.	University of Maryland, Baltimore
Yu, Dihua, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Yu, Qin, Ph.D.	Icahn School of Medicine at Mount Sinai
Yu, Weikuan, Ph.D.	Auburn University at Auburn
Yu, Xue-Zhong, M.D.	Medical University of South Carolina
Yuan, Zhi-Min, M.D., Ph.D.	The University of Texas Health Science Center at San Antonio
Yun, Changhyon C., Ph.D.	Emory University

Z

Zacharias, Wolfgang, Ph.D.	University of Louisville
Zahrbock, Cary A.C., M.S.W.	National Coalition for Cancer Survivorship
Zaia, John A., M.D.	City of Hope National Medical Center
Zaia, Joseph, Ph.D.	Boston University Medical Campus
Zarbl, Helmut, Ph.D.	Rutgers Biomedical and Health Sciences
Zaren, Howard A., M.D.	St. Joseph's/Candler Health System, Inc.
Zarour, Hassane M., M.D.	University of Pittsburgh
Zehnder, James L., M.D.	Stanford University
Zeleniuch-Jacquotte, Anne, M.D.	New York University School of Medicine
Zelevnik-Le, Nancy J., Ph.D.	Loyola University, Chicago
Zhang, David Y., M.D., Ph.D., M.P.H.	Icahn School of Medicine at Mount Sinai
Zhang, Donna D., Ph.D.	The University of Arizona
Zhang, Huang-Ge, D.V.M., M.D., Ph.D.	The University of Alabama at Birmingham
Zhang, Hui, Ph.D.	Johns Hopkins University
Zhang, Lin, M.D.	University of Pennsylvania

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Zhang, Lin, Ph.D.	University of Pittsburgh
Zhang, Ming, Ph.D.	Northwestern University
Zhang, Ruiwen, M.D., Ph.D.	Texas Tech University Health Sciences Center
Zhang, Xiao-Kun, Ph.D.	Krex Pharmaceuticals, Inc.
Zhang, Xiaoliu, M.D., Ph.D.	University of Houston
Zhang, Zhiguo, Ph.D.	Mayo Clinic
Zhang, Zhong-Yin, Ph.D.	Indiana University–Purdue University, Indianapolis
Zhao, Dawen, M.D., Ph.D.	The University of Texas Southwestern Medical Center at Dallas
Zhao, Ming, Ph.D.	Northwestern University
Zhao, Shaying, Ph.D.	The University of Georgia
Zheng, Bin, Ph.D.	The University of Oklahoma
Zheng, Gang, Ph.D.	University Health Network
Zheng, Tongzhang, M.D.	Yale University
Zheng, Wei, M.D., Ph.D., M.P.H.	Vanderbilt University
Zheng, Xiaofeng S., Ph.D.	Rutgers Biomedical and Health Sciences
Zhou, Jin-Rong, Ph.D.	Beth Israel Deaconess Medical Center
Zhou, Pengbo, Ph.D.	Weill Cornell Medical College of Cornell University
Zhu, Liang, M.D., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Zhu, Shu-Hong, Ph.D.	University of California, San Diego
Zhu, Weimo, Ph.D.	University of Illinois at Urbana-Champaign
Zhu, Wenge, Ph.D.	George Washington University
Zhu, Xiaofeng, Ph.D.	Case Western Reserve University
Zhu, Yong, Ph.D.	Yale University
Zhu, Zongjian, M.D., Ph.D.	Colorado State University
Zimmers, Teresa A., Ph.D.	Indiana University–Purdue University, Indianapolis
Zlotnik, Albert, Ph.D.	University of California, Irvine
Zondlo, Neal J., Ph.D.	University of Delaware
Zong, Wei-Xing, Ph.D.	The State University of New York at Stony Brook
Zou, Weiping, M.D., Ph.D.	University of Michigan
Zu, Youli, M.D., Ph.D.	The Methodist Hospital Research Institute
Zuna, Rosemary E., M.D.	University of Oklahoma Health Sciences Center

Total Number of Reviewers: 2,098

Appendix E: NCI Grant Mechanisms and Descriptions

Below is a brief description of different NIH funding mechanisms. Additional information on grants, contracts, and extramural policy notices may be

found by viewing the NCI DEA Web page on Grants Guidelines and Descriptions at <http://deainfo.nci.nih.gov/flash/awards.htm>.

C Series: Research Construction Programs	
C06	<p>Research Facilities Construction Grants</p> <p>To provide matching Federal funds, up to 75 percent, for construction or major remodeling to create new research facilities, which in addition to basic research laboratories may include, under certain circumstances, animal facilities and/or limited clinical facilities where they are an integral part of an overall research effort.</p>
D Series: Institutional Training and Director Program Projects	
D43	<p>International Training Grants in Epidemiology</p> <p>To improve and expand epidemiologic research and the utilization of epidemiology in clinical trials and prevention research in foreign countries through support of training programs for foreign health professionals, technicians, and other health care workers.</p>
DP1	<p>NIH Director's Pioneer Award (NDPA)</p> <p>To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director's Pioneer Award is not renewable.</p>
DP2	<p>NIH Director's New Innovator Awards</p> <p>To support highly innovative research projects by new investigators in all areas of biomedical and behavioral research.</p>
F Series: Fellowship Programs	
F30	<p>Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral M.D./Ph.D. Degree Fellows</p> <p>To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).</p>
F31	<p>Ruth L. Kirschstein National Research Service Award for Predoctoral Individuals</p> <p>To provide predoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.</p>
F32	<p>Ruth L. Kirschstein National Research Service Award for Individual Postdoctoral Fellows</p> <p>To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.</p>
F33	<p>Ruth L. Kirschstein National Research Service Award for Senior Fellows</p> <p>To provide opportunities for experienced scientists to make major changes in the direction of research careers, broaden scientific backgrounds, acquire new research capabilities, enlarge command of an allied research field, or take time from regular professional responsibilities to increase capabilities to engage in health-related research.</p>

K Series: Career Development Programs	
K01	<p>The Howard Temin Award (no longer supported through use of the K01 by the NCI; see the K99/R00)</p> <p>A previously used NCI-specific variant of the NIH Mentored Research Scientist Development Award that was designed to provide research scientists with an additional period of sponsored research experience as a way to gain expertise in a research area new to the applicant or in an area that would demonstrably enhance the applicant's scientific career.</p>
K01	<p>Mentored Career Development Award for Underrepresented Minorities</p> <p>To support scientists committed to research who are in need of both advanced research training and additional experience.</p>
K05	<p>Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population Research</p> <p>To support scientists qualified to pursue independent research that would extend the research program of the sponsoring institution, or to direct an essential part of this program.</p>
K07	<p>Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award</p> <p>To support the postdoctoral career development of investigators who are committed to academic research careers in cancer prevention, control, behavioral, epidemiological, and/or the population sciences. It supports up to 5 years of combined didactic and supervised (i.e., mentored) research experiences to acquire the methodological and theoretical research skills needed to become an independent scientist. The very broad nature of the prevention, control, and population sciences makes it applicable to those individuals doctorally trained in the basic sciences, medicine, behavioral sciences, and/or public health. The K07 award has been expanded from a scope limited to "preventive oncology" to include the entire spectrum of fields that are of vital importance to cancer prevention and control such as nutrition, epidemiology, and behavioral sciences.</p>
K08	<p>Mentored Clinical Scientists Development Award</p> <p>To provide the opportunity for promising medical scientists with demonstrated aptitude to develop into independent investigators, or for faculty members to pursue research in categorical areas applicable to the awarding unit, and to aid in filling the academic faculty gap in specific shortage areas within U.S. health professions institutions.</p>
K08	<p>Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology</p> <p>A specialized type of Mentored Clinical Scientist Developmental Award (K08) that supports the development of outstanding clinical research scientists, with this type being reserved for qualified individuals from underrepresented minority groups. Both types of K08 awards support periods of specialized study for clinically trained professionals who are committed to careers in research and who have the potential to develop into independent investigators. The K08 awards for Minorities in Clinical Oncology are distinct and important because they provide opportunities for promising medical scientists with demonstrated aptitudes who belong to underrepresented minority groups to develop into independent investigators, or for faculty members who belong to underrepresented minority groups to pursue research aspects of categorical areas applicable to the awarding unit(s), and aid in filling the academic faculty gaps in these shortage areas within U.S. health professions institutions.</p>

K12	Institutional Clinical Oncology Research Career Development Award To support a newly trained clinician appointed by an institution for development of independent research skills and experience in a fundamental science within the framework of an interdisciplinary research and development program.
K18	The Career Enhancement Award Provides either full-time or part-time support for experienced scientists who would like to broaden their scientific capabilities or to make changes in their research careers by acquiring new research skills or knowledge. Career enhancement experiences supported by this award should usually last no more than 1 year.
K22	The NCI Transition Career Development Award for Underrepresented Minorities To provide support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.
K22	The NCI Scholars Program To provide an opportunity for outstanding new investigators to begin their independent research careers, first within the special environment of the NCI and then at an institution of their choice. Specifically, this program provides necessary resources to initiate an independent research program of 3 to 4 years at the NCI, followed by an extramural funding mechanism (K22) to support their research program for 2 years at the extramural institution to which they are recruited.
K23	Mentored Patient-Oriented Research Career Development Award To provide support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.
K23	Mentored Patient-Oriented Research Career Development Award for Underrepresented Minorities To support the career development of investigators who have made a commitment to focus their research on patient-oriented research. This mechanism provides support for a period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators in patient-oriented research.
K24	Mid-Career Investigator Award in Patient-Oriented Research To provide support for clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators. The target candidates are outstanding clinical scientists engaged in patient-oriented research who are within 15 years of their specialty training, who can demonstrate the need for a period of intensive research focus as a means of enhancing their clinical research careers, and who are committed to mentoring the next generation of clinical investigators in patient-oriented research.

K25	Mentored Quantitative Research Career Development Award This award allows an independent scientist in a highly technical field of research to identify an appropriate mentor with extensive experience in cancer research and to receive the necessary training and career development required to become involved in multidisciplinary cancer research.
K99/ R00	NIH Pathway to Independence (PI) Award The Pathway to Independence Award, which is part of the NIH Roadmap Initiative but is known as the Howard Temin Award within the NCI, will provide up to 5 years of support consisting of two phases. The initial phase will provide 1 to 2 years of mentored support for highly promising postdoctoral research scientists. This phase will be followed by up to 3 years of independent support contingent on securing an independent research position. Award recipients will be expected to compete successfully for independent R01 support from the NIH during the career transition award period. The PI Award is limited to postdoctoral trainees within 5 years of completion of their training who propose research relevant to the mission of one or more of the participating NIH Institutes and Centers.
L Series: Loan Repayment Program	
L30	Loan Repayment Program for Clinical Researchers To provide for the repayment of the educational loan debt of qualified health professionals involved in clinical research. Qualified health professionals who contractually agree to conduct qualified clinical research are eligible to apply for this program.
L32	Loan Repayment Program for Clinical Researchers From Disadvantaged Backgrounds To provide for the repayment of the educational loan debt of qualified health professionals from disadvantaged backgrounds involved in clinical research. Qualified health professionals from disadvantaged backgrounds who contractually agree to conduct qualified clinical research are eligible to apply for this program.
L40	Loan Repayment Program for Pediatric Research To provide for the repayment of the educational loan debt of qualified health professionals involved in research directly related to diseases, disorders, and other conditions in children. Qualified health professionals who contractually agree to conduct qualified pediatric research are eligible to apply for this program. (See the NIH Guidelines about Loan Repayment at http://www.lrp.nih.gov/index.aspx .)
L50	Loan Repayment Program for Contraception and Infertility Research To provide for the repayment of the educational loan debt of qualified health professionals (including graduate students) who contractually agree to commit to conduct qualified contraception and/or infertility research.
L60	Loan Repayment Program for Health Disparities Research To provide for the repayment of the educational loan debt of qualified health professionals involved in minority health and health disparities research, for the purposes of improving minority health and reducing health disparities. Qualified health professionals who contractually agree to conduct qualified minority health disparities research or other health disparities research are eligible to apply for this program.

P Series: Research Program Projects and Centers	
P01	<p>Research Program Projects</p> <p>To support multidisciplinary or multifaceted research programs that have a focused theme. Each component project should be directly related to and contribute to the common theme.</p>
P20	<p>Exploratory Grants</p> <p>To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.</p>
P30	<p>Center Core Grants</p> <p>To support shared use of resources and facilities for categorical research by investigators from different disciplines who provide a multidisciplinary approach to a joint research effort, or by investigators from the same discipline who focus on a common research problem. The core grant is integrated with the Center's component projects or Program Projects, though funded independently from them. By providing more accessible resources, this support is expected to ensure greater productivity than that provided through the separate projects and Program Projects.</p>
P41	<p>Biotechnology Resource Grants</p> <p>To support biotechnology resources available to all qualified investigators without regard to the scientific disciplines or disease orientations of their research activities or specifically directed to a categorical program area.</p>
P50	<p>Specialized Center Grants</p> <p>To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. This spectrum of activities comprises a multidisciplinary attack on a specific disease or biomedical problem area. These grants differ from Program Project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division, and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.</p>

R Series: Research Projects	
R01	<p>Research Project</p> <p>Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific focus or objective in his or her area of interest and competence. Institutional sponsorship assures the NIH that the institution will provide facilities necessary to conduct the research and will be accountable for the grant funds. Applications are accepted for health-related research and development in all areas within the scope of the NIH's mission.</p>
R03	<p>Small Research Grants</p> <p>Small grants provide research support, specifically limited in time and amount, for activities such as pilot projects, testing of new techniques, or feasibility studies of innovative, high-risk research, which would provide a basis for more extended research.</p>
R13	<p>Conferences</p> <p>The NIH provides funding for conferences to coordinate, exchange, and disseminate information related to its program interests. Generally, such awards are limited to participation with other organizations in supporting conferences rather than provision of sole support. Costs eligible for support include salaries, consultant services, equipment rental, travel, supplies, conference services, and publications. Prospective applicants are encouraged to inquire in advance concerning possible interest on the part of an awarding Institute/Center (IC), and to obtain more information on application procedures and costs.</p>
R15	<p>The NIH Academic Research Enhancement Awards (AREA)</p> <p>To enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds, this award provides limited funds to those institutions' faculty members to develop new research projects or expand ongoing research activities in health sciences and to encourage students to participate in the research activity. As funds are anticipated to continue to be available each year, the NIH is now inviting applications for AREA grants through a standing, ongoing Program Announcement.</p>
R21	<p>Exploratory/Developmental Grants</p> <p>To encourage the development of new research activities in categorical program areas. (Support generally is restricted in the level of support and duration.)</p>
R24	<p>Resource-Related Research Projects</p> <p>To support research projects that will enhance the capability of resources to serve biomedical research.</p>

R25E	<p>Cancer Education Grant Program (CEGP)</p> <p>A flexible, curriculum-driven program aimed at developing and sustaining innovative educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality of life of cancer patients. The CEGP accepts investigator-initiated grant applications that pursue a wide spectrum of objectives ranging from short courses; to the development of new curricula in academic institutions; to national forums and seminar series; to hands-on workshop experiences for the continuing education of health care professionals, biomedical researchers, and the lay community; to structured short-term research experiences designed to motivate high school, college, medical, dental, and other health professional students to pursue careers in cancer research. Education grants can focus on education activities before, during, and after the completion of a doctoral-level degree, as long as they address a need that is not fulfilled adequately by any other grant mechanism available at the NIH and are dedicated to areas of particular concern to the National Cancer Program.</p>
R25T	<p>Cancer Education and Career Development Program</p> <p>To support the development and implementation of curriculum-dependent, team-oriented programs to train predoctoral and postdoctoral candidates in cancer research team settings that are highly interdisciplinary and collaborative. This specialized program is particularly applicable to the behavioral, prevention, control, nutrition, and population sciences but should also be considered by other areas of research (e.g., imaging, pathology) that will require sustained leadership, dedicated faculty time, specialized curriculum development and implementation, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives.</p>
R33	<p>Exploratory/Developmental Grants, Phase II</p> <p>To provide a second phase for support of innovative exploratory and developmental research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants who demonstrate program competency equivalent to that expected under R33</p>
R35	<p>Outstanding Investigator Award (OIA)</p> <p>To provide long-term support to experienced investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit an application nominating an established Program Director/Principal Investigator (PD/PI) for a 7-year grant.</p>
R37	<p>Method to Extend Research in Time (MERIT) Award</p> <p>To provide long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT Award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT Award during the course of reviewing competing research grant applications prepared and submitted in accordance with regular Public Health Service (PHS) requirements.</p>

R55	James A. Shannon Director's Award To provide a limited award to investigators to further develop, test, and refine research techniques; perform secondary analysis of available data sets; test the feasibility of innovative and creative approaches; and conduct other discrete projects that can demonstrate their research capabilities and lend additional weight to their already meritorious applications. Essentially replaced in FY2005 by the R56 award.
R56	High-Priority, Short-Term Project Award Begun in FY2005, this grant provides funds for 1- or 2-year high-priority new or competing renewal R01 applications that fall just outside the limits of funding of the participating NIH Institutes and Centers (ICs); recipients of R56 awards will be selected by IC staff from R01 applications that fall at or near the payline margins.

Small Business Innovation Research (SBIR) (R43/44) and Small Business Technology Transfer (STTR) (R41/42) Programs

The NIH welcomes grant applications from small businesses in any biomedical or behavioral

research area as described in the solicitations below. Support under the SBIR program is normally provided for 6 months/\$100,000 for Phase I and 2 years/\$500,000 for Phase II. Applicants may propose longer periods of time and greater amounts of funds necessary for completion of the project.

R41	STTR Grants, Phase I To support cooperative research and development (R&D) projects between small business concerns and research institutions, limited in time and amount, to establish the technical merit and feasibility of ideas that have potential for commercialization.
R42	STTR Grants, Phase II To support indepth development of cooperative R&D projects between small business concerns and research institutions, limited in time and amount, whose feasibility has been established in Phase I and that have potential for commercial products or services.
R43	SBIR Grants, Phase I To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas that may ultimately lead to commercial products or services.
R44	SBIR Grants, Phase II To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.
S Series: Research-Related Programs	
SC1	Research Enhancement Award Individual investigator-initiated research projects aimed at developing researchers at minority-serving institutions (MSIs) to a stage where they can transition successfully to other extramural support (RO1 or equivalent).
SC2	Pilot Research Project Individual investigator-initiated pilot research projects for faculty at minority-serving institutions (MSIs) to generate preliminary data for a more ambitious research project.
S06	Minority Biomedical Research Support (MBRS) To strengthen the biomedical research and research training capability of ethnic minority institutions and thus establish a more favorable milieu for increasing the involvement of minority faculty and students in biomedical research.

S07	<p>Biomedical Research Support Grants (NCRR BRSG)</p> <p>As an example of this funding mechanism, the NIH issued a Request for Applications (RFA) in FY2004 to provide short-term interim support for institutional activities that will strengthen oversight of human subjects research at institutions that receive significant NIH support for clinical research. Although there is considerable flexibility in the types of activities that could be supported under the BRSG program, that RFA emphasized the importance of efforts to enhance the protection of research subjects by means that would be sustained by the recipient institution after the award period ends. Awardees also are required to collaborate with other institutions conducting human subjects research and are not currently funded under this program, and to share educational resources, computer technologies, best practices, etc. Although all NIH components supporting clinical research (including the NCI) are providing support for this program, it is administered by the National Center for Research Resources (NCRR).</p>
S10	<p>Biomedical Research Support Shared Instrumentation Grants (NCRR SIG)</p> <p>The National Center for Research Resources (NCRR) initiated its competitive Shared Instrumentation Grant (SIG) Program in FY1982. Shared Instrumentation Grants provide support for expensive state-of-the-art instruments utilized in both basic and clinical research. This program is designed to meet the special problems of acquisition and updating of expensive shared-use instruments that are not generally available through other NIH funding mechanisms, such as the regular research project, program project, or center grant programs. Applications for funds to design or to advance the design of new instruments are not accepted. The objective of the program is to make available to institutions with a high concentration of NIH-supported biomedical investigators expensive research instruments that can only be justified on a shared-use basis and for which meritorious research projects are described.</p>
S21	<p>Research and Institutional Resources Health Disparities Endowment Grants—Capacity Building</p> <p>To strengthen the research and training infrastructure of the institution, while addressing current and emerging needs in minority health and other health disparities research.</p>
T Series: Training Programs	
T15	<p>Continuing Education Training Grants</p> <p>To assist professional schools and other public and nonprofit institutions in the establishment, expansion, or improvement of programs of continuing professional education, especially for programs of extensive continuation, extension, or refresher education dealing with new developments in the science and technology of the profession.</p>
T32	<p>NIH National Research Service Award—Institutional Research Training Grants</p> <p>To enable institutions to make National Research Service Awards to individuals selected by them for predoctoral and postdoctoral research training in specified shortage areas.</p>
T34	<p>Undergraduate NRSA Institutional Research Training Grants</p> <p>To enhance the undergraduate research training of individuals from groups underrepresented in biomedical, behavioral, clinical, and social sciences through Institutional National Research Service Award Training Grants in preparation for research doctorate degree programs.</p>

U Series: Cooperative Agreements	
U01	Research Projects—Cooperative Agreements To support a discrete, specified, circumscribed project to be performed by the named investigators in an area representing their specific interests and competencies.
U10	Cooperative Clinical Research—Cooperative Agreements To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between participating institutions and Principal Investigators and are usually conducted under established protocols.
U13	Conference—Cooperative Agreements To coordinate, exchange, and disseminate information related to its program interests, an NIH Institute or Center can use this type of award to provide funding and direction for appropriate scientific conferences. These cooperative agreements allow the NCI to partner with one or more outside organizations to support international, national, or regional meetings, conferences, and workshops that are of value in promoting the goals of the National Cancer Program.
U19	Research Program—Cooperative Agreements To support a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach.
U24	Resource-Related Research Projects—Cooperative Agreements To support research projects contributing to improvement of the capability of resources to serve biomedical research.
U42	Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Materials Resource Cooperative Agreements To develop and support animal (mammalian and nonmammalian) models or animal or biological materials resources available to all qualified investigators without regard to the scientific disciplines or disease orientations of their research activities or specifically directed to a categorical program. Nonmammalian resources include nonmammalian vertebrates, invertebrates, cell systems, and nonbiological systems.
U43	Small Business Innovation Research (SBIR) Cooperative Agreements - Phase I To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas that may ultimately lead to commercial products or services.
U44	Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.

U54	<p>Specialized Center—Cooperative Agreements</p> <p>To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program projects in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continual attention from its staff. Centers also may serve as regional or national resources for special research purposes, with assistance from staff of the funding component in identifying appropriate priority needs.</p>
U56	<p>Exploratory Grants—Cooperative Agreements</p> <p>To support planning for new programs, expansion, or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award.</p>
UH2	<p>Exploratory/Developmental Cooperative Agreement Phase I</p> <p>To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.)</p>
UM1	<p>Research Project With Complex Structure Cooperative Agreement</p> <p>To support cooperative agreements involving large-scale research activities with complicated structures that cannot be appropriately categorized into an available single component activity code (e.g., clinical networks, research programs, or consortia). The components represent a variety of supporting functions and are not independent of each component. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of the award. The performance period may extend up to 7 years but only through the established deviation request process. ICs desiring to use this activity code for programs greater than 5 years must receive OPERA prior approval through the deviation request process.</p>

Appendix F: Glossary of Acronyms

ABTC	Adult Brain Tumor Consortium	DCLG	Genetics Director's Consumer Liaison Group (now NCRA)
AHRQ	Agency for Healthcare Research and Quality	DCP	Division of Cancer Prevention
AIDS	Acquired Immune Deficiency Syndrome	DCTD	Division of Cancer Treatment and Diagnosis
AISB	Applied Information Systems Branch	DEA	Division of Extramural Activities
AMC	AIDS Malignancy Clinical Trials Consortium	DEAS	Division of Extramural Activities Support
ARA	Awaiting Receipt of Application	DEAIS	DEA Information System
AREA	Academic Research Enhancement Award	DFO	Designated Federal Officer
BRSG	Biomedical Research Support Grant	DHHS	U.S. Department of Health and Human Services (now HHS)
BSA	Board of Scientific Advisors	DPIC	Detection of Pathogen-Induced Cancer
BSC	Board of Scientific Counselors	DRR	Division of Receipt and Referral
CAM	Complementary and Alternative Medicine	EDRN	Early Detection Research Network
CATS	Concept to Award Tracking System	EEC	Electronic Early Concurrence
CBIIT	NCI Center for Biomedical Informatics and Information Technology	EPMC	Extramural Program Management Committee
CCCT	Coordinating Center for Clinical Trials	eRA	Electronic Research Administration
CCR	Center for Cancer Research	ESA	Extramural Support Assistant
CCSG	Cancer Center Support Grant	ESATTS	Extramural Officer Science Administrator Training – Tracking System
CCT	Center for Cancer Training	ETCTN	Experimental Therapeutics Clinical Trials Network
CD	Career Development	eTUG	NIH eRA Technical Users Group
CDC	Centers for Disease Control and Prevention	FACA	Federal Advisory Committee Act
CEGP	Cancer Education Grant Program	FDA	Food and Drug Administration
CGCHR	Center for Global Cancer Health Research	FFRDC	Federally Funded Research and Development Center
CHTN	Collaborative Human Tissue Network	FIC	Fogarty International Center
CISNET	Cancer Intervention and Surveillance Modeling Network	FLARE	Fiscal Linked Analysis of Research Emphasis
CIT	Center for Information Technology	FNLAC	Frederick National Laboratory Advisory Committee
CMO	Committee Management Office	FNLCR	Frederick National Laboratory for Cancer Research
COI	Conflict of Interest	FOA	Funding Opportunity Announcements
CPACHE	Comprehensive Partnerships to Advance Cancer Health Equity	FOIA	Freedom of Information Act
CRCHD	Center to Reduce Cancer Health Disparities	FY	Fiscal Year
CRP	Collaborative Research Partnership	HHS	Department of Health and Human Services (replaces DHHS)
CSO	Common Scientific Outline	IC	Institute/Center
CSPPC	Consortium of the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer	ICRP	International Cancer Research Partnership
CSR	Center for Scientific Review	IDeA	Institutional Development Award
CSSI	Center for Strategic Scientific Initiatives	IMAT	Innovative Molecular Analysis Technologies
CTAC	Clinical Trials and Translational Research Advisory Committee	IMPAC	Information for Management, Planning, Analysis, and Coordination
DCB	Division of Cancer Biology	IRG	Initial Review Group
DCCPS	Division of Cancer Control and Population Sciences	IRM	Information Resources Management
DCEG	Division of Cancer Epidemiology and		

IT	Information Technology	PAR	Reviewed Program Announcement
LOI	Letter of Intent	PCP	President's Cancer Panel
LRP	Loan Repayment Program	PCR	Program Coordination and Referral Branch
MBSR	Minority Biomedical Research Support	PD	Pharmacodynamics
MERIT	Method to Extend Research in Time	PHS	Public Health Service (HHS)
MSI	Minority-Serving Institution	PI	Principal Investigator
NCAB	National Cancer Advisory Board	PO	Program Official
NCCCP	NCI Community Cancer Centers Program	POA&M	Plan of Actions and Milestones
NCI	National Cancer Institute	PQ	Provocative Questions
NCORP	NCI Community Oncology Research Program	PRESTO	Program Review and Extramural Staff Training Office
NCRA	NCI Council of Research Advocates (replaces DCLG)	RAEB	Research Analysis and Evaluation Branch
NCRR	National Center for Research Resources	R&D	Research and Development
NCTN	National Clinical Trials Network	RFA	Request for Applications
NDPA	NIH Director Pioneer Award	RFP	Request for Proposals
NED	NIH Electronic Directory	RIO	Research Integrity Officer
NEXT	NCI Experimental Therapeutics	RM	Road Map
NFRP	NCI Funded Research Portfolio	RO	Referral Officer
NGRAD	NCI Grant-Related Directory	RPG	Research Project Grant
NHLBI	National Heart, Lung, and Blood Institute	RPRB	Research Programs Review Branch
NIAAA	National Institute on Alcohol Abuse and Alcoholism	RTCRB	Research Technology and Contract Review Branch
NIAID	National Institute of Allergy and Infectious Diseases	RTRB	Resources and Training Review Branch
NIEHS	National Institute of Environmental Health Sciences	SA	Staff Assistant
NIH	National Institutes of Health	SA&A	Security Assessment and Authorization
NLM	National Library of Medicine	SBIR	Small Business Innovation Research
NRSA	National Research Service Award	SBIRDC	SBIR Development Center
OBRR	Office of Biorepositories and Biospecimen Research	SEER	Surveillance, Epidemiology, and End Results
OBF	Office of Budget and Finance	SEP	Special Emphasis Panel
OCG	Office of Cancer Genomics	SGE	Special Government Employee
OD	Office of the Director	SIC	Special Interest Category
OEA	Office of Extramural Applications	SIG	Shared Instrumentation Grant
OER	Office of Extramural Research	SMW	Science Management Workspace
OFACP	Office of Federal Advisory Committee Policy	SPL	Scientific Program Leader
OHAM	Office of HIV and AIDS Malignancies	SPORE	Specialized Program of Research Excellence
OIA	Outstanding Investigator Award	SPRS	Secure Payee Reimbursement System
OPERA	Office of Policy for Extramural Research Administration	SRB	Special Review Branch
ORRPC	Office of Referral, Review, and Program Coordination	SREA	Scientific Review and Evaluation Activities
OSP	Office of Scientific Programs	SRLB	Special Review and Logistics Branch
PA	Program Announcement	SRO	Scientific Review Officer (formerly Scientific Review Administrator)
		STTR	Small Business Technology Transfer Research
		T&E	Training and Education
		TMEN	Tumor Microenvironment Network

Appendix G: Cancer Information Sources on the Internet

NCI Website

The National Cancer Institute maintains a number of websites containing information about the Institute and its programs. All NCI websites, including those designed to provide cancer-related information to the general public and physicians, can be reached from the NCI home page at <http://www.cancer.gov/>.

DEA Websites

The following websites are maintained by the DEA to provide detailed information to researchers and the public about NCI funding opportunities and the Advisory Boards and groups supported by the DEA.

Links to the individual DEA Web pages via the DEA home page are listed below.

Advisory Boards and Groups

<http://deainfo.nci.nih.gov/advisory/boards.htm>

Links to the home page of each NCI Advisory Board, Committee, Group, etc.

<http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm>

President's Cancer Panel Charter; meeting agendas, meeting minutes, annual reports.

<http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm>

National Cancer Advisory Board Charter; members of subcommittees, meeting agendas.

<http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm>

NCAB meeting information (agenda, minutes, and presentations).

<http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>

Board of Scientific Advisors Charter; members of subcommittees, meeting agendas.

<http://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm>

BSA meeting information (agenda, minutes, and presentations).

<http://deainfo.nci.nih.gov/advisory/fac/fac.htm>

NCI Frederick National Laboratory Advisory Committee Charter, functional statement, members, meeting information and subcommittees.

<http://deainfo.nci.nih.gov/advisory/bsc/bs/bs.htm>

Board of Scientific Counselors (Basic Sciences) Charter; functional statement, and members.

<http://deainfo.nci.nih.gov/advisory/bsc/cse/cse.htm>

Board of Scientific Counselors (Clinical Sciences and Epidemiology) Charter; functional statement, and members.

<http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm>

Clinical Trials and Translational Research Advisory Committee Charter; members, minutes, and agendas.

<http://deainfo.nci.nih.gov/advisory/ncra/ncra.htm>

NCI Council of Research Advocates (NCRA) Charter, functional statement, members, and meeting information

<http://deainfo.nci.nih.gov/advisory/irg/irg.htm>

NCI Initial Review Group (IRG) Charter; functional statement, and members.

<http://deainfo.nci.nih.gov/advisory/sep/sep.htm>

Special Emphasis Panel Charter; functional statement, rosters of most recent review meetings.

Funding Opportunities/Policies

<http://deainfo.nci.nih.gov/funding.htm>

Comprehensive information about external funding opportunities for cancer research; lists of active PAs and RFAs; recently cleared concepts; grant policies and guidelines; downloadable application forms.

<http://deais.nci.nih.gov/foastatus/RFA-PA.jsp?nt=P>
Active PAs, with links to detailed descriptions.

<http://deais.nci.nih.gov/foastatus/RFA-PA.jsp>
Active RFAs, with links to detailed descriptions.

<http://deainfo.nci.nih.gov/grantspolicies/index.htm>
Links to full-text NCI and NIH policies related to grants and grant review (e.g., *Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research* and *Instructions to Reviewers for Evaluating Research Involving Human Subjects in Grant and Cooperative Agreement Applications*).

http://grants.nih.gov/grants/new_investigators/index.htm
New and Early Stage Investigator Policies.

<http://www.cancer.gov/researchandfunding/training>
The Center for Cancer Training (CCT).

<http://report.nih.gov/index.aspx>
Research Portfolio Online Reporting Tools (RePORT): Reports, Data, and Analyses of NIH Research Activities.

Other NIH Websites

<http://www.nih.gov>
NIH Homepage

<http://grants.nih.gov/grants/ElectronicReceipt/>
Grants & Funding – Applying electronically

<http://grants.nih.gov/grants/policy/policy.htm>
Grants & Funding – Grants policies and guidance

<http://grants.nih.gov/grants/guide/index.html>
Grants & Funding – Funding opportunities and notices

<http://grants.nih.gov/training/extramural.htm>
Extramural training mechanisms

**An electronic version of this document can be viewed and downloaded
from the Internet at <http://deainfo.nci.nih.gov/>**



December 2015